



(86) Date de dépôt PCT/PCT Filing Date: 2016/01/12
(87) Date publication PCT/PCT Publication Date: 2016/07/21
(85) Entrée phase nationale/National Entry: 2017/06/29
(86) N° demande PCT/PCT Application No.: EP 2016/050456
(87) N° publication PCT/PCT Publication No.: 2016/113246
(30) Priorité/Priority: 2015/01/12 (EP15150786.0)

(51) Cl.Int./Int.Cl. *C07K 14/54* (2006.01),
A61K 38/00 (2006.01), *A61K 38/20* (2006.01)

(71) Demandeur/Applicant:
AFFIBODY AB, SE


(72) Inventeurs/Inventors:
FREJD, FREDRIK, SE;
FELDWISCH, JOACHIM, SE;
KLINT, SUSANNE, SE;
GUDMUNSDOTTER, LINDVI, SE

(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : POLYPEPTIDES DE LIAISON A L'IL-17A
(54) Title: IL-17A-BINDING POLYPEPTIDES


Figure 13

B



(57) Abrégé/Abstract:

The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-17A (IL-17A), and provides an IL-17A binding polypeptide comprising the sequence EX₂DX₄AX₆X₇EIX₁₀X₁₁LPNLX₁₆X₁₇X₁₈QX₂₀X₂₁AFIX₂₅X₂₆



(57) **Abrégé(suite)/Abstract(continued):**

LX₂₈X₂₉- Also disclosed is the use of such an interleukin-17A binding polypeptide as a diagnostic, prognostic and/or therapeutic agent.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

WIPO | PCT



(10) International Publication Number

WO 2016/113246 A1

(43) International Publication Date
21 July 2016 (21.07.2016)

(51) International Patent Classification:

C07K 14/54 (2006.01) A61K 38/00 (2006.01)
A61K 38/20 (2006.01)

(21) International Application Number:

PCT/EP2016/050456

(22) International Filing Date:

12 January 2016 (12.01.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

15150786.0 12 January 2015 (12.01.2015) EP

(71) Applicant: AFFIBODY AB [SE/SE]; Gunnar Asplunds
Allé 24, S-171 69 Solna (SE).(72) Inventors: FREJD, Fredrik; Skillinggränd 5, 112 20
Stockholm (SE). FELDWISCH, Joachim; Korallvägen
16, 135 42 Tyresö (SE). KLINT, Susanne; Olof Dalins
Väg 16, 112 52 Stockholm (SE). GUDMUNSDOTTER,
Lindvi; Fatburs Kvarngata 17, 118 64 Stockholm (SE).(74) Agent: AWAPATENT AB; Box 45086, 104 30 Stock-
holm (SE).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).


Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: IL-17A-BINDING POLYPEPTIDES

Figure 13

B

(57) Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-17A (IL-17A), and provides an IL-17A binding polypeptide comprising the sequence EX₂DX₄AX₆X₇EIX₁₀X₁₁ LPNL X₁₆X₁₇X₁₈QX₂₀X₂₁AFIX₂₅ X₂₆LX₂₈X₂₉. Also disclosed is the use of such an interleukin-17A binding polypeptide as a diagnostic, prognostic and/or therapeutic agent.

WO 2016/113246 A1

IL-17A-BINDING POLYPEPTIDES

Field of the invention

The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-17A (in the following referred to as IL-17A). The present disclosure also relates to the use of such an interleukin-17A binding polypeptide as a diagnostic, prognostic and/or therapeutic agent.

Background

The interleukin-17 (IL-17) family is a pro-inflammatory cytokine family that contributes to the pathogenesis of several inflammatory diseases. A major source of IL-17 is a lineage of T cells known as T helper 17 cells (Th17 cells), which are distinct from the classical Th1 and Th2 cell subsets. Results of studies in mouse models and in humans have identified a key role of IL-17 and Th17 cells in the pathogenesis of inflammation and autoimmunity as well as in host defense against certain pathogens. Based on these observations, IL-17 and Th17 cells are considered to be interesting targets for the treatment of several chronic inflammatory diseases such as psoriasis, rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE) and multiple sclerosis (MS) (Miossec and Kolls, 2012, Nat Rev Drug Discov 11:763-7).

The disulfide-linked homodimeric cytokine IL-17A is a member of the IL-17 family, which also includes IL-17B, IL-17C, IL-17D, IL-17E and IL-17F. Within the family, IL-17A and IL-17F show the highest amino acid sequence homology to each other (50 %) and they bind to the same receptors: IL-17 receptor A (IL-17RA) and IL-17 receptor C (IL-17RC). Furthermore, IL-17A can be expressed with IL-17F as a heterodimer. Although IL-17A and IL-17F share high amino acid sequence homology, they perform distinct functions. IL-17A is involved in the development of autoimmunity, inflammation and tumors and also plays important roles in the host defense against bacterial and fungal infections. IL-17F, on the other hand, is mainly involved in mucosal host defense mechanisms (Iwakura et al, 2011, Immunity 34:149-62).

When IL-17A is secreted, it promotes the production of a variety of proinflammatory cytokines, chemokines, antimicrobial peptides and metalloproteinases (MMPs) from fibroblast, endothelial and epithelial cells. One important action of IL-17A is to induce granulopoiesis and neutrophil

recruitment to inflammatory sites. However, if uncontrolled, this reaction may lead to chronic inflammation with tissue destruction and neovascularization (Iwakura et al. 2008, *Immunol Rev* 226:57-79; Reynolds et al. 2010, *Cytokine Growth Factor Rev* 21:413-23). IL-17A is central in the pathogenesis of

5 psoriasis, a common chronic inflammatory skin disease affecting about 2.5 % of the worldwide population (reviewed in Chiricozzi and Krueger, 2013, *Expert Opin. Investig. Drugs* 22(8):993-1005). Studies in patients with RA have shown that IL-17A positive cells are present in the inflamed synovium. In a mouse model of RA, the clinical scores were severely aggravated by

10 administration of IL-17A via intra-articular gene transfer (Lubberts et al. 2002, *Inflamm Res* 51:102-4). Conversely, inhibition of IL-17A with monoclonal antibodies against the ligand or the receptor protected against development and consequences of arthritis (Lubberts et al. 2004, *Arthritis Rheum* 50:650-9). In MS patients, the IL-17A gene is reported to be overexpressed (Lock et al. 2002, *Nat Med* 8:500-8) and IL-17A and Th17 cells have been clearly

15 implicated in the mouse model of experimental autoimmune encephalitis (Cua et al. 2003, *Nature* 421:744-8; Uyttenhove and Van Snick 2006, *Eur J Immunol* 36:2868-74). Increased levels of IL-17A have been shown to be clinically correlated with various ocular inflammatory diseases, such as

20 uveitis, scleritis and dry eye disease (DED) in patients suffering from arthritis (Kang et al. 2011, *J Korean Med Sci* 26:938-44). Recent studies have showed IL-17 and IFN γ positive cells in clinical specimens of coronary atherosclerosis suggesting a local effect on vessel dysfunction (Eid et al. 2009, *J Cardiothorac Surg* 4:58). IL-17A may also be of interest in chronic

25 obstructive pulmonary disease (COPD). The number of IL-17A positive cells is increased in lung tissues from COPD patients (Chu et al. 2011, *Int Immunopharmacol* 11:1780-8; Di Stefano et al. 2009, *Clin Exp Immunol* 157:316-24). IL-17RA deficient mice are resistant to the development of emphysema in a mouse model of COPD whereas overexpression of IL-17A

30 accelerates the development of emphysema suggesting that IL-17A is sufficient to mediate this response (Chen et al. 2011, *PLoS One* 6:e20333; Shan et al. 2012, *Sci Transl Med* 4:117ra9). Thus, the involvement of IL-17A in several different autoimmune and inflammatory diseases suggests a wide applicability of therapeutics targeting IL-17A.

35 Targeting of IL-17A or its receptors is the most direct way to block IL-17A-mediated functions. Several biologics that neutralize IL-17A signaling are now in clinical development, including the anti-IL-17A monoclonal antibodies

secukinumab and ixekizumab (Patel et al, 2013, Ann Rheum Dis 72 Suppl 2:ii116-23). Secukinumab has been approved for the treatment of psoriasis and is currently investigated for the treatment of psoriatic arthritis (PsA) and AS. Ixekizumab is currently in clinical trials for psoriasis, PsA and RA.

- 5 Blocking of IL-17 receptor mediated signaling is also under investigation in the clinic, including the human monoclonal anti-IL-17RA antibody brodalumab for treatment of psoriasis, RA and asthma (Hu et al. 2011, Ann N Y Acad Sci 1217:60-76). Thus, clinical efficacy of IL-17A-inhibition has been proven in different diseases, notably in psoriasis, and the safety profile, including phase
10 II and phase III data, shows good tolerability for IL-17A inhibitors (Genovese et al. 2010, Arthritis Rheum 62:929-39 and Hueber et al. 2010, Sci Transl Med 2:52ra72).

The unpredictable and chronic nature of psoriasis and other inflammatory diseases, as well as a high unmet medical need, warrants the
15 development of new modes of treatment.

Since tissue penetration rate is negatively associated with the size of the molecule, a relatively large antibody molecule inherently has poor tissue distribution and penetration capacity. Moreover, although antibodies are widely used in a variety of routine contexts owing to high affinity and
20 specificity to a multitude of possible antigens, such as for analytical, purification, diagnostic and therapeutic purposes, they still suffer from several drawbacks. Such drawbacks include the need for complex mammalian expression systems, aggregation tendencies, limited solubility, need to form and stably maintain disulfide bonds, and the risk of unwanted immune
25 responses.

Thus, the use of monoclonal antibodies is not always optimal for therapy, and there is continued need for provision of agents with a high affinity for IL-17A. Of great interest is also the provision of uses of such molecules in the treatment, diagnosis and prognosis of disease.

30

Summary of the invention

It is an object of the present disclosure to provide new IL-17A binding agents, which could for example be used for diagnostic, prognostic and therapeutic applications.

- 35 It is an object of the present disclosure to provide new IL-17A binding agents, which may be used as domains in fusion proteins comprising one or more additional domains having similar or other functions.

It is an object of the present disclosure to provide a molecule allowing for efficient therapy targeting various forms of inflammatory and autoimmune disease while alleviating the abovementioned and other drawbacks of current therapies.

5 It is a further object of the present disclosure to provide a molecule suitable for prognostic and diagnostic applications.

These and other objects which are evident to the skilled person from the present disclosure are met by different aspects of the invention as claimed in the appended claims and as generally disclosed herein.

10

Thus, in the first aspect of the disclosure, there is provided an IL-17A binding polypeptide, comprising an IL-17A binding motif *BM*, which motif consists of an amino acid sequence selected from:

15 i) $EX_2DX_4AX_6X_7EIX_{10}X_{11}LPNL\ X_{16}X_{17}X_{18}QX_{20}X_{21}AFIX_{25}\ X_{26}LX_{28}X_{29}$

wherein, independently from each other,

20 X_2 is selected from A, H, M and Y;
 X_4 is selected from A, D, E, F, K, L, M, N, Q, R, S and Y;
 X_6 is selected from A, Q and W;
 X_7 is selected from F, I, L, M, V, W and Y;
 X_{10} is selected from A and W;
 X_{11} is selected from A, D, E, F, G, L, M, N, Q, S, T and Y;
25 X_{16} is selected from N and T;
 X_{17} is selected from H, W and Y;
 X_{18} is selected from A, D, E, H and V;
 X_{20} is selected from A, G, Q, S and W;
 X_{21} is selected from A, D, E, F, H, K, N, R, T, V, W and Y;
30 X_{25} is selected from A, D, E, G, H, I, L, M, N, Q, R, S, T and V;
 X_{26} is selected from K and S;
 X_{28} is selected from I, L, N and R; and
 X_{29} is selected from D and R;

and

35

ii) an amino acid sequence which has at least 89 % identity to the sequence defined in i).

The above definition of a class of sequence related, IL-17A binding polypeptides is based on a statistical analysis of a number of random polypeptide variants of a parent scaffold, that were selected for their
5 interaction with IL-17A in several different selection experiments. The identified IL-17A binding motif, or “*BM*”, corresponds to the target binding region of the parent scaffold, which region constitutes two alpha helices within a three-helical bundle protein domain. In the parent scaffold, the varied amino acid residues of the two *BM* helices constitute a binding surface for interaction
10 with the constant Fc part of antibodies. In the present disclosure, the random variation of binding surface residues and subsequent selection of variants have replaced the Fc interaction capacity with a capacity for interaction with IL-17A.

As the skilled person will realize, the function of any polypeptide, such
15 as the IL-17A binding capacity of the polypeptide of the present disclosure, is dependent on the tertiary structure of the polypeptide. It is therefore possible to make minor changes to the sequence of amino acids in a polypeptide without affecting the function thereof. Thus, the disclosure encompasses modified variants of the IL-17A binding polypeptide, which are such that the
20 IL-17A binding characteristics are retained.

In this way, also encompassed by the present disclosure is an IL-17A binding polypeptide comprising an amino acid sequence with 89 % or greater identity to a polypeptide as defined in i). In some embodiments, the polypeptide may comprise a sequence which is at least 93 %, such as at least
25 96 % identical to a polypeptide as defined in i). For example, it is possible that an amino acid residue belonging to a certain functional grouping of amino acid residues (e.g. hydrophobic, hydrophilic, polar etc) could be exchanged for another amino acid residue from the same functional group.

In some embodiments, such changes may be made in any position of
30 the sequence of the IL-17A binding polypeptide as disclosed herein. In other embodiments, such changes may be made only in the non-variable positions, also denoted scaffold amino acid residues. In such cases, changes are not allowed in the variable positions, i.e. positions denoted with an “X” in sequence i).

35 The term “% identity”, as used throughout the specification, may for example be calculated as follows. The query sequence is aligned to the target sequence using the CLUSTAL W algorithm (Thompson *et al*, Nucleic Acids

Research, 22: 4673-4680 (1994)). A comparison is made over the window corresponding to the shortest of the aligned sequences. The shortest of the aligned sequences may in some instances be the target sequence. In other instances, the query sequence may constitute the shortest of the aligned sequences. The amino acid residues at each position are compared and the percentage of positions in the query sequence that have identical correspondences in the target sequence is reported as % identity.

In one particular embodiment according to the first aspect, there is provided a polypeptide as defined above, wherein, in sequence i),

X_2 is selected from A, H and M;

X_4 is selected from A, D, E, F, L, M, N, Q, R and Y;

X_{11} is selected from A, D, E, F, G, L, M, N, S, T and Y;

X_{18} is selected from A, D, E and V;

X_{20} is selected from A, G, Q and W;

X_{21} is selected from E, F, H, N, R, T, V, W and Y;

X_{25} is selected from A, D, E, G, H, I, L, N, Q, R, S, T and V; and

X_{28} is selected from I, N and R.

In another particular embodiment according to the first aspect, there is provided a polypeptide as defined in the paragraph immediately above, wherein in addition, in sequence i),

X_{16} is T;

X_{17} is W;

X_{21} is selected from E, F, H, W, T and Y;

X_{25} is selected from A, D, E, G, H, I, L, N, Q, R, S and T;

X_{26} is K; and

X_{29} is D.

" X_n " and " X_m " are used herein to indicate amino acids in positions n and m in the sequence i) as defined above, wherein n and m are integers indicating the position of an amino acid within sequence i) as counted from the N terminus. For example, X_3 and X_7 indicate the amino acids in positions three and seven, respectively, from the N-terminal end of sequence i).

In embodiments according to the first aspect, there are provided polypeptides wherein X_n in sequence i) is independently selected from a group of possible residues as listed in Table 1. The skilled person will

appreciate that X_n may be selected from any one of the listed groups of possible residues and that this selection is independent from the selection of amino acids in X_m , wherein $n \neq m$. Thus, any of the listed possible residues in position X_n in Table 1 may be independently combined with any of the listed possible residues any other variable position in Table 1.

The skilled person will appreciate that Table 1 is to be read as follows: In one embodiment according to the first aspect, there is provided a polypeptide wherein amino acid residue “ X_n ” in sequence i) is selected from “Possible residues”. Thus, Table 1 discloses several specific and individualized embodiments of the first aspect of the present disclosure. For example, in one embodiment according to the first aspect, there is provided a polypeptide wherein X_4 in sequence i) is selected from A, D, E, F, L, N, Q, R and Y, and in another embodiment according to the first aspect, there is provided a polypeptide wherein X_4 in sequence i) is selected from D, E, N and Y. For avoidance of doubt, the listed embodiments may be freely combined in yet other embodiments. For example, one such combined embodiment is a polypeptide in which X_4 is selected from D, E, F, N, Q, R and Y, while X_7 is selected from F, V and W, and X_{18} is selected from A, D, E and H, and so on.

Table 1:

X_n	Possible residues
X_2	A, M, Y
X_2	A, M
X_2	A
X_4	A, D, E, F, K, L, M, N, Q, R, Y
X_4	A, D, E, F, L, M, N, Q, R, S, Y
X_4	A, D, E, F, L, M, N, Q, R, Y
X_4	A, D, E, F, L, N, Q, R, Y
X_4	A, D, E, F, M, N, Q, Y
X_4	A, D, E, F, L, Q, R
X_4	A, D, E, L, Q, R
X_4	A, D, Q, R
X_4	D, Q
X_4	A, D, E, F, N, Q, Y
X_4	D, E, F, N, Q, R, Y
X_4	D, E, N, Q, Y
X_4	D, E, N, Y
X_4	D, E, Q, Y
X_4	D, E, Y
X_4	D, E
X_4	D

X_n	Possible residues
X_4	Q
X_6	A, Q
X_6	A, W
X_6	Q, W
X_6	W
X_6	A
X_6	Q
X_7	F, I, L, V, W, Y
X_7	F, I, L, V, Y
X_7	I, L, V, Y
X_7	L, V, Y
X_7	L, V
X_7	F, M, V, W, Y
X_7	F, V, W, Y
X_7	F, V, W
X_7	F, V
X_7	V
X_7	L
X_7	Y
X_{10}	A

X_n	Possible residues
X ₁₀	W
X ₁₁	A, D, E, F, G, L, M, N, S, T, Y
X ₁₁	A, D, E, F, L, M, S, T
X ₁₁	A, D, E, F, G, L, M, N, S, Y
X ₁₁	A, D, E, F, G, S, Y
X ₁₁	A, D, E, F, L, M, S
X ₁₁	A, D, E, L, M, S
X ₁₁	A, D, E, L, S
X ₁₁	A, D, E, L, M
X ₁₁	A, D, E, L
X ₁₁	D, E, L
X ₁₁	D, L
X ₁₁	A, D, E, F, S, Y
X ₁₁	A, D, E, S
X ₁₁	A, D, S
X ₁₁	A, S
X ₁₁	A, D
X ₁₁	D, S
X ₁₁	L
X ₁₁	D
X ₁₁	S
X ₁₁	A
X ₁₁	E
X ₁₆	T
X ₁₆	N
X ₁₇	H, W
X ₁₇	Y, W
X ₁₇	H, Y
X ₁₇	W
X ₁₇	H
X ₁₇	Y
X ₁₈	A, D, E, V
X ₁₈	A, D, E, H
X ₁₈	A, D, H
X ₁₈	A, D, E
X ₁₈	A, D
X ₁₈	D, E
X ₁₈	D
X ₁₈	A
X ₂₀	A, G, Q, W
X ₂₀	A, Q, S, W
X ₂₀	A, Q, W
X ₂₀	G, Q, W
X ₂₀	G, W
X ₂₀	Q, W

X_n	Possible residues
X ₂₀	A, W
X ₂₀	W
X ₂₀	A
X ₂₀	Q
X ₂₁	A, D, E, F, H, N, R, T, V, W, Y
X ₂₁	A, D, E, F, H, N, R, V, W, Y
X ₂₁	E, F, H, N, R, V, W, Y
X ₂₁	F, H, N, R, V, W, Y
X ₂₁	E, F, H, T, W, Y
X ₂₁	E, F, H, W, Y
X ₂₁	F, H, R, W, Y
X ₂₁	F, H, W, Y
X ₂₁	F, W, Y
X ₂₁	W, Y
X ₂₁	F, Y
X ₂₁	F, W
X ₂₁	Y
X ₂₁	W
X ₂₁	F
X ₂₅	A, D, E, G, H, I, L, N, Q, R, S, T, V
X ₂₅	A, D, E, G, H, I, L, N, Q, R, S, T
X ₂₅	A, D, E, G, H, N, Q, R, S, T, V
X ₂₅	D, E, G, N, Q, R, S, T, V
X ₂₅	D, E, N, Q, R, V
X ₂₅	A, D, E, G, I, L, N, Q, R, S, T
X ₂₅	D, E, G, N, Q, R, S
X ₂₅	D, E, N, Q, R, S
X ₂₅	A, E, G, L, N, Q, R, S, T
X ₂₅	E, N, Q, R, S
X ₂₅	E, N, Q, S, T
X ₂₅	E, N, Q, S
X ₂₅	N, Q, R
X ₂₅	E, Q, R
X ₂₅	Q, R, S
X ₂₅	Q, S
X ₂₅	Q, R
X ₂₅	Q
X ₂₅	S
X ₂₅	N
X ₂₅	E
X ₂₆	K
X ₂₆	S
X ₂₈	I, N, R
X ₂₈	I, L, R
X ₂₈	I, R

X _n	Possible residues
X ₂₈	N, R
X ₂₈	I, N
X ₂₈	R
X ₂₈	I

X _n	Possible residues
X ₂₈	N
X ₂₉	D
X ₂₉	R

In a more specific embodiment defining a sub-class of IL-17A binding polypeptides, sequence i) fulfills at least six of the eleven conditions I-XI:

- 5
- I. X₂ is A;
- II. X₄ is selected from D, E and Q;
- III. X₆ is A;
- IV. X₇ is selected from F and V;
- 10 V. X₁₆ is T;
- VI. X₁₇ is W;
- VII. X₁₈ is selected from A and D;
- VIII. X₂₀ is W;
- IX. X₂₆ is K;
- 15 X. X₂₈ is R; and
- XI. X₂₉ is D.

In some examples of an IL-17A binding polypeptide according to the first aspect, sequence i) fulfills at least seven of the eleven conditions I-XI.

- 20
- More specifically, sequence i) may fulfill at least eight of the eleven conditions I-XI, such as at least nine of the eleven conditions I-XI, such as at least ten of the eleven conditions I-XI, such as all of the eleven conditions I-XI.

In some embodiments of an IL-17A binding polypeptide according to the first aspect, X₂X₆, X₂X₁₀ or X₆X₁₀ is AA. In some embodiments, X₂X₁₇,
25 X₂X₂₀, X₆X₁₇, X₆X₂₀, X₁₀X₁₇ or X₁₀X₂₀ is AW. In some embodiments, X₂X₂₈, X₆X₂₈ or X₁₀X₂₈ is AR. In some embodiments, X₁₇X₂₈ or X₂₀X₂₈ is WR. In some embodiments, X₁₇X₂₀ is WW.

- 30
- As described in detail in the experimental section to follow, the selection of IL-17A binding polypeptide variants has led to the identification of a number of individual IL-17A binding motif (*BM*) sequences. These sequences constitute individual embodiments of sequence i) according to this aspect. The sequences of individual IL-17A binding motifs correspond to

amino acid positions 8-36 in SEQ ID NO:1-1216 presented in Figure 1. Hence, in one embodiment of the IL-17A binding polypeptide according to this aspect, sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NO:1-1216. In one embodiment, sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NO:1-66, 1200, 1206 and 1214. In one embodiment, sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NO:1-66. In one embodiment, sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NO:1-35. In one embodiment, sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NO:1-27. In one embodiment, sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NO:1-10. In one embodiment, sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NO:1-7. In one embodiment, sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NO:1-4. In one embodiment, sequence i) corresponds to the sequence from position 8 to position 36 in SEQ ID NO:1.

In some embodiments of the present disclosure, the *BM* as defined above “forms part of” a three-helix bundle protein domain. This is understood to mean that the sequence of the *BM* is “inserted” into or “grafted” onto the sequence of the original three-helix bundle domain, such that the *BM* replaces a similar structural motif in the original domain. For example, without wishing to be bound by theory, the *BM* is thought to constitute two of the three helices of a three-helix bundle, and can therefore replace such a two-helix motif within any three-helix bundle. As the skilled person will realize, the replacement of two helices of the three-helix bundle domain by the two *BM* helices has to be performed so as not to affect the basic structure of the polypeptide. That is, the overall folding of the C α backbone of the polypeptide according to this embodiment of the invention is substantially the same as that of the three-helix bundle protein domain of which it forms a part, e.g. having the same elements of secondary structure in the same order etc. Thus, a *BM* according to the disclosure “forms part” of a three-helix bundle

domain if the polypeptide according to this embodiment of the aspect has the same fold as the original domain, implying that the basic structural properties are shared, those properties e.g. resulting in similar CD spectra. The skilled person is aware of other parameters that are relevant.

5 In particular embodiments, the IL-17A binding motif (*BM*) thus forms part of a three-helix bundle protein domain. For example, the *BM* may essentially constitute two alpha helices with an interconnecting loop, within said three-helix bundle protein domain. In particular embodiments, said three-helix bundle protein domain is selected from domains of bacterial receptor
10 proteins. Non-limiting examples of such domains are the five different three-helical domains of Protein A from *Staphylococcus aureus*, such as domain B, and derivatives thereof. In some embodiments, the three-helical bundle protein domain is a variant of protein Z, which is derived from domain B of staphylococcal Protein A.

15

In some embodiments where the IL-17A binding polypeptide as disclosed herein forms part of a three-helix bundle protein domain, the IL-17A binding polypeptide may comprise an amino acid sequence binding module (*BMod*) selected from:

20

iii) K-[*BM*]-DPSQS X_aX_bLLX_c EAKKL X_dX_eX_fQ;

wherein

25

[*BM*] is an IL-17A binding motif as defined herein, provided that X₂₉ is D;

X_a is selected from A and S;

X_b is selected from N and E;

X_c is selected from A, S and C;

X_d is selected from E, N and S;

30

X_e is selected from D, E and S;

X_f is selected from A and S; and

iv) an amino acid sequence which has at least 85 % identity to a sequence defined by iii).

35

It may be beneficial in some embodiments that said polypeptides exhibit high structural stability, such as resistance to chemical modifications,

changes in physical conditions and proteolysis, during production or storage, as well as *in vivo*. Thus, in other embodiments where the IL-17A binding polypeptide as disclosed herein forms part of a three-helix bundle protein domain, the IL-17A binding polypeptide may comprise an amino acid
 5 sequence binding module (*BMod*) selected from:

v) K-[*BM*]-QPEQS $X_aX_bLLX_c$ EAKKL $X_dX_eX_fQ$,

wherein

10 [*BM*] is an IL-17A binding motif as defined herein, provided that X_{29} is R;

X_a is selected from A and S;

X_b is selected from N and E;

X_c is selected from A, S and C;

15 X_d is selected from E, N and S;

X_e is selected from D, E and S;

X_f is selected from A and S; and

vi) an amino acid sequence which has at least 85 % identity to a
 20 sequence defined by v).

As discussed above, polypeptides comprising minor changes as compared to the above amino acid sequences, which changes do not largely affect the tertiary structure or function of the polypeptide, are also within the
 25 scope of the present disclosure. Thus, in some embodiments, sequence iv and vi) have at least at least 87 %, such as at least 89 %, such as at least 91 %, such as at least 93 %, such as at least 95 %, such as at least 97 % identity to a sequence defined by iii) or v), respectively.

In one embodiment, X_a in sequence iii) or v) is A.

30 In one embodiment, X_a in sequence iii) or v) is S.

In one embodiment, X_b in sequence iii) or v) is N.

In one embodiment, X_b in sequence iii) or v) is E.

In one embodiment, X_c in sequence iii) or v) is A.

In one embodiment, X_c in sequence iii) or v) is S.

35 In one embodiment, X_c in sequence iii) or v) is C.

In one embodiment, X_d in sequence iii) or v) is E.

In one embodiment, X_d in sequence iii) or v) is N.

- In one embodiment, X_d in sequence iii) or v) is S.
- In one embodiment, X_e in sequence iii) or v) is D.
- In one embodiment, X_e in sequence iii) or v) is E.
- In one embodiment, X_e in sequence iii) or v) is S.
- 5 In one embodiment, X_dX_e in sequence iii) or v) is selected from EE, ES, SD, SE and SS.
- In one embodiment, X_dX_e in sequence iii) or v) is ES.
- In one embodiment, X_dX_e in sequence iii) or v) is SE.
- In one embodiment, X_dX_e in sequence iii) or v) is SD.
- 10 In one embodiment, X_f in sequence iii) or v) is A.
- In one embodiment, X_f in sequence iii) or v) is S.
- In one embodiment, in sequence iii) or v), X_a is A; X_b is N; X_c is A and X_f is A.
- In one embodiment, in sequence iii) or v), X_a is S; X_b is E; X_c is A and
- 15 X_f is A.
- In one embodiment, in sequence iii) or v), X_a is A; X_b is N; X_c is C and X_f is A.
- In one embodiment, in sequence iii) or v), X_a is S; X_b is E; X_c is S and X_f is S.
- 20 In one embodiment, in sequence iii) or v), X_a is S; X_b is E; X_c is S and X_f is A.
- In one embodiment, in sequence iii) or v), X_a is S; X_b is E; X_c is A and X_f is S.
- In one embodiment, in sequence iii) or v), X_a is S; X_b is E; X_c is C and
- 25 X_f is S.
- In one embodiment, in sequence iii) or v), X_a is A; X_b is N; X_c is A; X_dX_e is ND and X_f is A.
- In one embodiment, in sequence iii) or v), X_a is S; X_b is E; X_c is A; X_dX_e is ND and X_f is A.
- 30 In one embodiment, in sequence iii) or v), X_a is A; X_b is N; X_c is C; X_dX_e is ND and X_f is A.
- In one embodiment, in sequence iii) or v), X_a is S; X_b is E; X_c is S; X_dX_e is ND and X_f is S.
- In one embodiment, in sequence iii) or v), X_a is S; X_b is E; X_c is S; X_dX_e
- 35 is ND and X_f is A.
- In one embodiment, in sequence iii) or v), X_a is S; X_b is E; X_c is C; X_dX_e is ND and X_f is S.

In one embodiment, in sequence iii) or v), X_a is A; X_b is N; X_c is A; X_dX_e is SE and X_f is A.

In one embodiment, in sequence iii) or v), X_a is S; X_b is E; X_c is A; X_dX_e is SE and X_f is A.

5 In one embodiment, in sequence iii) or v), X_a is A; X_b is N; X_c is C; X_dX_e is SE and X_f is A.

In one embodiment, in sequence iii) or v), X_a is S; X_b is E; X_c is S; X_dX_e is SE and X_f is S.

10 In one embodiment, in sequence iii) or v), X_a is S; X_b is E; X_c is A; X_dX_e is SE and X_f is S.

In one embodiment, in sequence iii) or v), X_a is S; X_b is E; X_c is C; X_dX_e is SE and X_f is S.

In one embodiment, in sequence iii) or v), X_a is A; X_b is N; X_c is A; X_dX_e is ES and X_f is A.

15 In one embodiment, in sequence iii) or v), X_a is S; X_b is E; X_c is A; X_dX_e is ES and X_f is A.

In one embodiment, in sequence iii) or v), X_a is A; X_b is N; X_c is C; X_dX_e is ES and X_f is A.

20 In one embodiment, in sequence iii) or v), X_a is S; X_b is E; X_c is S; X_dX_e is ES and X_f is S.

In one embodiment, in sequence iii) or v), X_a is S; X_b is E; X_c is C; X_dX_e is ES and X_f is S.

In one embodiment, in sequence iii) or v), X_a is A; X_b is N; X_c is A; X_dX_e is SD and X_f is A.

25 In one embodiment, in sequence iii) or v), X_a is S; X_b is E; X_c is A; X_dX_e is SD and X_f is A.

In one embodiment, in sequence iii) or v), X_a is A; X_b is N; X_c is C; X_dX_e is SD and X_f is A.

30 In one embodiment, in sequence iii) or v), X_a is S; X_b is E; X_c is S; X_dX_e is SD and X_f is S.

In one embodiment, in sequence iii) or v), X_a is S; X_b is E; X_c is A; X_dX_e is SD and X_f is S.

In one embodiment, in sequence iii) or v), X_a is S; X_b is E; X_c is C; X_dX_e is SD and X_f is S.

35

In yet a further embodiment, sequence iii) corresponds to the sequence from position 7 to position 55 in a sequence selected from the

group consisting of SEQ ID NO:1-1216. In one embodiment, sequence iii) corresponds to the sequence from position 7 to position 55 in a sequence selected from the group consisting of SEQ ID NO:1-66, 1200, 1206 and 1214. In one embodiment, sequence iii) corresponds to the sequence from position 7 to position 55 in a sequence selected from the group consisting of SEQ ID NO:1-66. In one embodiment, sequence iii) corresponds to the sequence from position 7 to position 55 in a sequence selected from the group consisting of SEQ ID NO:1-35. In another embodiment, sequence iii) corresponds to the sequence from position 7 to position 55 in a sequence selected from the group consisting of SEQ ID NO:1-27. In one embodiment, sequence iii) corresponds to the sequence from position 7 to position 55 in a sequence selected from the group consisting of SEQ ID NO:1-10. In yet another embodiment, sequence iii) corresponds to the sequence from position 7 to position 55 in a sequence selected from the group consisting of SEQ ID NO:1-7. In one embodiment, sequence iii) corresponds to the sequence from position 7 to position 55 in a sequence selected from the group consisting of SEQ ID NO:1-4 and in another embodiment, sequence iii) corresponds to the sequence from position 7 to position 55 in SEQ ID NO:1.

Also, in a further embodiment, there is provided an IL-17A binding polypeptide, which comprises an amino acid sequence selected from:

vii) YA-[BMod]-AP;

wherein [BMod] is an IL-17A binding module as defined above; and

viii) an amino acid sequence which has at least 86 % identity to a sequence defined by vii).

In an alternative further embodiment, there is provided an IL-17A binding polypeptide, which comprises an amino acid sequence selected from:

ix) FA-[BMod]-AP;

wherein [BMod] is an IL-17A binding module as defined above; and

x) an amino acid sequence which has at least 86 % identity to a sequence defined by ix).

Alternatively, there is provided an IL-17A binding polypeptide, which comprises an amino acid sequence selected from:

xi) FN-[BMod]-AP;

wherein [BMod] is an IL-17A binding module as defined above; and

xii) an amino acid sequence which has at least 86 % identity to a sequence defined by xi).

As discussed above, polypeptides comprising minor changes as compared to the above amino acid sequences without largely affecting the tertiary structure and the function thereof also fall within the scope of the present disclosure. Thus, in some embodiments, the IL-17A binding

5 polypeptides as defined above may for example have a sequence which is at least 88 %, such as at least 90 %, such as at least 92 %, such as at least 94 %, such as at least 96 %, such as at least 98 % identical to a sequence defined by vii), ix) or xi).

10 In some embodiments, the IL-17A binding motif may form part of a polypeptide comprising an amino acid sequence selected from

SEQ ID NO:

1250	ADNNFNK-[BM]-DPSQSANLLSEAKKLNESQAPK;
1251	ADNKFNK-[BM]-DPSQSANLLAEAKKLNDQAQAPK;
1252	ADNKFNK-[BM]-DPSVSKEILAEAKKLNDQAQAPK;
1253	ADAQQNNFNK-[BM]-DPSQSTNVLGEAKKLNESQAPK;
1254	AQHDE-[BM]-DPSQSANVLGEAQKLNDQAPK;
1255	VDNKFNK-[BM]-DPSQSANLLAEAKKLNDQAQAPK;
1256	AEAKYAK-[BM]-DPSESSELLSEAKKLNKSQAPK;
1257	VDAKYAK-[BM]-DPSQSSELLAEAKKLNDQAQAPK;
1258	VDAKYAK-[BM]-DPSQSSELLAEAKKLNDQAPK;
1259	AEAKYAK-[BM]-DPSQSSELLSEAKKLNDQAPK;
1260	AEAKYAK-[BM]-DPSQSSELLSEAKKLNDQAP;
1261	AEAKYAK-[BM]-DPSQSSELLSEAKKLNDQAQAPK;
1262	AEAKYAK-[BM]-DPSQSSELLSEAKKLNDQAQAP;
1263	AEAKFAK-[BM]-DPSQSSELLSEAKKLNDQAPK;
1264	AEAKFAK-[BM]-DPSQSSELLSEAKKLNDQAP;
1265	AEAKYAK-[BM]-DPSQSSELLAEAKKLNDQAQAPK;
1266	AEAKYAK-[BM]-DPSQSSELLSEAKKLSESQAPK;
1267	AEAKYAK-[BM]-DPSQSSELLSEAKKLSESQAP;
1268	AEAKFAK-[BM]-DPSQSSELLSEAKKLSESQAPK;
1269	AEAKFAK-[BM]-DPSQSSELLSEAKKLSESQAP;
1270	AEAKYAK-[BM]-DPSQSSELLAEAKKLSEAQAPK;
1271	AEAKYAK-[BM]-QPEQSSELLSEAKKLSESQAPK;
1272	AEAKYAK-[BM]-DPSQSSELLSEAKKLESSQAPK;
1273	AEAKYAK-[BM]-DPSQSSELLSEAKKLESSQAP;

- 1274 AEAKEYAK-[BM]-DPSQSSELLAEAKKLESAQAPK;
- 1275 AEAKEYAK-[BM]-QPEQSSELLSEAKKLESSQAPK;
- 1276 AEAKEYAK-[BM]-DPSQSSELLSEAKKLSDSQAPK;
- 1277 AEAKEYAK-[BM]-DPSQSSELLSEAKKLSDSQAP;
- 1278 AEAKEYAK-[BM]-DPSQSSELLAEAKKLSDSQAPK;
- 1279 AEAKEYAK-[BM]-DPSQSSELLAEAKKLSDAQAPK;
- 1280 AEAKEYAK-[BM]-QPEQSSELLSEAKKLSDSQAPK;
- 1281 VDAKYAK-[BM]-DPSQSSELLSEAKKLNDSDQAPK;
- 1282 VDAKYAK-[BM]-DPSQSSELLSEAKKLSESDQAPK;
- 1283 VDAKYAK-[BM]-DPSQSSELLAEAKKLSEAQAPK;
- 1284 VDAKYAK-[BM]-QPEQSSELLSEAKKLSESDQAPK;
- 1285 VDAKYAK-[BM]-DPSQSSELLSEAKKLESSQAPK;
- 1286 VDAKYAK-[BM]-DPSQSSELLAEAKKLESAQAPK;
- 1287 VDAKYAK-[BM]-QPEQSSELLSEAKKLESSQAPK;
- 1288 VDAKYAK-[BM]-DPSQSSELLSEAKKLSDSQAPK;
- 1289 VDAKYAK-[BM]-DPSQSSELLAEAKKLSDSQAPK;
- 1290 VDAKYAK-[BM]-DPSQSSELLAEAKKLSDAQAPK;
- 1291 VDAKYAK-[BM]-QPEQSSELLSEAKKLSDSQAPK;
- 1292 VDAKYAK-[BM]-DPSQSSELLAEAKKLNKAQAPK;
- 1293 AEAKEYAK-[BM]-DPSQSSELLAEAKKLNKAQAPK; and
- 1294 ADAKYAK-[BM]-DPSQSSELLSEAKKLNDSDQAPK;

wherein [BM] is an IL-17A binding motif as defined above.

In one embodiment, the IL-17A binding polypeptide comprises an amino acid sequence selected from:

- 5 xiii) VDAKYAK-[BM]-DPSQSSELLSEAKKLNDSDQAPK;
wherein [BM] is an IL-17A binding motif as defined above; and
- xiv) an amino acid sequence which has at least 86 % identity to the sequence defined in xiii).

Again, polypeptides comprising minor changes as compared to the
 10 above amino acid sequences without largely affecting the tertiary structure and the function thereof are also within the scope of the present disclosure. Thus, in some embodiments, the IL-17A binding polypeptides as defined above may for example have a sequence which is at least 87 %, such as at least 89 %, such as at least 91 %, such as at least 93 %, such as at least
 15 94 %, such as at least 96 %, such as at least 98 % identical to the sequence defined by xiii).

Sequence xiii) in such a polypeptide may be selected from the group consisting of SEQ ID NO:1-1216. In one embodiment, sequence xiii) is selected from the group consisting of SEQ ID NO:1-66, 1200, 1206 and 1214. In one embodiment, sequence xiii) is selected from the group consisting of
 5 SEQ ID NO:1-66. In one embodiment, sequence xiii) is selected from the group consisting of SEQ ID NO:1-35. In another embodiment, sequence xiii) is selected from the group consisting of SEQ ID NO:1-27. In one embodiment, sequence xiii) is selected from the group consisting of SEQ ID NO:1-10. In one embodiment, sequence xiii) is selected from SEQ ID NO:1-7. In one
 10 embodiment, sequence xiii) is selected from the group consisting of SEQ ID NO:1-4. In one embodiment, sequence xiii) is SEQ ID NO:1.

In one embodiment, the IL-17A binding polypeptide comprises an amino acid sequence selected from:

- 15 xv) AEAKEYAK-[BM]-DPSQSSELLSEAKKLNDSQAPK;
 wherein [BM] is an IL-17A binding motif as defined above; and
 xvi) an amino acid sequence which has at least 86 % identity to the sequence defined in xv).

Again, polypeptides comprising minor changes as compared to the
 20 above amino acid sequences without largely affecting the tertiary structure and the function thereof are also within the scope of the present disclosure. Thus, in some embodiments, the IL-17A binding polypeptides as defined above may for example have a sequence which is at least 87 %, such as at least 89 %, such as at least 91 %, such as at least 93 %, such as at least
 25 94 %, such as at least 96 %, such as at least 98 % identical to the sequence defined by xv).

Sequence xv) in such a polypeptide may be selected from the group consisting of SEQ ID NO:1217-1222. In one embodiment, sequence xv) is selected from the group consisting of SEQ ID NO:1218-1222. In one
 30 embodiment, sequence xv) is selected from the group consisting of SEQ ID NO:1219-1222. In another embodiment, sequence xv) is selected from the group consisting of SEQ ID NO:1219 and SEQ ID NO:1222. In one embodiment, sequence xv) is SEQ ID NO:1219.

35 The small size and robustness of the IL-17A binding domains of the present disclosure confer several advantages over conventional monoclonal antibody based therapies. Such advantages include the possibility of

subcutaneous (s.c.) administration at higher doses than antibodies, alternative routes of administration, flexibility in formatting for superior potency and absence of Fc-mediated side effects. The small size combined with potential for very high solubility (>100 mg/ml) and stability allows for
5 extreme molar amounts of drug in a small volume for s.c. injections. For systemic administration, this suggests outpatient "home use" treatment using convenient small prefilled syringes or auto-injectors, with low volume and well tolerated administration of doses. In addition, the capacity for high molar concentrations in drug preparations in combination with the ability to retain
10 functional stability in diverse formulations opens up for topical (skin, eye, lung) administration routes. Psoriasis, asthma, uveitis and dry eye syndrome are examples of indications where alternative administration routes could be especially relevant in IL-17A mediated disease.

15 The terms "IL-17A binding" and "binding affinity for IL-17A" as used in this specification refer to a property of a polypeptide which may be tested for example by ELISA, by use of surface plasmon resonance (SPR) technology, or by use of the Kinetic Exclusion Assay (KinExA[®]). For example as described in the examples below, IL-17A binding affinity may be tested in an
20 experiment in which samples of the polypeptide are captured on antibody coated ELISA plates and biotinylated IL-17A, followed by streptavidin conjugated HRP, are added. TMB substrate is added and the absorbance at 450 nm is measured using a multi-well plate reader, such as Victor³ (Perkin Elmer). The skilled person may then interpret the results obtained by such
25 experiments to establish at least a qualitative measure of the binding affinity of the polypeptide for IL-17A. If a quantitative measure is desired, for example to determine the EC50 value (the half maximal effective concentration) for the interaction, ELISA may also be used. The response of the polypeptides against a dilution series of biotinylated IL-17A are measured using ELISA as
30 described above. The skilled person may then interpret the results obtained by such experiments and EC50 values may be calculated from the results using for example GraphPad Prism 5 and non-linear regression.

IL-17A binding affinity may also be tested in an experiment in which IL-17A, or a fragment thereof, is immobilized on a sensor chip of the surface
35 plasmon resonance (SPR) instrument, and the sample containing the polypeptide to be tested is passed over the chip. Alternatively, the polypeptide to be tested is immobilized on a sensor chip of the instrument, and a sample

containing IL-17A, or a fragment thereof, is passed over the chip. The skilled person may then interpret the results obtained by such experiments to establish at least a qualitative measure of the binding affinity of the polypeptide for IL-17A. If a quantitative measure is desired, for example to
5 determine a K_D value for the interaction, surface plasmon resonance methods may also be used. Binding values may for example be defined in a Biacore (GE Healthcare) or ProteOn XPR 36 (Bio-Rad) instrument. IL-17A is suitably immobilized on a sensor chip of the instrument, and samples of the polypeptide whose affinity is to be determined are prepared by serial dilution
10 and injected in random order. K_D values may then be calculated from the results using for example the 1:1 Langmuir binding model of the BIAevaluation 4.1 software, or other suitable software, provided by the instrument manufacturer.

Another method for determining binding affinity for IL-17A is the Kinetic
15 Exclusion Assay (KinExA[®]; Sapidyne Instruments Inc, Boise, USA; Darling and Brault, 2004. Assay and Drug Dev Tech 2(6):647-657) for measurements of the equilibrium binding affinity and kinetics between unmodified molecules in solution. For affinity analysis, the equilibrium dissociation constant, K_D , and the rate of association, k_a , are experimentally determined, while the rate of
20 dissociation, k_d , may be calculated based on the equation $k_d = K_D * k_a$.

A KinExA[®] K_D analysis requires immobilization of one interaction partner (e.g. the titrated binding partner) to a solid phase, which is then used as a probe to capture the other interaction partner (e.g. the constant binding partner) free in solution once an equilibrium is reached. For each experiment,
25 a series of solutions with a constant concentration of one binding partner and a titration of the other binding partner are equilibrated. The solutions are then briefly exposed to the solid phase and a portion of free constant binding partner is captured and labeled with a fluorescent secondary molecule. The short contact time with the solid phase is less than the time needed for
30 dissociation of the pre-formed complex in solution, meaning that competition between the solution and the solid phase titrated binding partner is "kinetically excluded". Since the solid phase is only used as a probe for the free constant binding partner in each sample, the solution equilibrium is not altered during measurements. A K_D value is calculated from signals generated from
35 captured free constant binding partner, which are directly proportional to the concentration of free constant binding partner in the equilibrated sample. The data may be analyzed using the KinExA[®] Pro software and least squares

analysis to fit the optimal solutions for the K_D and the Active Binding site Concentration (ABC) to a curve representative of a stoichiometric relevant model, for instance a 1:1 reversible bi-molecular interaction.

Determination of binding kinetics may be done in a similar format as the equilibrium analysis, except measurements are collected “pre-equilibrium” and the binding signals are a function of time and total concentration of the titrated binding partner. There are two methods that can be used to determine the k_a . The “direct method” holds the concentrations of titrated and constant binding partners fixed, and the solution is probed over time. The amount of the free constant binding partner in the solution will decrease as the sample moves toward equilibrium. The “inject method” holds incubation time and one partner’s concentration fixed, while titrating concentrations of the other partner. As the concentration of the titrated binding partner increases, the amount of free constant binding partner will decrease as more complexes are formed.

In one embodiment, the IL-17A binding polypeptide is capable of binding to IL-17A such that the K_D value of the interaction is at most 1×10^{-6} M, such as at most 1×10^{-7} M, such as at most 1×10^{-8} M, such as at most 1×10^{-9} M.

In one embodiment, an IL-17A binding polypeptide according to any aspect disclosed herein is capable of binding to an IL-17A molecule selected from the group consisting of human IL-17A and murine IL-17A. In one embodiment, the IL-17A binding polypeptide is capable of binding to human IL-17A. In one embodiment, the IL-17A binding polypeptide is capable of binding to murine IL-17A. In one embodiment, the IL-17A binding polypeptide is capable of binding to human IL-17A and to murine IL-17A. In this regard, human IL-17A may comprise the amino acid sequence SEQ ID NO:1226, or an antigenically effective fragment thereof. Likewise, murine IL-17A may comprise the amino acid sequence SEQ ID NO:1227, or an antigenically effective fragment thereof.

The skilled person will understand that various modifications and/or additions can be made to an IL-17A binding polypeptide according to any aspect disclosed herein in order to tailor the polypeptide to a specific application without departing from the scope of the present disclosure.

For example, in one embodiment, there is provided an IL-17A binding polypeptide as described herein, which polypeptide has been extended by and/or comprises additional amino acids at the C terminus and/or N terminus. Such a polypeptide should be understood as a polypeptide having one or
5 more additional amino acid residues at the very first and/or the very last position in the polypeptide chain, i.e. at the N- and/or C-terminus of sequence i) or ii). Thus, an IL-17A binding polypeptide may comprise any suitable number of additional amino acid residues, for example at least one additional amino acid residue. Each additional amino acid residue may individually or
10 collectively be added in order to, for example, improve and/or simplify production, purification, stabilization *in vivo* or *in vitro*, coupling or detection of the polypeptide. Such additional amino acid residues may comprise one or more amino acid residues added for the purpose of chemical coupling. One example of this is the addition of a cysteine residue. Additional amino acid
15 residues may also provide a "tag" for purification or detection of the polypeptide, such as a His₆ tag, a (HisGlu)₃ tag ("HEHEHE" tag) or a "myc" (c-myc) tag or a "FLAG" tag for interaction with antibodies specific to the tag or immobilized metal affinity chromatography (IMAC) in the case of the His₆-tag.

The further amino acids as discussed above may be coupled to the IL-
20 17A binding polypeptide by means of chemical conjugation (using known organic chemistry methods) or by any other means, such as expression of the IL-17A binding polypeptide as a fusion protein or joined in any other fashion, either directly or via a linker, for example an amino acid linker.

The further amino acids as discussed above may for example
25 comprise one or more polypeptide domain(s). A further polypeptide domain may provide the IL-17A binding polypeptide with another function, such as for example yet another binding function, an enzymatic function, a toxic function, a fluorescent signaling function or combinations thereof.

A further polypeptide domain may moreover provide another IL-17A
30 binding moiety with the same IL-17A binding function. Thus, in a further embodiment, there is provided an IL-17A binding polypeptide in a multimeric form. Said multimer is understood to comprise at least two IL-17A binding polypeptides as disclosed herein as monomer units, the amino acid sequences of which may be the same or different. Multimeric forms of the
35 polypeptides may comprise a suitable number of domains, each having an IL-17A binding motif, and each forming a monomer within the multimer. These domains may have the same amino acid sequence, but alternatively, they

may have different amino acid sequences. In other words, the IL-17A binding polypeptide of the invention may form homo- or heteromultimers, for example homo- or heterodimers. In one embodiment, there is provided an IL-17A binding polypeptide, wherein said monomeric units are covalently coupled
5 together. In another embodiment, said IL-17A binding polypeptide monomer units are expressed as a fusion protein. In one embodiment, there is provided an IL-17A binding polypeptide in dimeric form.

Additionally, "heterogenic" fusion polypeptides or proteins, or conjugates, in which an IL-17A binding polypeptide described herein, or
10 multimer thereof, constitutes a first domain, or first moiety, and the second and further moieties have other functions than binding IL-17A, are also contemplated and fall within the ambit of the present disclosure. The second and further moiety/moieties of the fusion polypeptide or conjugate in such a protein suitably have a desired biological activity.

15

Thus, in a second aspect of the present disclosure, there is provided a fusion protein or a conjugate, comprising a first moiety consisting of an IL-17A binding polypeptide according to the first aspect, and a second moiety consisting of a polypeptide having a desired biological activity. In another
20 embodiment, said fusion protein or conjugate may additionally comprise further moieties, comprising desired biological activities that can be either the same or different from the biological activity of the second moiety.

Non-limiting examples of a desired biological activity comprise a
25 therapeutic activity, a binding activity and an enzymatic activity.

In one embodiment, the second moiety having a desired biological activity is a therapeutically active polypeptide.

Non-limiting examples of therapeutically active polypeptides are
30 biomolecules, such as molecules selected from the group consisting of human endogenous enzymes, hormones, growth factors, chemokines, cytokines and lymphokines. Non-limiting examples of contemplated cytokines are IL-2, IL-4, IL-7, IL-10, IL-11, IL-13, IL-21, IL-27, IL-35, IFN β and TGF β . Non-limiting examples of contemplated chemokines are SDF-1/CXCL12,
35 BCL/BCA-1/CXCL13, CXCL16, HCC1/CCL14, TARC/CCL17, PARC/CCL18, MIP-3 β /ELC/CCL19, SLC/CCL21, CCL25/TECK and CCL27/CTACK.

Non-limiting examples of binding activities are binding activities which increase the *in vivo* half-life of the fusion protein or conjugate. In one particular embodiment, said binding activity is an albumin binding activity which increases the *in vivo* half-life of the fusion protein or conjugate. In one
5 embodiment, said albumin binding activity is provided by the albumin binding domain of streptococcal protein G or a derivative thereof. In another particular embodiment, said binding activity is an FcRn binding activity which increases the *in vivo* half-life of the fusion protein or conjugate.

In one embodiment, the fusion protein or conjugate of this second
10 aspect comprises two monomers of the IL-17A binding polypeptide of the first aspect, whose amino acid sequences may be the same or different, linked by an albumin binding moiety. In a specific embodiment of this construct, the fusion protein or conjugate comprises two IL-17A binding monomers with an albumin binding moiety between them. Said albumin binding moiety may e.g.
15 be a “GA” albumin binding domain from streptococcal protein G, such as “GA3”, or a derivative thereof as described in any one of WO2009/016043, WO2012/004384, WO2014/048977 and WO2015/091957.

In one embodiment, the format of such a fusion protein or conjugate is “Z-A-Z”, where each “Z” individually is an IL-17A binding polypeptide as
20 described herein, and “A” is an albumin binding domain. In one embodiment, such an IL-17A binding polypeptide with the “Z-A-Z” format is capable of binding to IL-17A such that the K_D value of the interaction is at most 1×10^{-10} M, such as at most 1×10^{-11} M, such as at most 1×10^{-12} M, such as at most 1×10^{-13} M. In one embodiment, such a “Z-A-Z” polypeptide
25 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1233-1247, for example selected from the group consisting of SEQ ID NO:1236, 1237 and 1242-1247, such as selected from the group consisting of SEQ ID NO:1236, 1244 and 1247 or the group consisting of SEQ ID NO:1237, 1244 and 1247. In an even more specific embodiment, the
30 “Z-A-Z” polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1244 and 1245. In one embodiment, the “Z-A-Z” polypeptide comprises SEQ ID NO:1244.

In one embodiment, said binding activity is binding to an angiogenesis
35 associated factor. Non-limiting examples of angiogenesis associated factors include fibroblast growth factor (FGF), fibroblast growth factor 1 (FGF-1), basic FGF, angiogenin 1 (Ang-1), angiogenin 2 (Ang-2), angiopoietin 1

(Angpt-1), angiopoietin 2 (Angpt-2), angiopoietin 3 (Angpt-3), angiopoietin 4 (Angpt-4), tyrosine kinase with immunoglobulin-like domains 1 (TIE-1), tyrosine kinase with immunoglobulin-like domains 2 (TIE-2), vascular endothelial growth factor receptor 1 (VEGFR-1), vascular endothelial growth factor receptor 2 (VEGFR-2), vascular endothelial growth factor receptor 3 (VEGFR-3), vascular endothelial growth factor A (VEGF-A), vascular endothelial growth factor B (VEGF-B), vascular endothelial growth factor C (VEGF-C), vascular endothelial growth factor D (VEGF-D), vascular endothelial growth factor E (VEGF-E), placental growth factor (PIGF), transforming growth factor β 1 (TGF- β 1), transforming growth factor β 2 (TGF- β 2), transforming growth factor β receptors (type I, type II and type III), matrix metalloproteinase (MMP), MET receptor tyrosine kinase (also denoted cMET and hepatocyte growth factor receptor (HGFR)), members of the Notch family of receptors and beta-catenin.

In one embodiment, said binding activity is binding to an immune response associated factor. Non-limiting examples of immune response associated factors include

- T-cell regulatory factors such as CD3, CD4, CD6, CD28, T-cell receptor α (TCR α), T-cell receptor β (TCR β), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), programmed death-ligand 2 (PD-L2), B7 homolog 3 (B7-H3), B7 homolog 4 (B7-H4), herpes virus entry mediator (HVEM)/B- and T-lymphocyte attenuator (BTLA), killer inhibitory receptor (KIR), lymphocyte-activation gene 3 (LAG3), galectin-9 (Gal9)/T cell immunoglobulin mucin-3 (TIM3) and adenosine/alpha-2 adrenergic receptors (A2aR);

- NK-cell recruitment factors such as CD16, natural killer cell lectin-like receptor gene 2D product (NKG2D), lymphocyte function-associated antigen 1 (LFA1) and the natural cytotoxicity receptors NKp30 and NKp40;

- inflammation-associated factors such as

- cytokines and their receptors, including tumor necrosis factors (TNF); tumor necrosis factor ligand super family (TNFSF) members TNFSF11/RANKL, TNFSF12/TWEAK, TNFSF13, TNFSF13B/BAFF/BLys, TNFSF14, TNFSF15; interleukins (IL) IL-1 α , IL-1 β , IL-2, IL-5, IL-6, IL-10, IL-12, IL-17B, IL-17C, IL-17D, IL-17E, IL-17F, IL-18, IL-22, IL-23, IL-26, IL-32, IL33 and IL-34; interferons INF α

and INF γ ; granulocyte colony-stimulating factor (GCSF), granulocyte colony-stimulating factor (GM-CSF); and

- inflammatory chemokines and their receptors, including IL-8/CXCL8, ENA-78/CXCL5, GRO α /CXCL1, CTAP-III/CXCL7, IP-10/CXCL10, Mig/CXCL9, PF4/CXCL4, GCP-2/CXCL6, MCP-1/CCL2, MIP-1 α /CCL3, MIP-3 α /CCL20, RANTES/CCL5, lymphotactin/XCL1 and fractalkine/CX3CL1.

In particularly selected embodiments, the binding activity of said second moiety is binding to a target selected from the group consisting of TNF, IL-1 β , IL-6, IL-17F and IL-23.

In one embodiment of either the first or second aspect of the present disclosure, there is provided an IL-17A binding polypeptide, fusion protein or conjugate which comprises an immune response modifying agent. Non-limiting examples of such immune response modifying agents include immunosuppressive or immunomodulating agents or other anti-inflammatory agents. For example, an IL-17A binding polypeptide, fusion protein or conjugate as described herein may comprise an agent selected from the group consisting of disease-modifying antirheumatic drugs (DMARDs), such as gold salts, azathioprine, methotrexate and leflunomide; calcineurin inhibitors, such as cyclosporin A or FK 506; modulators of lymphocyte recirculation; mTOR inhibitors, such as rapamycin; an ascomycin having immunosuppressive properties; glucocorticoids; corticosteroids; cyclophosphamide; immunosuppressive monoclonal antibodies, for example monoclonal antibodies with affinity for leukocyte receptors such as MHC, CD2, CD3, CD4, CD7, CD8, CD25, CD28, CD40, CD45, CD58, CD80, CD86 or their ligands; adhesion molecule inhibitors, such as LFA-1 antagonists, ICAM-1 or -3 antagonists, VCAM-4 antagonists or VLA-4 antagonists; anti-TNF agents, such as etanercept and monoclonal antibodies to TNF such as infliximab and adalimumab; inhibitors of proinflammatory cytokines; IL-1 blockers such as anakinra or IL-1 trap; IL-6 blockers; chemokine inhibitors; non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin; and anti-infectious agents and other immune response modulating agents; as well as combinations of any two or more of the above.

In one embodiment of either the first or second aspect of the present disclosure, there is provided an IL-17A binding polypeptide, fusion protein or

conjugate which comprises a toxic compound. Non-limiting examples of such toxic compounds include calicheamicin, maytansinoid, neocarzinostatin, esperamicin, dynemicin, kedarcidin, maduropeptin, doxorubicin, daunorubicin, auristatin, ricin-A chain, modeccin, truncated *Pseudomonas* exotoxin A, diphtheria toxin and recombinant gelonin.

Recently, considerable progress has been made in the development of multispecific agents, such as antibodies with the ability to bind to more than one antigen, for example through engineering of the complementarity determining regions (CDRs) to address two antigens in a single antibody combining site (Bostrom *et al*, 2009, Science 323(5921):1610-1614; Schaefer *et al*, 2011, Cancer Cell 20(4):472-486), via construction of heterodimeric antibodies using engineered Fc units (Carter, 2001, J Immunol Methods 248(1-2):7-15; Schaefer *et al*, 2011, Proc Natl Acad Sci USA 108(27):11187-11192) and via genetic fusion of auxiliary recognition units to N- or C-termini of light or heavy chains of full-length antibodies (Kanakaraj *et al*, 2012, MAbs 4(5):600-613; LaFleur *et al*, 2013, MAbs 5(2):208-218).

As discussed above, it may be beneficial for a polypeptide with affinity for IL-17A as disclosed herein to also exhibit affinity for another factor, such as an immune response associated factor, for example an inflammation-associated factor.

Thus, in a third aspect of the present disclosure, there is provided a complex comprising at least one IL-17A binding polypeptide as defined herein and at least one antibody or an antigen binding fragment thereof.

When used herein to denote the third aspect of the disclosure, the term “complex” is intended to refer to two or more associated polypeptide chains, one having an affinity for IL-17A by virtue of its IL-17A binding motif as defined above, and the other being an antibody or an antigen binding fragment thereof. These polypeptide chains may each contain different protein domains, as described amply above for the IL-17A binding polypeptide of the first and second aspects, and the resulting multiprotein complex can have multiple functions. “Complex” intends to refer to two or more polypeptides as defined herein, connected by covalent bonds, for example two or more polypeptide chains connected by covalent bonds through expression thereof as a recombinant fusion protein, or associated by chemical conjugation.

The third aspect provides a complex comprising an antibody or an antigen binding fragment thereof. As is well known, antibodies are immunoglobulin molecules capable of specific binding to a target (an antigen), such as a carbohydrate, polynucleotide, lipid, polypeptide or other, through at least one antigen recognition site located in the variable region of the immunoglobulin molecule. As used herein, the term “antibody or an antigen binding fragment thereof” encompasses not only full-length or intact polyclonal or monoclonal antibodies, but also antigen-binding fragments thereof, such as Fab, Fab', F(ab')₂, Fab₃, Fv and variants thereof, fusion proteins comprising one or more antibody portions, humanized antibodies, chimeric antibodies, minibodies, diabodies, triabodies, tetrabodies, linear antibodies, single chain antibodies, multispecific antibodies (e.g. bispecific antibodies) and any other modified configuration of the immunoglobulin molecule that comprises an antigen recognition site of the required specificity, including glycosylation variants of antibodies, amino acid sequence variants of antibodies and covalently modified antibodies. Further examples of modified antibodies and antigen binding fragments thereof include nanobodies, AlbuDabs, DARTs (dual affinity re-targeting), BiTEs (bispecific T-cell engager), TandAbs (tandem diabodies), DAFs (dual acting Fab), two-in-one antibodies, SMIPs (small modular immunopharmaceuticals), FynomAbs (fynomers fused to antibodies), DVD-Igs (dual variable domain immunoglobulin), CovX-bodies (peptide modified antibodies), duobodies and triomAbs. This listing of variants of antibodies and antigen binding fragments thereof is not to be seen as limiting, and the skilled person is aware of other suitable variants.

A full-length antibody comprises two heavy chains and two light chains. Each heavy chain contains a heavy chain variable region (V_H) and first, second and third constant regions (C_H1, C_H2 and C_H3). Each light chain contains a light chain variable region (V_L) and a light chain constant region (C_L). Depending on the amino acid sequence of the constant domain of its heavy chains, antibodies are assigned to different classes. There are six major classes of antibodies: IgA, IgD, IgE, IgG, IgM and IgY, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2. The term “full-length antibody” as used herein refers to an antibody of any class, such as IgD, IgE, IgG, IgA, IgM or IgY (or any sub-class thereof). The subunit structures and three-dimensional configurations of different classes of antibodies are well known.

An “antigen binding fragment” is a portion or region of an antibody molecule, or a derivative thereof, that retains all or a significant part of the antigen binding of the corresponding full-length antibody. An antigen binding fragment may comprise the heavy chain variable region (V_H), the light chain variable region (V_L), or both. Each of the V_H and V_L typically contains three complementarity determining regions CDR1, CDR2 and CDR3. The three CDRs in V_H or V_L are flanked by framework regions (FR1, FR2, FR3 and FR4). As briefly listed above, examples of antigen binding fragments include, but are not limited to: (1) a Fab fragment, which is a monovalent fragment having a V_L - C_L chain and a V_H - C_H1 chain; (2) a Fab' fragment, which is a Fab fragment with the heavy chain hinge region, (3) a $F(ab')_2$ fragment, which is a dimer of Fab' fragments joined by the heavy chain hinge region, for example linked by a disulfide bridge at the hinge region; (4) an Fc fragment; (5) an Fv fragment, which is the minimum antibody fragment having the V_L and V_H domains of a single arm of an antibody; (6) a single chain Fv (scFv) fragment, which is a single polypeptide chain in which the V_H and V_L domains of an scFv are linked by a peptide linker; (7) an $(scFv)_2$, which comprises two V_H domains and two V_L domains, which are associated through the two V_H domains via disulfide bridges and (8) domain antibodies, which can be antibody single variable domain (V_H or V_L) polypeptides that specifically bind antigens.

Antigen binding fragments can be prepared via routine methods. For example, $F(ab')_2$ fragments can be produced by pepsin digestion of a full-length antibody molecule, and Fab fragments can be generated by reducing the disulfide bridges of $F(ab')_2$ fragments. Alternatively, fragments can be prepared via recombinant technology by expressing the heavy and light chain fragments in suitable host cells (e.g., *E. coli*, yeast, mammalian, plant or insect cells) and having them assembled to form the desired antigen-binding fragments either *in vivo* or *in vitro*. A single-chain antibody can be prepared via recombinant technology by linking a nucleotide sequence coding for a heavy chain variable region and a nucleotide sequence coding for a light chain variable region. For example, a flexible linker may be incorporated between the two variable regions. The skilled person is aware of methods for the preparation of both full-length antibodies and antigen binding fragments thereof.

Thus, in one embodiment, this aspect of the disclosure provides a complex as defined herein, wherein said at least one antibody or antigen

binding fragment thereof is selected from the group consisting of full-length antibodies, Fab fragments, Fab' fragments, F(ab')₂ fragments, Fc fragments, Fv fragments, single chain Fv fragments, (scFv)₂ and domain antibodies. In one embodiment, said at least one antibody or antigen
5 binding fragment thereof is selected from full-length antibodies, Fab fragments and scFv fragments. In one particular embodiment, said at least one antibody or antigen binding fragment thereof is a full-length antibody.

In one embodiment of said complex as defined herein, the antibody or antigen binding fragment thereof is selected from the group consisting of
10 monoclonal antibodies, human antibodies, humanized antibodies, chimeric antibodies, and antigen-binding fragments thereof.

The term "monoclonal antibodies" as used herein refers to antibodies having monovalent affinity, meaning that each antibody molecule in a sample of the monoclonal antibody binds to the same epitope on the antigen,
15 whereas the term "polyclonal antibodies" as used herein refers to a collection of antibodies that react against a specific antigen, but in which collection there may be different antibody molecules for example identifying different epitopes on the antigen. Polyclonal antibodies are typically produced by inoculation of a suitable mammal and are purified from the mammal's serum. Monoclonal
20 antibodies are made by identical immune cells that are clones of a unique parent cell (for example a hybridoma cell line). The term "human antibody" as used herein refers to antibodies having variable and constant regions corresponding substantially to, or derived from, antibodies obtained from human subjects. The term "chimeric antibodies" as used herein, refers to
25 recombinant or genetically engineered antibodies, such as for example mouse monoclonal antibodies, which contain polypeptides or domains from a different species, for example human, introduced to reduce the antibodies' immunogenicity. The term "humanized antibodies" refers to antibodies from non-human species whose protein sequences have been modified to
30 increase their similarity to antibody variants produced naturally in humans, in order to reduce immunogenicity.

It may be beneficial for a complex as defined herein to, in addition to being capable of binding IL-17A, target at least one additional antigen, such as an antigen selected from the group consisting of an antigen associated
35 with an angiogenesis related disorder and an antigen associated with the immune response. In one embodiment, said additional antigen is associated

with angiogenesis. In one embodiment, said additional antigen is associated with the immune response.

In one embodiment, the antigen is associated with angiogenesis and is selected from the group consisting of fibroblast growth factor (FGF), fibroblast growth factor 1 (FGF-1), basic FGF, angiogenin 1 (Ang-1), angiogenin 2 (Ang-2), angiopoietin 1 (Angpt-1), angiopoietin 2 (Angpt-2), angiopoietin 3 (Angpt-3), angiopoietin 4 (Angpt-4), tyrosine kinase with immunoglobulin-like domains 1 (TIE-1), tyrosine kinase with immunoglobulin-like domains 2 (TIE-2), vascular endothelial growth factor receptor 1 (VEGFR-1), vascular endothelial growth factor receptor 2 (VEGFR-2), vascular endothelial growth factor receptor 3 (VEGFR-3), vascular endothelial growth factor A (VEGF-A), vascular endothelial growth factor B (VEGF-B), vascular endothelial growth factor C (VEGF-C), vascular endothelial growth factor D (VEGF-D), vascular endothelial growth factor E (VEGF-E), placental growth factor (PIGF), transforming growth factor β 1 (TGF- β 1), transforming growth factor β 2 (TGF- β 2), transforming growth factor β receptors (type I, type II and type III), matrix metalloproteinase (MMP), MET receptor tyrosine kinase (also denoted cMET and hepatocyte growth factor receptor (HGFR)), members of the Notch family of receptors and beta-catenin. In one embodiment, said antibody or fragment thereof is selected from the group consisting of AMG 780, AMG 386, MEDI-3617, nesvacumab, CVX-241, bevacizumab, ranibizumab, VGX100, CVX-241, ABP 215, PF-06439535, fresolimumab, metelimumab, onartuzumab, emibetuzumab and tarextumab.

In one embodiment, the antigen is associated with the immune response or a disorder of the immune system, and is selected from the group consisting of

- T-cell regulatory factors such as CD3, CD4, CD6, CD28, T-cell receptor α (TCR α), T-cell receptor β (TCR β), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), programmed death-ligand 2 (PD-L2), B7 homolog 3 (B7-H3), B7 homolog 4 (B7-H4), herpes virus entry mediator (HVEM)/B- and T-lymphocyte attenuator (BTLA), killer inhibitory receptor (KIR), lymphocyte-activation gene 3 (LAG3), galectin-9 (Gal9)/T cell immunoglobulin mucin-3 (TIM3) and adenosine/alpha-2 adrenergic receptors (A2aR);

- NK-cell recruitment factors such as CD16, natural killer cell lectin-like receptor gene 2D product (NKG2D), lymphocyte function-associated antigen 1 (LFA1) and the natural cytotoxicity receptors NKp30 and NKp40;

- inflammation-associated factors such as

- 5 • cytokines and their receptors, including tumor necrosis factors (TNF); tumor necrosis factor ligand super family (TNFSF) members TNFSF11/RANKL, TNFSF12/TWEAK, TNFSF13, TNFSF13B/BAFF/BLys, TNFSF14, TNFSF15; interleukins (IL) IL-1 α , IL-1 β , IL-2, IL-5, IL-6, IL-10, IL-12, IL-17B, IL-17C, IL-17D, IL-17E, IL-17F, IL-18, IL-22, IL-23, IL-26, IL-32, IL33 and IL-34; interferons INF α and INF γ ; granulocyte colony-stimulating factor (GCSF), granulocyte colony-stimulating factor (GM-CSF); and
- 10 • inflammatory chemokines and their receptors, including IL-8/CXCL8, ENA-78/CXCL5, GRO α /CXCL1, CTAP-III/CXCL7, IP-10/CXCL10, Mig/CXCL9, PF4/CXCL4, GCP-2/CXCL6, MCP-1/CCL2, MIP-1 α /CCL3, MIP-3 α /CCL20, RANTES/CCL5, lymphotactin/XCL1 and fractalkine/CX3CL1.
- 15

20 In one embodiment, the antigen is selected from the group consisting of TNF, IL-1 β , IL-6, IL-17F and IL-23.

 In one embodiment, said antibody or fragment thereof is selected from the group consisting of visilizumab, orelizumab, ipilimumab, tremelimumab, pembrolizumab, nivolumab, pidilizumab, MPDL3280A, MEDI-4736, MPDL3280A and lirilumab, and antigen-binding fragments thereof.

25 In one particular embodiment, said antigen is TNF. In one embodiment, said antibody or fragment thereof is selected from the group consisting of adalimumab, infliximab, golimumab, certolimumab pegol, and antigen binding fragments thereof. In another embodiment said antibody or fragment thereof is a full-length antibody selected from the group consisting of adalimumab, infliximab, golimumab and certolimumab pegol. In one particular embodiment, said antibody or antigen binding fragment thereof is adalimumab or an antigen binding fragment thereof, for example full-length adalimumab.

30

 The complex as described herein may for example be present in the form of a fusion protein or a conjugate. Thus, said at least one IL-17A binding polypeptide and said at least one antibody, or antigen binding fragment thereof, may be coupled by means of chemical conjugation (using known

35

organic chemistry methods) or by any other means, such as expression of the complex as a fusion protein or joined in any other fashion, either directly or via a linker, for example an amino acid linker.

Thus, in one embodiment, there is provided a complex as defined
5 herein, wherein said complex is a fusion protein or a conjugate. In one embodiment, said complex is a fusion protein. In another embodiment, said complex is a conjugate. In one embodiment of said complex, said IL-17A binding polypeptide is attached to the N-terminus or C-terminus of the heavy chain of said antibody or antigen binding fragment thereof. In another
10 embodiment, said IL-17A binding polypeptide is attached to the N-terminus or C-terminus of the light chain of said antibody or antigen binding fragment thereof. In one embodiment, said IL-17A binding polypeptide is attached to the N-terminus and/or C-terminus of the light chain and heavy chain of said antibody or antigen binding fragment thereof. For example, the IL-17A binding
15 polypeptide may be attached to only the N-terminus of the heavy chain(s), only the N-terminus of the light chain(s), only the C-terminus of the heavy chain(s), only the C-terminus of the light chain(s), both the N-terminus and the C-terminus of the heavy chain(s), both the N-terminus and the C-terminus of the light chain(s), only the C-terminus of the light chain(s) and the N-terminus
20 of the heavy chain(s), only the C-terminus of the heavy chain(s) and the N-terminus of the light chain(s), of said antibody or antigen binding fragment thereof.

As the skilled person understands, the construction of a fusion protein
25 often involves use of linkers between functional moieties to be fused. The skilled person is aware of different kinds of linkers with different properties, such as flexible amino acid linkers, rigid amino acid linkers and cleavable amino acid linkers. Linkers have been used to for example increase stability or improve folding of fusion proteins, to increase expression, improve
30 biological activity, affinity and/or binding, enable targeting and alter pharmacokinetics of fusion proteins. Thus, in one embodiment, the IL-17A binding polypeptide, fusion protein, conjugate or complex as defined herein further comprises at least one linker. The linker may for example be selected from the group consisting of flexible amino acid linkers, rigid amino acid
35 linkers and cleavable amino acid linkers. Alternatively, the linker may be a non-peptidic linker. In one embodiment of a fusion protein or conjugate as disclosed herein, said linker is arranged between a first moiety consisting of

an IL-17A binding polypeptide as defined herein and a second moiety consisting of a polypeptide having a desired biological activity. In one embodiment of a complex as disclosed herein, said linker is arranged between said IL-17A binding polypeptide and said antibody or antigen binding
 5 fragment thereof. The skilled person will appreciate that the presence of linker arranged in any of above mentioned contexts does not exclude the presence of additional linkers in the same or any other context.

Flexible linkers are often used when the joined domains require a
 10 certain degree of movement or interaction, and may be particularly useful in some embodiments of the IL-17A binding polypeptide, fusion protein, conjugate or complex as defined herein. Such linkers are generally composed of small, non-polar (for example G) or polar (for example S or T) amino acids. Some flexible linkers primarily consist of stretches of G and S residues, for
 15 example (GGGGS)_p and (SSSSG)_p. Adjusting the copy number “p” allows for optimization of the linker in order to achieve appropriate separation between the functional moieties or to maintain necessary inter-moiety interaction. Apart from G and S linkers, other flexible linkers are known in the art, such as G and S linkers containing additional amino acid residues, such as T, A, K and
 20 E, to maintain flexibility, as well as polar amino acid residues to improve solubility.

In one embodiment, said linker is a flexible linker comprising glycine (G), serine (S) and/or threonine (T) residues. In one embodiment, said linker comprises a sequence with a general formula selected from (G_nS_m)_p and
 25 (S_nG_m)_p, wherein, independently, n = 1-7, m = 0-7, n + m ≤ 8 and p = 1-10. In one embodiment, n = 1-5. In one embodiment, m = 0-5. In one embodiment, p = 1-5. In a more specific embodiment, n = 4, m = 1 and p = 1-4.

In one embodiment, said linker comprises a sequence selected from the group consisting of G₄S, (G₄S)₂, (G₄S)₃ and (G₄S)₄.

30 In one embodiment, said linker comprises a sequence with the general formula GT(G_nS_m)_p, wherein, independently, n = 1-7, m = 0-7, n + m ≤ 8 and p = 1-10. In one embodiment, n = 1-5. In one embodiment, m = 0-5. In one embodiment, p = 1-5. In a more specific embodiment, n = 4, m = 1 and p = 1-4. Thus, in one embodiment wherein n = 4, said linker comprises GT(G₄S)_p.
 35 In one specific embodiment, n = 4 and p = 1, so that said linker comprises GTG₄S. In one embodiment, said linker comprises a sequence selected from the group consisting of GT(G₄S)_pTS, GT(G₄S)_pPR and GT(G₄S)_pPK.

In one embodiment, said linker comprises a sequence with the general formula $\text{GAP}(\text{G}_n\text{S}_m)_p$, wherein, independently, $n = 1-7$, $m = 0-7$, $n + m \leq 8$ and $p = 1-10$. In one embodiment, $n = 1-5$. In one embodiment, $m = 0-5$. In one embodiment, $p = 1-5$. In a more specific embodiment, $n = 4$, $m = 1$ and $p = 1-4$. Thus, in one embodiment wherein $n = 4$, said linker comprises $\text{GAP}(\text{G}_4\text{S})_p$. In one specific embodiment, $n = 4$ and $p = 1$, so that said linker comprises GAPG_4S . In one embodiment, said linker comprises a sequence selected from the group consisting of $\text{GAP}(\text{G}_4\text{S})_p\text{TS}$, $\text{GAP}(\text{G}_4\text{S})_p\text{PR}$ and $\text{GAP}(\text{G}_4\text{S})_p\text{PK}$.

10 In one embodiment, said linker comprises a sequence selected from the group consisting of $\text{KL}(\text{G}_4\text{S})_p$, $\text{LQ}(\text{G}_4\text{S})_p$ and $\text{YV}(\text{G}_4\text{S})_p\text{PK}$. In one embodiment, said linker comprises a sequence selected from the group consisting of S_4G , $(\text{S}_4\text{G})_3$, $(\text{S}_4\text{G})_4$ and $(\text{S}_4\text{G})_8$. In one embodiment, said linker comprises a sequence selected from the group consisting of VDGS , ASGS and VEGS . In a specific embodiment, said linker comprises ASGS .

With regard to the description above of fusion proteins, conjugates or complexes incorporating an IL-17A binding polypeptide according to the disclosure, it is to be noted that the designation of first, second and further
20 moieties is made for clarity reasons to distinguish between IL-17A binding polypeptide or polypeptides according to the invention on the one hand, and moieties exhibiting other functions on the other hand. These designations are not intended to refer to the actual order of the different domains in the polypeptide chain of the fusion protein, conjugate or complex. Thus, for
25 example, said first moiety may without restriction appear at the N-terminal end, in the middle, or at the C-terminal end of the fusion protein, conjugate or complex.

The disclosure furthermore encompasses polypeptides in which the IL-
30 17A binding polypeptide according to the first aspect, the IL-17A binding polypeptide as comprised in a fusion protein or conjugate according to the second aspect or in a complex according to the third aspect, further comprises a label, such as a label selected from the group consisting of fluorescent dyes and metals, chromophoric dyes, chemiluminescent
35 compounds and bioluminescent proteins, enzymes, radionuclides and particles. Such labels may for example be used for detection of the polypeptide.

In embodiments where the labeled IL-17A binding polypeptide comprises an IL-17A binding polypeptide according to the first aspect of the disclosure and a label, this labeled polypeptide may be used for indirect labeling of IL-17A expressing cells, such as cells of inflammation-associated
5 cancers. Non-limiting examples of inflammation-associated cancers include gastric cancers, colorectal cancers, non-small cell lung cancers, hepatocellular carcinomas and adenocarcinomas (Wu et al., 2014 Tumour Biol. 35(6):5347-56; Wu et al., 2012 PLoS One 7(12); Zhang et al. 2012 Asian Pac J Cancer Prev 13(8):3955-60; Liu et al., 2011 Biochem Biophys Res
10 Commun.407(2):348-54).

In other embodiments, the labeled IL-17A binding polypeptide is present as a moiety in a fusion protein, conjugate or complex also comprising a second and possible further moiety having a desired biological activity. The label may in some instances be coupled only to the IL-17A binding
15 polypeptide, and in some instances both to the IL-17A binding polypeptide and to the second moiety of the fusion protein or conjugate and/or the antibody or antigen binding fragment of the complex. Furthermore, it is also possible that the label may be coupled to a second moiety, or antibody or antigen binding fragment thereof only and not to the IL-17A binding moiety.
20 Hence, in yet another embodiment, there is provided an IL-17A binding polypeptide comprising a second moiety, wherein said label is coupled to the second moiety only. In another embodiment, there is provided a complex as defined herein, wherein said label is coupled to the antibody or antigen binding fragment thereof only.

25

In one embodiment, said IL-17A binding polypeptide, fusion protein, conjugate or complex as described herein comprises a chelating environment provided by a polyaminopolycarboxylate chelator conjugated to the IL-17A binding polypeptide via a thiol group of a cysteine residue or an amine group
30 of a lysine residue.

In embodiments where the IL-17A binding polypeptide, fusion protein, conjugate or complex is radiolabeled, such a radiolabeled polypeptide may comprise a radionuclide. A majority of radionuclides have a metallic nature and metals are typically incapable of forming stable covalent bonds with
35 elements presented in proteins and peptides. For this reason, labeling of proteins and peptides with radioactive metals is performed with the use of chelators, i.e. multidentate ligands, which form non-covalent compounds,

called chelates, with the metal ions. In an embodiment of the IL-17A binding polypeptide, fusion protein, conjugate or complex, the incorporation of a radionuclide is enabled through the provision of a chelating environment, through which the radionuclide may be coordinated, chelated or complexed to
5 the polypeptide.

One example of a chelator is the polyaminopolycarboxylate type of chelator. Two classes of such polyaminopolycarboxylate chelators can be distinguished: macrocyclic and acyclic chelators.

In one embodiment, the IL-17A binding polypeptide, fusion protein or
10 conjugate comprises a chelating environment provided by a polyaminopolycarboxylate chelator conjugated to the IL-17A binding polypeptide via a thiol group of a cysteine residue or an epsilon amine group of a lysine residue.

The most commonly used macrocyclic chelators for radioisotopes of
15 indium, gallium, yttrium, bismuth, radioactinides and radiolanthanides are different derivatives of DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid). In one embodiment, a chelating environment of the IL-17A polypeptide, fusion protein, conjugate or complex is provided by DOTA or a derivative thereof. More specifically, in one embodiment, the chelating
20 polypeptides encompassed by the present disclosure are obtained by reacting the DOTA derivative 1,4,7,10-tetraazacyclododecane-1,4,7-tris-acetic acid-10-maleimidoethylacetamide (maleimidomonoamide-DOTA) with said polypeptide.

Additionally, 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) and
25 derivatives thereof may be used as chelators. Hence, in one embodiment, there is provided an IL-17A binding polypeptide, fusion protein, conjugate or complex, wherein the the polyaminopolycarboxylate chelator is 1,4,7-triazacyclononane-1,4,7-triacetic acid or a derivative thereof.

The most commonly used acyclic polyaminopolycarboxylate chelators
30 are different derivatives of DTPA (diethylenetriamine-pentaacetic acid). Hence, polypeptides having a chelating environment provided by diethylenetriaminepentaacetic acid or derivatives thereof are also encompassed by the present disclosure.

35 In one embodiment, said IL-17A binding polypeptide, fusion protein, conjugate or complex as described herein further comprises one or more

polyethylene glycol (PEG) moieties, e.g. in order to improve pharmacokinetic properties of the molecule.

In a fourth aspect of the present disclosure, there is provided a
5 polynucleotide encoding an IL-17A binding polypeptide or a fusion protein as described herein; an expression vector comprising said polynucleotide; and a host cell comprising said expression vector.

Also encompassed by this disclosure is a method of producing a polypeptide or fusion protein as described above, comprising culturing said
10 host cell under conditions permissive of expression of said polypeptide from its expression vector, and isolating the polypeptide.

The IL-17A binding polypeptide of the present disclosure may alternatively be produced by non-biological peptide synthesis using amino acids and/or amino acid derivatives having protected reactive side-chains, the
15 non-biological peptide synthesis comprising

- step-wise coupling of the amino acids and/or the amino acid derivatives to form a polypeptide according to the first aspect having protected reactive side-chains,
- removal of the protecting groups from the reactive side-chains of the
20 polypeptide, and
- folding of the polypeptide in aqueous solution.

It should be understood that the IL-17A binding polypeptide according to the present disclosure may be useful as a therapeutic, diagnostic or
25 prognostic agent in its own right or as a means for targeting other therapeutic or diagnostic agents, with e.g. direct or indirect effects on IL-17A. A direct therapeutic effect may for example be accomplished by inhibiting IL-17A signaling, such as by blocking IL-17A from binding to one or more of its receptors.

30

In another aspect, there is provided a composition comprising an IL-17A binding polypeptide, fusion protein, conjugate or complex as described herein and at least one pharmaceutically acceptable excipient or carrier. In one embodiment, said composition further comprises at least one additional
35 active agent, such as at least two additional active agents, such as at least three additional active agents. Non-limiting examples of additional active agents that may prove useful in such a composition are the therapeutically

active polypeptides, immune response modifying agents and toxic compounds described herein.

The skilled person will appreciate that said IL-17A binding polypeptide, fusion protein, conjugate or complex, or a pharmaceutical composition comprising an anti-IL-17A binding polypeptide, fusion protein, conjugate or complex as described herein may be administered to a subject using standard administration techniques, such as including oral, topical, intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal, sublingual or suppository administration. Thus, in one embodiment there is provided an IL-17A binding polypeptide, fusion protein, conjugate or complex or a pharmaceutical composition as described herein for oral, topical, intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal, sublingual or suppository administration. In one particular embodiment there is provided an IL-17A binding polypeptide, fusion protein, conjugate or complex or a pharmaceutical composition as described herein for oral administration. In another particular embodiment there is provided an IL-17A binding polypeptide, fusion protein, conjugate or complex or a pharmaceutical composition as described herein for topical administration, such as topical administration to the eye.

IL-17A may also serve as a valuable marker to for diagnosis and prognosis of certain cancers, such as inflammation-associated cancers for example gastric cancers, colorectal cancers, non-small cell lung cancers, hepatocellular carcinomas and adenocarcinomas. For example, IL-17 has been linked to the prognosis and poor survival in patients suffering from colorectal carcinoma and hepatocellular carcinoma.

Hence, in another aspect of the present disclosure, there is provided an IL-17A binding polypeptide, fusion protein, conjugate, complex or composition as described herein for use as a medicament, a diagnostic agent or a prognostic agent.

In one embodiment, there is provided an IL-17A binding polypeptide, fusion protein, conjugate, complex or composition as described herein, for use as a medicament to modulate IL-17A function *in vivo*. As used herein, the term "modulate" refers to changing the activity, such as rendering IL-17A function hypomorph, partially inhibiting or fully inhibiting IL-17A function.

Non-limiting examples of IL-17A associated conditions or diseases, wherein the IL-17A binding polypeptides may be useful for treatment, prognosis and/or diagnosis of include arthritis, such as rheumatoid arthritis, arthritis chronica progrediente, arthritis deformans and rheumatic diseases, diseases involving bone loss, inflammatory pain, spondyloarhropathies including ankylosing spondylitis, Reiter syndrome, reactive arthritis, psoriatic arthritis, enteropathic arthritis, pauciarticular rheumatoid arthritis, polyarticular rheumatoid arthritis, systemic onset rheumatoid arthritis, osteoarthritis; hypersensitivity conditions, such as hypersensitivity (including both airways hypersensitivity and dermal hypersensitivity), allergies and responses to allergen exposure; gastrointestinal conditions or diseases, such as autoimmune inflammatory bowel disease (including e.g. ulcerative colitis, Crohn's disease and Irritable Bowel Syndrome), celiac disease (idiopathic sprue), intraperitoneal abscesses and adhesions, primary biliary sclerosis, sclerosing cholangitis, autoimmune hepatitis, viral hepatitis, chronic active hepatitis and *Helicobacter pylori* associated gastritis; ophthalmic conditions and diseases, such as endocrine ophthalmopathy, Graves disease, uveitis (anterior and posterior), keratoconjunctivitis sicca (dry eye disease), vernal keratoconjunctivitis, herpetic stromal keratitis and dry eye disease; nephrological conditions and disease, such as glomerulonephritis (with and without nephrotic syndrome, e.g. including idiopathic nephrotic syndrome or minimal change nephropathy); acute conditions and disease, such as acute and hyperacute inflammatory reactions, septic shock (e.g., endotoxic shock and adult respiratory distress syndrome), meningitis, pneumonia, severe burns, acute infections, septicemia, stroke and ischemia; cachexia (wasting syndrome), such as cachexia associated with morbid TNF release, cachexia consequent to infection, cachexia associated with cancer, cachexia associated with organ dysfunction and AIDS-related cachexia; bone related conditions and diseases, such as diseases of bone metabolism including osteoarthritis, osteoporosis, inflammatory arthritides, bone loss such as age-related bone loss, periodontal disease, loosening of bone implants and bone erosion; juvenile conditions and diseases, such as juvenile rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, juvenile ankylosing spondylitis, juvenile enteropathic arthritis, juvenile reactive arthritis, juvenile Reiter's Syndrome, SEA Syndrome (Seronegativity, Enthesopathy, Arthropathy Syndrome), juvenile dermatomyositis, juvenile

psoriatic arthritis, juvenile scleroderma, juvenile systemic lupus erythematosus and juvenile vasculitis; vasculitis including vasculitis of large vessels, such as Polymyalgia rheumatica, Takayasu's arteritis and Temporal arteritis, vasculitis of medium vessels, such as Buerger's disease, Cutaneous
5 vasculitis, Kawasaki disease and Polyarteritis nodosa, vasculitis of small vessels, such as Behçet's syndrome, Churg–Strauss syndrome, cutaneous vasculitis, Henoch–Schönlein purpura, microscopic polyangiitis, Wegener's granulomatosis and Golfer's vasculitis, vasculitis of variable vessels and arteritis; dermatological conditions or diseases, such as psoriasis, plaque
10 psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, dermatitis and atopic dermatitis; pulmonary conditions and diseases, such as obstructive or inflammatory airways diseases, asthma, bronchitis, COPD, pneumoconiosis, pulmonary emphysema, acute and hyperacute inflammatory reactions, interstitial lung
15 fibrosis, airway inflammation and bronchial asthma; metabolic conditions and diseases, such as atherosclerosis, dyslipidemia and Type I diabetes mellitus; as well as other systemic autoimmune conditions and diseases, such as systemic lupus erythematosus (SLE), lupus nephritis, polychondritis, myasthenia gravis, Steven-Johnson syndrome, tumors, myositis,
20 dermatomyositis, adult-onset Still's disease, polymyalgia rheumatica, sarcoidosis, scleroderma, sclerosis, systemic sclerosis, Sjogren's syndrome, multiple sclerosis (MS), Guillain-Barre disease, Addison's disease and Raynaud's phenomenon.

The IL-17A binding polypeptides as disclosed herein may furthermore
25 be useful for the treatment of recipients of heart, lung, combined heart- lung, liver, kidney, pancreatic, skin or corneal transplants, including allograft rejection or xenograft rejection, and for the prevention of graft-versus-host disease, such as following bone marrow transplant, and organ transplant associated arteriosclerosis.

30 The IL-17A binding polypeptides as disclosed herein may furthermore be useful for the treatment, diagnosis or prognosis of inflammation-associated cancers. The term "cancer" as used herein refers to tumor diseases and/or cancer, such as metastatic or invasive cancers, for example lung cancer, non small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone
35 cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, colorectal cancer, cancer of

the small intestines, esophageal cancer, liver cancer, pancreas cancer, breast cancer, ovarian cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the endocrine
 5 system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, bladder cancer, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, mesothelioma, hepatocellular carcinoma, biliary cancer, neoplasms of the central nervous
 10 system (CNS), spinal axis tumors, brain stem glioma, glioblastoma multiforme, astrocytomas, schwannomas, ependymomas, medulloblastomas, meningiomas, squamous cell carcinomas, pituitary adenoma, adenocarcinomas, lymphoma, lymphocytic leukemia, or cancer of unknown origin, or other hyperplastic or neoplastic IL-17A associated condition,
 15 including refractory versions of any of the above cancers or a combination of one or more of the above cancers or hyperproliferative diseases.

Non-limiting examples of inflammation-associated cancers include gastric cancers, colorectal cancers, non-small cell lung cancers, hepatocellular carcinomas and adenocarcinomas.

20

In one embodiment, there is provided an IL-17A binding polypeptide, fusion protein, conjugate, complex or composition for use in the treatment, diagnosis or prognosis of an IL-17A associated condition, such as a condition selected from the group consisting of inflammatory diseases, autoimmune
 25 diseases and cancer, such as inflammatory diseases and autoimmune diseases. In one embodiment, said condition is selected from the group consisting of inflammatory conditions, allergic conditions, hypersensitivity reactions, autoimmune diseases, severe infections and transplant rejections.

In one particular embodiment, said IL-17A associated condition is selected from the group consisting of rheumatoid arthritis, ankylosing
 30 spondylitis, psoriatic arthritis, psoriasis, multiple sclerosis, systemic lupus erythematosus, uveitis and dry eye disease.

In an even more particular embodiment, said IL-17A associated condition is psoriasis.

35 In another embodiment, said IL-17A associated condition is an inflammation-associated cancer, such as a cancer selected from the group

consisting of gastric cancers, colorectal cancers, non-small cell lung cancers, hepatocellular carcinomas and adenocarcinomas.

In a related aspect, there is provided a method of detecting IL-17A, comprising providing a sample suspected to contain IL-17A, contacting said sample with an IL-17A binding polypeptide, fusion protein, conjugate, complex or composition as described herein, and detecting the binding of the IL-17A binding polypeptide, fusion protein, conjugate, complex or composition to indicate the presence of IL-17A in the sample. In one embodiment, said method further comprises an intermediate washing step for removing non-bound polypeptide, fusion protein, conjugate, complex or composition, after contacting the sample.

In one embodiment, said method is a diagnostic or prognostic method, for determining the presence of IL-17A in a subject, the method comprising the steps:

- contacting the subject, or a sample isolated from the subject, with an IL-17A binding polypeptide, fusion protein, conjugate, complex or composition as described herein, and
- obtaining a value corresponding to the amount of the IL-17A binding polypeptide, fusion protein, conjugate, complex or composition that has bound in said subject or to said sample.

In one embodiment, said method further comprises an intermediate washing step for removing non-bound polypeptide, fusion protein, conjugate, complex or composition, after contacting the subject or sample and before obtaining a value.

In one embodiment, said method further comprises a step of comparing said value to a reference. Said reference may be scored by a numerical value, a threshold or a visual indicator, for example based on a color reaction. The skilled person will appreciate that different ways of comparison to a reference are known in the art may be suitable for use.

In one embodiment of such a method, said subject is a mammalian subject, such as a human subject.

In one embodiment, said method is performed *in vivo*.

In one embodiment, said method is performed *in vitro*.

In a related aspect, there is provided a method of treatment of an IL-17A associated condition, comprising administering to a subject in need thereof an effective amount of an IL-17A binding polypeptide, fusion protein, conjugate, complex or composition as described herein. In a more specific
5 embodiment of said method, the IL-17A binding polypeptide, fusion protein, conjugate, complex or composition as described herein modulates IL-17A function *in vivo*.

In one embodiment, said IL-17A associated condition is selected from the group consisting of inflammatory diseases, autoimmune diseases and
10 cancer, such as a group consisting of inflammatory diseases and autoimmune diseases. In one particular embodiment of said aspect, the IL-17A associated condition is selected from the group consisting of inflammatory conditions, allergic conditions, hypersensitivity reactions, autoimmune diseases, severe infections and transplant rejections. In one embodiment, said IL-17A
15 associated condition is selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, multiple sclerosis, systemic lupus erythematosus, uveitis and dry eye disease. In a more specific embodiment, said IL-17A associated condition is psoriasis. In another embodiment, said IL-17A associated condition is cancer, such as a cancer
20 selected from the group consisting of gastric cancers, colorectal cancers, non-small cell lung cancers, hepatocellular carcinomas and adenocarcinomas.

It may be beneficial to administer a therapeutically effective amount of an IL-17A binding polypeptide, fusion protein, conjugate, complex or
25 composition as described herein together with least one second drug substance, such as an immune response modifying agent, toxic compound or an anti-cancer agent.

As used herein, the term “co-administration” encompasses concomitant administration and administration in sequence. Thus, in one embodiment,
30 there is provided a method as defined above, further comprising co-administration of an immune response modulating agent. In another embodiment, there is provided a method as defined above, further comprising co-administration of an additional anti-inflammatory agent. In another embodiment, there is provided a method as defined above, further comprising
35 co-administration of a toxic compound. In another embodiment, there is provided a method as defined above, further comprising co-administration of an anti-cancer agent.

Non-limiting examples of immune response modulating agents and toxic compounds are given above. Non-limiting examples of anti-cancer agents include agents selected from the group consisting of auristatin, anthracycline, calicheamycin, combretastatin, doxorubicin, duocarmycin, the
5 CC-1065 anti-tumorantibiotic, ecteinsascidin, geldanamycin, maytansinoid, methotrexate, mycotoxin, taxol, ricin, bouganin, gelonin, pseudomonas exotoxin 38 (PE38), diphtheria toxin (DT), and their analogues, and derivatives thereof and combinations thereof. A skilled person would appreciate that the non-limiting examples of cytotoxic agents include all possible variant of said
10 agents, for example the agent auristatin includes for example auristatin E, auristatin F, auristatin PE, and derivatives thereof.

While the invention has been described with reference to various exemplary aspects and embodiments, it will be understood by those skilled in
15 the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In addition, many modifications may be made to adapt a particular situation or molecule to the teachings of the invention without departing from the essential scope thereof. Therefore, it is intended that the invention not be
20 limited to any particular embodiment contemplated, but that the invention will include all embodiments falling within the scope of the appended claims.

Brief description of the figures

25 Figure 1 is a listing of the amino acid sequences of examples of IL-17A binding polypeptides of the present disclosure (SEQ ID NO:1-1222), a control polypeptide (SEQ ID NO:1223), the albumin binding polypeptides PP013 (SEQ ID NO:1224) and PEP07843 (SEQ ID NO:1225) as well as the amino acid sequences of human IL-17A (SEQ ID NO:1226), murine IL-17A (SEQ ID
30 NO:1227), cynomolgus monkey IL-17A (SEQ ID NO:1229), rhesus monkey IL-17A (SEQ ID NO:1230) and human IL-17F (SEQ ID NO:1228) used for selection, screening and/or characterization for illustration of the invention. In the IL-17A binding polypeptides of the present disclosure, the deduced IL-17A binding motifs (*BMs*) extend from residue 8 to residue 36 in each sequence.
35 The amino acid sequences of the 49 amino acid residues long polypeptides (BMod) predicted to constitute the complete three-helix bundle within each of these Z variants extend from residue 7 to residue 55.

Figure 2 shows inhibition of IL-17A induced IL-6 production assessed by the NHDF assay described in Example 3. (A) His₆-Z06260 (open diamonds), His₆-Z06282 (open squares) and His₆-Z06455 (open circles) were titrated in a medium containing IL-17A. (B) Z06260-ABD (closed diamonds), His₆-Z06282 (open squares), Z06282-ABD (filled squares), His₆-Z06455 (open circles) and Z06455-ABD (filled circles) were titrated in a medium containing IL-17A and HSA.

Figure 3 shows the IL-17A binding capacity of a set of Z variants from the first and second maturation library assayed by ELISA as described in Example 8. The results are displayed as percent binding capacity compared to the IL-17A binding variant Z10241 (SEQ ID NO:11).

Figure 4 shows the result of binding specificity analysis performed in a Biacore instrument as described in Example 8. Sensorgrams were obtained by injection of 20 nM of the His₆-tagged Z variants Z10508 (SEQ ID NO:2) (A), Z10532 (SEQ ID NO:1) (B) and Z15167 (SEQ ID NO:4) (C) over human IL-17A (black), human IL-17A/F (dark grey) and human IL-17F (light grey), respectively, immobilized on the surface of a CM5 chip.

Figure 5 shows inhibition of IL-17A induced IL-6 production for a selection of Z variants originating from the first maturation selection (solid curves) compared to one binder from the primary selection (broken curve) assayed as described in Example 8. All binders inhibited IL-17A in a dose dependent manner and the matured binders had an increased blocking capacity compared to the primary binder.

Figure 6 shows binding of human IL-17A (grey) and cynomolgus IL-17A (black) to (A) ZAZ3363 (SEQ ID NO:1244), (B) ZAZ3364 (SEQ ID NO:1245) and (C) ZAZ3365 (SEQ ID NO:1246), analyzed in a Biacore instrument as described in Example 11. The resulting curves, from which responses from a blank surface were subtracted, correspond to injections of the respective IL-17A protein at concentrations 2.5, 10 and 40 nM.

Figure 7 shows inhibition of IL-17A induced IL-6 production in the NHDF assay described in Example 14. Figure 7A shows a superior inhibitory efficacy with the dimeric Z-ABD-Z polypeptide ZAZ3220 (SEQ ID NO:1236; solid black line) compared to the corresponding monomeric Z variant Z10241 (SEQ ID NO:11; dotted black line). Figure 7B shows an evaluation of different linker lengths between the Z and the ABD moieties in Z-ABD-Z polypeptides comprising the Z variant Z06282 (SEQ ID NO:1206). The Z-ABD-Z polypeptides ZAZ3174 (SEQ ID NO:1233), ZAZ3176 (SEQ ID NO:1235),

ZAZ3234 (SEQ ID NO:1238), ZAZ3235 (SEQ ID NO:1239), ZAZ3236 (SEQ ID NO:1240) and ZAZ3237 (SEQ ID NO:1241) with various numbers of G₄S repeats, or minimal linkers, on each side of the ABD were compared.

Figure 8 shows dose dependent inhibition by Z-ABD-Z polypeptides in the hIL-17A induced KC-model described in Example 15. (A) Complete inhibition of KC production by ZAZ3174 (SEQ ID NO:1233) was obtained at a dose of 2.5 mg/kg. (B) Complete inhibition of KC production by ZAZ3220 (SEQ ID NO:1236) was obtained at a dose of 0.4 mg/kg. Doses indicated on the x-axis are given in mg/kg and the corresponding pmol dose. The numbers above the bar indicate percent inhibition in each dose group; 72 % inhibition was obtained with 0.1 mg/kg ZAZ3220. LOQ = limit of quantification.

Figure 9 shows the pharmacokinetic profiles of the Z-ABD-Z polypeptides (A) ZAZ3220 (SEQ ID NO:1236) and (B) ZAZ3363 (SEQ ID NO:1244), following a single i.v. (black line) or s.c. (gray broken line) administration to SD rats as described in Example 16. The mean serum concentrations versus time is displayed.

Figure 10 shows the result of topical administration to the eyes of rabbits performed as described in Example 17. Uptake of Z variant Z10199 (SEQ ID NO:1217) and the Z-ABD-Z polypeptide ZAZ3174 (SEQ ID NO:1233) was demonstrated both in aqueous humor and vitreous humor, whereas the control IgG antibody did not penetrate the eye.

Figure 11 shows the activity of ZAZ3363 (SEQ ID NO:1244) formulated in OAF1 and OAF2, respectively, in comparison to formulation in PBS, and analyzed in the NHDF assay described in Example 18. A) OAF1 (filled circles), PBS (crosses) and OAF1 without ZAZ3363 (open diamonds). B) OAF2 (open triangles), PBS (crosses) and OAF2 without ZAZ3363 (open diamonds).

Figure 12 shows the pharmacokinetic profile of intraduodenal administration of ZAZ3363 formulated in OAF1 (filled circles), OAF2 (open triangles) and PBS (crosses) performed as described in Example 18.

Figure 13 shows the evaluation of the complexes HC_{Ada}-Z14253 and LC_{Ada}-Z14253 in the NHDF assay described in Example 19. (A) Schematic of the complexes HC_{Ada}-Z14253 (left) and LC_{Ada}-Z14253 (right). (B) Inhibition of IL-17A induced IL-6 production. (C) Inhibition of TNF-induced IL-8 production. (D) Inhibition of TNF and IL-17A-induced IL-8 production. Z04726-ABD is a negative control, included in all three assays.

Figure 14 shows the pharmacokinetic profiles of the Z-ABD-Z polypeptide ZAZ3363 (SEQ ID NO:1244) in cynomolgus monkeys following i.v. administration of 20 mg/kg (black) or 40 mg/kg (grey) on day 1, 4, 7 and 10 as described in Example 20. Mean plasma concentrations versus time are shown following analysis of (A) the first injection on day 1 and (B) the fourth injection on day 10. Error bars represent standard deviation.

Figure 15 shows the pharmacokinetic profiles of the Z-ABD-Z polypeptide ZAZ3363 (SEQ ID NO:1244) in individual beagle dogs following oral administration. 150 mg of ZAZ3363 was administered as enteric coated capsules on day 0.

Examples

15 *Summary*

The following Examples disclose the development of novel Z variant molecules targeted to interleukin 17A (IL-17A) based on phage display technology. The IL-17A binding polypeptides described herein were sequenced, and their amino acid sequences are listed in Figure 1 with the sequence identifiers SEQ ID NO:1-1222. The Examples further describe the characterization of IL-17A binding polypeptides and *in vitro* and *in vivo* functionality of said polypeptides.

25

Example 1

Selection and screening of IL-17A binding Z variants

Materials and methods

Biotinylation of target protein: Human IL-17A (hIL-17A Peprtech cat. no. 200-17; SEQ ID NO:1226) and murine IL-17A (mIL-17A Peprtech cat. no. 210-17; SEQ ID NO:1227) were biotinylated according to the manufacturer's recommendations at room temperature (RT) for 30 min using No-Weigh EZ-Link Sulfo-NHS-LC-Biotin (Thermo Scientific, cat. no. 21327) at a 20 x molar excess. Subsequent buffer exchange to phosphate buffered saline (PBS, 10 mM phosphate, 137 mM NaCl, 2.68 mM KCl, pH 7.4) was performed using a dialysis cassette (Slide-a-lyzer 3.5 K, 3500 MWCO,

Thermo Scientific, cat. no. 66333) according to the manufacturer's instructions.

Phage display selection of IL-17A binding Z variants: A library of random variants of protein Z displayed on bacteriophage, constructed in phagemid pAY02592 essentially as described in Grönwall *et al.* (2007) J Biotechnol, 128:162-183, was used to select IL-17A binding Z variants. In this library, an albumin binding domain (abbreviated ABD and corresponding to GA3 of protein G from *Streptococcus* strain G148) is used as fusion partner to the Z variants. The library is denoted Zlib006Naive.II and has a size of 1.5 x 10¹⁰ library members (Z variants). *E. coli* RRIΔM15 cells (Rüther *et al.*, (1982) Nucleic Acids Res 10:5765-5772) from a glycerol stock containing the phagemid library Zlib006Naive.II, were inoculated in 20 l of a defined proline free medium [3 g/l KH₂PO₄, 2 g/l K₂HPO₄, 0.02 g/l uracil, 6.7 g/l YNB (Difco™ Yeast Nitrogen Base w/o amino acids, Becton Dickinson), 5.5 g/l glucose monohydrate, 0.3 g/l L-alanine, 0.24 g/l L-arginine monohydrochloride, 0.11 g/l L-asparagine monohydrate, 0.1 g/l L-cysteine, 0.3 g/l L-glutamic acid, 0.1 g/l L-glutamine, 0.2 g/l glycine, 0.05 g/l L-histidine, 0.1 g/l L-isoleucine, 0.1 g/l L-leucine, 0.25 g/l L-lysine monohydrochloride, 0.1 g/l L-methionine, 0.2 g/l L-phenylalanine, 0.3 g/l L-serine, 0.2 g/l L-threonine, 0.1 g/l L-tryptophane, 0.05 g/l L-tyrosine, 0.1 g/l L-valine], supplemented with 100 µg/ml ampicillin. The cultivations were grown at 37 °C in a fermenter (Belach Biotechnik, BR20). When the cells reached an optical density at 600 nm (OD₆₀₀) of 0.75, approximately 2.6 l of the cultivation was infected using a 10 x molar excess of M13K07 helper phage (New England Biolabs, cat. no. N0315S). The cells were incubated for 30 min, whereupon the fermenter was filled up to 20 l with cultivation medium [2.5 g/l (NH₄)₂SO₄; 5.0 g/l Yeast Extract (Merck 1.03753.0500); 25 g/l Peptone (Scharlau 07-119); 2 g/l K₂HPO₄; 3 g/l KH₂PO₄; 1.25 g/l Na₃C₆H₅O₇ · 2 H₂O; 0.1 ml/l Breox FMT30 antifoaming agent] supplemented with 100 µM isopropyl-β-D-1-thiogalactopyranoside (IPTG) for induction of expression and with 50 µg/ml ampicillin, 12.5 µg/ml carbenicillin, 25 µg/ml kanamycin, 35 ml/l of 1.217 M MgSO₄ and 10 ml of a trace element solution [129 mM FeCl₃; 36.7 mM ZnSO₄; 10.6 mM CuSO₄; 78.1 mM MnSO₄; 94.1 mM CaCl₂, dissolved in 1.2 M HCl]. A glucose-limited fed-batch cultivation was started where a 600 g/l glucose solution was fed to the reactor (15 g/h in the start, 40 g/h at the end of the fermentation after 17 h). Through the automatic addition of 25 % NH₄OH, the pH was controlled at 7. Air was supplemented (10 l/min) and the stirrer was set to keep the

dissolved oxygen level above 30 %. The cells in the cultivation were removed by tangential flow filtration.

The phage particles were precipitated from the supernatant twice in PEG/NaCl (polyethylene glycol/sodium chloride), filtered and dissolved in
 5 PBS and glycerol as described in Grönwall *et al.*, *supra*. Phage stocks were stored at -80 °C before use.

Selections against biotinylated hIL-17A (b-hIL-17A) or biotinylated mL-17A (b-mIL-17A) were performed in four cycles divided in six different tracks (Table 2). Phage stock preparation, selection procedure and amplification of
 10 phage between selection cycles were performed essentially as described in WO2009/077175 for selection against another target with the following exceptions. Exception 1: PBS supplemented with 3 % bovine serum albumin (BSA, Sigma, cat. no. A3059) and 0.1 % Tween20 (Acros Organics, cat. no. 233362500) was used as selection buffer. Exception 2: pre-selection was
 15 performed in cycles 1-3 by incubation of phage stock with Dynabeads® M-280 Streptavidin (SA beads, Invitrogen, cat. no. 11206D). Exception 3: all tubes and beads used in the selections were pre-blocked with PBS supplemented with 5 % BSA and 0.1 % Tween20. Exception 4: selections were performed in solution at RT and the time for selection was 200 min in the first cycle and
 20 120 min in the following cycles. Exception 5: this was followed by catching of target-phage complexes on SA beads using 1 mg beads per 6.4 µg b-hIL-17A or b-mIL-17A. Exception 6: *E. coli* strain XL1-Blue cells (Agilent Technologies, cat. no. 200268) grown in medium supplemented with 10 µg/ml tetracycline (exception 7) were used for infection. Exception 8: tryptone yeast extract
 25 plates (15 g/l agar, 10 g/l tryptone water (Merck), 5 g/l yeast extract, 3 g/l NaCl, 2 % glucose) supplemented with 0.1 g/l ampicillin and 0.01 g/l tetracycline were used for spreading of bacteria. Exception 9: a 10 x excess of M13K07 helper phage compared to bacteria was allowed to infect log phase bacteria.

30 An overview of the selection strategy, describing an increased stringency in subsequent cycles obtained using a lowered target concentration and an increased number of washes, is shown in Table 2.

Table 2: Overview of the selection from a primary library

Cycle	Selection track	Phage stock from library or selection track	Target	Target concentration (nM)	Number of washes	Higher amount of phage into selection track
1	1	Zlib006Naive.II	hIL-17A	50	2	-
2	1-1	1	hIL-17A	25	4	Yes
2	1-2	1	hIL-17A	25	4	-
2	1-3	1	hIL-17A	5	5	-
2	1-4	1	mIL-17A	50	4	-
3	1-1-1	1-1	hIL-17A	12.5	6	Yes
3	1-2-1	1-2	hIL-17A	12.5	6	-
3	1-3-1	1-3	hIL-17A	1	8	-
3	1-4-1	1-4	hIL-17A	12.5	6	-
3	1-4-2	1-4	mIL-17A	5	8	-
4	1-1-1-1	1-1-1	hIL-17A	5	8	Yes
4	1-2-1-1	1-2-1	hIL-17A	5	8	-
4	1-3-1-1	1-3-1	hIL-17A	0.25	12	-
4	1-3-1-2	1-3-1	hIL-17A	0.05	15	-
4	1-4-1-1	1-4-1	mIL-17A	5	8	-
4	1-4-2-1	1-4-2	hIL-17A	0.5	12	-

Track 1 was divided in the second to the fourth cycles, resulting in a total of four tracks (1-1 to 1-4) in cycle 2, five tracks (1-1-1 to 1-4-2) in cycle 3 and six tracks (1-1-1-1 to 1-4-2-1) in cycle 4. The number of phage particles used for selections was about 2000 times the number of eluted phage particles in the previous cycle, but a higher amount was used in selection tracks 1-1, 1-1-1 and 1-1-1-1.

Washes were performed for 1 min using PBST 0.1 % (PBS supplemented with 0.1 % Tween-20), and elution was carried out as described in WO2009/077175.

Production of Z variants for ELISA: The Z variants were produced by inoculating single colonies from the selections into 1 ml TSB-YE medium supplemented with 100 µg/ml ampicillin and 0.1 mM IPTG in deep-well plates (Nunc, cat. no. 278752). The plates were incubated for 18-24 h at 37 °C. Cells were pelleted by centrifugation, re-suspended in 400 µl PBST 0.05 % and frozen at -80 °C to release the periplasmic fraction of the cells. Frozen samples were thawed in a water bath and the freeze-thawing procedure was

repeated six times. 400 µl PBST 0.05 % was added to the thawed samples and cells were pelleted by centrifugation.

The final supernatant of the periplasmic extract contained the Z-variants as fusions to ABD, expressed as AQHDEALE-[Z#####]-VDYV-[ABD]-YVPG (Grönwall *et al.*, *supra*). Z##### refers to individual 58 amino acid residue Z variants.

ELISA screening of Z variants: The binding of Z variants to human IL-17A was analyzed in ELISA assays. Half-area 96-well ELISA plates (Costar, cat. no. 3690) were coated at 4 °C overnight with 2 µg/ml of an anti-ABD goat antibody (produced in-house) diluted in coating buffer (50 mM sodium carbonate, pH 9.6; Sigma, cat. no. C3041). The antibody solution was poured off and the wells were washed in water and blocked with 100 µl of PBSC (PBS supplemented with 0.5 % casein) for 1 to 3 h at RT. The blocking solution was discarded and 50 µl periplasmic solutions were added to the wells and incubated for 1.5 h at RT under slow agitation. As a blank control, PBST 0.05 % was added instead of the periplasmic sample. The supernatants were poured off and the wells were washed 4 times with PBST 0.05 %. Next, 50 µl of b-hIL-17A at a concentration of 6.5 nM in PBSC was added to each well. The plates were incubated for 1.5 h at RT followed by washes as described above. Streptavidin conjugated HRP (Thermo Scientific, cat. no. N100) diluted 1:30,000 in PBSC, was added to the wells and the plates were incubated for 1 h. After washing as described above, 50 µl ImmunoPure TMB substrate (Thermo Scientific, cat. no. 34021) was added to the wells and the plates were treated according to the manufacturer's recommendations. The absorbance at 450 nm was measured using a Victor³ multi-well plate reader (Perkin Elmer).

Sequencing: In parallel with the ELISA screening, all clones were picked for sequencing. PCR fragments were amplified from single colonies, sequenced and analyzed essentially as described in WO2009/077175.

Results

Phage display selection of IL-17A binding Z variants: Individual clones were obtained after four cycles of phage display selections against b-hIL-17A and b-mIL-17A.

ELISA screening of Z variants: The clones obtained after four cycles of selection were expanded in 96-well plates and screened for hIL-17A binding activity in ELISA. 42 Z variants were found to give a response of 4 x the blank

control or higher (0.43-3.2 AU) against hIL-17A at a concentration of 6.5 nM. No response was obtained for the blank control.

Sequencing: Sequencing was performed for clones obtained after four cycles of selection. Each variant was given a unique identification number #####, and individual variants are referred to as Z#####. The amino acid sequences of the 58 amino acid residues long Z variants are listed in Figure 1 and in the sequence listing as SEQ ID NO: 1200-1216. The deduced IL-17A binding motifs extend from residue 8 to residue 36 in each sequence. The amino acid sequences of the 49 amino acid residues long polypeptides predicted to constitute the complete three-helix bundle within each of these Z variants extend from residue 7 to residue 55.

Example 2

Production of monomeric IL-17A binding Z variants

This Example describes the general procedure for subcloning and production of His-tagged Z variants and Z variants in fusion with ABD, which are used throughout in characterization experiments below.

20

Materials and methods

Subcloning of Z variants with a His-tag: The DNA of respective Z variant was amplified from the library vector pAY02592. A subcloning strategy for construction of monomeric Z variant molecules with N-terminal His₆ tag was applied using standard molecular biology techniques (essentially as described in WO2009/077175 for Z variants binding another target). The Z gene fragments were subcloned into the expression vector pAY01448 resulting in the encoded sequence MGSSHHHHHLQ-[Z#####]-VD.

Subcloning of Z variants in fusion with ABD: The DNA of respective Z variant was amplified from the library vector pAY02592. A PCR was performed using suitable primer pairs and the resulting gene fragments were cleaved with restriction enzymes *Pst*I and *Acc*I and ligated into the expression vector pAY03362 digested with the same enzymes, resulting in an ABD fusion protein, wherein the ABD variant is PP013 (SEQ ID NO:1224). The constructs encoded by the expression vectors were MGSSLQ-[Z#####]-VDSS-PP013.

Cultivation: *E. coli* BL21(DE3) cells (Novagen) were transformed with plasmids containing the gene fragment of each respective IL-17A binding Z variant and cultivated at 37 °C in 800 or 1000 ml of TSB-YE medium supplemented with 50 µg/ml kanamycin. In order to induce protein
5 expression, IPTG was added to a final concentration of 0.2 mM at OD₆₀₀ = 2 and the cultivation was incubated at 37 °C for another 5 h. The cells were harvested by centrifugation.

Purification of IL-17A binding Z variants with a His₆-tag: Approximately 2-5 g of each cell pellet was re-suspended in 30 ml of binding buffer (20 mM
10 sodium phosphate, 0.5 M NaCl, 20 mM imidazole, pH 7.4) supplemented with Benzonase[®] (Merck) to a concentration of 15 U/ml. After cell disruption, cell debris was removed by centrifugation and each supernatant was applied on a 1 ml His GraviTrap IMAC column (GE Healthcare). Contaminants were removed by washing with wash buffer (20 mM sodium phosphate, 0.5 M
15 NaCl, 60 mM imidazole, pH 7.4 and the IL-17A binding Z variants were subsequently eluted with elution buffer (20 mM sodium phosphate, 0.5 M NaCl, 500 mM imidazole, pH 7.4).

Purification of IL-17A binding Z variants in fusion with ABD:
Approximately 1-2 g of each cell pellet was re-suspended in 30 ml TST-buffer
20 (25 mM Tris-HCl, 1 mM EDTA, 200 mM NaCl, 0.05 % Tween20, pH 8.0) supplemented with Benzonase[®] (Merck). After cell disruption by sonication and clarification by centrifugation, each supernatant was applied on a gravity flow column with 1 ml agarose immobilized with an anti-ABD ligand (produced in-house). After washing with TST-buffer and 5 mM NH₄Ac pH 5.5 buffer, the
25 ABD fused Z variants were eluted with 0.1 M HAc. To fractions eluted in the anti-ABD agarose affinity chromatography purification step, acetonitrile (ACN) was added to a final concentration of 10 % and the sample was loaded on 1 ml Resource 15RPC column (GE Healthcare), previously equilibrated with RPC solvent A (0.1 % TFA, 10 % ACN, 90 % water). After column wash with
30 RPC solvent A, bound proteins were eluted with a linear gradient 0-50 % RPC solvent B (0.1 % TFA, 80 % ACN, 20 % water) for 20 ml. Fractions containing pure ABD-fused Z variants were identified by SDS-PAGE analysis and pooled. After the RPC purification, the buffer of the pool was exchanged to PBS (2.68 mM KCl, 137 mM NaCl, 1.47 mM KH₂PO₄, 8.1 mM Na₂HPO₄, pH
35 7.4) using PD-10 columns (GE Healthcare). Finally, the ABD fused Z variants were purified on 1 ml EndoTrap[®] red columns (Hyglos) to ensure low endotoxin content.

Protein concentrations were determined by measuring the absorbance at 280 nm, using a NanoDrop[®] ND-1000 spectrophotometer and the extinction coefficient of the respective protein. The purity was analyzed by SDS-PAGE stained with Coomassie Blue and the identity of each purified
5 Z variant was confirmed using LC/MS analysis.

Results

Cultivation and purification: The IL-17A binding Z variants with a His₆-tag as well as the Z variants fused at their C-terminus to ABD, were
10 expressed as soluble gene products in *E. coli*. The amount of purified protein from approximately 1-5 g bacterial pellet was determined spectrophotometrically by measuring the absorbance at 280 nm and ranged from approximately 5 mg to 20 mg for the different IL-17A binding Z variants. SDS-PAGE analysis of each final protein preparation showed that these
15 predominantly contained the IL-17A binding Z variant. The correct identity and molecular weight of each Z variant were confirmed by HPLC-MS analysis.

Example 3

20 Assessment of blocking ability of primary IL-17A binding Z variants

Normal human dermal fibroblasts (NHDF) produce IL-6 upon stimulation with IL-17A (Chang and Dong 2007, Cell Research 17:435-440) and the amount of released IL-6 to the supernatant is correlated to the
25 concentration of added IL-17A. Thus, blocking of IL-17A leads to a reduction of IL-6 in the supernatant that can be quantified. In this Example, the assay was used to evaluate the blocking ability of IL-17A binding Z variants Z06260 (SEQ ID NO:1200), Z06282 (SEQ ID NO:1206) and Z06455 (SEQ ID NO:1214), alone or in fusion with ABD (PP013; SEQ ID NO:1224).

30

Materials and methods

NHDF assay with His₆-tagged Z-variants: NHDF cells (Lonza, cat. no. CC-2511) were cultured in fibroblast basal medium (Lonza, cat. no. CC-3132) supplied with growth promoting factors (Lonza, cat. no. CC-5034). On the day
35 before the experiment, 10⁵ cells were seeded in 100 µl per well into 96-well culture plates (Greiner, cat.no. 655180). On the day of the experiment, dilutions of the IL-17A specific Z variants His₆-Z06260, His₆-Z06282 and His₆-

Z06455 were prepared in a separate 96-well plate. The Z variants were titrated in three-fold steps from 3130 nM to 0.2 nM in medium containing 0.031 nM hIL-17A. A standard curve of hIL-17A was also prepared (0.002-31 nM) as well as controls containing medium with 0.031 nM hIL-17A or medium alone. The medium in the plate with the overnight cultured NHDF cells was discarded. Test samples, standard curve samples and controls were transferred to the cell-containing plate. The NHDF cells were stimulated for 18-24 h at 37 °C and the IL-6 content in the supernatants was subsequently quantified using the IL-6 specific ELISA described below.

10 NHDF assay with His₆-tagged and ABD fused Z variants: NHDF cells were prepared as described above. On the day of the experiment, dilutions of the IL-17A specific Z variant constructs His₆-Z06282, His₆-Z06455, Z06260-ABD, Z06282-ABD and Z06455-ABD were prepared in a separate 96-well plate. The Z variant constructs were titrated in four-fold steps from 780 nM to 15 0.2 nM in medium containing 0.031 nM IL-17A and 8 µM HSA. Preparation of a standard IL-17A curve and controls, as well as downstream analysis, was performed as described above.

IL-6 ELISA: 96-well half area plates (Costar, cat. no. 3690) were coated with the anti-IL-6 monoclonal antibody MAB206 (R&D systems) at a concentration of 4 µg/ml in PBS (50 µl/well) and incubated overnight at 4 °C. On the next day, the plates were rinsed twice in tap water and blocked with PBS + 2 % BSA (Sigma) for 2 h. An IL-6 standard (R&D systems, cat. no. 206-IL-50), titrated in a 2-fold dilution series (0.2-50 ng/ml) and supernatants from the cell assay plate were added to the coated ELISA plates (50 µl/well) 25 and incubated for 1.5 h at RT. The plates were washed 4 times in an automated ELISA washer and 0.25 µg/ml (50 µl/well) of biotinylated anti-IL-6 polyclonal antibody (R&D systems, BAF206) was added. After incubation for 1 h, the plate was washed and 50 µl of streptavidin-HRP (Thermo Fisher, cat. no. N100) diluted 8000 times was added to each well. After one additional 30 hour of incubation and subsequent washing, the plate was developed with 50 µl TMB (Thermo Fisher, cat. no. 34021) per well and the reactions were stopped with 50 µl 2M H₂SO₄. The absorbance at 450 nm was measured in a 96-well plate reader (Victor³) and the concentration of IL-6 in each sample was calculated. The results are presented as the percentage of maximum 35 IL-6 production, calculated as:

$$100 - [(ABS_{IL-17A \text{ blocker}} - ABS_{background}) / (ABS_{Max \text{ IL-6 prod}} - ABS_{background})] \times 100$$

Results

Results from the first NHDF assay showed that all three Z variants His₆-Z06260, His₆-Z06282 and His₆-Z06455 blocked IL-17A induced IL-6
5 production in a dose dependent manner (Figure 2A). The IC50 values were approximately 40-140 nM.

The NHDF assay was repeated with the same Z variants fused to ABD as well as inclusion of HSA in the assay to ascertain retained binding to the antigen when mimicking *in vivo* conditions. *In vivo*, ABD will bind to albumin
10 and convey longer circulation half-life. The results showed that all three binders in fusion with ABD blocked IL-17A induced IL-6 production equally well or better than the His₆-tagged Z variants (Figure 2B). The IC50 values from the second assay are summarized in Table 3.

15 *Table 3: IC50 values for primary Z-variants blocking IL-17A induced IL-6 production in the presence of HSA*

Analyte	SEQ ID NO of Z variant	IC50 (nM)
Z06260-ABD	1200	8
His ₆ -Z06282	1206	16
Z06282-ABD	1206	15
His ₆ -Z06455	1214	67
Z06455-ABD	1214	15

Example 4

20 Design and construction of a first matured library of IL-17A binding Z variants

In this Example, a matured library was designed and constructed. The library was used for selection of further IL-17A binding Z variants.
25 Selections from matured libraries are usually expected to result in binders with increased affinity (Orlova *et al.*, (2006) Cancer Res 66(8):4339-48). In this study, randomized single stranded linkers were generated using split-pool DNA synthesis, enabling incorporation of defined codons in desired positions in the synthesis.

Materials and methods

Library design: The library was based on the sequences of the IL-17A binding Z variants identified as described in Example 1. In the new library, 13 variable positions in the Z molecule scaffold were biased towards certain amino acid residues, according to a strategy based on the Z variant sequences defined in SEQ ID NO:1200-1216. A DNA linker was generated using split-pool synthesis containing the following 147 bp sequence ordered from DNA 2.0 (Menlo Park, CA, USA): 5'- AA ATA AAT CTC GAG GTA GAT GCC AAA TAC GCC AAA GAA NNN NNN NNN GCG NNN NNN GAG ATC NNN NNN TTA CCT AAC TTA ACC NNN NNN CAA NNN NNN GCC TTC ATC NNN AAA TTA NNN GAT GAC CCA AGC CAG AGC TCA TTA TTT A-3' (SEQ ID NO:1248; randomized codons are denoted NNN), comprising a coding sequence for a partially randomized helix 1 and 2 in the corresponding amino acid sequence, flanked by restriction sites for *Xho*I and *Sac*I. The theoretical distributions of amino acid residues in the new library including 13 variable Z positions (9, 10, 11, 13, 14, 17, 18, 24, 25, 27, 28, 32 and 35) in the Z molecule scaffold are given in Table 4. The resulting theoretical library size is 6.1 x 10⁹ variants.

Table 4: Library design, first maturation

Amino acid position in the Z variant molecule	Randomization (amino acid abbreviations)	No of amino acids	Proportion
9	A,H,M,W,Y	5	1/5
10	A,D (60 %),G,L,N	5	1/10, 6/10 (D)
11	D,E,F,N,Q R,Y	7	1/7
13	A,E,Q,W	4	1/4
14	F,I,L,M,V,W	6	1/6
17	A,F,Q,W	4	1/4
18	A,D,E,L,M,S,T	7	1/7
24	A,H,R,T,W,Y	6	1/6
25	A,D,H,R,V	5	1/5
27	A,G,Q,R,S,W	6	1/6
28	F,H,K,N,R,S,T,V,Y	9	1/9
32	A,G,H,I,Q,R,S,V	8	1/8
35	I,L,N,R	4	1/4

Library construction: The library was amplified using *AmpliTaq Gold* polymerase (Applied Biosystems, cat. no. 4311816) during 12 cycles of PCR, and pooled products were purified with QIAquick PCR Purification Kit (QIAGEN, cat. no. 28106) according to the supplier's recommendations. The
5 purified pool of randomized library fragments was digested with restriction enzymes *XhoI* and *SacI*-HF (New England Biolabs, cat. no. R0146L and cat. no. R3156M, respectively) and concentrated using the QIAquick PCR Purification Kit. Subsequently, the product was subjected to gel electrophoresis using a preparative 2.5 % agarose gel (Nisieve GTC
10 agarose, Cambrex, Invitrogen) and purified from said gel using QIAGEN Gel Extraction Kit (QIAGEN, cat. no. 28706) according to the supplier's recommendations.

The phagemid vector pAY02592 (essentially as pAffi1 described in Grönwall *et al.*, *supra*) was restricted with the same enzymes, purified using
15 phenol/chloroform extraction and ethanol precipitation. The restricted fragments and the restricted vector were ligated in a molar ratio of 5:1 with T4 DNA ligase (Fermentas, cat. no. EL0011) for 2 h at RT, followed by overnight incubation at 4 °C. The ligated DNA was recovered by phenol/chloroform extraction and ethanol precipitation, followed by dissolution in 10 mM Tris-
20 HCl, pH 8.5. Thus, the resulting library in vector pAY02592 encoded Z variants each fused to an albumin binding domain (ABD) derived from streptococcal Protein G.

The ligation reactions (approximately 160 ng DNA/transformation) were electroporated into electrocompetent *E. coli* ER2738 cells (Lucigen,
25 Middleton, WI, USA, 50 µl). Immediately after electroporation, approximately 1 ml of recovery medium (supplied with *E. coli* ER2738 cells) was added. The transformed cells were incubated at 37 °C for 60 min. Samples were taken for titration and for determination of the number of transformants. The cells were thereafter pooled and cultivated overnight at 37 °C in 1 l of TSB-YE medium,
30 supplemented with 2 % glucose, 10 µg/ml tetracycline and 100 µg/ml ampicillin. The cells were pelleted for 15 min at 4,000 g and resuspended in a PBS/glycerol solution (approximately 40 % glycerol). The cells were aliquoted and stored at -80 °C. Clones from the library of Z variants were sequenced in order to verify the content and to evaluate the outcome of the constructed
35 library vis-à-vis the library design. Sequencing was performed as described in Example 1 and the amino acid distribution was verified.

Preparation of phage stock: Phage stock containing the phagemid library was prepared in a 20 l fermenter (Belach Bioteknik). Cells from a glycerol stock containing the phagemid library were inoculated in 10 l of TSB-YE supplemented with 1 g/l glucose, 100 mg/l ampicillin and 10 mg/l tetracycline. When the cells reached an optical density at 600 nm (OD_{600}) of 0.52, approximately 1.7 l of the cultivation was infected using a 5 x molar excess of M13K07 helper phage. The cells were incubated for 30 min, whereupon the fermenter was filled up to 10 l with complex fermentation medium [2.5 g/l $(NH_4)_2SO_4$; 5.0 g/l yeast extract; 30 g/l tryptone, 2 g/l K_2HPO_4 ; 3 g/l KH_2PO_4 , 1.25 g/l; $Na_3C_6H_5O_7 \cdot 2 H_2O$; Breox FMT30 antifoaming agent 0.1 ml/l]. The following components were added: 10 ml carbenicillin 25 mg/ml; 5 ml kanamycin 50 mg/ml; 1 ml 1 M IPTG; 17.5 ml/l 1.217 M $MgSO_4$ and 5 ml of a trace element solution [129 mM $FeCl_3$; 36.7 mM $ZnSO_4$; 10.6 mM $CuSO_4$; 78.1 mM $MnSO_4$; 94.1 mM $CaCl_2$, dissolved in 1.2 M HCl]. A glucose limited fed-batch cultivation was started where a 600 g/l glucose solution was fed to the reactor (3.5 g/h at the start, 37.5 g/h after 20 h continuing until the end of the cultivation). Through the automatic addition of 25 % NH_4OH , the pH was controlled at pH 7. Air was supplemented (5 l/min) and the stirrer was set at 500 rpm. After 24 h of fed-batch cultivation the OD_{600} was 19.4. The cells in the cultivation were pelleted by centrifugation at 15,900 g. The phage particles were precipitated from the supernatant twice in PEG/NaCl, filtered and dissolved in PBS and glycerol as described in Example 1. Phage stocks were stored at -80 °C until use in selection.

25 Results

Library construction: The new library was designed based on a set of IL-17A binding Z variants with verified binding properties (Example 1 and 3). The theoretical size of the designed library was 6.1×10^9 Z variants. The actual size of the library, determined by titration after transformation to *E. coli* ER2738 cells, was 4.5×10^9 transformants.

The library quality was tested by sequencing of 96 transformants and by comparing their actual sequences with the theoretical design. The contents of the actual library compared to the designed library were shown to be satisfactory. A matured library of potential binders to IL-17A was thus successfully constructed.

Example 5Selection, screening and characterization of Z variants from the first
maturated library5 *Materials and methods*

- Phage display selection of IL-17A binding Z variants: The target proteins hIL-17A and mL-17A were biotinylated as described in Example 1. Phage display selections, using the new library of Z variant molecules constructed as described in Example 4, were performed in four cycles against
- 10 hIL-17A and mL-17A essentially as described in Example 1, with the following exceptions. Exception 1: PBST 0.1 % was used as selection buffer. At selection, fetal calf serum (FCS, Gibco, cat. no.10108-165) and human serum albumin (HSA, Albucult, Novozymes, cat. no. 230-005) were added to the selection buffer to a final concentration of 10 % and 1.5 μ M, respectively.
- 15 Exception 2: a pre-selection step was performed in cycle 1 by incubating the phage stock with SA beads. Exception 3: all tubes and beads used in the selection were pre-blocked with PBS supplemented with 3 % BSA and 0.1 % Tween20. Exception 4: the time for selection was 140, 70, 60 and 50 min in cycles 1, 2, 3 and 4, respectively.
- 20 An overview of the selection strategy, describing an increased stringency in subsequent cycles obtained by using a lowered target concentration and an increased number of washes, is shown in Table 5.

Table 5: Overview of the selection from the first maturated library

Cycle	Selection track	Phage stock from library or selection track	Target	Target conc. (nM)	Number of 1 min washes	Number of 10 min washes	Number of overnight washes	Elution at
1	1	Zlib006IL-17A.I	hIL-17A	25	2	-	-	pH 5.5
1	2	Zlib006IL-17A.I	hIL-17A	12.5	3	-	-	pH 2.2
1	3	Zlib006IL-17A.I	hIL-17A	25	2	-	-	pH 2.2
2	1-1	1	hIL-17A	12.5	6	-	-	pH 5.5
2	2-1	2	hIL-17A	2.5	10	-	-	pH 2.2
2	2-2	2	hIL-17A	5	6	-	-	pH 2.2
2	3-1	3	hIL-17A	7.5	10	-	-	pH 2.2
2	3-2	3	hIL-17A	12.5	6	-	-	pH 2.2

Cycle	Selection track	Phage stock from library or selection track	Target	Target conc. (nM)	Number of 1 min washes	Number of 10 min washes	Number of overnight washes	Elution at
2	3-3	3	mIL-17A	12.5	6	-	-	pH 2.2
3	1-1-1	1-1	hIL-17A	2.5	10	-	-	pH 5.5
3	2-1-1	2-1	hIL-17A	0.05	15	1	-	pH 2.2
3	2-2-1	2-2	hIL-17A	0.5	15	1	-	pH 2.2
3	3-1-1	3-1	hIL-17A	0.75	15	1	-	pH 2.2
3	3-2-1	3-2	hIL-17A	2.5	10	-	-	pH 2.2
3	3-3-1	3-3	hIL-17A	5	10	-	-	pH 2.2
4	1-1-1-1a	1-1-1	hIL-17A	0.05	20	-	-	pH 5.5
4	1-1-1-1b	1-1-1	hIL-17A	0.05	20	-	1	pH 5.5
4	1-1-1-2a	1-1-1	hIL-17A	1	12	-	-	pH 5.5
4	1-1-1-2b	1-1-1	hIL-17A	1	12	-	1	pH 5.5
4	2-1-1-1a	2-1-1	hIL-17A	0.0025	30	-	-	pH 2.2
4	2-1-1-1b	2-1-1	hIL-17A	0.0025	30	-	1	pH 2.2
4	2-1-1-2a	2-1-1	hIL-17A	0.025	20	-	-	pH 2.2
4	2-1-1-2b	2-1-1	hIL-17A	0.025	20	-	1	pH 2.2
4	2-2-1-1a	2-2-1	hIL-17A	0.005	30	-	-	pH 2.2
4	2-2-1-1b	2-2-1	hIL-17A	0.005	30	-	1	pH 2.2
4	2-2-1-2a	2-2-1	hIL-17A	0.05	20	-	-	pH 2.2
4	2-2-1-2b	2-2-1	hIL-17A	0.05	20	-	1	pH 2.2
4	3-1-1-1a	3-1-1	hIL-17A	0.025	30	-	-	pH 2.2
4	3-1-1-1b	3-1-1	hIL-17A	0.025	30	-	1	pH 2.2
4	3-1-1-2a	3-1-1	hIL-17A	0.25	20	-	-	pH 2.2
4	3-1-1-2b	3-1-1	hIL-17A	0.25	20	-	1	pH 2.2
4	3-2-1-1a	3-2-1	hIL-17A	0.05	20	-	-	pH 2.2
4	3-2-1-1b	3-2-1	hIL-17A	0.05	20	-	1	pH 2.2
4	3-2-1-2a	3-2-1	hIL-17A	1	12	-	-	pH 2.2
4	3-2-1-2b	3-2-1	hIL-17A	1	12	-	1	pH 2.2
4	3-3-1-1a	3-3-1	mIL-17A	0.05	20	-	-	pH 2.2
4	3-3-1-1b	3-3-1	mIL-17A	0.05	20	-	1	pH 2.2
4	3-3-1-2a	3-3-1	mIL-17A	1	15	-	-	pH 2.2
4	3-3-1-2b	3-3-1	mIL-17A	1	15	-	1	pH 2.2

Tracks 1-3 in cycle 1 were split in the second to fourth cycles, resulting in a total of six tracks (1-1 to 3-3) in cycle 2, six tracks (1-1-1 to 3-3-1) in cycle 3 and 24 tracks (1-1-1-1a to 3-3-1-2b) in cycle 4. Washes were performed
5 using PBST 0.1 % for 1 min. However, for track 1-3 in cycle 3, one of the washes lasted for 10 min.

After the last wash in cycle 4, the target-phage complexes on SA beads from all tracks were divided in two equal parts. Bound phage particles from the first part were immediately eluted, while the second part was
10 subjected to an overnight wash before elution of phage particles. The bound phage particles were eluted using two different procedures: 1) with glycine-HCl, pH 2.2, as in Example 1, or 2) 500 µl of 100 mM sodium phosphate, 150 mM sodium chloride, pH 5.5 and neutralization with 500 µl PBS.

Amplification of phage particles: Amplification of phage particles
15 between selection cycle 1 and 2 was performed essentially as described in Example 1, with the following three exceptions. Exception 1: *E. coli* ER2738 was used for phage amplification. Exception 2: M13K07 helper phage were used in 5 x excess. Exception 3: the amplification of phage particles between the selection cycles 2 and 4 was performed as follows: after infection of log
20 phase *E. coli* ER2738 with phage particles, TSB supplemented with 2 % glucose, 10 µg/ml tetracycline and 100 µg/ml ampicillin was added and followed by incubation with rotation for 30 min at 37 °C. Next, the bacteria were infected with M13K07 helper phage. The infected bacteria were pelleted by centrifugation, re-suspended in TSB-YE medium supplemented with 100
25 µM IPTG, 25 µg/ml kanamycin and 100 µg/ml ampicillin, and grown overnight at 30 °C. The overnight cultures were centrifuged, and phage particles in the supernatant were precipitated twice with PEG/NaCl buffer. Lastly, phages were re-suspended in selection buffer before entering the next selection cycle.

30 In the final selection cycle, log phase bacteria were infected with eluate and diluted before spreading onto TBAB plates (30 g/l tryptose blood agar base, Oxoid cat. no. CMO233B) supplemented with 0.2 g/l ampicillin in order to form single colonies to be used in ELISA screening.

Sequencing of potential binders: Individual clones from the different
35 selection tracks were picked for sequencing. Amplification of gene fragments and sequence analysis of gene fragments were performed essentially as described in Example 1.

ELISA screening of Z variants: Single colonies containing Z variants (expressed as Z variant ABD fusion proteins as described in Example 1) were randomly picked from the selected clones of the matured library, and grown in cultivations essentially as described in Example 1. Preparation of the periplasmic supernatants and ELISA screenings were also performed essentially as described in Example 1 with the following two exceptions. Exception 1: biotinylated hIL-17A was used at a concentration of 0.4 nM. Exception 2: the periplasmic fraction of Z variant Z06282 (SEQ ID NO:1206) from the primary selection was used as a positive control.

EC50 analysis of Z variants: A selection of IL-17A binding Z variants was subjected to an analysis of response against a dilution series of b-hIL-17A using ELISA as described above. Biotinylated target protein was added at a concentration of 6 nM and diluted stepwise 1:3 down to 8 pM. As a background control, the Z variants were also assayed with no target protein added. Periplasm samples containing the primary IL-17A binder Z06282 (SEQ ID NO:1206) were included as a positive control. Data were analyzed using GraphPad Prism 5 and non-linear regression, and EC50 values (the half maximal effective concentration) were calculated.

20 *Results*

Phage display selection of matured IL-17A binding Z variants:

Selection was performed in a total of 24 parallel tracks containing four cycles each. The different selection tracks differed in target concentration, target species origin (human IL-17A or murine IL-17A), selection time, wash conditions and the pH of the elution buffer. Clones originating from the selection tracks using only human IL-17 and elution at pH 2.2 were shown to have the best performance in ELISA screen.

Sequencing: Randomly picked clones were sequenced. Each individual Z variant was given an identification number, Z#####, as described in Example 1. In total, 932 new unique Z variant molecules were identified. For the 494 best performing variants in the ELISA screen below, the amino acid sequences of the 58 amino acid residues long Z variants are listed in Figure 1 as SEQ ID NO:1-3, SEQ ID NO:11-16, SEQ ID NO:28-31, SEQ ID NO:36-63 and SEQ ID NO:67-519. The deduced IL-17A binding motifs extend from residue 8 to residue 36 in each sequence. The amino acid sequences of the 49 amino acid residues long polypeptides predicted to constitute the

complete three-helix bundle within each of these Z variants extend from residue 7 to residue 55.

ELISA screening of Z variants: Clones obtained after four selection cycles were produced in 96-well plates and screened for human IL-17A binding activity using ELISA. All randomly picked clones were analyzed. 494 of the 932 unique Z variants were found to give a response of 2 x the blank control or higher (0.15-2.0 AU) against hIL-17A at a concentration of 0.4 nM. Positive signals were shown for clones originating from all selection tracks. The blank controls had absorbances of 0.055-0.075 AU.

EC50 analysis of Z variants: A subset of Z variants was selected based on the result of the ELISA screening experiment described above (absorbance over 1.25 AU) or based on variation in amino acid sequence, and subjected to a target titration in ELISA format. Periplasm samples were incubated with a serial dilution of b-hIL-17A ranging from 6 nM to 8 pM. A periplasm sample containing Z06282 (SEQ ID NO:1206) identified in the primary selection was included as a positive control. Obtained values were analyzed and the respective EC50 values were calculated (Table 6).

Table 6: Calculated EC50 values from ELISA titration analysis

Z variant	SEQ ID NO	EC50 (M)	Z variant	SEQ ID NO	EC50 (M)
Z10210	36	1.1×10^{-9}	Z10703	48	7.5×10^{-10}
Z10241	11	3.4×10^{-10}	Z10708	49	4.1×10^{-10}
Z10255	37	4.6×10^{-10}	Z10710	50	5.4×10^{-10}
Z10257	38	6.7×10^{-10}	Z10718	16	5.1×10^{-10}
Z10433	28	9.4×10^{-10}	Z10728	51	5.3×10^{-10}
Z10459	39	4.7×10^{-10}	Z10745	52	6.8×10^{-10}
Z10462	12	3.4×10^{-10}	Z10756	53	6.4×10^{-10}
Z10465	40	5.0×10^{-10}	Z10759	54	6.7×10^{-10}
Z10470	41	4.7×10^{-10}	Z10775	55	5.1×10^{-10}
Z10483	42	4.0×10^{-10}	Z10778	56	4.7×10^{-10}
Z10508	2	3.8×10^{-10}	Z10779	57	5.7×10^{-10}
Z10529	43	6.4×10^{-10}	Z10800	58	6.4×10^{-10}
Z10532	1	3.6×10^{-10}	Z10807	59	6.0×10^{-10}
Z10534	13	4.1×10^{-10}	Z10844	60	7.5×10^{-10}
Z10550	44	7.9×10^{-10}	Z10857	61	4.5×10^{-10}
Z10565	45	3.8×10^{-10}	Z10858	62	5.2×10^{-10}
Z10566	14	5.5×10^{-10}	Z10859	31	6.9×10^{-10}
Z10675	15	3.6×10^{-10}	Z10863	3	4.5×10^{-10}
Z10676	46	4.0×10^{-10}	Z10914	63	5.1×10^{-10}
Z10690	47	5.9×10^{-10}	Z06282	1206	5.0×10^{-9}

Example 6Design and construction of a second matured library of IL-17A binding Z variants

5

In this Example, a second matured library was constructed essentially as described in Example 4. The library was used for selections of additional IL-17A binding Z variants.

10 *Materials and methods*

Library design: The library was based on the sequences of IL-17A binding Z variants selected and characterized in Example 5. In the new library, the 13 positions in the Z molecule scaffold that were varied in the maturation library described in Examples 4 and 5 were biased towards certain amino acid residues, according to a strategy based on the Z variant sequences of the 37 top performing variants in the EC50 analysis (Table 6). A DNA linker was generated using split-pool synthesis and ordered from DNA 2.0. It contained the following 147 bp, encoding partially randomized helix 1 and 2 of the amino acid sequence: 5'- AA ATA AAT CTC GAG GTA GAT
15 GCC/GCA AAA TAC GCC AAA GAA/GAG NNN NNN NNN GCG NNN NNN
20 GAG ATC/ATT NNN NNN TTA/CTG CCT/CCC AAC TTA/CTC ACC NNN
NNN CAA/CAG NNN NNN GCC TTC ATC NNN AAA TTA NNN GAT GAC
CCA AGC CAG AGC TCA TTA TTT A -3' (SEQ ID NO:1249; randomized codons are denoted NNN) flanked by restriction sites *Xho*I and *Sac*I. The
25 theoretical distributions of amino acid residues in the new library, including six variable amino acid positions (11, 14, 18, 25, 28 and 32) and seven constant amino acid positions (9, 10, 13, 17, 24, 27 and 35) in the Z molecule scaffold are given in Table 7. The resulting theoretical library size is 3.9×10^6 variants.

Library construction: The library was constructed essentially as described in Example 4 with the following exception: the cells were cultivated overnight in 0.5 l of TSB-YE medium, supplemented with 2 % glucose, 10 µg/ml tetracycline and 100 µg/ml ampicillin.

Preparation of phage stock: Phage stock containing the phagemid library was prepared in shake flasks. Cells from a glycerol stock containing the phagemid library were inoculated in 0.5 l of TSB-YE medium,
35 supplemented with 2 % glucose, 10 µg/ml tetracycline and 100 µg/ml

ampicillin. The cultivations were grown at 37 °C until OD₆₀₀ reached 0.6 and then approximately 83 ml of the cultivation was infected using a 5 x molar excess of M13K07 helper phage and incubated for 40 min at 37 °C. The cells in the cultivation were pelleted by centrifugation, dissolved in TSB-YE medium, supplemented with 100 µg/ml ampicillin, 25 µg/ml kanamycin and 0.1 mM IPTG and grown at 30 °C for 18 h. After cultivation, the cells were pelleted by centrifugation at 4,000 g and the phage particles remaining in the medium were thereafter precipitated twice in PEG/NaCl, filtered and dissolved in PBS and glycerol as described in Example 1. Phage stocks were stored at -80 °C until use in selection.

Table 7: Library design, second maturation

Amino acid position in the Z variant molecule	Randomization (amino acid abbreviations)	No of amino acids	Proportion
9	A	1	1/1
10	D	1	1/1
11	A,D,E,F,G,H,I,K,L,M,N,Q,R,S,T,V,W	17	1/17
13	A	1	1/1
14	A,F,I,L,M,V,Y	7	1/7
17	A	1	1/1
18	A,D,E,F,G,H,I,K,L,M,N,Q,R,S,V,W,Y	17	1/17
24	W	1	1/1
25	A,D (50 %),E,F,I,L,M,V,W,Y	10	1/18, 1/2 (D)
27	W	1	1/1
28	A,D,E,F,G,H,I,L,M,Q,W,Y	12	1/12
32	A,D,E,F,G,H,K,L,M,N,Q,R,S,T,W,Y	16	1/16
35	R	1	1/1

15 Results

Library construction: The new library was designed based on a set of IL-17A binding Z variants with verified binding properties (Example 5). The theoretical size of the designed library was 3.9 x 10⁶ Z variants. The actual size of the library, determined by titration after transformation to *E. coli* ER2738 cells, was 1.4 x 10⁹ transformants.

The library quality was tested by sequencing of 96 transformants and by comparing their actual sequences with the theoretical design. The contents

of the actual library compared to the designed library were shown to be satisfactory. A matured library of potential binders to IL-17A was thus successfully constructed.

5

Example 7

Selection, screening and characterization of Z variants from the second matured library

10 *Materials and methods*

Phage display selection of IL-17A binding Z variants: The target protein hIL-17A was biotinylated as described in Example 1. Phage display selections, using the second matured library of Z variant molecules constructed as described in Example 6, were performed against hIL-17A
15 essentially as described in Example 5 with the following exceptions.
Exception 1: selections were performed in solution or at solid phase in RT.
Exception 2: the time for selection was 60 min, 10 min or 1 min in cycle 1 and 30 min, 4 min or 10 sec in cycles 2, 3 and 4. Selection in solution was followed by catching of target-phage complexes on SA beads as described in
20 Example 1. Exception 3: during selection on solid phase, the target was caught on SA beads prior to selection.

An overview of the selection strategy, summarizing the differences between selection in solution and selection on solid phase, as well as the increased stringency in subsequent cycles obtained by using a lowered target
25 concentration and an increased number of washes, is shown in Table 8.

Tracks 1-6 in cycle 1 were divided in the second to fourth cycles, resulting in total of seven tracks (1-1 to 6-1) in cycle 2, eight tracks (1-1-1 to 6-1-1) in cycle 3 and 16 tracks (1-1-1-1 to 6-1-1-1) in cycle 4. Washes were performed using PBST 0.1 % during 1 min. However, one of the washes
30 lasted for 15 min in tracks 2-1-1, 3-1-1 and 5-1-1 in cycle 3.

After the last wash in cycle 4, the target-phage complexes on SA beads from five of the tracks (1-1-1-1, 1-2-1-2, 3-1-1-1, 4-1-1-1 and 5-1-1-2) were divided in two equal parts. Bound phage particles from the first part were immediately eluted, while the second part was subjected to a wash
35 during approximately 65 h before the elution of phage particles. The bound phage were eluted using glycine-HCl, pH 2.2, as described in Example 1.

The amplification of phage particles between selection cycles was performed essentially as described in Example 1.

Table 8: Overview of the selection from the second matured library

Cycle	Selection track	Phage stock from library or selection track	Target conc. (pM)	Selection time (min)	Number of 1 min washes	Number of 15 min washes	Number of ~65 h washes	Selection method
1	1	Zlib006IL-17A.II	12500	60	3	-	-	solution
1	2	Zlib006IL-17A.II	12500	60	3	-	-	solution
1	3	Zlib006IL-17A.II	1250	60	3	-	-	solution
1	4	Zlib006IL-17A.II	12500	10	3	-	-	solid phase
1	5	Zlib006IL-17A.II	2500	10	3	-	-	solid phase
1	6	Zlib006IL-17A.II	2500	1	3	-	-	solid phase
2	1-1	1	5000	30	6	-	-	solution
2	1-2	1	2500	30	10	-	-	solution
2	2-1	2	1000	30	10	-	-	solution
2	3-1	3	100	30	10	-	-	solution
2	4-1	4	5000	4	6	-	-	solid phase
2	5-1	5	250	4	10	-	-	solid phase
2	6-1	6	250	0.17	10	-	-	solid phase
3	1-1-1	1-1	500	30	15	-	-	solution
3	1-2-1	1-2	50	30	15	-	-	solution
3	2-1-1	2-1	25	30	14	1	-	solution
3	3-1-1	3-1	5	30	14	1	-	solution
3	4-1-1	4-1	500	4	15	-	-	solid phase
3	4-1-2	4-1	50	4	15	-	-	solid phase
3	5-1-1	5-1	25	4	14	1	-	solid phase
3	6-1-1	6-1	5	0.17	15	-	-	solid phase
4	1-1-1-1	1-1-1	50	30	20	-	-	solution
4	1-1-1-1X	1-1-1	50	30	20	-	1	solution
4	1-1-1-2	1-1-1	5	30	20	-	-	solution
4	1-2-1-1	1-2-1	25	30	20	-	-	solution
4	1-2-1-2	1-2-1	5	30	20	-	-	solution
4	1-2-1-2X	1-2-1	5	30	20	-	1	solution
4	2-1-1-1	2-1-1	0.5	30	20	-	-	solution
4	3-1-1-1	3-1-1	0.05	30	20	-	-	solution
4	3-1-1-1X	3-1-1	0.05	30	20	-	1	solution

Cycle	Selection track	Phage stock from library or selection track	Target conc. (pM)	Selection time (min)	Number of 1 min washes	Number of 15 min washes	Number of ~65 h washes	Selection method
4	4-1-1-1	4-1-1	50	4	20	-	-	solid phase
4	4-1-1-1X	4-1-1	50	4	20	-	1	solid phase
4	4-1-2-1	4-1-2	25	4	20	-	-	solid phase
4	5-1-1-1	5-1-1	2.5	4	20	-		solid phase
4	5-1-1-2	5-1-1	0.5	4	20	-	-	solid phase
4	5-1-1-2X	5-1-1	0.5	4	20	-	1	solid phase
4	6-1-1-1	6-1-1	0.5	0.17	20	-	-	solid phase

Sequencing of potential binders: Individual clones from the different selection tracks were picked for sequencing. Amplification and sequence analysis of gene fragments were performed essentially as described in

5 Example 1.

ELISA screening of Z variants: Single colonies containing Z variants (expressed as Z variant ABD fusion proteins as described in Example 1) were randomly picked from the selected clones of the IL-17A second matured library and grown in cultivations as described in Example 1. Preparation of the
10 periplasmic supernatants and ELISA screenings were performed essentially as described in Example 1 with the following two exceptions. Exception 1: biotinylated hIL-17A was used at a concentration of 0.2 or 0.33 nM. Exception 2: the periplasmic fraction of Z variant Z10241 (SEQ ID NO:11), identified in selections from the first matured library, was used as a positive control and
15 the blank control was created by exchanging the periplasmic step with addition of PBST 0.05 %.

EC50 analysis of Z variants: A selection of IL-17A binding Z variants was subjected to an analysis of the response against a dilution series of b-hIL-17A using ELISA as described in Example 5. Biotinylated protein was
20 added at a concentration of 10 nM and diluted stepwise 1:2 eight times followed by one 1:5 dilution down to 8 pM. As a background control, the Z variants were also assayed with no target protein added. A periplasm sample containing the previously matured Z variant Z10241 (SEQ ID NO:11) was included as positive control. Data were analyzed using GraphPad Prism 5
25 and non-linear regression and EC50 values were calculated.

Results

5 Phage display selection of IL-17A binding Z variants from a second
6 maturated library: Selection was performed in a total of 16 parallel tracks
7 containing four cycles each. The selection tracks differed in target
8 concentration, selection time, wash conditions and if the selection was
9 performed in solution or on solid phase.

10 Sequencing: Randomly picked clones were sequenced. Each
11 individual Z variant was given an identification number, Z#####, as described
12 in Example 1. In total, 759 new unique Z variant molecules were identified.

13 For the 704 best performing variants in the ELISA screen below, the
14 amino acid sequences of the 58 amino acid residues long Z variants are listed
15 in Figure 1 and in the sequence listing as SEQ ID NO:5-10, SEQ ID NO:17-
16 27, SEQ ID NO:32-35, SEQ ID NO:64-66 and SEQ ID NO:520-1199. The
17 deduced IL-17A binding motifs extend from residue 8 to residue 36 in each
18 sequence. The amino acid sequences of the 49 amino acid residues long
19 polypeptides predicted to constitute the complete three-helix bundle within
20 each of these Z variants extend from residue 7 to residue 55.

21 ELISA screening of Z variants: Clones obtained after four selection
22 cycles were produced in 96-well plates and screened for hIL-17A binding
23 activity using ELISA. All randomly picked clones were analyzed. 704 of the
24 759 unique Z variants were found to give a response of 2 x the blank controls
25 or higher (0.22-2.2 AU) against hIL-17A at a concentration of 0.2 or 0.33 nM.
26 Positive signals were collected for clones originating from all selection tracks.
27 The average response of the blank controls was 0.11 AU, based on a
28 representative set of plates.

29 EC50 analysis of Z variants: A subset of IL-17A binding Z variants was
30 selected based on the result in the ELISA experiment described above
31 (Z variants with absorbances over the response of the positive control
32 Z10241, SEQ ID NO:11) and subjected to a target titration in ELISA format as
33 described in Example 5. Obtained values were analyzed and their respective
34 EC50 values were calculated (Table 9).

Table 9: Calculated EC50 values from ELISA titration analysis

Z variant	SEQ ID NO	EC50 (M)	Z variant	SEQ ID NO	EC50 (M)
Z12059	17	5.3×10^{-10}	Z12211	22	4.6×10^{-10}
Z12060	5	5.1×10^{-10}	Z12212	64	7.8×10^{-10}
Z12073	18	4.3×10^{-10}	Z12256	23	4.7×10^{-10}
Z12078	8	5.2×10^{-10}	Z12264	10	3.9×10^{-10}
Z12081	6	5.6×10^{-10}	Z12275	24	4.2×10^{-10}
Z12115	20	4.2×10^{-10}	Z12285	65	9.1×10^{-10}
Z12163	9	5.0×10^{-10}	Z12439	66	6.1×10^{-10}
Z12180	21	3.7×10^{-10}			

Example 8

5 In vitro characterization of a subset of matured IL-17A binding Z variants

Materials and methods

Subcloning and production of Z variants with an N-terminal His₆-tag were performed as described in Example 2. One additional variant, His₆-Z15167 (SEQ ID NO:4), was created by site directed mutagenesis of His₆-Z10532 (SEQ ID NO:1) resulting in substitution of D in position 25 with A. Production of His₆-Z15167 was performed as described above for other Z variants.

Circular dichroism (CD) spectroscopy analysis: Purified His₆-tagged Z variants were diluted to 0.5 mg/ml in PBS. For each diluted Z variant, a CD spectrum at 250-195 nm was obtained at 20 °C. In addition, a variable temperature measurement (VTM) was performed to determine the melting temperature (T_m). In the VTM, the absorbance was measured at 221 nm while the temperature was raised from 20 to 90 °C, with a temperature slope of 5 °C/min. A new CD spectrum was obtained at 20 °C after the heating procedure in order to study the refolding ability of the Z variants. The CD measurements were performed on a Jasco J-810 spectropolarimeter (Jasco Scandinavia AB) using a cell with an optical path length of 1 mm.

IL-17 binding ELISA screening: 96-well half area plates (Costar, 3690) were coated overnight at 4 °C with hIL-17A at 1 µg/ml in PBS in a volume of 50 µl/well. On the day of analysis, the plate was rinsed twice in tap water and then blocked with PBS + 2 % BSA (Sigma) for 2 h. Z10241 (SEQ ID NO:11) was used as a standard and was titrated in a 3-fold dilution series (300-0.005

ng/ml) and the other Z variants were added in four different dilutions to the coated ELISA plate (50 μ l/well) and incubated for 1.5 h at RT. The plate was washed 4 times in an automated ELISA washer and 2 μ g/ml (50 μ l/well) of a goat anti-Z antibody was added. After 1 h of incubation, the plate was washed
 5 and 50 μ l of anti-goat IgG-HRP (DAKO) diluted 5000 times was added per well. The plate was developed after another 1 h incubation, washed with 50 μ l TMB (Thermo Fisher, 34021) per well and the reaction was stopped with 50 μ l 2 M H_2SO_4 . The plates were read in a multi label reader (Victor³, Perkin Elmer).

10 Biacore kinetic analysis: Kinetic constants (k_{on} and k_{off}) and affinities (K_D) for human IL-17A were determined for 27 His₆-tagged Z variants. The hIL-17A was immobilized in the flow cell on the carboxylated dextran layer of a CM5 chip surface (GE Healthcare, cat. no. BR100012). The immobilization was performed using amine coupling chemistry according to the
 15 manufacturer's protocol and using HBS-EP (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005 % v/v surfactant P20, GE Healthcare, cat. no. BR100188) as running buffer. One flow cell surface on the chip was activated and deactivated for use as blank during analyte injections. In the kinetic experiment, HBS-EP was used as running buffer and the flow rate was
 20 50 μ l/min. The analytes, i.e. the Z variants, were each diluted in HBS-EP buffer to final concentrations of 100 nM, 20 nM and 4 nM and injected for 4 min, followed by dissociation in running buffer for 8 min. After 8 min dissociation, the surfaces were regenerated with two injections of 10 mM HCl. Kinetic constants were calculated from the sensorgrams using the Langmuir
 25 1:1 model of BiaEvaluation software 4.1 (GE Healthcare).

Biacore binding specificity analysis: The interactions of three His₆-tagged IL-17A binding Z variants (Z10508 (SEQ ID NO:2), Z10532 (SEQ ID NO:1) and Z15167 (SEQ ID NO:4)) with hIL-17A (SEQ ID NO:1226), hIL-17F (SEQ ID NO:1228; R&D Systems, cat. no. 1335-IL/CF) and the human IL-
 30 17A/F heterodimer (R&D Systems, cat. no. 5194-IL-025/CF) were analyzed in a Biacore 2000 instrument. The three different IL-17 variants were immobilized in the flow cells on the carboxylated dextran layer of a CM5 chip surface. The immobilization was performed using amine coupling chemistry according to the manufacturer's protocol and using HBS-EP as running
 35 buffer. One flow cell surface on the chip was activated and deactivated for use as blank during analyte injections. In the binding experiment, HBS-EP was used as running buffer and the flow rate was 50 μ l/min. The analytes, i.e.

the Z variants, were each diluted in HBS-EP running buffer to final concentrations of 4, 20, 100 and 500 nM and injected for 4 min. After 15 min of dissociation, the surfaces were regenerated with four injections of 10 mM HCl. The results were analyzed using the BiaEvaluation software.

- 5 Blocking of IL-17A induced IL-6 production in the NHDF assay: The NHDF assay and quantification by the IL-6 specific ELISA was performed essentially as described in Example 3. In brief, on the day before the experiment, 5000 cells were seeded per well into a half area 96-well culture plates in 100 μ l. On the day of the experiment, dilutions of 36 IL-17A specific
10 Z variants were prepared in a separate 96-well plate. The Z variants were titrated in three-fold steps from 4690 nM to 0.08 nM in medium containing 0.9 nM hIL-17A. A standard curve of hIL-17A (6.2-0.0001 nM) was prepared, as well as controls containing medium with 0.9 nM hIL-17A or medium alone.

15 *Results*

- CD analysis: The CD spectra determined for the IL-17A binding Z variants with a His₆ tag showed that each had a α -helical structure at 20 °C. The results of the variable temperature measurements, wherein melting temperatures (T_m) were determined, are shown in Table 10. Reversible
20 folding was seen for all the IL-17A binding Z variants when overlaying spectra measured before and after heating to 90 °C.

- Analysis of IL-17A binding capacity by ELISA: Purified His₆-tagged Z variant molecules from the first and second maturation round were screened for their capacity to bind IL-17A in an ELISA assay. The results are shown in
25 Figure 3 as percent binding capacity compared to the variant Z10241.

- Biacore kinetic analysis: The interactions of 28 His₆-tagged IL-17A-binding Z variants with hIL-17A were analyzed in a Biacore instrument by injecting various concentrations of the Z variants over a surface containing immobilized IL-17A. A summary of the kinetic parameters (K_D, k_a (k_{on}) and k_d
30 (k_{off})) for binding of the Z variants to hIL-17A using a 1:1 interaction model is given in Table 11.

Table 10: Melting temperatures (T_m)

Analyte	SEQ ID NO of Z variant	T _m (°C)	Analyte	SEQ ID NO of Z variant	T _m (°C)
His6-Z10241	11	48	His6-Z12081	6	50
His6-Z10433	28	56	His6-Z12115	20	51
His6-Z10462	12	51	His6-Z12163	9	54
His6-Z10508	2	54	His6-Z12180	21	51
His6-Z10532	1	57	His6-Z12192	32	45
His6-Z10534	13	41	His6-Z12211	22	49
His6-Z10566	14	51	His6-Z12256	23	47
His6-Z10675	15	52	His6-Z12264	10	54
His6-Z10681	29	52	His6-Z12275	24	46
His6-Z10718	16	48	His6-Z12283	25	45
His6-Z10722	30	51	His6-Z12289	33	51
His6-Z10859	31	52	His6-Z12344	26	49
His6-Z10863	3	51	His6-Z12481	27	49
His6-Z12059	17	50	His6-Z12498	34	48
His6-Z12060	5	52	His6-Z12522	35	51
His6-Z12073	18	49	His6-Z12634	7	50
His6-Z12077	19	52	Z10241-His6	11	47
His6-Z12078	8	51	His6-Z15167	4	57
			Z10199	1217	56

Biacore binding specificity analysis: The binding of three His₆-tagged IL-17A binding Z variants (Z10508, Z10532 and Z15167) to hIL-17A, hIL-17F and hIL-17A/F were tested in a Biacore instrument by injecting the Z variants over surfaces containing the IL-17 variants. The ligand immobilization levels on the surfaces were 657 RU, 977 RU and 770 RU of IL-17A, IL-17F and IL-17A/F, respectively. All tested Z variants showed binding to human IL-17A and weaker binding to IL-17A/F, whereas no binding to IL-17F could be detected. The resulting curves, from which responses from a blank surface were subtracted, are displayed in Figure 4. Z15167 showed the fastest association curve to human IL-17A.

Blocking of IL-17A induced IL-6 production in the NHDF assay: Purified His₆-tagged Z variants from the first and second maturation rounds were screened for their capacity to block IL-17A induced IL-6 production in the NHDF assay. Results from the NHDF assay showed that all tested matured binders had an increased IL-17A specific blocking capacity compared to the primary binder His₆-Z06282. A graph displaying typical inhibition profiles of a selection of binders from the first maturation library are shown in Figure 5,

and the calculated IC50 values for all analysed binders are shown in Table 12.

Table 11: Kinetic parameters for binding of Z variants to hIL-17A

Analyte	SEQ ID NO of Z variant	k_a (1/Ms)	k_d (1/s)	K_D (M)
His6-Z10241	11	5.2×10^5	1.2×10^{-3}	2.2×10^{-9}
His6-Z10433	28	4.7×10^5	3.1×10^{-3}	6.4×10^{-9}
His6-Z10508	2	5.1×10^5	2.0×10^{-3}	4.0×10^{-9}
His6-Z10532	1	6.2×10^5	1.5×10^{-3}	2.4×10^{-9}
His6-Z10566	14	6.1×10^5	5.7×10^{-3}	9.3×10^{-9}
His6-Z10675	15	5.7×10^5	1.1×10^{-3}	1.9×10^{-9}
His6-Z10681	29	6.7×10^5	3.5×10^{-3}	5.2×10^{-9}
His6-Z10859	31	5.6×10^5	6.8×10^{-3}	1.2×10^{-8}
His6-Z10863	3	8.3×10^5	2.5×10^{-3}	3.0×10^{-9}
His6-Z12060	5	7.5×10^5	3.3×10^{-3}	4.3×10^{-9}
His6-Z12073	18	4.9×10^5	1.2×10^{-3}	2.3×10^{-9}
His6-Z12077	19	6.5×10^5	2.0×10^{-3}	3.1×10^{-9}
His6-Z12078	8	4.5×10^5	8.1×10^{-4}	1.8×10^{-9}
His6-Z12081	6	6.2×10^5	3.8×10^{-3}	6.2×10^{-9}
His6-Z12163	9	7.3×10^5	1.6×10^{-3}	2.2×10^{-9}
His6-Z12192	32	4.6×10^5	5.6×10^{-3}	1.2×10^{-8}
His6-Z12211	22	5.8×10^5	1.4×10^{-3}	2.4×10^{-9}
His6-Z12256	23	3.5×10^5	1.2×10^{-3}	3.4×10^{-9}
His6-Z12264	10	6.0×10^5	5.5×10^{-4}	9.3×10^{-10}
His6-Z12275	24	5.2×10^5	1.1×10^{-3}	2.0×10^{-9}
His6-Z12283	25	5.5×10^5	1.8×10^{-3}	3.3×10^{-9}
His6-Z12289	33	6.2×10^5	3.3×10^{-3}	5.3×10^{-9}
His6-Z12344	26	7.1×10^5	6.6×10^{-4}	9.2×10^{-10}
His6-Z12481	27	5.2×10^5	8.9×10^{-4}	1.7×10^{-9}
His6-Z12498	34	6.0×10^5	2.3×10^{-3}	3.8×10^{-9}
His6-Z12522	35	7.1×10^5	4.4×10^{-3}	6.2×10^{-9}
His6-Z12634	7	6.9×10^5	4.3×10^{-3}	6.3×10^{-9}
His6-Z15167	4	1.3×10^6	1.4×10^{-3}	1.1×10^{-9}

Table 12: IC50 values for matured Z-variants

Analyte	SEQ ID NO of Z variant:	IC50 (nM)	Analyte	SEQ ID NO of Z variant:	IC50 (nM)
His6-Z10241	11	5.3	His6-Z12081	6	8.1
His6-Z10433	28	14	His6-Z12115	20	3.0
His6-Z10462	12	6.6	His6-Z12163	9	7.0
His6-Z10508	2	5.7	His6-Z12180	21	4.3
His6-Z10532	1	6.4	His6-Z12192	32	28
His6-Z10534	13	6.5	His6-Z12211	22	2.9
His6-Z10566	14	9.6	His6-Z12256	23	4.4
His6-Z10675	15	5.3	His6-Z12264	10	4.4
His6-Z10681	29	25	His6-Z12275	24	4.8
His6-Z10718	16	28	His6-Z12283	25	6.9
His6-Z10722	30	35	His6-Z12289	33	18
His6-Z10859	31	26	His6-Z12344	26	4.8
His6-Z10863	3	8.5	His6-Z12481	27	3.0
His6-Z12059	17	3.7	His6-Z12498	34	11
His6-Z12060	5	7.9	His6-Z12522	35	10
His6-Z12073	18	4.0	His6-Z12634	7	9.8
His6-Z12077	19	5.5	Z10241-His6	11	3.3
His6-Z12078	8	4.5			

Example 9

5

Production of IL-17 binding Z-ABD-Z polypeptides

IL-17A is a homodimeric cytokine that possesses two receptor binding sites. It was speculated that a polypeptide comprising two moieties of an IL-17A binding Z variant of the present disclosure would block IL-17A more efficiently than a polypeptide comprising one such moiety. This Example describes the general procedure for subcloning and production of polypeptides comprising two Z variants in fusion with the albumin binding domain variant PP013 (SEQ ID NO:1224) in the general format Z-[L1]-ABD-[L2]-Z where [L1] and [L2] are linkers separating the Z and ABD moieties.

15

Materials and methods

Subcloning of Z-[L1]-ABD-[L2]-Z polypeptides with different [L1] and [L2] linker lengths: The DNA of Z06282 (SEQ ID NO:1206), Z10241 (SEQ ID NO:11) and Z10532 (SEQ ID NO:1) were amplified from the library vector pAY02592 by PCR using Pfu Turbo DNA polymerase (Agilent Technologies,

20

cat. no. 600254) together with suitable primer pairs. The Z-[L1]-ABD-[L2]-Z constructs were generated by ligation of DNA encoding each moiety into the expression vector pET26b(+) (Novagen, Madison,WI) in three subsequent cloning steps using T4 DNA ligase (Fermentas, cat.no. EL0011). DNA
5 encoding the three moieties were separated by DNA encoding hybridized linkers with different number of repeats of (GGGGS)_n, flanked by restriction enzyme sites. The constructs encoded by the expression vectors were Z#####-[GAP-(G₄S)_n-TS]-PP013-[GT-(G₄S)_n-PR]-Z#####, where each n individually is 1-4, and as further specified in Table 13.

10

Table 13: Dimeric Z variants fused to ABD via different [L1] and [L2] lengths

Designation	SEQ ID NO	Z-[L1]-ABD-[L2]-Z polypeptide
ZAZ3174	1233	Z06282-[GAP-(G ₄ S) ₄ -TS]-PP013-[GT-(G ₄ S) ₄ -PR]-Z06282
ZAZ3175	1234	Z06282-[GAP -(G ₄ S) ₃ -TS]- PP013-[GT-(G ₄ S) ₃ -PR]-Z06282
ZAZ3176	1235	Z06282-[GAP -(G ₄ S) ₂ -TS]- PP013-[GT-(G ₄ S) ₂ -PR]-Z06282
ZAZ3236	1240	Z06282-[GAP-G ₄ S-TS]- PP013-[GT-G ₄ S-PR]-Z06282
ZAZ3237	1241	Z06282-[GAP-G ₄ S-TS]- PP013-[GT-(G ₄ S) ₂ -PR]-Z06282
ZAZ3220	1236	Z10241-[GAP-(G ₄ S) ₄ -TS]- PP013-[GT-(G ₄ S) ₄ -PR]-Z10241
ZAZ3221	1237	Z10532-[GAP-(G ₄ S) ₄ -TS]- PP013-[GT-(G ₄ S) ₄ -PR]-Z10532

Restriction sites (I)-(IV) in DNA encoding Z#####-[(I)-(G₄S)_n-(II)]-PP013-[(III)-(G₄S)_n-(IV)]-Z##### are cleavable with restriction enzymes *AscI* (I), *SpeI* (II), *KpnI* (III) and *SacII* (IV), respectively

15

Subcloning of Z-[L1]-ABD-[L2]-Z polypeptides with a minimal [L1] linker: DNA encoding additional dimeric Z variants comprising Z06282 (SEQ ID NO:1206) but with a minimal linker [L1] were generated using standard molecular biology techniques. The constructs encoded by the expression
20 vectors were Z06282-VDGS-PP013-GT-(G₄S)_n-PR-Z06282 and as further specified in Table 14.

The genes encoding Z12876 (SEQ ID NO:1218), Z14253 (SEQ ID NO:1219), Z14254 (SEQ ID NO:1220) and Z14255 (SEQ ID NO:1221) (corresponding to Z10241 (SEQ ID NO:11), Z10532 (SEQ ID NO:1), Z10508
25 (SEQ ID NO:2) and Z10863 (SEQ ID NO:3), respectively, but starting with the amino acid residues AE instead of VD) were amplified by PCR using Pfu Turbo DNA polymerase together with suitable primer pairs. The Z-[L1]-ABD-[L2]-Z constructs were generated by ligation of each fragment into the expression vector pET26b(+) in three subsequent cloning steps using T4
30 DNA ligase. DNA encoding the three moieties were separated by linkers further modified by site-directed mutagenesis using standard molecular

biology techniques. The constructs encoded by the expression vectors were Z####-[VDGS]-PP013-[GT-G₄S-PK]-Z#### and Z#####-[ASGS]-PP013-[GT-G₄S]-Z#####, and as further specified in Table 14.

5 Table 14: Dimeric Z variants fused to ABD via a minimal [L1] linker

Designation	SEQ ID NO	Z-[L1]-ABD-[L2]-Z polypeptide	Mutations
ZAZ3234	1238	Z06282-[VDGS]-PP013-GT-G ₄ S-PR-Z06282	
ZAZ3235	1239	Z06282-[VDGS]-PP013-GT-(G ₄ S) ₂ -PR-Z06282	
ZAZ3269	1242	Z12876-[VDGS]-PP013-[GT-G ₄ S-PK]-Z12876	R117K
ZAZ3270	1243	Z12876-[ASGS]-PP013-[GT-G ₄ S]-Z12876	V59A, D60S, Δ116P, Δ117R
ZAZ3363	1244	Z14253-[ASGS]-PP013-[GT-G ₄ S]-Z14253	V59A, D60S, Δ116P, Δ117R
ZAZ3364	1245	Z14254-[ASGS]-PP013-[GT-G ₄ S]-Z14254	V59A, D60S, Δ116P, Δ117R
ZAZ3365	1246	Z14255-[ASGS]-PP013-[GT-G ₄ S]-Z14255	V59A, D60S, Δ116P, Δ117R
ZAZ3422	1247	Z15166-[ASGS]-PP013-[GT-G ₄ S]-Z15166	D25A in both Z14253 moieties in ZAZ3363

Δ: deletion of the indicated amino acid residue

10 Cultivation: *E. coli* BL21(DE3) cells (Novagen) were transformed with plasmids containing the gene fragment of each respective Z-ABD-Z polypeptide and cultivated at 37 °C in 800 or 1000 ml of TSB-YE medium supplemented with 50 µg/ml kanamycin. In order to induce protein expression, IPTG was added to a final concentration of 0.2 mM at OD₆₀₀ = 2 and the cultivation was incubated at 37 °C for another 5 h. The cells were harvested by centrifugation.

15 Purification of IL-17A binding Z-ABD-Z polypeptides: Cell pellets were re-suspended in TST buffer (25 mM Tris-HCl, 1 mM EDTA, 200 mM NaCl, 0.05 % Tween 20, pH 8.0) supplemented with Benzonase[®] (Merck). After cell disruption by sonication and clarification by centrifugation, each supernatant was applied onto a column packed with agarose and immobilized with an anti-ABD ligand (produced in-house). After washing with TST buffer and 5 mM
20 NH₄Ac pH 5.5 buffer, the Z-ABD-Z polypeptides were eluted with 0.1 M HAc. Acetonitrile (ACN) was added to eluted fractions to a final concentration of 10 % and the samples were loaded on SOURCE 15RPC columns (GE Healthcare), previously equilibrated with RPC solvent A (0.1 % TFA, 10 %

ACN, 90 % water). After column wash with RPC solvent A, bound proteins were eluted with a linear gradient from RPC solvent A to RPC solvent B (0.1 % TFA, 80 % ACN, 20 % water). Fractions containing pure Z-ABD-Z polypeptides were identified by SDS-PAGE analysis and pooled. After the
5 RPC purification, the buffer of the pool was exchanged to PBS (2.68 mM KCl, 137 mM NaCl, 1.47 mM KH₂PO₄, 8.1 mM Na₂HPO₄, pH 7.4) using Sephadex G-25 columns (GE Healthcare). Finally, the Z-ABD-Z variants were purified on EndoTrap[®] red columns (Hyglos) to ensure low endotoxin content.

Protein concentrations were determined by measuring the absorbance
10 at 280 nm, using a NanoDrop[®] ND-1000 spectrophotometer and the extinction coefficient of the respective protein. Purity was analyzed by SDS-PAGE stained with Coomassie Blue, and the identity of each purified Z-ABD-Z variant was confirmed by HPLC-MS analysis.

15 *Results*

Cultivation and purification: The IL-17A binding Z variants in fusion with ABD were expressed as soluble gene products in *E. coli*. SDS-PAGE analysis of each final protein preparation showed that these predominantly contained the desired IL-17A binding Z-ABD-Z polypeptide. The correct identity and
20 molecular weight of each Z-ABD-Z polypeptide were confirmed by HPLC-MS analysis.

Example 10

25 Solubility of Z-ABD-Z polypeptides

The solubility of three Z-ABD-Z polypeptides in physiological buffer was investigated by consecutive concentrations of the samples using ultrafiltration, followed by concentration measurements by absorbance
30 readings at 280 nm and visual inspection of the samples.

Materials and methods

The Z-ABD-Z polypeptides ZAZ3363 (SEQ ID NO:1244), ZAZ3364 (SEQ ID NO:1245) and ZAZ3422 (SEQ ID NO:1247) were diluted in PBS, pH
35 7.4, to 2.5 mg/ml. 12 Amicon Ultra centrifugal filter units with a cut-off of 3 kDa (Millipore, cat. no. UFC800324) were prerinsed with PBS by centrifugation at 4000 g for 10 min in a swinging bucket rotor centrifuge. The

concentrators were emptied, and 4 ml of each Z-ABD-Z polypeptide were added to a first set of three different centrifugal filter units. Centrifugation was performed at 4000 *g*, 20 °C, for 13-16 min, resulting in approximately 1 ml concentrate. A 20 µl sample was removed from each concentrate (UF sample 1) for further analysis and the rest of the sample volumes were transferred to a second set of three centrifugal filter units. The centrifugation and sample removal were repeated three times with spinning times of 8-10 min, 7 min and 13 min, respectively, (UF samples 2, 3 and 4, respectively). Absorbance readings were performed using a NanoDrop® ND-1000 Spectrophotometer and by diluting UF samples 1-4 in PBS 3, 6, 12 and 24 times, respectively. The concentrations were calculated using the theoretical extinction coefficient 1 Abs₂₈₀=0.612 mg/ml (the same for all three Z-ABD-Z polypeptides). Absorbance readings of the undiluted filtrates were also performed.

15 Results

Concentrations determined by absorbance readings at 280 nm after each centrifugal step are shown in Table 15. No aggregates were detected by visual inspection of the concentrates. Thus, the solubility of ZAZ3363, ZAZ3364 and ZAZ3422 were determined to be at least 60 mg/ml in PBS, pH 7.4. Absorbance readings of the undiluted filtrates showed concentrations very close to 0 mg/ml.

Table 15: Concentration after consecutive concentration of Z-ABD-Z samples

Z-ABD-Z polypeptide	SEQ ID NO	Concentration (mg/ml)				Total time of centrifugation (min)
		UF1	UF2	UF3	UF4	
ZAZ3363	1244	9.6	21	36	64	44
ZAZ3364	1245	8.2	21	38	60	43
ZAZ3322	1247	9.3	20	35	64	44

25

Example 11

Biacore binding cross-species analysis

Materials and methods

The interaction of the Z-ABD-Z polypeptides ZAZ3363 (SEQ ID NO:1244), ZAZ3364 (SEQ ID NO:1245) and ZAZ3365 (SEQ ID NO:1246) with hIL-17A and cynomolgus monkey IL-17A (cIL-17A, SEQ ID NO:1229;

30

Evitria, custom order) as well as the interaction of ZAZ3220 (SEQ ID NO:1236) with hIL-17A and rhesus monkey IL-17A (rmIL-17-A, SEQ ID NO:1230; Cusabio, cat. no. CSB-EP011597MOV) were analyzed in a Biacore 2000. HSA was immobilized in the flow cell on the carboxylated dextran layer of a CM5 chip surface. The immobilization was performed using amine coupling chemistry according to the manufacturer's protocol and using HBS-EP as running buffer. The HSA immobilization levels on the surfaces were 953 RU (used for ZAZ3363, ZAZ3364 and ZAZ3365) and 493 RU (used for ZAZ3220), respectively. One flow cell surface on the chip was activated and deactivated for use as blank during analyte injections. In the binding experiments, HBS-EP was used as running buffer and the flow rate was 30 μ l/min. ZAZ3363, ZAZ3364 and ZAZ3365 were diluted in HBS-EP running buffer to a final concentration of 200 nM and injected for 5 min, followed by injections of the IL-17A variants. ZAZ3220 was diluted in HBS-EP running buffer to a final concentration of 500 nM and injected for 4 min followed by injections of the IL-17A variants. hIL-17A and cIL-17A were each diluted in HBS-EP running buffer to final concentrations of 2.5, 10 and 40 nM and injected for 5 min over surfaces with ZAZ3363, ZAZ3364 and ZAZ3365 captured on HSA. After 10 min of dissociation, the surface was regenerated with two injections of 10 mM HCl. hIL-17A and rmIL-17A were diluted in HBS-EP running buffer to final concentrations of 0.1, 0.3, 0.9, 2.7, and 8.1 nM and 2.7, 8.1, 24.3, 72 and 216 nM, respectively, and injected for 6 min over surfaces with ZAZ3220 captured on HSA. After 5 min of dissociation, the surface was regenerated with two injections of 10 mM HCl. The results were analyzed using the BiaEvaluation software.

Results

Binding of hIL-17A and cIL-17A to ZAZ3363, ZAZ3364 and ZAZ3365, and hIL-17A and rmIL-17A to ZAZ3220 were tested in a Biacore instrument by injecting the Z-ABD-Z polypeptides over a surface containing HSA followed by injections of the IL-17A variants. All tested Z variants showed binding to the tested IL-17A variants, i.e. ZAZ3363, ZAZ3364 and ZAZ3365 showed binding to human and cynomolgus monkey IL-17A (Figure 6) and ZAZ3220 to human and rhesus monkey IL-17A.

Example 12Biacore binding specificity analysis

In this Example, the specificities of two Z-ABD-Z polypeptides were tested by analysing their potential interaction with a set of proteins of the IL-17 family, with other interleukins and with other abundant plasma proteins. The same set of analyte proteins were also analyzed for their potential interaction with the ABD variant PEP07843.

10 *Materials and methods*

The interaction of ZAZ3363 (SEQ ID NO:1244) or ZAZ3422 (SEQ ID NO:1247) with panels of 24 or 12 different proteins (specified in Table 16), respectively, were analyzed in a Biacore 2000 instrument. HSA and the ABD variant PEP07843 (SEQ ID NO:1225, corresponding to PP013 (SEQ ID NO:1224) with an N-terminal extension of GSS) were immobilized on a CM5 chip surface and a blank surface was prepared as described in Example 11. The ligand immobilization levels on the surfaces were 1315 RU and 99 RU of HSA and PEP07843, respectively, for the chip used in ZAZ3363 runs, and 791 RU and 100 RU of HSA and PEP07843, respectively, for the chip used in ZAZ3422 runs. In the binding experiment, HBS-EP was used as running buffer and the flow rate was 30 µl/min. ZAZ3363 and ZAZ3422 were diluted in HBS-EP or HBS-EP supplemented with 500 mM NaCl to a final concentration of 200 nM and injected for 7 min followed by injections of the analytes. The analytes, i.e. the panels of 24 or 12 different proteins, were each diluted in HBS-EP or HBS-EP supplemented with 500 mM NaCl to final concentrations of from 0.4 to 250 nM and injected for 5 min. After 7 (ZAZ3363) or 10 (ZAZ3422) min of dissociation, the surfaces were regenerated with four (ZAZ3363) or five (ZAZ3422) injections of 10 mM NaOH and two injections of 10 mM HCl. The results were analyzed using the BiaEvaluation software.

30

Table 16: Analyte proteins tested with ZAZ3363 and ZAZ3422

First injection		Second injection			Buffer for sample dilution
ZAZ3363 (200 nM)	ZAZ3422 (200 nM)	Analyte protein	Cat. No.	Analyte conc. (nM)	
Yes	Yes	hIL-17A ¹	200-17	2, 10, 50	HBS-EP and HBS-EP + NaCl
Yes	Yes	hIL-17A/F ²	5194-IL-025/CF	50, 250	HBS-EP + NaCl

Yes	Yes	hIL-17B²	1248-IB-025/CF	50, 250	HBS-EP + NaCl
Yes	Yes	hIL-17C²	1234-IL-025/CF	50, 250	HBS-EP
Yes	Yes	hIL-17D²	1504-IL-025/CF	50, 250	HBS-EP + NaCl
Yes	Yes	hIL-17E²	1258-IL-025/CF	50, 250	HBS-EP
Yes	Yes	hIL-17F²	1335-IL/CF	50, 250	HBS-EP + NaCl
Yes	Yes	hIL-1beta¹	200-1B	50, 250	HBS-EP
Yes	Yes	hIL-6²	206IL/CF	50, 250	HBS-EP
Yes	Yes	hIL23²	1290-IL	50, 250	HBS-EP
Yes	Yes	hGM-CSF²	215-GM/CF	50, 250	HBS-EP
Yes	Yes	IgG (RoActemra)³	ATC L04AC07	50, 250	HBS-EP
Yes	No	IgA⁴	P80-102	50, 250	HBS-EP
Yes	No	IL-17RA²	177-IR	50, 250	HBS-EP
Yes	No	IL-1R1²	269-1R/CF	50, 250	HBS-EP
Yes	No	Alpha-2-HS-glycoprotein (AHSG Human HEK)⁵	PRO-1644	50, 250	HBS-EP
Yes	No	Haptoglobin Human (seems to be beta chain)⁵	PRO-567	50, 250	HBS-EP
Yes	No	Alpha-1-antitrypsin (SERPINA1 Human)⁵	PRO-529	50, 250	HBS-EP
Yes	No	Human a-2 macroglobulin⁶	10952-H08B	50, 250	HBS-EP
Yes	No	Human Hemopexin / HPX Protein⁶	10870-H08H	50, 250	HBS-EP
Yes	No	AMBP / Alpha 1 microglobulin⁶	13141-H08H1	50, 250	HBS-EP
Yes	No	Beta-2-microglobulin / B2M⁶	11976-H08H	50, 250	HBS-EP
Yes	No	Transthyretin / TTR / Prealbumin / PALB Protein⁶	12091-H08H	50, 250	HBS-EP
Yes	No	holo-Transferrin⁷	T4132	50, 250	HBS-EP
Yes	No	IL-17RA²	177-IR	50, 250	HBS-EP
Yes	No	IL-1R1²	269-1R/CF	50, 250	HBS-EP

Suppliers: ¹Peprtech; ²R&D Systems; ³Roche/Apoteket AB; ⁴Bethyl; ⁵ProSpec; ⁶Sino Biological Inc; ⁷Sigma

Results

The specificity of ZAZ3363 and ZAZ3422 was tested in a Biacore instrument by investigating their interaction with 24 or 12 analyte proteins, respectively. The Z-ABD-Z polypeptides were injected over surfaces
5 containing HSA followed by injection of the analyte proteins. The only interactions detected for ZAZ3363 and ZAZ3422 were strong binding by hIL-17A and weaker binding by hIL-17A/F, as expected and in line with the results presented in Example 8. The analyte proteins were also assessed for their potential interaction with the ABD variant PEP07843, but no interactions were
10 detected. Thus, the Z-ABD-Z polypeptides appear to be highly specific.

Example 13

Kinetic measurements of Z-ABD-Z, IL-17A and HSA complexes using
15 KinExA[®]

Technical limitations of SPR to accurately determine kinetic parameters for high affinity interactions and the higher complexity of determining the affinity between two dimeric targets by SPR warranted the
20 use of Kinetic Exclusion Assay (KinExA[®]) technology to further analyze the binding of Z-ABD-Z polypeptides in complex with HSA to IL-17A, as well as the binding of Z-ABD-Z polypeptides alone, or in complex with IL-17A, to HSA. The KinExA[®] measures the equilibrium binding affinity and kinetics between unmodified molecules in solution phase (Darling and Brault, 2004.
25 Assay and Drug Dev Tech 2(6):647-657)

Materials and methods

The Z-ABD-Z polypeptides ZAZ3220 (SEQ ID NO:1236), ZAZ3363 (SEQ ID NO:1244) and ZAZ3422 (SEQ ID NO:1247), as well as HSA
30 (Novozymes, cat. no. 230-005), human IL-17A (Peprotech, cat. no. 200-17), biotinylated (as described in Example 1) human IL-17A, mouse monoclonal anti-HSA antibody (Abcam, cat. no. 10241) and an in house produced goat polyclonal anti-Z antibody were sent to Sapidyne Instruments Inc (Boise, Idaho, USA) who performed the KinExA[®] measurements and analysis.
35 Binding of Z-ABD-Z/HSA to IL-17A: For determination of the affinity, i.e. K_D , the respective Z-ABD-Z polypeptide, in complex with HSA, were used

as a constant binding partner (CBP) and IL-17A was used as titrant. Data analysis was performed using the KinExA[®] Pro software and applying a least squares analysis to fit the optimal solutions for the K_D and the Active Binding site Concentration (ABC) to a curve representative of a 1:1 reversible bi-molecular interaction.

For determination of k_a , the direct binding curve analysis was applied, using the same immobilized IL-17A as the capture reagent for kinetic experiments as for equilibrium experiments. The amount of free Z-ABD-Z/HSA in the sample was measured pre-equilibrium, yielding data points that monitored the decrease in free Z-ABD-Z/HSA as the sample moved toward equilibrium.

Binding of Z-ABD-Z and Z-ABD-Z/IL-17A to HSA: The Z-ABD-Z polypeptide ZAZ3363 was further analyzed for binding to HSA in the presence or absence of IL-17A. For determination of K_D , ZAZ3363, free or in complex with IL-17A, was used as a constant binding partner (CBP) and HSA was used as titrant. Data analysis was performed using the KinExA[®] Pro software as described above.

For determination of k_a , the direct binding curve analysis was applied, using the same immobilized HSA as the capture reagent for kinetic experiments as for equilibrium experiments. The amount of ZAZ3363/IL-17A, in the sample was measured pre-equilibrium, yielding data points that monitored the decrease in free ZAZ3363/IL-17A as the sample moved toward equilibrium.

Results

In a first set of KinExA[®] measurements, the Z-ADB-Z polypeptides ZAZ3220, ZAZ3363 and ZAZ3422, respectively, in complex with HSA were shown to bind IL-17A with an exceptionally high affinity, with K_D values in the subpicomolar to femtomolar range. The calculated kinetic parameters when assuming a monovalent binding between these Z-ABD-Z polypeptides and dimeric IL-17A are shown in Table 17.

In a second set of KinExA[®] measurements, the interaction between ZAZ3363, free or in complex with IL-17A, and HSA was measured. The calculated kinetic parameters from these analyses are shown in Table 18. The affinity of ZAZ3363 for HSA was not significantly affected by the presence of IL-17A.

To summarize, measurements using KinExA[®] technology indicated an exceptionally high affinity of Z-ABD-Z polypeptides for IL-17A. The measured K_D of < 0.33 pM is superior to the reported affinities for two of the clinically most advanced comparators secukinumab (K_D = 122 pM; WO2006/013107 and WO2012/125680) and ixekizumab (K_D = 2 pM; WO2007/070750). In addition, simultaneous binding to both IL-17A and albumin was demonstrated, i.e. both binding functions are intact in the Z-ABD-Z fusion protein.

Table 17: Kinetic parameters for Z-ABD-Z polypeptides binding to IL-17A

CBP	SEQ ID NO	k_a^a [*] ($M^{-1}s^{-1}$)	k_d (s^{-1})	K_D [*] (M)
ZAZ3220/HSA	1236	1.35×10^7 [1.25×10^7 - 1.46×10^7]	1.51×10^{-7}	$<6.5 \times 10^{-14}$ [**]
ZAZ3363/HSA	1244	4.78×10^6 [5.64×10^6 - 4.04×10^6]	1.55×10^{-6}	3.23×10^{-13} [1.54×10^{-13} – 5.54×10^{-13}]
ZAZ3422/HSA	1247	7.80×10^6 [6.37×10^6 - 9.56×10^6]	6.08×10^{-7}	7.85×10^{-14} [1.63×10^{-14} – 1.73×10^{-13}]

* 95% confidence interval
** 95% confidence interval for K_D was not resolved

Table 18: Kinetic parameters for a Z-ABD-Z polypeptide binding to HSA

CBP	SEQ ID NO	k_a [*] ($M^{-1}s^{-1}$)	k_d (s^{-1})	K_D [*] (M)
ZAZ3363	1244	n.d.	n.d.	4.85×10^{-11} [3.23×10^{-11} - 6.87×10^{-11}]
ZAZ3363/IL-17A	1244	1.21×10^6 [9.35×10^5 - 1.50×10^6]	3.56×10^{-5}	2.94×10^{-11} [1.72×10^{-11} - 4.64×10^{-11}]

* 95% confidence interval

Example 14Characterization of Z-ABD-Z polypeptides in the NHDF assay*Materials and methods*

5 Blocking of IL-17A induced IL-6 production in NHDF assay: NHDF cells (Lonza, cat.no. CC-2511) were cultured in fibroblast basal medium (Lonza, cat.no CC-3132) supplied with growth promoting factors (Lonza, cat.no. CC-5034). On the day before the experiment, 5000 cells per well were seeded into half area 96 well culture plates (Greiner, cat.no. 675180) in 100 μ l. On the
10 day of the experiment, dilutions of IL-17A specific Z-ABD-Z polypeptides with different linker lengths between the Z and ABD moieties (ZAZ3174 (SEQ ID NO:1233), ZAZ3175 (SEQ ID NO:1234), ZAZ3176 (SEQ ID NO:1235), ZAZ3220 (SEQ ID NO:1236), ZAZ3221 (SEQ ID NO:1237), ZAZ3234 (SEQ ID NO:1238), ZAZ3235 (SEQ ID NO:1239), ZAZ3236 (SEQ ID NO:1240),
15 ZAZ3237 (SEQ ID NO:1241), ZAZ3269 (SEQ ID NO:1242) and ZAZ3270 (SEQ ID NO:1243)) were prepared in a separate 96-well plate. The Z-ABD-Z polypeptides were titrated in three-fold steps from 190 nM to 0.003 nM in medium containing 0.9 nM hIL-17A and 8 μ M HSA. A standard IL-17A curve was also prepared (6.2-0.0001 nM), as well as controls containing medium
20 with 0.9 nM IL-17A or medium alone. The medium in the plate with NHDF cells cultured overnight was discarded and 100 μ l/well of the sample was transferred to the cell plate, which was placed in an incubator at 37 °C for 18-24 h. The next day, the IL-6 content in supernatants was quantified using IL-6 specific ELISA as described in Example 3. Additional Z-ABD-Z polypeptides
25 (ZAZ3363 (SEQ ID NO:1244), ZAZ3364 (SEQ ID NO:1245), ZAZ3365 (SEQ ID NO:1246) and ZAZ3422 (SEQ ID NO:1247)) were analyzed in subsequent NHDF assays essentially as described above, but using an NHDF cell line from ATCC (cat. no. PSC-201-012). The blocking capacities of these Z-ABD-Z polypeptides were also analyzed after incubation of the polypeptides at
30 40 °C for 2 and 4 weeks.

Results

 Z-ABD-Z polypeptides were investigated for their capacity to block IL-17A induced IL-6 production in the NHDF assay. First, it was seen that the Z-
35 ABD-Z format increased the blocking capacity significantly compared to the monomeric His₆-Z format, as shown in Figure 7A where inhibitory curves for

His₆-Z10241 and ZAZ3220 (comprising Z10241) are displayed. The shape of the curve for ZAZ3220 suggests that the limit of detection for this cell assay is reached, with a one-to-one inhibition effect of the ZAZ3220, and it is likely that the Z-ABD-Z polypeptide has an even better inhibitory effect than can be appreciated from this experiment. It is contemplated that the potency of ZAZ3220 is increased to the assay limit due to the strong avidity effect obtained by binding the homodimeric IL-17A. Second, a comparison of Z-ABD-Z polypeptides with different linker lengths and comprising the Z variants Z06282 (SEQ ID NO:1206) and Z12876 (SEQ ID NO:1218) revealed that the length of the linker had a minor effect on the blocking capacity. A set of Z-ABD-Z polypeptides comprising Z06282 with different linker lengths is displayed in Figure 7B. Additional Z-ABD-Z polypeptides, ZAZ3363, ZAZ3364, ZAZ3365 and ZAZ3422, were analyzed in subsequent NHDF assays, also after incubation of the Z-ABD-Z polypeptides at 40 °C for two and four weeks. The IL-17A inhibitory capacity was retained even after four weeks' incubation at 40 °C. Calculated IC₅₀ values, reflecting the capacity of different Z-ABD-Z polypeptides to inhibit IL-17A, are summarized in Table 19. These IC₅₀ values are more than three-fold lower than the reported hIL-6 production neutralizing activity (IC₅₀=2.1±0.1 nM) of the IL-17A inhibiting monoclonal antibody secukinumab, AIN457, (WO2006/013107 and WO2012/125680) currently in clinical development.

Table 19: Calculated IC50 values from NHDF assays

Z-ABD-Z polypeptide	SEQ ID NO	Incubation at 40 °C (weeks)	IC50 (nM)
ZAZ3174	1233	n.a.	0.63
ZAZ3175	1234	n.a.	0.56
ZAZ3176	1235	n.a.	0.50
ZAZ3220	1236	n.a.	0.27
ZAZ3221	1237	n.a.	0.39
ZAZ3234	1238	n.a.	0.66
ZAZ3235	1239	n.a.	0.60
ZAZ3236	1240	n.a.	0.54
ZAZ3237	1241	n.a.	0.49
ZAZ3269	1242	n.a.	0.42
ZAZ3270	1243	n.a.	0.41
ZAZ3363	1244	0	0.38
ZAZ3363	1244	2	0.25
ZAZ3363	1244	4	0.49
ZAZ3364	1245	0	0.20
ZAZ3364	1245	2	0.40
ZAZ3364	1245	4	0.47
ZAZ3365	1246	0	0.45
ZAZ3365	1246	2	0.34
ZAZ3365	1246	4	0.55
ZAZ3422	1247	0	0.38
ZAZ3422	1247	2	0.45
ZAZ3422	1247	4	0.42

Example 15

5

In vivo neutralization of hIL-17A

Human IL-17A is able to bind to and stimulate the mouse IL-17 receptor, leading to elevation and subsequent secretion of mouse KC (CXCL1) chemokine.

10

Materials and methods

In vivo neutralization of hIL-17A in the KC mouse model: Dose ranging experiments were performed to identify the optimal dose of human IL-17A for induction of mouse KC. These experiments revealed that a 150 µg/kg dose of human IL-17A induced a suitable level of KC in mouse serum collected 2 h

15

after IL-17A administration. ZAZ3174 (SEQ ID NO:1233) and ZAZ3220 (SEQ ID NO:1236) were analyzed in this model at two different occasions. In the first experiment, ZAZ3174 was administered s.c. to mice at three different doses; 0.25, 2.5 and 25 mg/kg, 9 h prior to a subcutaneous injection of human IL-17A. The mice were sacrificed 2 h post administration of human IL-17A, and KC levels were determined by ELISA using a commercially available kit according to the manufacturer's instruction (KC Quantikine; R&D Systems, cat no. D1700). In the second experiment, ZAZ3220 was administered s.c. to mice at three different doses, 0.05, 0.1, 0.4 mg/kg, 9 h prior to a subcutaneous injection of human IL-17A. The mice were sacrificed 2 h post administration of human IL-17A, and KC levels were determined by ELISA as above.

Results

In vivo neutralization of hIL-17A in the KC mouse model: The assayed Z-ABD-Z polypeptides block the ability of human IL-17A to stimulate the mouse IL-17 receptor, leading to inhibition of an elevation of mouse KC, in a dose dependent manner. ZAZ3174 at a dose of 2.5 mg/kg under the conditions described, blocked the induction of KC completely, as shown in Figure 8A. The second experiment revealed that the Z-ABD-Z polypeptide ZAZ3220, comprising an affinity matured Z variant, blocked the IL-17A induced KC-response completely at a dose of 0.4 mg/kg (Figure 8B). This corresponds to a 6-fold enhanced *in vivo* blocking effect compared to ZAZ3174. 72 % inhibition was obtained with 0.1 mg/kg ZAZ3220.

Example 16

In vivo pharmacokinetics of Z-ABD-Z polypeptides in rats

This Example describes two separate experiments in which the pharmacokinetic parameters in rat were determined for two different Z-ABD-Z polypeptides following subcutaneous (s.c.) and/or intravenous (i.v.) injections.

Materials and methods

In a first experiment, ZAZ3220 (SEQ ID NO:1236) formulated in PBS was administered i.v. (n=3) to Sprague Dawley (SD) male rats (Charles River, Germany) at a dose of 1.2 mg/kg corresponding to 57 nmol/kg. Blood

samples were collected from the tail vein of each rat at time points 0.08, 8, 24, 48, 72, 120, 168, 240, 336, 408 and 504 h after administration.

In a second experiment, ZAZ3363 (SEQ ID NO:1244) formulated in PBS was administered i.v. (n=5) or s.c. (n=6) to SD male rats at a dose of 1.2 mg/kg corresponding to 64 nmol/kg. Blood samples were collected from the tail vein of each rat at time points 0, 0.08, 0.5, 1, 3, 8, 24, 72, 120, 168, 216, 264, 336, 408, 456 and 504 h post i.v. administration or at time points 0, 0.08, 0.5, 1, 3, 8, 24, 72, 120 and 168 h post s.c. administration.

Serum was prepared from the blood samples and stored at -20 °C until analysis. Quantification of ZAZ3220 and ZAZ3363 in serum from rats was performed using a PK-ELISA.

PK-ELISA: 96-well, half-area plates (50 µl/well) were coated with 4 µg/well of goat anti-Z Ig (produced in-house) in coating buffer (Sigma, cat.no. C3041) overnight at 4 °C. The next day, the plates were blocked with PBS + 0.5 % casein for 1.5 h. Individual rat serum, minimally diluted 10 x in PBS-casein + 10 % rat serum pool (assay matrix) was added to the plates and titrated in 2-fold dilution series. Included on one plate was standard of each Z-ABD-Z polypeptide (titrated between 300 ng/ml and 3 pg/ml) and on each plate four controls of each Z-ABD-Z polypeptide diluted to concentration within the linear range of the assay. Standard and controls were diluted in assay matrix. The diluted standard, controls and samples were prepared in separate plates and transferred to the coated ELISA plates. The plates were incubated for 1.5 h at RT followed by 1.5 h incubation with a custom made detection rabbit anti-ABD Ig (4 µg/ml, CUV002) and 1 h incubation with donkey anti-rabbit IgG-HRP (Jackson ImmunoResearch, cat. no. 711-035-152). The reaction was developed with TMB (Thermo Fisher) and the development reaction was stopped after 15 min with 2 M H₂SO₄. The absorbance was read at 450 nm in an ELISA reader (Victor³, Perkin Elmer). The concentrations of the respective Z-ABD-Z variant in samples were calculated from the standard curve using GraphPad Prism5 and a four parameter logistic (4-PL) curve-fit.

Pharmacokinetic analysis: The pharmacokinetic analysis was based on individual rat serum concentration versus time. Terminal half-life (T_{1/2}) and bioavailability was estimated using Microsoft Excel and GraphPad Prism and applying a two compartment model.

Results

Mean serum concentration-time profiles of the Z-ABD-Z polypeptides ZAZ3220 and ZAZ3363 following single administrations of 1.2 mg/kg to SD rats are shown in Figure 9A and Figure 9B, respectively, and the calculated pharmacokinetic parameters using a two-compartment analysis are summarized in Table 20. The estimated half-life ($t_{1/2}$) was approximately 49 h for both ZAZ3220 and ZAZ3363 following i.v. administration. The $t_{1/2}$ for ZAZ3363 administrated s.c. was 45 h and the bioavailability was calculated to 45 %.

Table 20: Mean pharmacokinetic parameters of Z-ABD-Z polypeptides following a single i.v. or s.c. administration to SD rats

Pharmakokinetic parameter	ZAZ3220 i.v.	ZAZ3363 i.v.	ZAZ3363 s.c.
Cmax (nmol/L)	1905	1870	330
Tmax (h)	0.08	0.08	24
AUC _{0-t} (h*nmol/L)	46369	42757	19351
$t_{1/2}$ elimination (h)	49	49	45
MRT (h)	35	33	47
CL (L/h/kg)	0.003	0.003	0.003
F (%)	n.a.	n.a.	45

Cmax: Peak serum concentration; Tmax: Time to reach the peak serum concentration; AUC_{0-t}: Area under the concentration-time curve from time zero to last quantifiable concentration; $T_{1/2}$: Half-life; MRT: Mean residence time; CL: Clearance; F: Percentage absolute bioavailability, calculated as $F = [(Mean\ AUC_{s.c.} \times Dose_{i.v.}) / (Mean\ AUC_{i.v.} \times Dose_{s.c.})] \times 100$

Example 17

Topical administration of Z variant to eyes of rabbits

Local administration to the eye is beneficial in ophthalmologic disorders, e.g. uveitis or dry eye diseases. Topical administration enables extremely high local drug concentrations with a minimal risk of systemic side effects. In this Example, the possibility to topically administer Z variant molecules to eyes was investigated in rabbits. The concentration of a Z

variant molecule and a control IgG was measured in the anterior chamber (aqueous humor), in the vitreous humor and in serum after four repeated topical dosings.

5 *Materials and methods*

Production of Z variant: The Z variant Z10199 (SEQ ID NO:1217) derived from Z06282 (SEQ ID NO:1206) but starting AE was subcloned without any tag but with the C-terminal addition of amino acid residues VD. Expression was performed essentially as described in Example 2, and
10 purification was carried out by anion exchange and reverse phase chromatography. The sample was buffer exchanged to PBS pH 7.2 and endotoxins were removed using an EndoTrap[®] red 10 column (Hyglos).

Animal study: 48 nmol (1 drop, 50 µl) of Z10199 and ZAZ3174 (SEQ ID NO:1233), respectively, was administered topically to each eye of rabbits
15 (n=2 per molecule) at time points 0, 1, 2 and 3 hours. A control human IgG antibody (Xolair; Novartis) was administered in the same way to two different rabbits. As a negative control, one rabbit was administered PBS only. After each administration, the eyelids were held closed during approximately 30 s to keep the sample on the cornea. After 4 h, vitreous humor, aqueous humor
20 and serum were collected. The samples were centrifuged to remove tissue debris and aggregates and the levels of Z10199, ZAZ3174 and antibody, respectively, were quantified by ELISA.

Quantification by ELISA: The concentration of Z10199 and ZAZ3174, respectively, in the collected samples was analyzed by a sandwich ELISA
25 using an in-house produced polyclonal goat anti-protein Z immunoglobulin for capture, an in-house produced polyclonal rabbit anti-protein Z immunoglobulin as primary antibody and goat anti-rabbit IgG-HRP (Dako cat. no. P0448) as secondary antibody. Detection was performed by incubation with ImmunoPure TMB for 15 min at RT and the reaction was stopped by
30 addition of 2 M H₂SO₄. Absorption at 450 nm was measured with the microplate reader Victor³. The concentration of Z10199 was calculated from a standard curve prepared with the same molecule and using GraphPad prism5 and a non-linear regression formula.

The concentration of IgG in the collected samples was analyzed by an
35 IgG ELISA kit (Abcam 100547) and performed as described by the manufacturer, using a standard curve provided and analysis by non-linear regression as above.

Results

Figure 10 shows that both Z10199 and ZAZ3174 penetrated the eye after topical administration and was present in aqueous and vitreous humor at low nM concentrations. In contrast, the control IgG antibody was not detected in either aqueous or vitreous humor. The serum samples could be regarded as negative for both the Z variant and IgG. Thus, the Z variant molecules of the present disclosure may be delivered by this alternative route of administration, which is not available to antibodies, and a local effect that avoids systemic exposure may be achieved.

Example 18

Pharmacokinetic analysis of duodenal administration of ZAZ3363 formulations in rat

Materials and methods

Test item: ZAZ3363 (SEQ ID NO:1244) was formulated in 1) OAF1: 0.12 M sodium chenodeoxycholate (Sigma, cat.no. C8261) and 0.12 M propyl gallate (Sigma, cat.no. P3130), pH 7.4; 2) OAF2: 50 mg/ml sodium caprate (Sigma, cat.no. C4151); or 3) 50 mM sodium phosphate (PBS), pH 7.0, at a concentration of 50 mg/ml (OAF1 and OAF2) or 100 mg/ml (PBS).

NHDF cell assay: The activity of ZAZ3363 (SEQ ID NO:1244) formulated in OAF1, OAF2 or PBS was verified in the IL-17 dependent NHDF cell assay described in Example 14.

Duodenal administration: Male Sprague Dawley rats (Charles River) were anesthetized with isofluorane, and a small incision was made to localise the duodenum. An indwelling catheter (R-DUOD, AgnTho's, Sweden) was inserted surgically into the duodenum 20 mm from its origin in an area of minimal vasculature. The catheter was tunnelled subcutaneously to the back of the animals. Abdominal musculature was closed with sutures, while the abdominal skin incision and sub scapular exteriorization site was closed with stainless steel wound clips. The animals were left to recover for 5-6 days before being taken to the study. Post-operative analgesia was administered s.c. prior to surgery (carprofen 5 mg/kg and buprenorphine 0.05 mg/kg). Carprofen was administered once daily also on the two days following surgery. Additional doses of buprenorphine were administered when

necessary. Antibiotics (enrofloxacin 0.3 mg/ml) was administered in the drinking water during the recovery period (3-5 days), as well as during the experiment. To mask the bitter taste of enrofloxacin, one piece of sugar was added to 500 ml of drinking water. To ensure a maintained patency, the
5 duodenal catheter was flushed daily with sterile water (0.2-0.5 ml).

ZAZ3363 was administered directly into duodenum at a dose of 5.4 $\mu\text{mol/kg}$ body weight formulated in OAF1 or OAF2 (n=2) or at 10.8 $\mu\text{mol/kg}$ formulated in PBS (n=2) in a volume of 0.5 ml at time-point zero. Blood samples were taken under isoflurane anesthesia at 1, 3, 8, 24, 72, 120 and
10 168 h after administration and serum was prepared by standard procedures. The concentration of ZAZ3363 in serum was measured by the quantitative PK-ELISA described in Example 16, but titrating the standard of ZAZ3363 between 70 and 1 ng/ml.

Pharmacokinetic analysis: The pharmacokinetic analysis was based on
15 individual rat serum concentration versus time. Terminal half-life ($T_{1/2}$) and bioavailability was estimated using Microsoft Excel and GraphPad Prism.

Results

Activity of formulated ZAZ3363: The activity of ZAZ3363 formulated in
20 OAF1 and OAF2, respectively, was compared to formulation in PBS in the NHDF cell assay. Figure 11 shows the titration curves of OAF1 compared to PBS formulated ZAZ3363 (Figure 11A) and OAF2 compared to PBS formulated ZAZ3363 (Figure 11B). The experiment showed that the activity of ZAZ3363 in the two formulations was identical to PBS, i.e. the biological
25 activity of ZAZ3363 was not affected by the different excipients.

Intraduodenal uptake of ZAZ3363: Intestinal uptake of OAF1, OAF2 and PBS formulated ZAZ3363 was examined in a rat model of intraduodenal administration (i.d.). The experiment showed an increased uptake with OAF1 and OAF2 formulations compared to PBS (Figure 12). The bioavailabilities
30 were 0.2, 0.8 and 0.0007 for OAF1, OAF2 and PBS, respectively, as shown in Table 21. OAF2 formulated ZAZ3363 showed the best uptake, on average 1160 times better compared to formulation in PBS although great individual variation was seen. Formulation of ZAZ3363 in OAF1 was on average 260 times better than formulation in PBS.

Table 21: Bioavailability and $T_{1/2}$ after intraduodenal administration of ZAZ3363 in three different formulations

Formulation	$T_{1/2}$ (h)	Bioavailability (%)
PBS	43	0.0007 +/- 0.0002
OAF1	43	0.2 +/- 0.02
OAF2	50	0.8 +/- 1.2

5

Example 19

Characterization of anti-IL-17A/anti-TNF complexes in the NHDF assay

Materials and methods

Production of complexes and control antibody: Two different
10 complexes targeting IL-17A and TNF were constructed, as well as an
antibody with affinity for TNF. The antibody denoted “Ada”, having the same
CDR sequences and specificity as the commercially available monoclonal
antibody adalimumab, was constructed using the heavy chain (HC) and light
chain (LC) sequences HC_{Ada} (SEQ ID NO:1231) and LC_{Ada} (SEQ ID
15 NO:1232). The IL-17A targeting Z variant Z14253 (SEQ ID NO:1219) moiety
was genetically fused, via a flexible 15 residue (GGGGS)₃ linker, to the C-
termini of HC_{Ada} or LC_{Ada}, resulting in the complexes HC_{Ada}-Z14253 and
LC_{Ada}-Z14253, respectively. A schematic of the constructed complexes is
shown in Figure 13A. Gene synthesis, cloning, production by transient gene
20 expression in CHO cells and purification using Protein A affinity
chromatography was performed by Evitria AG (Switzerland).

Blocking of IL-17A induced IL-6 production in NHDF assay: The NHDF
assay was performed essentially as described in Example 14, titrating the
study samples HC_{Ada}-Z14253 and LC_{Ada}-Z14253 and their comparators in
25 three-fold steps from 63 nM to 0.003 nM in a medium containing 0.9 nM rhIL-
17A. The comparators were ZAZ3363 (SEQ ID NO:1244), the anti-TNF
antibody Ada, as well as a negative control Z variant Z04726 (SEQ ID
NO:1223; targeting *taq* polymerase) recombinantly fused to the ABD variant
PP013 (SEQ ID NO:1224) via a VDSS linker (denoted Z04726-PP013), as
30 described in Example 2. A standard IL-17A curve was also prepared (6.2-
0.0001 nM) as well as controls containing medium with 0.9 nM IL-17A or
medium alone. The IL-6 content in supernatants was quantified using the IL-6
specific ELISA described in Example 3.

Blocking of TNF or TNF/IL-17A induced IL-8 production in NHDF

assay: NHDF (Lonza, cat.no. CC-2511) cells were cultured in fibroblast basal medium (Lonza, cat.no. CC-3132) supplied with growth promoting factors (Lonza, cat.no CC-5034). On the day before the experiment, 5000 cells per
 5 well were seeded into a half area 96 well culture plates (Greiner, cat.no 675180) in 100 µl. On the day of the experiment, dilutions of HC_{Ada}-Z14253 and LC_{Ada}-Z14253 and the comparators described above were prepared in a separate 96-well plate. The complexes and comparators were titrated in three-fold steps from 5 nM to 0.0007 nM in medium containing 0.1 nM human
 10 TNF (R&D Systems, cat. no. 2210-TA/CF) or a mixture of 0.05 nM and 0.1 nM rhIL-17A. Controls containing medium with 0.1 nM TNF or a mixture of 0.05 nM and 0.1 nM rhIL-17A or medium alone were also prepared. The medium in the plate with the overnight cultured NHDF cells was discarded and 100 µl/well of the sample was transferred to the cell plate. The plate was
 15 placed in an incubator at 37 °C for 18-24 h. The next day, the IL-8 content in supernatants was quantified using an IL-8 specific ELISA.

IL-8 ELISA: IL-8 was quantified by a DuoSet ELISA kit (R&D systems, cat. no. DY208). Half area plates (Costar, cat.no. 3690) were coated with the anti-IL-8 capture antibody, 4 µg/ml in PBS, 50 µl/well, overnight at 4 °C. On
 20 the day of the analysis, the plate was rinsed twice in tap water and then blocked with PBS + 1 % BSA for 2 h. IL-8 standard (R&D Systems, cat.no. 890806), titrated in a 2-fold dilution series (20-0.01 ng/ml) and supernatants from the cell assay plate were added to the coated ELISA plate (50 µl/well) and incubated for 1.5 h at RT. The plate was washed 4 times in an automated
 25 ELISA washer and 20 ng/ml (50 µl/well) of biotinylated anti-IL-8 detection antibody was added. After another 1 h incubation, the plate was washed and 50 µl of streptavidin-HRP (Thermo Fisher, cat. no. N100) diluted 8000 x was added per well. The plate was developed after one additional hour's
 30 incubation and washing, with 50 µl TMB (Thermo Fisher, cat. no 34021) per well, and the reaction was stopped with 50 µl 2 M H₂SO₄. The absorbances were read in a multi label reader (Victor³, Perkin Elmer).

Results

Blocking of IL-17A induced IL-6 production in NHDF assay: The two complexes HC_{Ada}-Z14253 and LC_{Ada}-Z14253 were studied with regard to their capacity to block IL-17A induced IL-6 production in the NHDF assay. Results from the NHDF assay are presented in Figure 13B. Both HC_{Ada}-Z14253 and LC_{Ada}-Z14253 has a similar capacity to block IL-17A as ZAZ3363. As expected, no inhibition was seen for Ada or the negative control Z04726-PP013.

Blocking of TNF or TNF/IL-17A induced IL-8 production in NHDF assay: The two complexes HC_{Ada}-Z14253 and LC_{Ada}-Z14253 were studied with regard to their capacity to block TNF or a mixture of TNF/IL-17A induced IL-8 production in the NHDF assay. Results from the NHDF assay showed that HC_{Ada}-Z14253 and LC_{Ada}-Z14253 have similar inhibitory profiles as the anti-TNF antibody Ada with regard to specific TNF blocking capacity (Figure 13C). However, HC_{Ada}-Z14253 and LC_{Ada}-Z14253 had superior inhibitory profiles compared to Ada and ZAZ3363 in the combination assay, where the blocking effect to both TNF and IL-17 was investigated (Figure 13D).

20

Example 20

In vivo pharmacokinetics of Z-ABD-Z polypeptide in monkeys

This Example describes a repeated dose study conducted over 10 days in cynomolgus monkeys administered with the Z-ABD-Z polypeptide ZAZ3363. The results were used for estimation of the half-life of ZAZ3363 in cynomolgus.

Materials and methods

ZAZ3363 (SEQ ID NO:1244) was administered at 20 mg/kg (n=2; 1 male and 1 female) and 40 mg/kg (n=4; 2 male and 2 female) as a short i.v. infusion on days 1, 4, 7 and 10. Plasma samples for determination of ZAZ3363 concentration were collected in connection with the first dose on day 1 (at time points 0 (pre-dose), 5 min, 0.5, 1, 2, 6, 24 and 48 h after administration) and last dose on day 10 (at time points 0 (pre-dose), 5 min, 0.5, 1, 2, 6, 24, 48 h, 5, 7, 10, 12, 14 and 21 days after administration). Quantification of ZAZ3363 in plasma samples was carried out by LC-MS/MS based on peptides obtained after tryptic digestion of ZAZ3363. Concentration-

time profiles were evaluated using both non-compartmental methods with separate analyses for day 1 and day 10 and compartmental methods evaluating the data for day 1 and day 10 combined for each animal.

5 *Results*

Mean plasma concentration-time profiles of ZAZ3363 following administration on day 1 and day 10 are shown in Figure 14A and Figure 14B, respectively. Despite the fact that ZAZ3363 was not administered as a single dose with full PK evaluation, the available results after multiple dosing allows
10 for a prediction of the concentration-time profile after single doses. The plasma concentrations decreased in two phases according to a two-compartment behavior. The $t_{1/2}$ of the second phase estimated from this and a second repeated dose study (data not shown) was approximately 4-7.5 days, which is in agreement with the reported $t_{1/2}$ for monkey albumin (Deo et al.,
15 1974, J Nutr 104:858-64). No significant gender differences were observed.

Example 21

Oral administration of Z-ABD-Z polypeptide in dogs

20

Materials and methods

Preparation of capsules: ZAZ3363 (SEQ ID NO:1244) was formulated in OAF1 (see Example 18) at a concentration of 100 mg/ml. The formulation was lyophilized and filled in hard shell capsules subsequently enteric coated
25 (performed by Catalent Pharma Solutions, Beinheim, France). Each capsule contained approximately 25 mg ZAZ3363.

Animal study: The animal study was performed at Huntingdon Life Science (Cambridgeshire, UK). Fasted beagle dogs (n=3; female individuals) each received six capsules containing ZAZ3363 (approximately 150 mg).
30 Serum samples were taken at 0.5, 1, 2, 4, 6, 8, 12, 24 and 96 h after administration.

Quantification: The concentration of ZAZ3363 in serum samples was quantified using a PK sandwich ELISA essentially as described in Example 16, but using an in-house produced monoclonal anti-Z IgG in the first coating
35 step.

Results

The individual dog serum concentrations versus time profiles of ZAZ3363 are shown in Figure 15. The results showed intestinal uptake of ZAZ3363 in all three animals, but with some variation between individuals.

- 5 The ZAZ3363 serum concentration reached a maximum of 2-30 nM. Once in the circulation, the serum levels of ZAZ3363 remains stable at least up to 96 h, which is ascribed the interaction with dog albumin of the ABD moiety PP013 (SEQ ID NO:1223) within ZAZ3363. The ability of PP013 to bind dog albumin has been demonstrated previously (WO2012/004384).

ITEMIZED LISTING OF EMBODIMENTS

1. IL-17A binding polypeptide, comprising an IL-17A binding motif *BM*, which motif consists of an amino acid sequence selected from:

5

i) $EX_2DX_4AX_6X_7EIX_{10}X_{11}LPNLX_{16}X_{17}X_{18}QX_{20}X_{21}AFIX_{25}X_{26}LX_{28}X_{29}$

wherein, independently from each other,

10

X_2 is selected from A, H, M and Y;

X_4 is selected from A, D, E, F, K, L, M, N, Q, R, S and Y;

X_6 is selected from A, Q and W;

X_7 is selected from F, I, L, M, V, W and Y;

X_{10} is selected from A and W;

X_{11} is selected from A, D, E, F, G, L, M, N, Q, S, T and Y;

15

X_{16} is selected from N and T;

X_{17} is selected from H, W and Y;

X_{18} is selected from A, D, E, H and V;

X_{20} is selected from A, G, Q, S and W;

X_{21} is selected from A, D, E, F, H, K, N, R, T, V, W and Y;

20

X_{25} is selected from A, D, E, G, H, I, L, M, N, Q, R, S, T and V;

X_{26} is selected from K and S;

X_{28} is selected from I, L, N and R; and

X_{29} is selected from D and R;

and

25

ii) an amino acid sequence which has at least 89% identity to the sequence defined in i).

2. IL-17A binding polypeptide according to item 1, wherein, in sequence i),

30

X_2 is selected from A, H and M;

X_4 is selected from A, D, E, F, L, M, N, Q, R and Y;

X_{11} is selected from A, D, E, F, G, L, M, N, S, T and Y;

X_{18} is selected from A, D, E and V;

X_{20} is selected from A, G, Q and W;

35

X_{21} is selected from E, F, H, N, R, T, V, W and Y;

X_{25} is selected from A, D, E, G, H, I, L, N, Q, R, S, T and V; and

X_{28} is selected from I, N and R.

3. IL-17A binding polypeptide according to item 2, wherein, in sequence i),

- 5 X₁₆ is T;
 X₁₇ is W;
 X₂₁ is selected from E, F, H, W, T and Y;
 X₂₅ is selected from A, D, E, G, H, I, L, N, Q, R, S and T;
 X₂₆ is K; and
 X₂₉ is D.

10

4. IL-17A binding polypeptide according to any preceding item, wherein sequence i) fulfills at least six of the eleven conditions I-XI:

- 15 I. X₂ is A;
 II. X₄ is selected from D, E and Q;
 III. X₆ is A;
 IV. X₇ is selected from F and V;
 V. X₁₆ is T;
 VI. X₁₇ is W;
 VII. X₁₈ is selected from A and D;
 VIII. X₂₀ is W;
 IX. X₂₆ is K;
 X. X₂₈ is R; and
 XI. X₂₉ is D.

20

25 5. IL-17A binding polypeptide according to item 4, wherein sequence i) fulfills at least seven of the eleven conditions I-XI.

6. IL-17A binding polypeptide according to item 5, wherein sequence i) fulfills at least eight of the eleven conditions I-XI.

30 7. IL-17A binding polypeptide according to item 6, wherein sequence i) fulfills at least nine of the eleven conditions I-XI.

8. IL-17A binding polypeptide according to item 7, wherein sequence i) fulfills at least ten of the eleven conditions I-XI.

9. IL-17A binding polypeptide according to item 8, wherein sequence i) fulfills all of the eleven conditions I-XI.

35 10. IL-17A binding polypeptide according to any preceding item, wherein X₂X₆, X₂X₁₀ or X₆X₁₀ is AA.

11. IL-17A binding polypeptide according to any preceding item, wherein X_2X_{17} , X_2X_{20} , X_6X_{17} , X_6X_{20} , $X_{10}X_{17}$ or $X_{10}X_{20}$ is AW.

12. IL-17A binding polypeptide according to any preceding item, wherein X_2X_{28} , X_6X_{28} or $X_{10}X_{28}$ is AR.

5 13. IL-17A binding polypeptide according to any preceding item, wherein $X_{17}X_{28}$ or $X_{20}X_{28}$ is WR.

14. IL-17A binding polypeptide according to any preceding item, wherein $X_{17}X_{20}$ is WW.

10 15. IL-17A binding polypeptide according to any preceding item, wherein sequence i) is the sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NO:1-1216.

16. IL-17A binding polypeptide according to item 15, wherein sequence i) is the sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NO:1-66, 1200, 1206 and 1214.

15 17. IL-17A binding polypeptide according to item 16, wherein sequence i) is the sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NO:1-66.

18. IL-17A binding polypeptide according to item 17, wherein sequence i) is the sequence from position 8 to position 36 in a sequence selected from
20 the group consisting of SEQ ID NO:1-35.

19. IL-17A binding polypeptide according to item 18, wherein sequence i) is the sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NO:1-27.

20. IL-17A binding polypeptide according to item 19, wherein sequence
25 i) is the sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NO:1-10.

21. IL-17A binding polypeptide according to item 20, wherein sequence i) is the sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NO:1-7.

30 22. IL-17A binding polypeptide according to item 21, wherein sequence i) is the sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NO:1-4.

23. IL-17A binding polypeptide according to item 22, wherein sequence i) is the sequence from position 8 to position 36 in SEQ ID NO:1.

35 24. IL-17A binding polypeptide according to any preceding item, wherein said IL-17A binding motif forms part of a three-helix bundle protein domain.

25. IL-17A binding polypeptide according to item 24, wherein said IL-17A binding motif essentially forms part of two helices with an interconnecting loop, within said three-helix bundle protein domain.

26. IL-17A binding polypeptide according to item 25, wherein said
5 three-helix bundle protein domain is selected from bacterial receptor domains.

27. IL-17A binding polypeptide according to item 26, wherein said three-helix bundle protein domain is selected from domains of protein A from *Staphylococcus aureus* or derivatives thereof.

28. IL-17A binding polypeptide according to any preceding item, which
10 comprises an amino acid sequence binding module, *BMod*, selected from:

iii) K-[*BM*]-DPSQS $X_aX_bLLX_c$ EAKKL $X_dX_eX_fQ$;

wherein

[*BM*] is an IL-17A binding motif as defined in any one of items 1-23 provided that X_{29} is D;

15 X_a is selected from A and S;

X_b is selected from N and E;

X_c is selected from A, S and C;

X_d is selected from E, N and S;

X_e is selected from D, E and S;

20 X_f is selected from A and S; and

iv) an amino acid sequence which has at least 85 % identity to a sequence defined by iii).

29. IL-17A binding polypeptide according to any one of items 1-27, which comprises an amino acid sequence binding module, *BMod*, selected
25 from:

v) K-[*BM*]-QPEQS $X_aX_bLLX_c$ EAKKL $X_dX_eX_fQ$;

wherein

[*BM*] is an IL-17A binding motif as defined in any one of items 1-23 provided that X_{29} is R;

30 X_a is selected from A and S;

X_b is selected from N and E;

X_c is selected from A, S and C;

X_d is selected from E, N and S;

X_e is selected from D, E and S;

35 X_f is selected from A and S; and

vi) an amino acid sequence which has at least 85 % identity to a sequence defined by v).

30. IL-17A binding polypeptide according to item 28 or 29, wherein X_a in sequence iii) or v) is A.

31. IL-17A binding polypeptide according to item 28 or 29, wherein X_a in sequence iii) or v) is S.

5 32. IL-17A binding polypeptide according to any one of items 28-31, wherein X_b in sequence iii) or v) is N.

33. IL-17A binding polypeptide according to any one of items 28-31, wherein X_b in sequence iii) or v) is E.

34. IL-17A binding polypeptide according to any one of items 28-33,
10 wherein X_c in sequence iii) or v) is A.

35. IL-17A binding polypeptide according to any one of items 28-33, wherein X_c in sequence iii) or v) is S.

36. IL-17A binding polypeptide according to any one of items 28-33, wherein X_c in sequence iii) or v) is C.

15 37. IL-17A binding polypeptide according to any one of items 28-36, wherein X_d in sequence iii) or v) is E.

38. IL-17A binding polypeptide according to any one of items 28-36, wherein X_d in sequence iii) or v) is N.

39. IL-17A binding polypeptide according to any one of items 28-36,
20 wherein X_d in sequence iii) or v) is S.

40. IL-17A binding polypeptide according to any one of items 28-39, wherein X_e in sequence iii) or v) is D.

41. IL-17A binding polypeptide according to any one of items 28-39, wherein X_e in sequence iii) or v) is E.

25 42. IL-17A binding polypeptide according to any one of items 28-39, wherein X_e in sequence iii) or v) is S.

43. IL-17A binding polypeptide according to any one of items 37 and 39-42, wherein X_dX_e in sequence iii) or v) is selected from EE, ES, SD, SE and SS.

30 44. IL-17A binding polypeptide according to item 43, wherein X_dX_e in sequence iii) or v) is ES.

45. IL-17A binding polypeptide according to item 43, wherein X_dX_e in sequence iii) or v) is SE.

35 46. IL-17A binding polypeptide according to item 43, wherein X_dX_e in sequence iii) or v) is SD.

47. IL-17A binding polypeptide according to any one of items 28-46, wherein X_f in sequence iii) or v) is A.

48. IL-17A binding polypeptide according to any one of items 28-46, wherein X_f in sequence iii) or v) is S.

49. IL-17A binding polypeptide according to item 28 or 29, wherein, in sequence iii) or v), X_a is A; X_b is N; X_c is A and X_f is A.

5 50. IL-17A binding polypeptide according to item 28 or 29, wherein, in sequence iii) or v), X_a is S; X_b is E; X_c is A and X_f is A.

51. IL-17A binding polypeptide according to item 28 or 29, wherein, in sequence iii) or v), X_a is A; X_b is N; X_c is C and X_f is A.

10 52. IL-17A binding polypeptide according to item 28 or 29, wherein, in sequence iii) or v), X_a is S; X_b is E; X_c is S and X_f is S.

53. IL-17A binding polypeptide according to item 28 or 29, wherein, in sequence iii) or v), X_a is S; X_b is E; X_c is S and X_f is A.

54. IL-17A binding polypeptide according to item 28 or 29, wherein, in sequence iii) or v), X_a is S; X_b is E; X_c is A and X_f is S.

15 55. IL-17A binding polypeptide according to item 28 or 29, wherein, in sequence iii) or v), X_a is S; X_b is E; X_c is C and X_f is S.

56. IL-17A binding polypeptide according to item 49, wherein, in sequence iii) or v), X_a is A; X_b is N; X_c is A; X_dX_e is ND and X_f is A.

20 57. IL-17A binding polypeptide according to item 50, wherein, in sequence iii) or v), X_a is S; X_b is E; X_c is A; X_dX_e is ND and X_f is A.

58. IL-17A binding polypeptide according to item 51, wherein, in sequence iii) or v), X_a is A; X_b is N; X_c is C; X_dX_e is ND and X_f is A.

59. IL-17A binding polypeptide according to item 52, wherein, in sequence iii) or v), X_a is S; X_b is E; X_c is S; X_dX_e is ND and X_f is S.

25 60. IL-17A binding polypeptide according to item 53, wherein, in sequence iii) or v), X_a is S; X_b is E; X_c is S; X_dX_e is ND and X_f is A.

61. IL-17A binding polypeptide according to item 55, wherein, in sequence iii) or v), X_a is S; X_b is E; X_c is C; X_dX_e is ND and X_f is S.

30 62. IL-17A binding polypeptide according to item 49, wherein, in sequence iii) or v), X_a is A; X_b is N; X_c is A; X_dX_e is SE and X_f is A.

63. IL-17A binding polypeptide according to item 50, wherein, in sequence iii) or v), X_a is S; X_b is E; X_c is A; X_dX_e is SE and X_f is A.

64. IL-17A binding polypeptide according to item 51, wherein, in sequence iii) or v), X_a is A; X_b is N; X_c is C; X_dX_e is SE and X_f is A.

35 65. IL-17A binding polypeptide according to item 52, wherein, in sequence iii) or v), X_a is S; X_b is E; X_c is S; X_dX_e is SE and X_f is S.

66. IL-17A binding polypeptide according to item 54, wherein, in sequence iii) or v), X_a is S; X_b is E; X_c is A; X_dX_e is SE and X_f is S.

67. IL-17A binding polypeptide according to item 55, wherein, in sequence iii) or v), X_a is S; X_b is E; X_c is C; X_dX_e is SE and X_f is S.

5 68. IL-17A binding polypeptide according to item 49, wherein, in sequence iii) or v), X_a is A; X_b is N; X_c is A; X_dX_e is ES and X_f is A.

69. IL-17A binding polypeptide according to item 50, wherein, in sequence iii) or v), X_a is S; X_b is E; X_c is A; X_dX_e is ES and X_f is A.

70. IL-17A binding polypeptide according to item 51, wherein, in
10 sequence iii) or v), X_a is A; X_b is N; X_c is C; X_dX_e is ES and X_f is A.

71. IL-17A binding polypeptide according to item 52, wherein, in sequence iii) or v), X_a is S; X_b is E; X_c is S; X_dX_e is ES and X_f is S.

72. IL-17A binding polypeptide according to item 55, wherein, in sequence iii) or v), X_a is S; X_b is E; X_c is C; X_dX_e is ES and X_f is S.

15 73. IL-17A binding polypeptide according to item 49, wherein, in sequence iii) or v), X_a is A; X_b is N; X_c is A; X_dX_e is SD and X_f is A.

74. IL-17A binding polypeptide according to item 50, wherein, in sequence iii) or v), X_a is S; X_b is E; X_c is A; X_dX_e is SD and X_f is A.

75. IL-17A binding polypeptide according to item 51, wherein, in
20 sequence iii) or v), X_a is A; X_b is N; X_c is C; X_dX_e is SD and X_f is A.

76. IL-17A binding polypeptide according to item 52, wherein, in sequence iii) or v), X_a is S; X_b is E; X_c is S; X_dX_e is SD and X_f is S.

77. IL-17A binding polypeptide according to item 54, wherein, in sequence iii) or v), X_a is S; X_b is E; X_c is A; X_dX_e is SD and X_f is S.

25 78. IL-17A binding polypeptide according to item 55, wherein, in sequence iii) or v), X_a is S; X_b is E; X_c is C; X_dX_e is SD and X_f is S.

79. IL-17A binding polypeptide according to item 28, wherein said sequence iii) is the sequence from position 7 to position 55 in a sequence selected from the group consisting of SEQ ID NO:1-1216.

30 80. IL-17A binding polypeptide according to item 79, wherein sequence iii) is the sequence from position 7 to position 55 in a sequence selected from the group consisting of SEQ ID NO:1-66, 1200, 1206 and 1214.

81. IL-17A binding polypeptide according to item 80, wherein sequence iii) is the sequence from position 7 to position 55 in a sequence selected from
35 the group consisting of SEQ ID NO:1-66.

82. IL-17A binding polypeptide according to item 81, wherein sequence iii) is the sequence from position 7 to position 55 in a sequence selected from the group consisting of SEQ ID NO:1-35.

5 83. IL-17A binding polypeptide according to item 82, wherein sequence iii) is the sequence from position 7 to position 55 in a sequence selected from the group consisting of SEQ ID NO:1-27.

84. IL-17A binding polypeptide according to item 83, wherein sequence iii) is the sequence from position 7 to position 55 in a sequence selected from the group consisting of SEQ ID NO:1-10.

10 85. IL-17A binding polypeptide according to item 84, wherein sequence iii) is the sequence from position 7 to position 55 in a sequence selected from the group consisting of SEQ ID NO:1-7.

86. IL-17A binding polypeptide according to item 85, wherein sequence iii) is the sequence from position 7 to position 55 in a sequence selected from
15 the group consisting of SEQ ID NO:1-4.

87. IL-17A binding polypeptide according to item 86, wherein sequence iii) the sequence from position 7 to position 55 in SEQ ID NO:1.

88. IL-17A binding polypeptide according to any preceding item, which comprises an amino acid sequence selected from:

20 vii) YA-[BMod]-AP;
wherein [BMod] is an IL-17A binding module as defined in any one of items 28-87; and
viii) an amino acid sequence which has at least 86 % identity to a sequence defined by vii).

25 89. IL-17A binding polypeptide according to any one of items 1-87, which comprises an amino acid sequence selected from:

ix) FA-[BMod]-AP;
wherein [BMod] is an IL-17A binding module as defined in any one of items 28-87; and
30 x) an amino acid sequence which has at least 86 % identity to a sequence defined by ix).

90. IL-17A binding polypeptide according to any one of items 1-87, which comprises an amino acid sequence selected from:

xi) FN-[BMod]-AP;
35 wherein [BMod] is an IL-17A binding module as defined in any one of items 28-87; and

xii) an amino acid sequence which has at least 86 % identity to a sequence defined by xi).

91. IL-17A binding polypeptide according to any preceding item, which comprises an amino acid sequence selected from:

- 5 ADNNFNK-[BM]-DPSQSANLLSEAKKLNESQAPK;
ADNKFNK-[BM]-DPSQSANLLAEAKKLNDQAQAPK;
ADNKFNK-[BM]-DPSVSKEILAEAKKLNDQAQAPK;
ADAQQNNFNK-[BM]-DPSQSTNVLGEAKKLNESQAPK;
AQHDE-[BM]-DPSQSANVLGEAQKLNDSQAPK;
- 10 VDNKFNK-[BM]-DPSQSANLLAEAKKLNDQAQAPK;
AEAKYAK-[BM]-DPSESSELLSEAKKLNKSQAPK;
VDAKYAK-[BM]-DPSQSSELLAEAKKLNDQAQAPK;
VDAKYAK-[BM]-DPSQSSELLAEAKKLNDSQAPK;
AEAKYAK-[BM]-DPSQSSELLSEAKKLNDSQAPK;
- 15 AEAKYAK-[BM]-DPSQSSELLSEAKKLNDSQAP;
AEAKYAK-[BM]-DPSQSSELLSEAKKLNDQAQAPK;
AEAKYAK-[BM]-DPSQSSELLSEAKKLNDQAQAP;
AEAKFAK-[BM]-DPSQSSELLSEAKKLNDSQAPK;
AEAKFAK-[BM]-DPSQSSELLSEAKKLNDSQAP;
- 20 AEAKYAK-[BM]-DPSQSSELLAEAKKLNDQAQAPK;
AEAKYAK-[BM]-DPSQSSELLSEAKKLSESQAPK;
AEAKYAK-[BM]-DPSQSSELLSEAKKLSESQAP;
AEAKFAK-[BM]-DPSQSSELLSEAKKLSESQAPK;
AEAKFAK-[BM]-DPSQSSELLSEAKKLSESQAP;
- 25 AEAKYAK-[BM]-DPSQSSELLAEAKKLSEAQAPK;
AEAKYAK-[BM]-QPEQSSELLSEAKKLSESQAPK;
AEAKYAK-[BM]-DPSQSSELLSEAKKLESSQAPK;
AEAKYAK-[BM]-DPSQSSELLSEAKKLESSQAP;
AEAKYAK-[BM]-DPSQSSELLAEAKKLESAQAPK;
- 30 AEAKYAK-[BM]-QPEQSSELLSEAKKLESSQAPK;
AEAKYAK-[BM]-DPSQSSELLSEAKKLSDSQAPK;
AEAKYAK-[BM]-DPSQSSELLSEAKKLSDSQAP;
AEAKYAK-[BM]-DPSQSSELLAEAKKLSDSQAPK;
AEAKYAK-[BM]-DPSQSSELLAEAKKLSDAQAPK;
- 35 AEAKYAK-[BM]-QPEQSSELLSEAKKLSDSQAPK;
VDAKYAK-[BM]-DPSQSSELLSEAKKLNDSQAPK;
VDAKYAK-[BM]-DPSQSSELLSEAKKLSESQAPK;

VDAKYAK-[BM]-DPSQSSELLAEAKKLSEAQAPK;
 VDAKYAK-[BM]-QPEQSSELLSEAKKLSESQAPK;
 VDAKYAK-[BM]-DPSQSSELLSEAKKLESSQAPK;
 VDAKYAK-[BM]-DPSQSSELLAEAKKLESAQAPK;
 5 VDAKYAK-[BM]-QPEQSSELLSEAKKLESSQAPK;
 VDAKYAK-[BM]-DPSQSSELLSEAKKLSDSQAPK;
 VDAKYAK-[BM]-DPSQSSELLAEAKKLSDSQAPK;
 VDAKYAK-[BM]-DPSQSSELLAEAKKLSDAQAPK;
 VDAKYAK-[BM]-QPEQSSELLSEAKKLSDSQAPK;
 10 VDAKYAK-[BM]-DPSQSSELLAEAKKLNKAQAPK;
 AEAKYAK-[BM]-DPSQSSELLAEAKKLNKAQAPK; and
 ADAKYAK-[BM]-DPSQSSELLSEAKKLNDSQAPK;

wherein [BM] is an IL-17A binding motif as defined in any one of items 1-23.

92. IL-17A binding polypeptide according to any preceding item, which
 15 comprises an amino acid sequence selected from:

xiii) VDAKYAK-[BM]-DPSQSSELLSEAKKLNDSQAPK;

wherein [BM] is an IL-17A binding motif as defined in any one of items 1-23; and

xiv) an amino acid sequence which has at least 86 % identity to the
 20 sequence defined in xiii).

93. IL-17A binding polypeptide according to item 92, wherein sequence xiii) is selected from SEQ ID NO:1-1216.

94. IL-17A binding polypeptide according to item 93, wherein sequence xiii) is selected from SEQ ID NO:1-66, 1200, 1206 and 1214.

25 95. IL-17A binding polypeptide according to item 94, wherein sequence xiii) is selected from SEQ ID NO:1-66.

96. IL-17A binding polypeptide according to item 95, wherein sequence xiii) is selected from SEQ ID NO:1-35.

30 97. IL-17A binding polypeptide according to item 96, wherein sequence xiii) is selected from SEQ ID NO:1-27.

98. IL-17A binding polypeptide according to item 97, wherein sequence xiii) is selected from SEQ ID NO:1-10.

99. IL-17A binding polypeptide according to item 98, wherein sequence xiii) is selected from SEQ ID NO:1-7.

35 100. IL-17A binding polypeptide according to item 99, wherein sequence xiii) is selected from SEQ ID NO:1-4.

112

101. IL-17A binding polypeptide according to item 100, wherein sequence xiii) is SEQ ID NO:1.

102. IL-17A binding polypeptide according to any one of items 1-91, which comprises an amino acid sequence selected from:

5 xv) AEAKEYAK-[BM]-DPSQSSELLSEAKKLNDSQAPK;

wherein [BM] is an IL-17A binding motif as defined in any one of items 1-23; and

xvi) an amino acid sequence which has at least 86 % identity to the sequence defined in xv).

10 103. IL-17A binding polypeptide according to item 102, wherein sequence xv) is selected from SEQ ID NO:1217-1222.

104. IL-17A binding polypeptide according to item 103, wherein sequence xv) is selected from SEQ ID NO:1218-1222.

15 105. IL-17A binding polypeptide according to item 104, wherein sequence xv) is selected from SEQ ID NO:1219-1222.

106. IL-17A binding polypeptide according to item 105, wherein sequence xv) is selected from SEQ ID NO:1219 and SEQ ID NO:1222.

107. IL-17A binding polypeptide according to item 106, wherein sequence xv) is SEQ ID NO:1219.

20 108. IL-17A binding polypeptide according to any preceding item, which is capable of binding to IL-17A such that the K_D value of the interaction is at most 1×10^{-6} M, such as at most 1×10^{-7} M, such as at most 1×10^{-8} M, such as at most 1×10^{-9} M.

25 109. IL-17A binding polypeptide according to any preceding item, which is capable of binding to an IL-17A molecule selected from the group consisting of human IL-17A and murine IL-17A.

110. IL-17A binding polypeptide according to item 109, which is capable of binding to human IL-17A.

30 111. IL-17A binding polypeptide according to item 109, which is capable of binding to murine IL-17A.

112. IL-17A binding polypeptide according to any one of items 109-111, which is capable of binding to human IL-17A and to murine IL-17A.

35 113. IL-17A binding polypeptide according to any one of items 109, 110 and 112, wherein said human IL-17A comprises the amino acid sequence SEQ ID NO:1226 or an antigenically effective fragment thereof.

113

114. IL-17A binding polypeptide according to any one of items 109, 111 and 112, wherein said murine IL-17A comprises the amino acid sequence SEQ ID NO:1227 or an antigenically effective fragment thereof.

115. IL-17A binding polypeptide according to any preceding item which
5 comprises additional amino acids at the C-terminal and/or N-terminal end.

116. IL-17A binding polypeptide according to item 115, wherein said additional amino acid(s) improve(s) and/or simplify/simplifies production, purification, stabilization *in vivo* or *in vitro*, coupling or detection of the polypeptide.

10 117. IL-17A binding polypeptide according to any preceding item in multimeric form, comprising at least two IL-17A binding polypeptide monomer units, whose amino acid sequences may be the same or different.

118. IL-17A binding polypeptide according to item 117, wherein said IL-17A binding polypeptide monomer units are covalently coupled together.

15 119. IL-17A binding polypeptide according to item 118, wherein the IL-17A binding polypeptide monomer units are expressed as a fusion protein.

120. IL-17A binding polypeptide according to any one of items 117-119, in dimeric form.

20 121. Fusion protein or conjugate comprising
- a first moiety consisting of an IL-17A binding polypeptide according to any preceding item; and
- a second moiety consisting of a polypeptide having a desired biological activity.

25 122. Fusion protein or conjugate according to item 121, wherein said desired biological activity is a therapeutic activity.

123. Fusion protein or conjugate according to item 121, wherein said desired biological activity is a binding activity.

30 124. Fusion protein or conjugate according to item 123, wherein said binding activity is albumin binding activity which increases *in vivo* half-life of the fusion protein or conjugate.

125. Fusion protein or conjugate according to item 124, comprising two IL-17A binding polypeptides, each as defined in any one of items 1-116, with an albumin binding moiety between them.

35 126. Fusion protein or conjugate according to item 125, which is capable of binding to IL-17A such that the K_D value of the interaction is at most 1×10^{-10} M, such as at most 1×10^{-11} M, such as at most 1×10^{-12} M, such as at most 1×10^{-13} M.

127. Fusion protein or conjugate according to any one of items 124-126, wherein said second moiety comprises the albumin binding domain of streptococcal protein G or a derivative thereof.

128. Fusion protein or conjugate according to item 123, wherein said
5 binding activity acts to inhibit a biological activity.

129. Fusion protein or conjugate according to item 123, wherein said binding activity acts to stimulate a biological activity.

130. Fusion protein or conjugate according to item 121, wherein said desired biological activity is an enzymatic activity.

10 131. Fusion protein or conjugate according to item 122, wherein the second moiety is a therapeutically active polypeptide.

132. Fusion protein or conjugate according to item 131, wherein the second moiety is an immune response modifying agent, for example an anti-inflammatory agent.

15 133. Fusion protein or conjugate according to any one of items 121-122 and 130-132, wherein the second moiety is selected from the group consisting of human endogenous enzymes, hormones, growth factors, chemokines, cytokines and lymphokines, and agonists, antagonists and inhibitors thereof.

20 134. Fusion protein or conjugate according to item 131, wherein the second moiety is a toxic compound.

135. Fusion protein or conjugate according to item 123, wherein said binding activity is binding to an immune response associated factor, for example an inflammation-associated factor.

25 136. Complex, comprising at least one IL-17A binding polypeptide according to any one of items 1-117 or at least one fusion protein or conjugate according to any one of items 121-135, and at least one antibody or an antigen binding fragment thereof.

30 137. Complex according to item 136, wherein said at least one antibody or antigen binding fragment thereof is selected from the group consisting of full-length antibodies, Fab fragments, Fab' fragments, F(ab')₂ fragments, Fc fragments, Fv fragments, single chain Fv fragments, (scFv)₂ and domain antibodies.

35 138. Complex according to item 137, wherein said at least one antibody or antigen binding fragment thereof is selected from the group consisting of full-length antibodies, Fab fragments and scFv fragments.

139. Complex according to item 138, wherein said at least one antibody or antigen binding fragment thereof is a full-length antibody.

140. Complex according to any one of items 136-139, wherein said antibody or antigen binding fragment thereof is a monoclonal antibody or an
5 antigen binding fragment thereof.

141. Complex according to any one of items 136-140, wherein said antibody or antigen binding fragment thereof is selected from the group consisting of human antibodies, humanized antibodies and chimeric antibodies, and antigen-binding fragments thereof.

10 142. Complex according to item 141, wherein said antibody or antigen binding fragment thereof is a human or humanized antibody, or an antigen binding fragment thereof.

143. Complex according to any one of items 136-142, wherein said antibody or antigen binding fragment thereof has affinity for an antigen, such
15 as selected from the group consisting of an antigen associated with an angiogenesis related disorder and an antigen associated with the immune response or with a disorder of the immune system.

144. Complex according to item 143, wherein said antigen is associated with an angiogenesis related disorder.

20 145. Complex according to item 143, wherein said antigen is associated with the immune response or with a disorder of the immune system, for example associated with inflammation.

146. Complex according to any one of items 136-145, which is a fusion protein or a conjugate.

25 147. Complex according to any one of items 136-146, wherein said IL-17A binding polypeptide is attached to the N-terminus or C-terminus of the heavy chain of said antibody or antigen binding fragment thereof.

148. Complex according to any one of items 136-146, wherein said IL-17A binding polypeptide is attached to the N-terminus or C-terminus of the
30 light chain of said antibody or antigen binding fragment thereof.

149. Complex according to any one of items 136-146, wherein said IL-17A binding polypeptide is attached to the N-terminus and/or C-terminus of the light chain and heavy chain of said antibody or antigen binding fragment thereof.

35 150. Complex according to any one of items 146-149, which is a fusion protein.

151. IL-17A binding polypeptide, fusion protein, conjugate or complex according to any preceding item, further comprising at least one linker, for example selected from the group consisting of non-peptidic linkers, flexible amino acid linkers, rigid amino acid linkers and cleavable amino acid linkers.

5 152. Fusion protein or conjugate according item 151, wherein said linker is arranged between said first moiety and said second moiety.

153. Complex according to item 151, wherein said linker is arranged between said IL-17A binding polypeptide and said antibody or antigen binding fragment thereof.

10 154. IL-17A binding polypeptide, fusion protein, conjugate or complex according any one of items 151-153, wherein said linker is a flexible linker comprising amino acid residues selected from the group consisting of glycine, serine and threonine.

15 155. IL-17A binding polypeptide, fusion protein, conjugate or complex according to item 154, wherein said linker comprises a sequence with a general formula selected from

$$(G_n S_m)_p \text{ and } (S_n G_m)_p,$$

wherein, independently,

20 $n = 1-7,$
 $m = 0-7,$
 $n + m \leq 8$ and
 $p = 1-10.$

25 156. IL-17A binding polypeptide, fusion protein, conjugate or complex according to item 155, wherein $n = 1-5.$

157. IL-17A binding polypeptide, fusion protein, conjugate or complex according to any one of items 155-156, wherein $m = 0-5.$

158. IL-17A binding polypeptide, fusion protein, conjugate or complex according to any one of items 155-157, wherein $p = 1-5.$

30 159. IL-17A binding polypeptide, fusion protein, conjugate or complex according to any one of items 156-158, wherein $n = 4, m = 1$ and $p = 1-4.$

160. IL-17A binding polypeptide, fusion protein, conjugate or complex according to item 159, wherein said linker comprises a sequence selected from the group consisting of $G_4S, (G_4S)_2, (G_4S)_3$ and $(G_4S)_4.$

35 161. IL-17A binding polypeptide, fusion protein, conjugate or complex according to item 160, wherein said linker comprises the sequence $G_4S.$

162. IL-17A binding polypeptide, fusion protein, conjugate or complex according to any one of items 155-159, wherein said general formula is $GT(G_nS_m)_p$.

163. IL-17A binding polypeptide, fusion protein, conjugate or complex according to item 162, wherein said linker comprises the sequence GTG_4S .

164. IL-17A binding polypeptide, fusion protein, conjugate or complex according to any preceding item, further comprising a label.

165. IL-17A binding polypeptide, fusion protein, conjugate or complex according to item 164, wherein said label is selected from the group consisting of fluorescent dyes and metals, chromophoric dyes, chemiluminescent compounds and bioluminescent proteins, enzymes, radionuclides and particles.

166. IL-17A binding polypeptide, fusion protein, conjugate or complex according to any preceding item, comprising a chelating environment provided by a polyaminopolycarboxylate chelator conjugated to the IL-17A binding polypeptide via a thiol group of a cysteine residue or an amine group of a lysine residue.

167. IL-17A binding polypeptide, fusion protein, conjugate or complex according to any preceding item, comprising one or more polyethylene glycol moieties.

168. Polynucleotide encoding a polypeptide according to any one of items 1-163.

169. Expression vector comprising a polynucleotide according to item 168.

170. Host cell comprising an expression vector according to item 169.

171. Method of producing a polypeptide according to any one of items 1-163, comprising

- culturing a host cell according to item 170 under conditions permissive of expression of said polypeptide from said expression vector, and

- isolating said polypeptide.

172. Composition comprising an IL-17A binding polypeptide, fusion protein, conjugate or complex according to any one of items 1-167 and at least one pharmaceutically acceptable excipient or carrier.

173. Composition according to item 172, further comprising at least one additional active agent, such as an agent selected from the group consisting of therapeutically active polypeptides, immune response modifying agents, anti-inflammatory agents and toxic compounds.

174. IL-17A binding polypeptide, fusion protein, conjugate or complex according to any one of items 1-167 or a composition according to any one of items 172-173 for oral, topical, intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal, sublingual or
5 suppository administration, such as for oral administration or such as for topical administration.

175. IL-17A binding polypeptide, fusion protein, conjugate or complex according to any one of items 1-167 or a composition according to any one of items 172-173 for use as a medicament, a diagnostic agent or a prognostic
10 agent.

176. IL-17A binding polypeptide, fusion protein, conjugate, complex or composition for use according to item 175, wherein said polypeptide, fusion protein, conjugate, complex or composition modulates IL-17A function *in vivo*.

177. IL-17A binding polypeptide, fusion protein, conjugate, complex or
15 composition for use according to any one of items 175-176, wherein said polypeptide, fusion protein, conjugate, complex or composition inhibits IL-17A signaling.

178. IL-17A binding polypeptide, fusion protein, conjugate, complex or composition for use according to any one of items 175-177, wherein said
20 polypeptide, fusion protein, conjugate, complex or composition blocks binding of IL-17A to at least one of its cognate receptors.

179. IL-17A binding polypeptide, fusion protein, conjugate, complex or composition for use according to any one of items 175-178, in the treatment, diagnosis or prognosis of an IL-17A associated condition.

25 180. IL-17A binding polypeptide, fusion protein, conjugate, complex or composition for use according to item 179, wherein said IL-17A associated condition is selected from the group consisting of inflammatory diseases, autoimmune diseases and cancer.

181. IL-17A binding polypeptide, fusion protein, conjugate, complex or
30 composition for use according to item 180, wherein said IL-17A associated condition is selected from the group consisting of inflammatory diseases and autoimmune diseases.

182. IL-17A binding polypeptide, fusion protein, conjugate, complex or composition for use according to item 181, wherein said IL-17A associated
35 condition is selected from the group consisting of inflammatory conditions, allergic conditions, hypersensitivity reactions, autoimmune diseases, severe infections and transplant rejections.

183. IL-17A binding polypeptide, fusion protein, conjugate, complex or composition for use according to item 182, wherein said IL-17A associated condition is selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, multiple sclerosis, systemic lupus erythematosus, uveitis and dry eye disease.

184. IL-17A binding polypeptide, fusion protein, conjugate, complex or composition for use according to item 183, wherein said IL-17A associated condition is psoriasis.

185. IL-17A binding polypeptide, fusion protein, conjugate or complex for use in prognosis according to item 179, wherein said IL-17A associated condition is cancer, such as a cancer selected from the group consisting of gastric cancers, colorectal cancers, non-small cell lung cancers, hepatocellular carcinomas and adenocarcinomas.

186. Method of detecting IL-17A, comprising providing a sample suspected to contain IL-17A, contacting said sample with an IL-17A binding polypeptide, fusion protein, conjugate or complex according to any one of items 1-167 or a composition according to any one of items 172-173, and detecting the binding of the IL-17A binding polypeptide, fusion protein, conjugate, complex or composition to indicate the presence of IL-17A in the sample.

187. Method for determining the presence of IL-17A in a subject, the method comprising the steps:

- contacting the subject, or a sample isolated from the subject, with an IL-17A binding polypeptide, fusion protein, conjugate or complex according to any one of items 1-167 or a composition according to any one of items 172-173, and
- obtaining a value corresponding to the amount of the IL-17A binding polypeptide, fusion protein, conjugate, complex or composition that has bound in said subject or to said sample.

188. Method according to item 187, further comprising a step of comparing said value to a reference.

189. Method according to item 187 or 188, wherein said subject is a mammalian subject, such as a human subject.

190. Method according to any one of items 187-189, performed *in vivo*.

191. Method according to any one of items 187-189, performed *in vitro*.

192. Method of treatment of an IL-17A associated condition, comprising administering to a subject in need thereof an effective amount of

an IL-17A binding polypeptide, fusion protein, conjugate or complex according to any one of items 1-167 or a composition according to any one of items 172-173.

193. Method according to item 192, wherein said IL-17A associated
5 condition is selected from the group consisting of inflammatory diseases, autoimmune diseases and cancer.

194. Method according to item 193, wherein said IL-17A associated condition is selected from the group consisting of inflammatory diseases and autoimmune diseases.

10 195. Method according to item 194, wherein said IL-17A associated condition is selected from the group consisting of inflammatory conditions, allergic conditions, hypersensitivity reactions, autoimmune diseases, severe infections and transplant rejections.

196. Method according to item 195, wherein said IL-17A associated
15 condition is selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, multiple sclerosis, systemic lupus erythematosus, uveitis and dry eye disease.

197. Method according to item 196, wherein said IL-17A associated condition is psoriasis.

121

CLAIMS

1. IL-17A binding polypeptide, comprising an IL-17A binding motif *BM*, which motif consists of an amino acid sequence selected from:

5

i) $EX_2DX_4AX_6X_7EIX_{10}X_{11}LPNLX_{16}X_{17}X_{18}QX_{20}X_{21}AFIX_{25}X_{26}LX_{28}X_{29}$

wherein, independently from each other,

10

X_2 is selected from A, H, M and Y;

X_4 is selected from A, D, E, F, K, L, M, N, Q, R, S and Y;

X_6 is selected from A, Q and W;

X_7 is selected from F, I, L, M, V, W and Y;

X_{10} is selected from A and W;

X_{11} is selected from A, D, E, F, G, L, M, N, Q, S, T and Y;

15

X_{16} is selected from N and T;

X_{17} is selected from H, W and Y;

X_{18} is selected from A, D, E, H and V;

X_{20} is selected from A, G, Q, S and W;

X_{21} is selected from A, D, E, F, H, K, N, R, T, V, W and Y;

20

X_{25} is selected from A, D, E, G, H, I, L, M, N, Q, R, S, T and V;

X_{26} is selected from K and S;

X_{28} is selected from I, L, N and R; and

X_{29} is selected from D and R;

and

25

ii) an amino acid sequence which has at least 89% identity to the sequence defined in i).

2. IL-17A binding polypeptide according to claim 1, wherein, in sequence i),

30

X_2 is selected from A, H and M;

X_4 is selected from A, D, E, F, L, M, N, Q, R and Y;

X_{11} is selected from A, D, E, F, G, L, M, N, S, T and Y;

X_{18} is selected from A, D, E and V;

X_{20} is selected from A, G, Q and W;

35

X_{21} is selected from E, F, H, N, R, T, V, W and Y;

X_{25} is selected from A, D, E, G, H, I, L, N, Q, R, S, T and V; and

X_{28} is selected from I, N and R.

3. IL-17A binding polypeptide according to claim 2, wherein, in sequence i),

X_{16} is T;

5 X_{17} is W;

X_{21} is selected from E, F, H, W, T and Y;

X_{25} is selected from A, D, E, G, H, I, L, N, Q, R, S and T;

X_{26} is K; and

X_{29} is D.

10

4. IL-17A binding polypeptide according to any preceding claim, wherein sequence i) is the sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NO:1-1216.

15 5. IL-17A binding polypeptide according to any preceding claim, which comprises an amino acid sequence binding module, *BMod*, selected from:

iii) K-[*BM*]-DPSQS $X_a X_b LLX_c$ EAKKL $X_d X_e X_f Q$;

wherein

[*BM*] is an IL-17A binding motif as defined in any one of claims 1-4

20 provided that X_{29} is D;

X_a is selected from A and S;

X_b is selected from N and E;

X_c is selected from A, S and C;

X_d is selected from E, N and S;

25 X_e is selected from D, E and S;

X_f is selected from A and S; and

iv) an amino acid sequence which has at least 85 % identity to a sequence defined by iii).

30 6. IL-17A binding polypeptide according to claim 5, wherein said sequence iii) is the sequence from position 7 to position 55 in a sequence selected from the group consisting of SEQ ID NO:1-1216.

7. IL-17A binding polypeptide according to any preceding claim, which comprises an amino acid sequence selected from:

35 vii) YA-[*BMod*]-AP;

wherein [*BMod*] is an IL-17A binding module as defined in any one of claims 5-6; and

viii) an amino acid sequence which has at least 86 % identity to a sequence defined by vii).

5

8. IL-17A binding polypeptide according to any preceding claim, which comprises an amino acid sequence selected from:

xiii) VDAKYAK-[*BM*]-DPSQSSELLSEAKKLND SQAPK;

wherein [*BM*] is an IL-17A binding motif as defined in any one of claims

10 1-4; and

xiv) an amino acid sequence which has at least 86 % identity to the sequence defined in xiii).

9. IL-17A binding polypeptide according to claim 8, wherein sequence

15 xiii) is selected from SEQ ID NO:1-1216.

10. IL-17A binding polypeptide according to any one of claims 1-7, which comprises an amino acid sequence selected from:

xv) AEA KYAK-[*BM*]-DPSQSSELLSEAKKLND SQAPK;

20 wherein [*BM*] is an IL-17A binding motif as defined in any one of claims 1-4; and

xvi) an amino acid sequence which has at least 86 % identity to the sequence defined in xv).

25 11. IL-17A binding polypeptide according to claim 10, wherein sequence xv) is selected from SEQ ID NO:1217-1222.

12. IL-17A binding polypeptide according to any preceding claim, which is capable of binding to IL-17A such that the K_D value of the interaction is at
30 most 1×10^{-6} M, such as at most 1×10^{-7} M, such as at most 1×10^{-8} M, such as at most 1×10^{-9} M.

13. Fusion protein or conjugate comprising

35 - a first moiety consisting of an IL-17A binding polypeptide according to any preceding claim; and

- a second moiety consisting of a polypeptide having a desired biological activity.

14. Complex, comprising at least one IL-17A binding polypeptide according to any one of claims 1-12 or at least one fusion protein or conjugate according to claim 13, and at least one antibody or an antigen binding
5 fragment thereof.

15. Polynucleotide encoding a polypeptide according to any one of claims 1-14.

10 16. Composition comprising an IL-17A binding polypeptide, fusion protein, conjugate or complex according to any one of claims 1-14 and at least one pharmaceutically acceptable excipient or carrier.

15 17. IL-17A binding polypeptide, fusion protein, conjugate or complex according to any one of claims 1-14 or a composition according to claim 16 for use as a medicament, a diagnostic agent or a prognostic agent.

Z number	SEQUENCE	SEQ ID NO
Z10532	VDKYYAKEADDAAVEIASLPNLTWDQWYAFIQKLRDDPSQSSELLSEAKKLND SQAPK	1
Z10508	VDKYYAKEADDAAVEIAALPNLTWDQWFAFISKLRDDPSQSSELLSEAKKLND SQAPK	2
Z10863	VDKYYAKEADQAAVEIADLPNLTWAQWYAFIQKLRDDPSQSSELLSEAKKLND SQAPK	3
Z15167	VDKYYAKEADDAAVEIASLPNLTWAQWYAFIQKLRDDPSQSSELLSEAKKLND SQAPK	4
Z12060	VDKYYAKEADAAAVEIAELPNLTWDQWWAFINKLRDDPSQSSELLSEAKKLND SQAPK	5
Z12081	VDKYYAKEADDAALEIADLPNLTWDQWWAFISKLRDDPSQSSELLSEAKKLND SQAPK	6
Z12634	VDKYYAKEADRAAVEIADLPNLTWDQWYAFIEKLRDDPSQSSELLSEAKKLND SQAPK	7
Z12078	VDKYYAKEADDAAYEIAYPNLTWDQWFAFITKLRDDPSQSSELLSEAKKLND SQAPK	8
Z12163	VDKYYAKEADQAAVEIAFLPNLTWDQWFAFINKLRDDPSQSSELLSEAKKLND SQAPK	9
Z12264	VDKYYAKEADDAAYEIAFLPNLTWDQWWAFIQKLRDDPSQSSELLSEAKKLND SQAPK	10
Z10241	VDKYYAKEADDAAVEIADLPNLTWDQWYAFISKLRDDPSQSSELLSEAKKLND SQAPK	11
Z10462	VDKYYAKEADEAAVEIADLPNLTWDQWYAFIQKLRDDPSQSSELLSEAKKLND SQAPK	12
Z10534	VDKYYAKEADDAAVEIADLPNLTWAQWYAFIGKLRDDPSQSSELLSEAKKLND SQAPK	13
Z10566	VDKYYAKEADDAAEIASLPNLTWDQWYAFIGKLRDDPSQSSELLSEAKKLND SQAPK	14
Z10675	VDKYYAKEADDAAVEIADLPNLTWDQWFAFIQKLRDDPSQSSELLSEAKKLND SQAPK	15
Z10718	VDKYYAKEADDAAVEIADLPNLTWDQWHAFIQKLRDDPSQSSELLSEAKKLND SQAPK	16
Z12059	VDKYYAKEADDAAYEIAFLPNLTWDQWFAFISKLRDDPSQSSELLSEAKKLND SQAPK	17
Z12073	VDKYYAKEADDAAVEIADLPNLTWDQWYAFITKLRDDPSQSSELLSEAKKLND SQAPK	18
Z12077	VDKYYAKEADLAAVEIADLPNLTWDQWWAFIQKLRDDPSQSSELLSEAKKLND SQAPK	19
Z12115	VDKYYAKEADDAAYEIAYPNLTWDQWYAFIQKLRDDPSQSSELLSEAKKLND SQAPK	20
Z12180	VDKYYAKEADDAAVEIAALPNLTWDQWWAFIGKLRDDPSQSSELLSEAKKLND SQAPK	21
Z12211	VDKYYAKEADEAAVEIADLPNLTWDQWWAFINKLRDDPSQSSELLSEAKKLND SQAPK	22
Z12256	VDKYYAKEADDAAVEIADLPNLTWDQWYAFIAKLRDDPSQSSELLSEAKKLND SQAPK	23
Z12275	VDKYYAKEADDAAVEIADLPNLTWDQWFAFINKLRDDPSQSSELLSEAKKLND SQAPK	24
Z12283	VDKYYAKEADDAAYEIAFLPNLTWEQWFAFIDKLRDDPSQSSELLSEAKKLND SQAPK	25
Z12344	VDKYYAKEADDAAVEIAYPNLTWDQWWAFIRKLRDDPSQSSELLSEAKKLND SQAPK	26
Z12481	VDKYYAKEADDAAVEIADLPNLTWDQWWAFILKLRDDPSQSSELLSEAKKLND SQAPK	27
Z10433	VDKYYAKEADDAAFEIAALPNLTWDQWYAFIIKLRDDPSQSSELLSEAKKLND SQAPK	28

Z10681	VD	A	K	Y	A	K	E	A	D	E	A	A	V	E	I	A	E	L	P	N	L	T	W	D	Q	W	Y	A	F	I	R	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10722	VD	A	K	Y	A	K	E	A	D	D	A	A	L	E	I	A	E	L	P	N	L	T	W	V	Q	W	Y	A	F	I	Q	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10859	VD	A	K	Y	A	K	E	A	D	F	A	A	V	E	I	A	E	L	P	N	L	T	W	D	Q	W	Y	A	F	I	Q	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z12192	VD	A	K	Y	A	K	E	A	D	D	A	A	V	E	I	A	D	L	P	N	L	T	W	A	Q	W	E	A	F	I	S	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z12289	VD	A	K	Y	A	K	E	A	D	D	A	A	Y	E	I	A	G	L	P	N	L	T	W	D	Q	W	Y	A	F	I	E	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z12498	VD	A	K	Y	A	K	E	A	D	D	A	A	Y	E	I	A	S	L	P	N	L	T	W	D	Q	W	W	A	F	I	G	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z12522	VD	A	K	Y	A	K	E	A	D	R	A	A	V	E	I	A	D	L	P	N	L	T	W	D	Q	W	W	A	F	I	E	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10210	VD	A	K	Y	A	K	E	M	D	Y	A	Q	W	E	I	W	L	L	P	N	L	T	W	D	Q	G	H	A	F	I	S	K	L	I	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10255	VD	A	K	Y	A	K	E	A	D	D	A	A	V	E	I	A	D	L	P	N	L	T	W	D	Q	W	F	A	F	I	H	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10257	VD	A	K	Y	A	K	E	A	D	D	A	F	E	I	A	M	L	P	N	L	T	W	D	Q	W	Y	A	F	I	R	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z10459	VD	A	K	Y	A	K	E	A	D	N	A	A	V	E	I	A	D	L	P	N	L	T	W	V	Q	W	Y	A	F	I	Q	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10465	VD	A	K	Y	A	K	E	A	D	D	A	A	V	E	I	A	E	L	P	N	L	T	W	D	Q	W	F	A	F	I	Q	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10470	VD	A	K	Y	A	K	E	A	D	D	A	A	V	E	I	A	S	L	P	N	L	T	W	D	Q	W	Y	A	F	I	S	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10483	VD	A	K	Y	A	K	E	A	D	Q	A	A	V	E	I	A	D	L	P	N	L	T	W	D	Q	W	Y	A	F	I	Q	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10529	VD	A	K	Y	A	K	E	A	D	D	A	A	V	E	I	A	M	L	P	N	L	T	W	D	Q	W	Y	A	F	I	Q	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10550	VD	A	K	Y	A	K	E	A	D	N	A	A	V	E	I	A	M	L	P	N	L	T	W	D	Q	W	Y	A	F	I	Q	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10550	VD	A	K	Y	A	K	E	A	D	N	A	A	V	E	I	A	D	L	P	N	L	T	W	D	Q	W	F	A	F	I	H	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10565	VD	A	K	Y	A	K	E	A	D	E	A	A	V	E	I	A	D	L	P	N	L	T	W	D	Q	W	Y	A	F	I	A	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10676	VD	A	K	Y	A	K	E	A	D	D	A	A	V	E	I	A	D	L	P	N	L	T	W	D	Q	W	Y	A	F	I	Q	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10690	VD	A	K	Y	A	K	E	A	D	D	A	A	V	E	I	A	M	L	P	N	L	T	W	D	Q	W	Y	A	F	I	G	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10703	VD	A	K	Y	A	K	E	A	D	R	A	A	M	E	I	A	E	L	P	N	L	T	W	D	Q	W	Y	A	F	I	S	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10708	VD	A	K	Y	A	K	E	A	D	D	A	A	V	E	I	A	E	L	P	N	L	T	W	D	Q	W	Y	A	F	I	G	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10710	VD	A	K	Y	A	K	E	A	D	N	A	A	V	E	I	A	M	L	P	N	L	T	W	D	Q	W	Y	A	F	I	G	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10728	VD	A	K	Y	A	K	E	A	D	D	A	A	V	E	I	A	A	L	P	N	L	T	W	D	Q	W	Y	A	F	I	G	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10745	VD	A	K	Y	A	K	E	A	D	N	A	A	V	E	I	A	S	L	P	N	L	T	W	D	Q	W	F	A	F	I	G	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10756	VD	A	K	Y	A	K	E	A	D	D	A	A	V	E	I	A	L	L	P	N	L	T	W	D	Q	W	Y	A	F	I	G	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10745	VD	A	K	Y	A	K	E	A	D	N	A	A	V	E	I	A	S	L	P	N	L	T	W	D	Q	W	F	A	F	I	G	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10756	VD	A	K	Y	A	K	E	A	D	D	A	A	V	E	I	A	L	L	P	N	L	T	W	D	Q	W	Y	A	F	I	G	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10759	VD	A	K	Y	A	K	E	A	D	D	A	A	V	E	I	A	S	L	P	N	L	T	W	D	Q	W	F	A	F	I	S	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10775	VD	A	K	Y	A	K	E	A	D	D	A	A	V	E	I	A	D	L	P	N	L	T	W	D	Q	W	F	A	F	I	G	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10778	VD	A	K	Y	A	K	E	A	D	D	A	A	V	E	I	A	D	L	P	N	L	T	W	A	Q	W	F	A	F	I	Q	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z10779	VD	A	K	Y	A	K	E	A	D	D	A	A	V	E	I	A	A	L	P	N	L	T	W	D	Q	W	F	A	F	I	Q	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K

Z10800	VDKYYAKEADNAAVEIAADLPNLTWQWYAFIAKLRRDDPSQSSELLSEAKKLNDSQAPK	58
Z10807	VDKYYAKEADEAAVEIAELPNLTWQWYAFIGKLRRDDPSQSSELLSEAKKLNDSQAPK	59
Z10844	VDKYYAKEADNAAVEIAADLPNLTWQWFAFIQKLRRDDPSQSSELLSEAKKLNDSQAPK	60
Z10857	VDKYYAKEADDAAVEIAALPNLTWQWYAFIQKLRRDDPSQSSELLSEAKKLNDSQAPK	61
Z10858	VDKYYAKEADDAAVEIAELPNLTWAQWFAFVGKLRRDDPSQSSELLSEAKKLNDSQAPK	62
Z10914	VDKYYAKEADEAAVEIAADLPNLTWQWFAFIQKLRRDDPSQSSELLSEAKKLNDSQAPK	63
Z12212	VDKYYAKEADDAAVEIAALLPNLTWQWYAFINKLRRDDPSQSSELLSEAKKLNDSQAPK	64
Z12285	VDKYYAKEADNAALEIANLPNLTWQWWAFITKLRRDDPSQSSELLSEAKKLNDSQAPK	65
Z12439	VDKYYAKEADMAAVEIAELPNLTWEQWFAFVGKLRRDDPSQSSELLSEAKKLNDSQAPK	66
Z10249	VDKYYAKEADEAAVEIAMLPNLTWQWHAFIGKLRRDDPSQSSELLSEAKKLNDSQAPK	67
Z10424	VDKYYAKEADNAAWEIASLPNLTWQWFAFIGKLRRDDPSQSSELLSEAKKLNDSQAPK	68
Z10449	VDKYYAKEADRAAVEIAELPNLTWQWHAFIGKLRRDDPSQSSELLSEAKKLNDSQAPK	69
Z10454	VDKYYAKEADDAAMEIAADLPNLTWAQWNAFISKLRRDDPSQSSELLSEAKKLNDSQAPK	70
Z10463	VDKYYAKEADNAAVEIAALPNLTWQWSAFIQKLRRDDPSQSSELLSEAKKLNDSQAPK	71
Z10485	VDKYYAKEADEAAVEIAELPNLTWQWFAFIGKLRRDDPSQSSELLSEAKKLNDSQAPK	72
Z10505	VDKYYAKEADDAAVEIAALLPNLTWAQWFAFIQKLRRDDPSQSSELLSEAKKLNDSQAPK	73
Z10516	VDKYYAKEADDAAVEIAADLPNLTWQWNAFIRKLRRDDPSQSSELLSEAKKLNDSQAPK	74
Z10531	VDKYYAKEADNAAIEIALPNLTWVQWHAFIGKLRRDDPSQSSELLSEAKKLNDSQAPK	75
Z10539	VDKYYAKEADNAAVEIAADLPNLTWAQWHAFIGKLRRDDPSQSSELLSEAKKLNDSQAPK	76
Z10540	VDKYYAKEADNAAVEIAALPNLTWQWFAFIHKLRRDDPSQSSELLSEAKKLNDSQAPK	77
Z10556	VDKYYAKEADDAALEIAADLPNLTWQWFAFISKLRRDDPSQSSELLSEAKKLNDSQAPK	78
Z10663	VDKYYAKEADQAAVEIAADLPNLTWQWYAFIVKLRRDDPSQSSELLSEAKKLNDSQAPK	79
Z10664	VDKYYAKEADDAAVEIAATLPNLTWQWSAFIRKLRRDDPSQSSELLSEAKKLNDSQAPK	80
Z10668	VDKYYAKEADEAAFEIAALPNLTWQWFAFIRKLRRDDPSQSSELLSEAKKLNDSQAPK	81
Z10674	VDKYYAKEADDAAVEIAALPNLTWQWFAFIRKLRRDDPSQSSELLSEAKKLNDSQAPK	82
Z10693	VDKYYAKEADDAAVEIAADLPNLTWQWFAFIGKLRRDDPSQSSELLSEAKKLNDSQAPK	83
Z10733	VDKYYAKEADDAAVEIAADLPNLTWQWHAFIGKLRRDDPSQSSELLSEAKKLNDSQAPK	84
Z10734	VDKYYAKEADDAAFEIAALPNLTWAQWFAFIGKLRRDDPSQSSELLSEAKKLNDSQAPK	85
Z10746	VDKYYAKEADEAAFEIAADLPNLTWVQWFAFIQKLRRDDPSQSSELLSEAKKLNDSQAPK	86

Z10748	VDKYYAKEADQAAVEIAADLPNLTWQWFAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	87
Z10757	VDKYYAKEADDAAMEIAELPNLTWAQWSAFIAKLRDDPSQSSELLSEAKKLNDSQAPK	88
Z10774	VDKYYAKEADDAIEIAELPNLTWQWYAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	89
Z10780	VDKYYAKEADDAAFEIAALLPNLTWQWSAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	90
Z10790	VDKYYAKEADEAAAMEIAELPNLTWQWFAFISKLRDDPSQSSELLSEAKKLNDSQAPK	91
Z10791	VDKYYAKEADDAAFEIAALPNLTWQWFAFISKLRDDPSQSSELLSEAKKLNDSQAPK	92
Z10793	VDKYYAKEADEAAVEIASLPNLTWQWHAFI IKLRDDPSQSSELLSEAKKLNDSQAPK	93
Z10805	VDKYYAKEADRAAAVEIASLPNLTWAQWHAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	94
Z10868	VDKYYAKEADNAAVEIAALPNLTWQWHAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	95
Z10880	VDKYYAKEADEAAAMEIADLPNLTWVQWSAFISKLRDDPSQSSELLSEAKKLNDSQAPK	96
Z10881	VDKYYAKEADEAAVEIATLPNLTWQWFAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	97
Z10887	VDKYYAKEADDAAVEIAALLPNLTWQWHAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	98
Z10892	VDKYYAKEADEAAVEIASLPNLTWQWYAFIRKLRDDPSQSSELLSEAKKLNDSQAPK	99
Z10893	VDKYYAKEADDAALEIAELPNLTWQWYAFIVKLRDDPSQSSELLSEAKKLNDSQAPK	100
Z10896	VDKYYAKEADDAAFEIAALPNLTWQWFAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	101
Z10897	VDKYYAKEADDAAVEIADLPNLTWRQWYAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	102
Z10903	VDKYYAKEADDAAVEIAELPNLTWQWYAFIVKLRDDPSQSSELLSEAKKLNDSQAPK	103
Z10912	VDKYYAKEADDAAVEIADLPNLTWAQWYAFIVKLRDDPSQSSELLSEAKKLNDSQAPK	104
Z10916	VDKYYAKEADDAAMEIADLPNLTWQWFAFISKLRDDPSQSSELLSEAKKLNDSQAPK	105
Z10931	VDKYYAKEADDAAVEIADLPNLTWRQWFAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	106
Z10932	VDKYYAKEADDAAVEIAALPNLTWHQWNAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	107
Z10947	VDKYYAKEADQAAVEIAALPNLTWRQWYAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	108
Z10958	VDKYYAKEADDAAVEIADLPNLTWAQWHAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	109
Z10960	VDKYYAKEADEAAVEIAALPNLTWHQWHAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	110
Z10964	VDKYYAKEADQAAVEIADLPNLTTAQWYAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	111
Z10966	VDKYYAKEADQAAVEIADLPNLTWQWHAFI IKLRDDPSQSSELLSEAKKLNDSQAPK	112
Z10970	VDKYYAKEADYAAFEIASLPNLTWQWFAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	113
Z10972	VDKYYAKEADDAAFEIAELPNLTWQWHAFISKLRDDPSQSSELLSEAKKLNDSQAPK	114
Z10201	VDKYYAKEYDEAWFEI WALPNLTWQAVAFIRKLNDDPSQSSELLSEAKKLNDSQAPK	115

Z10202	VDKYYAKEADEAWFEIWTLPNLTHAQQVAFIRKLIDDPQSQSSELLSEAKKLNDSQAPK	116
Z10203	VDKYYAKEMDDAWWEIWSLPNLTYDQQYAFIVKLLDDPSQSSELLSEAKKLNDSQAPK	117
Z10204	VDKYYAKEHDNAWFEIWSLPNLTWDAQARAFIVKLNDDPQSQSSELLSEAKKLNDSQAPK	118
Z10205	VDKYYAKEADYAWFEIWMPLNLTYDQQAQAFIVKLNDDPQSQSSELLSEAKKLNDSQAPK	119
Z10206	VDKYYAKEMDDAQWEIWLNLPTWDDQQHAFIQKLIDDPQSQSSELLSEAKKLNDSQAPK	120
Z10207	VDKYYAKEMADAQWEIWMPLNLPTWAQGNAFISKLIDDPQSQSSELLSEAKKLNDSQAPK	121
Z10209	VDKYYAKEMDDAQWEIWMPLNLPTWHQSHAFIRKLDDPSQSSELLSEAKKLNDSQAPK	122
Z10211	VDKYYAKEMAYAQWEIWLNLPTYDQGHAFIVKLLDDPSQSSELLSEAKKLNDSQAPK	123
Z10212	VDKYYAKEMDEAWFEIWMPLNLTYVQQVAFIQKLIDDPQSQSSELLSEAKKLNDSQAPK	124
Z10213	VDKYYAKEHDYAWFEIWA LPNLTWDDQQVAFIHKLNDDPSQSSELLSEAKKLNDSQAPK	125
Z10214	VDKYYAKEMDEAQWEIWLNLPTWDDQSNAFIRKLIDDPQSQSSELLSEAKKLNDSQAPK	126
Z10216	VDKYYAKEMDEAQWEIWLNLPTWHQQNAFIRKLIDDPQSQSSELLSEAKKLNDSQAPK	127
Z10217	VDKYYAKEYDYAWFEIWE LPNLTWDDQQYAFIQKLNDDPQSQSSELLSEAKKLNDSQAPK	128
Z10218	VDKYYAKEADEAWWEIWSLPNLTYAQAYAFIQKLDDPSQSSELLSEAKKLNDSQAPK	129
Z10219	VDKYYAKEADFAWFEIWMPLNLTWDDQQYAFISKLNDDPSQSSELLSEAKKLNDSQAPK	130
Z10220	VDKYYAKEMDEAQWEIWLNLPTWHQQNAFIRKLDDPSQSSELLSEAKKLNDSQAPK	131
Z10221	VDKYYAKEMDDAQWEIWLNLPTWAQSNAFIRKLIDDPQSQSSELLSEAKKLNDSQAPK	132
Z10222	VDKYYAKEMDEAQWEIWTLPNLTWAAQSHAFISKLIDDPQSQSSELLSEAKKLNDSQAPK	133
Z10223	VDKYYAKEADEAWFEIWA LPNLTWDAQAVAFIHKLNDDPSQSSELLSEAKKLNDSQAPK	134
Z10224	VDKYYAKEYDYAWFEIWLNLPTWVQQTAFIHKLNDDPSQSSELLSEAKKLNDSQAPK	135
Z10225	VDKYYAKEADYAWFEIWLNLPTWDDQQYAFIRKLIDDPQSQSSELLSEAKKLNDSQAPK	136
Z10226	VDKYYAKEADEAWWEIWSLPNLTHDQGVAFIRKLDDPSQSSELLSEAKKLNDSQAPK	137
Z10227	VDKYYAKEMDEAQWEIWLNLPTWAQSRAFIQKLIDDPQSQSSELLSEAKKLNDSQAPK	138
Z10228	VDKYYAKEMDEAWWEIWLNLPTHDQQFAFISKLIDDPQSQSSELLSEAKKLNDSQAPK	139
Z10229	VDKYYAKEYDYAWFEIWTLPNLTWDDQQKAFIHKLNDDPSQSSELLSEAKKLNDSQAPK	140
Z10230	VDKYYAKEMDYAQWEIWLNLPTWDDQQHAFISKLIDDPQSQSSELLSEAKKLNDSQAPK	141
Z10231	VDKYYAKEHDDAWFEIWLNLPTWDDQAYAFIVKLNDDPQSQSSELLSEAKKLNDSQAPK	142
Z10232	VDKYYAKEMGYAQLEIWLNLPTWHQSNAFIRKLIDDPQSQSSELLSEAKKLNDSQAPK	143
Z10233	VDKYYAKEMDEAQWEIWLNLPTHDQQTAFIRKLIDDPQSQSSELLSEAKKLNDSQAPK	144

Z10234	VDKYYAKEMDYAQWEIWLPLNLTWTDQGNAFIRKLLIDDPQSQSSELLSEAKKLNDSQAPK	145
Z10235	VDKYYAKEMDFAQWEIWTLPNLTWTDQSNAFIRKLLIDDPQSQSSELLSEAKKLNDSQAPK	146
Z10236	VDKYYAKEADYAWWEI WALPNLTHAQQVAFIQKLLDDPSQSSELLSEAKKLNDSQAPK	147
Z10237	VDKYYAKEMDYAQWEIWLPLNLTYDQGHAFIQKLLDDPSQSSELLSEAKKLNDSQAPK	148
Z10238	VDKYYAKEMDDAQWEIWLPLNTWAQSHAFIVKLLDDPSQSSELLSEAKKLNDSQAPK	149
Z10239	VDKYYAKEYDQAWFEIWMLPNLTHRQORAFIHKLNDDPSQSSELLSEAKKLNDSQAPK	150
Z10240	VDKYYAKEMDNAQWEIWMPLPNLTWTDQGRAFIVKLLIDDPQSQSSELLSEAKKLNDSQAPK	151
Z10242	VDKYYAKEHDEAWFEIWMLPNLTWHQARAFIVKLNDDPSQSSELLSEAKKLNDSQAPK	152
Z10243	VDKYYAKEMDDAQIEIWMLPNLTWAQGHAFIRKLLIDDPQSQSSELLSEAKKLNDSQAPK	153
Z10244	VDKYYAKEADYAQWEIWLPLNLTTHAQGTAFIQKLLIDDPQSQSSELLSEAKKLNDSQAPK	154
Z10245	VDKYYAKEMDFAQWEIWLPLNLTWTDQAHAFIQKLLIDDPQSQSSELLSEAKKLNDSQAPK	155
Z10246	VDKYYAKEYDEAWFEIWSLPNLTYDQQYAFIVKLLIDDPQSQSSELLSEAKKLNDSQAPK	156
Z10247	VDKYYAKEHDYAWFEI WALPNLTHDQQVAFIRKLNDDPSQSSELLSEAKKLNDSQAPK	157
Z10248	VDKYYAKEMDYAWFEIWMPLPNLTHDQARAFIVKLNDDPSQSSELLSEAKKLNDSQAPK	158
Z10250	VDKYYAKEMDEAWWEIWTLPNLTYAQARAFIVKLLIDDPQSQSSELLSEAKKLNDSQAPK	159
Z10251	VDKYYAKEMDEAQWEIWLPLNTWVQQNAFISKLLIDDPQSQSSELLSEAKKLNDSQAPK	160
Z10252	VDKYYAKEMDDAQWEIWMPLPNLTWAQGNAFIRKLLDDPSQSSELLSEAKKLNDSQAPK	161
Z10254	VDKYYAKEMDEAQWEIWLPLNTWHQQNAFIQKLLIDDPQSQSSELLSEAKKLNDSQAPK	162
Z10256	VDKYYAKEADNAQWEIWLPLNTWAQGHAFIQKLLIDDPQSQSSELLSEAKKLNDSQAPK	163
Z10258	VDKYYAKEMDEAQWEIWLPLNTWAQQNAFISKLLIDDPQSQSSELLSEAKKLNDSQAPK	164
Z10259	VDKYYAKEMDDAWFEIWLPLNLTWTDQQYAFIQKLLIDDPQSQSSELLSEAKKLNDSQAPK	165
Z10260	VDKYYAKEMDFAQWEIWLPLNTWHQQNAFIRKLLIDDPQSQSSELLSEAKKLNDSQAPK	166
Z10261	VDKYYAKEHAEAWFEI WALPNLTHAQQYAFIHKLNDDPSQSSELLSEAKKLNDSQAPK	167
Z10262	VDKYYAKEMDEAQWEIWMPLPNLTWHQQHAFIRKLLIDDPQSQSSELLSEAKKLNDSQAPK	168
Z10263	VDKYYAKEMDYAQWEIWMPLNLTWTDQQHAFIVKLLDDPSQSSELLSEAKKLNDSQAPK	169
Z10265	VDKYYAKEMDDAQWEIWMPLNLTWTDQGNAFIRKLLIDDPQSQSSELLSEAKKLNDSQAPK	170
Z10266	VDKYYAKEHDQAWFEI WALPNLTHAQAVAFIVKLNDDPSQSSELLSEAKKLNDSQAPK	171
Z10267	VDKYYAKEADEAWWEIWLPLNLTHTDQQYAFIVKLLDDPSQSSELLSEAKKLNDSQAPK	172
Z10268	VDKYYAKEMDYAWFEI WALPNLTYDQQYAFISKLLDDPSQSSELLSEAKKLNDSQAPK	173

Z10269	VDKYYAKEADFAWWEIWSLPNLTTHQAKAFIVKLIDDPQSQSELLSEAKKLNDSQAPK	174
Z10270	VDKYYAKEMDYAQWEIWMLPNLTWDQSHAFIQKLIDDPQSQSELLSEAKKLNDSQAPK	175
Z10271	VDKYYAKEMDDAQWEIWMLPNLTTHDQGAFFIQKLIDDPQSQSELLSEAKKLNDSQAPK	176
Z10272	VDKYYAKEADEAWFEIWMLPNLTYAQQVAFIRKLNDDPPSQSELLSEAKKLNDSQAPK	177
Z10273	VDKYYAKEMDEAQWEIWLNPNTYAQQSAFFIQKLIDDPQSQSELLSEAKKLNDSQAPK	178
Z10274	VDKYYAKEMDFAQWEIWLNPNTWDQQHAFIQKLIDDPQSQSELLSEAKKLNDSQAPK	179
Z10275	VDKYYAKEMDDAWWEIWALPNLTYYDQYAFIAKLIDDPQSQSELLSEAKKLNDSQAPK	180
Z10276	VDKYYAKEMDEAQWEIWMLPNLTWDQSHAFIQKLIDDPQSQSELLSEAKKLNDSQAPK	181
Z10277	VDKYYAKEHDYAWFEIWLNPNTYYDQQHAFIVKLNDDPPSQSELLSEAKKLNDSQAPK	182
Z10278	VDKYYAKEMDYAWWEIWLNPNTLTHDQAKAFIQKLIDDPQSQSELLSEAKKLNDSQAPK	183
Z10279	VDKYYAKEADEAQWEIWTLPNLTWDQGHAFIRKLIIDDPQSQSELLSEAKKLNDSQAPK	184
Z10280	VDKYYAKEMDYAQWEIWLNPNTLTHAQQNAFFIQKLIDDPQSQSELLSEAKKLNDSQAPK	185
Z10282	VDKYYAKEADYAWWEIWLNPNTLTHAQQTAFIHKLLDDPPSQSELLSEAKKLNDSQAPK	186
Z10292	VDKYYAKEMDYAQWEIWMLPNLTLTHAQSRAFIQKLIDDPQSQSELLSEAKKLNDSQAPK	187
Z10336	VDKYYAKEYDYAWFEIWALPNLTTHHQVAFIRKLNDDPPSQSELLSEAKKLNDSQAPK	188
Z10341	VDKYYAKEMDDAWWEIWLNPNTLTHDQQRAFIQKLIDDPQSQSELLSEAKKLNDSQAPK	189
Z10343	VDKYYAKEMDNAAWWEIWTLPNLTLTHAQARAFIVKLIDDPQSQSELLSEAKKLNDSQAPK	190
Z10344	VDKYYAKEMDFAQWEIWLNPNTLTHHQQNAFFIRKLIIDDPQSQSELLSEAKKLNDSQAPK	191
Z10361	VDKYYAKEADQAWWEIWALPNLTLDQAVAFIRKLIIDDPQSQSELLSEAKKLNDSQAPK	192
Z10366	VDKYYAKEYDYAWFEIWALPNLTTRAQATAFISKLNDDPPSQSELLSEAKKLNDSQAPK	193
Z10367	VDKYYAKEADYAWFEIWSLPNLTYAQQVAFIRKLNDDPPSQSELLSEAKKLNDSQAPK	194
Z10369	VDKYYAKEAGYAWFEIWSLPNLTTHRQQVAFIRKLNDDPPSQSELLSEAKKLNDSQAPK	195
Z10375	VDKYYAKEHGDWFEIWLNPNTWDQQRAFIVKLNDDPPSQSELLSEAKKLNDSQAPK	196
Z10376	VDKYYAKEADEAWFEIWALPNLTTHDQGAFFIRKLLDDPPSQSELLSEAKKLNDSQAPK	197
Z10377	VDKYYAKEADYAWWEIWLNPNTLTHDQARAFISKLNDDPPSQSELLSEAKKLNDSQAPK	198
Z10379	VDKYYAKEADEAWWEIWALPNLTLTHAQQVAFIRKLIIDDPQSQSELLSEAKKLNDSQAPK	199
Z10380	VDKYYAKEADYAWFEIWSLPNLTWDQSRAFIGKLNDDPPSQSELLSEAKKLNDSQAPK	200
Z10385	VDKYYAKEMDFAWFEIWALPNLTTHVQQVAFIRKLIIDDPQSQSELLSEAKKLNDSQAPK	201
Z10387	VDKYYAKEADEAWFEIWALPNLTYYDQSKAFIRKLIIDDPQSQSELLSEAKKLNDSQAPK	202

Z10389	VDKYYAKEADYAWFEI WALPNLTHAQQYAFI QKLNDDPSQSSELLSEAKKLND SQAPK	203
Z10390	VDKYYAKEYL YAWMEI WTL PNLTWDAQARAFI VKLLDDPSQSSELLSEAKKLND SQAPK	204
Z10391	VDKYYAKEYDFAWFEI WALPNLTHDQ GKAFI SKLNDDPSQSSELLSEAKKLND SQAPK	205
Z10401	VDKYYAKEADYAWWEI WSLPNLTHAQAYAFI RKLIDDPSQSSELLSEAKKLND SQAPK	206
Z10402	VDKYYAKEADYAWWEI WALPNLTHAQAVAFI QKLLDDPSQSSELLSEAKKLND SQAPK	207
Z10404	VDKYYAKEMDYAWWEI WLLPNLTHDQQVAFI RKLIDDPSQSSELLSEAKKLND SQAPK	208
Z10409	VDKYYAKEWDYAWWEI WALPNLTHDQARAFI IKLNDDPSQSSELLSEAKKLND SQAPK	209
Z10410	VDKYYAKEMDFAWWEI WSLPNLTHAQARAFI VKLIDDPSQSSELLSEAKKLND SQAPK	210
Z10415	VDKYYAKEADYAWWEI WALPNLTHAQQVAFI SKLLDDPSQSSELLSEAKKLND SQAPK	211
Z10417	VDKYYAKEADYAWWEI WSLPNLTHAQAKAFI QKLLDDPSQSSELLSEAKKLND SQAPK	212
Z10420	VDKYYAKEHDYAWFEI WMLPNLTHAQQVAFI HKLNDDPSQSSELLSEAKKLND SQAPK	213
Z10422	VDKYYAKEMDYAWFEI WDLPNLTYDQAVAFI HKLNDDPSQSSELLSEAKKLND SQAPK	214
Z10423	VDKYYAKEYDYAWFEI WALPNLTHAQQVAFI QKLLDDPSQSSELLSEAKKLND SQAPK	215
Z10426	VDKYYAKEYDYAWFEI WLLPNLTYDQRAF I VKLNDDPSQSSELLSEAKKLND SQAPK	216
Z10428	VDKYYAKEHDYAWFEI WSLPNLTHDQQVAFI RKLNDPSQSSELLSEAKKLND SQAPK	217
Z10430	VDKYYAKEYDEAWWEI WLLPNLTHDQAYAFI HKLNDDPSQSSELLSEAKKLND SQAPK	218
Z10431	VDKYYAKEMDYAQFEI WLLPNLTHAQSNAFI RKLIDDPSQSSELLSEAKKLND SQAPK	219
Z10434	VDKYYAKEADYAWFEI WDLPNLTYDQQYAFI RKLDDPSQSSELLSEAKKLND SQAPK	220
Z10435	VDKYYAKEMDYAWFEI WALPNLTHDQAVAFI QKLLDDPSQSSELLSEAKKLND SQAPK	221
Z10438	VDKYYAKEADYAWFEI WALPNLTHAQQTAFI RKLNDPSQSSELLSEAKKLND SQAPK	222
Z10440	VDKYYAKEADYAQWEI WLLPNLTHDQGHAFI QKLLDDPSQSSELLSEAKKLND SQAPK	223
Z10441	VDKYYAKEMDYAWFEI WLLPNLTYDQGHAFI RKLDDPSQSSELLSEAKKLND SQAPK	224
Z10442	VDKYYAKEMDEAQWEI WLLPNLTHVQGNAFI RKLDDPSQSSELLSEAKKLND SQAPK	225
Z10443	VDKYYAKEYD NAWFEI WLLPNLTHDQQRAF I VKLNDDPSQSSELLSEAKKLND SQAPK	226
Z10444	VDKYYAKEMDEAQWEI WMLPNLTYDQGHAFI RKLIDDPSQSSELLSEAKKLND SQAPK	227
Z10445	VDKYYAKEMDFAQLEI WTL PNLTHAQGHAFI QKLLDDPSQSSELLSEAKKLND SQAPK	228
Z10446	VDKYYAKEHDYAWFEI WLLPNLTHDQQTAFI HKLNDDPSQSSELLSEAKKLND SQAPK	229
Z10447	VDKYYAKEMDQAQWEI WLLPNLTHQSHAFI SKLIDDPSQSSELLSEAKKLND SQAPK	230
Z10450	VDKYYAKEADYAWFEI WALPNLTHDQARAFI RKLIDDPSQSSELLSEAKKLND SQAPK	231

Z10451	VDKYYAKEMDDAQWEIWLPLNLTWDDQQHAFIVKLIDDPQSQSSELLSEAKKLNDSQAPK	232
Z10452	VDKYYAKEYDDAFWEIWLPLNLTWDDQQYAFIHKLNDDPSQSSELLSEAKKLNDSQAPK	233
Z10453	VDKYYAKEMDEAWWEIWLPLNLTYAQQYAFIQKLDDPSQSSELLSEAKKLNDSQAPK	234
Z10455	VDKYYAKEADYAWFEIWSLPLNLTHAQAYAFIVKLIDDPQSQSSELLSEAKKLNDSQAPK	235
Z10456	VDKYYAKEMDDAQWEIWMPLPNLTWDDQSHAFIAKLIDDPQSQSSELLSEAKKLNDSQAPK	236
Z10457	VDKYYAKEMDYAQWEIWMPLPNLTWDDQSNAFIRKLIDDPQSQSSELLSEAKKLNDSQAPK	237
Z10458	VDKYYAKEADYAWWEIWWALPNLTHDQARAFIVKLIDDPQSQSSELLSEAKKLNDSQAPK	238
Z10460	VDKYYAKEADYAWWEIWLPLNLTWDDQQRAFI IKLNDDPSQSSELLSEAKKLNDSQAPK	239
Z10461	VDKYYAKEADEAQWEIWLPLNLTYDQGTAFIRKLIDDPQSQSSELLSEAKKLNDSQAPK	240
Z10464	VDKYYAKEMDEAQWEIWLPLNLTWDDQQHAFIQKLDDPSQSSELLSEAKKLNDSQAPK	241
Z10467	VDKYYAKEYDEAWFEIWTLPNLTHDQARAFI IKLNDDPSQSSELLSEAKKLNDSQAPK	242
Z10469	VDKYYAKEMDRAQWEIWLPLNLTWHQQNAFIRKLIDDPQSQSSELLSEAKKLNDSQAPK	243
Z10472	VDKYYAKEHDFAWWEIWLPLNLTWDDQQRAFI VKLNDDPSQSSELLSEAKKLNDSQAPK	244
Z10474	VDKYYAKEMDQAQWEIWMPLNLTWDDQGHAFIRKLDDPSQSSELLSEAKKLNDSQAPK	245
Z10475	VDKYYAKEADYAWFEIWMPLNLTWDDQQRAFIGKLIDDPQSQSSELLSEAKKLNDSQAPK	246
Z10476	VDKYYAKEADYAWFEIWMPLNLTYDQQRAFI VKLDDPSQSSELLSEAKKLNDSQAPK	247
Z10477	VDKYYAKEMDRAQWEIWLPLNLTAQSNAFIRKLIDDPQSQSSELLSEAKKLNDSQAPK	248
Z10478	VDKYYAKEADYAWFEIWMPLNLTWDDQQVAFIRKLNDDPQSQSSELLSEAKKLNDSQAPK	249
Z10480	VDKYYAKEMDNAQWEIWLPLNLTWDDQQNAFIRKLIDDPQSQSSELLSEAKKLNDSQAPK	250
Z10481	VDKYYAKEADEAWWEIWWALPNLTYAQGRAFI VKLIDDPQSQSSELLSEAKKLNDSQAPK	251
Z10482	VDKYYAKEADFAWFEIWLPLNLTWDDQQTAFIQKLNDDPQSQSSELLSEAKKLNDSQAPK	252
Z10487	VDKYYAKEMDDAQWEIWLPLNLTWDDQQHAFIQKLDDPSQSSELLSEAKKLNDSQAPK	253
Z10488	VDKYYAKEMNEAQWEIWLPLNLTWDDQGHAFIAKLIDDPQSQSSELLSEAKKLNDSQAPK	254
Z10489	VDKYYAKEMDDAQWEIWMPLNLTWDDQHA FIRKLIDDPQSQSSELLSEAKKLNDSQAPK	255
Z10490	VDKYYAKEMDYAQWEIWTLPNLTW HQGHAFIQKLDDPSQSSELLSEAKKLNDSQAPK	256
Z10491	VDKYYAKEYDYAWFEIWLPLNLTYAQQRAFI AKLNDDPSQSSELLSEAKKLNDSQAPK	257
Z10493	VDKYYAKEMDQAWFEIWLPLNLTYDQQYAFIQKLIDDPQSQSSELLSEAKKLNDSQAPK	258
Z10494	VDKYYAKEMDNAQWEIWMPLNLTWDDQSHAFIVKLDDPSQSSELLSEAKKLNDSQAPK	259
Z10495	VDKYYAKEMDYAWFEIWSLPLNLTHAQAVAFIRKLNDDPQSQSSELLSEAKKLNDSQAPK	260

Z10496	VDKYYAKEADYAWFEIWLPNLTYAQAVAFIRKLNDDPSQSSELLSEAKKLNDSQAPK	261
Z10498	VDKYYAKEMDDAQWEIWLPLNLTWHQQNAFIAKLIDDPQSQSSELLSEAKKLNDSQAPK	262
Z10499	VDKYYAKEHDYAWFEIWMPLNLTWDQQTAFIHKLNDDPSQSSELLSEAKKLNDSQAPK	263
Z10500	VDKYYAKEAADAWEFEIWLPLNLTHAQQVAFIRKLNDDPSQSSELLSEAKKLNDSQAPK	264
Z10501	VDKYYAKEYDYAWFEIWMPLNLTHAQAFAFIQKLNDDPSQSSELLSEAKKLNDSQAPK	265
Z10502	VDKYYAKEYDEAWFEIWLPLNLTDQQRAFIVKLNDDPSQSSELLSEAKKLNDSQAPK	266
Z10503	VDKYYAKEMDDAWFEIWMPLNLTHDQAYAFIQKLIDDPQSQSSELLSEAKKLNDSQAPK	267
Z10504	VDKYYAKEMGEAQLEIWMPLNLTDQGNAFIRKLIDDPQSQSSELLSEAKKLNDSQAPK	268
Z10506	VDKYYAKEMDDAQWEIWLPLNLTYDQGTAFIRKLIDDPQSQSSELLSEAKKLNDSQAPK	269
Z10507	VDKYYAKEAGEAWFEIWLPLNLTYDQAYAFIRKLNDDPSQSSELLSEAKKLNDSQAPK	270
Z10509	VDKYYAKEYDDAWFEIWLPLNLTHAQAKAFIHKLNDDPSQSSELLSEAKKLNDSQAPK	271
Z10511	VDKYYAKEADYAWFEIWMPLNLTHDQAYAFIQKLNDDPSQSSELLSEAKKLNDSQAPK	272
Z10512	VDKYYAKEMDYAWFEIWLPLNLTYDQQYAFIQKLIDDPQSQSSELLSEAKKLNDSQAPK	273
Z10513	VDKYYAKEYDYAWFEIWLPLNLTHDQQYAFIRKLNDDPSQSSELLSEAKKLNDSQAPK	274
Z10514	VDKYYAKEYDYAWFEIWLPLNLTHAQASAFIVKLNDDPSQSSELLSEAKKLNDSQAPK	275
Z10515	VDKYYAKEMGDAQWEIWLPLNLTWHQNAFIAKLIDDPQSQSSELLSEAKKLNDSQAPK	276
Z10517	VDKYYAKEADFAWFEIWLPLNLTHDQQRAFIVKLDDPSQSSELLSEAKKLNDSQAPK	277
Z10518	VDKYYAKEHDYAWFEIWLPLNLTDQAVAFIHKLNDDPSQSSELLSEAKKLNDSQAPK	278
Z10519	VDKYYAKEHDNAWFEIWLPLNLTYDQQVAFIHKLNDDPSQSSELLSEAKKLNDSQAPK	279
Z10520	VDKYYAKEMDEAQWEIWLPLNLTHDQSRAFIQKLIDDPQSQSSELLSEAKKLNDSQAPK	280
Z10521	VDKYYAKEADEAWFEIWLPLNLTHAQAVAFIRKLNDDPSQSSELLSEAKKLNDSQAPK	281
Z10522	VDKYYAKEMDYAQWEIWSLPNLTDQGNAFIRKLIDDPQSQSSELLSEAKKLNDSQAPK	282
Z10523	VDKYYAKEAAEAQLEIWLPLNLTDQGHAFI I KLIDDPQSQSSELLSEAKKLNDSQAPK	283
Z10524	VDKYYAKEMAYAQAWEIWLPLNLTDWHQSNAFIRKLIDDPQSQSSELLSEAKKLNDSQAPK	284
Z10525	VDKYYAKEMDNAQWEIWMPLNLTDWHQQHAFIQKLIDDPQSQSSELLSEAKKLNDSQAPK	285
Z10526	VDKYYAKEYDQAWFEIWLPLNLTDQAYAFIQKLNDDPSQSSELLSEAKKLNDSQAPK	286
Z10527	VDKYYAKEWDYAWFEIWEIWLPLNLTDQARAFI I KLNDDPSQSSELLSEAKKLNDSQAPK	287
Z10528	VDKYYAKEADYAWFEIWSLPNLTDQQRAFIHKLNDDPSQSSELLSEAKKLNDSQAPK	288
Z10530	VDKYYAKEADFAQWEIWLPLNLTDQGHAFIQKLIDDPQSQSSELLSEAKKLNDSQAPK	289

Z10535	VDKYYAKEYDEAWFEIWLPLNLTYPDQQRAFIKLNDDPSQSSELLSEAKKLNDSQAPK	290
Z10536	VDKYYAKEMDDAQWEIWMLPNLTWDDQGHAFIRKLLDDPSQSSELLSEAKKLNDSQAPK	291
Z10537	VDKYYAKEMDEAWFEIWTLPLNLTYPDQQYAFIAKLLDDPSQSSELLSEAKKLNDSQAPK	292
Z10541	VDKYYAKEADDAQWEIWLPLNLTWDDQSHAFIQKLIDDPQSQSSELLSEAKKLNDSQAPK	293
Z10542	VDKYYAKEMDDAWFEIWLPLNLTYPDQQYAFIQKLIDDPQSQSSELLSEAKKLNDSQAPK	294
Z10543	VDKYYAKEMDEAQWEIWMLPNLTWAAQSHAFIQKLIDDPQSQSSELLSEAKKLNDSQAPK	295
Z10544	VDKYYAKEYDFAWFEIWLPLNLTWAAQRAFISKLNDDPQSQSSELLSEAKKLNDSQAPK	296
Z10545	VDKYYAKEHANAWFEIWLPLNLTYPDQQVAFIRKLNDDPSQSSELLSEAKKLNDSQAPK	297
Z10546	VDKYYAKEYDNAWFEIWLPLNLTYPDQATAFIHKLNDDPSQSSELLSEAKKLNDSQAPK	298
Z10547	VDKYYAKEWDEAWFEIWAIPNLTHAQAARAFIQKLIDDPQSQSSELLSEAKKLNDSQAPK	299
Z10548	VDKYYAKEYDFAWFEIWLPLNLTYPDQAVAFIRKLNDDPSQSSELLSEAKKLNDSQAPK	300
Z10549	VDKYYAKEADYAWFEIWAIPNLTHAQQRAFIKLNDDPSQSSELLSEAKKLNDSQAPK	301
Z10551	VDKYYAKEADYAWWEIWLPLNLTYPDQQRAFIVKLNDDPSQSSELLSEAKKLNDSQAPK	302
Z10553	VDKYYAKEHDYAWFEIWLPLNLTWDDQKAFIAKLNDDPSQSSELLSEAKKLNDSQAPK	303
Z10554	VDKYYAKEADYAWFEIWMLPNLTYPDQAVAFIKNLDDPSQSSELLSEAKKLNDSQAPK	304
Z10555	VDKYYAKEMDFAQWEIWLPLNLTWDDQSHAFISKLIDDPQSQSSELLSEAKKLNDSQAPK	305
Z10557	VDKYYAKEMGEAQIEIWLPLNLTYPDQGHAFIQKLIDDPQSQSSELLSEAKKLNDSQAPK	306
Z10558	VDKYYAKEADYAWFEIWAIPNLTYDQARAFIQKLIDDPQSQSSELLSEAKKLNDSQAPK	307
Z10560	VDKYYAKEADYAWWEIWSLPNLTHAQAARAFIVKLIDDPQSQSSELLSEAKKLNDSQAPK	308
Z10561	VDKYYAKEYDQAWFEIWLPLNLTHTDQAKAFIKNLDDPSQSSELLSEAKKLNDSQAPK	309
Z10564	VDKYYAKEADEAWWEIWLPLNLTWDDQGHAFIRKLIIDDPQSQSSELLSEAKKLNDSQAPK	310
Z10567	VDKYYAKEMDYAQWEIWMLPNLTWDDQGHAFIRKLIIDDPQSQSSELLSEAKKLNDSQAPK	311
Z10568	VDKYYAKEYDFAQWEIWLPLNLTWDDQSHAFIQKLIDDPQSQSSELLSEAKKLNDSQAPK	312
Z10569	VDKYYAKEADYAWFEIWLPLNLTWDDQQTAFISKLNDDPQSQSSELLSEAKKLNDSQAPK	313
Z10570	VDKYYAKEMDYAQWEIWLPLNLTWHQSNAFIRKLIIDDPQSQSSELLSEAKKLNDSQAPK	314
Z10571	VDKYYAKEHAEAWFEIWAIPNLTWDDQARAFIVKLNDDPSQSSELLSEAKKLNDSQAPK	315
Z10572	VDKYYAKEADYAWFEIWAIPNLTYDQQFAFIRKLLDDPSQSSELLSEAKKLNDSQAPK	316
Z10573	VDKYYAKEYDNAWFEIWMLPNLTHTAQAARAFIRKLNDDPSQSSELLSEAKKLNDSQAPK	317
Z10576	VDKYYAKEADFAWWEIWLPLNLTHTDQQRAFIVKLLDDPSQSSELLSEAKKLNDSQAPK	318

Z10587	VDKYYAKEADFAWFEI WALPNLTHDQAVAFIRKLNDDPSQSSELLSEAKKLND SQAPK	319
Z10588	VDKYYAKEHDYAWFEI WMLPNLT YDQAHAFIRKLNDDPSQSSELLSEAKKLND SQAPK	320
Z10589	VDKYYAKEADEAWFEI WLLPNLT YDQQHAFIVKLIDDPSQSSELLSEAKKLND SQAPK	321
Z10590	VDKYYAKEMDYAWFEI WLLPNLTHDQAYAFIVKLIDDPSQSSELLSEAKKLND SQAPK	322
Z10592	VDKYYAKEYLAWFEI WTLPNLT YDQQVAFIRKLLDDPSQSSELLSEAKKLND SQAPK	323
Z10593	VDKYYAKEYDDAWFEI WTLPNLT RDQQTAFI IKLNDDPSQSSELLSEAKKLND SQAPK	324
Z10594	VDKYYAKEMDEAWFEI WSLPNLT YAQQYAFIVKLIDDPSQSSELLSEAKKLND SQAPK	325
Z10596	VDKYYAKEADYAWFEI WSLPNLTHVQQVAFIRKLLDDPSQSSELLSEAKKLND SQAPK	326
Z10599	VDKYYAKEADEAWFEI WSLPNLTHAQARAFIQKLIDDPSQSSELLSEAKKLND SQAPK	327
Z10603	VDKYYAKEYDEAWFEI WMLPNLT RDQASAFI IKLNDDPSQSSELLSEAKKLND SQAPK	328
Z10605	VDKYYAKEHADAWFEI WSLPNLTHVQARAFI IKLNDDPSQSSELLSEAKKLND SQAPK	329
Z10606	VDKYYAKEADFAWFEI WLLPNLTHAQQTAFIRKLLDDPSQSSELLSEAKKLND SQAPK	330
Z10610	VDKYYAKEADYAWFEI WSLPNLTHAQATAFISKLNDDPSQSSELLSEAKKLND SQAPK	331
Z10611	VDKYYAKEYDYAWFEI WELPNLT WDQQTAFIRKLNDDPSQSSELLSEAKKLND SQAPK	332
Z10612	VDKYYAKEADYAWFEI WLLPNLTHDQATAFIRKLI DDPSQSSELLSEAKKLND SQAPK	333
Z10613	VDKYYAKEADYAWFEI WSLPNLTHDQQVAFIRKLNDDPSQSSELLSEAKKLND SQAPK	334
Z10614	VDKYYAKEADFAWFEI WSLPNLTHVQQVAFIRKLLDDPSQSSELLSEAKKLND SQAPK	335
Z10615	VDKYYAKEADYAWFEI WALPNLTHAQQVAFIAKLND DPSSQSSELLSEAKKLND SQAPK	336
Z10620	VDKYYAKEADYAWFEI WALPNLTHAQAVAFIGKLNDDPSQSSELLSEAKKLND SQAPK	337
Z10623	VDKYYAKEADFAWFEI WSLPNLTHDQARAFI SKLNDDPSQSSELLSEAKKLND SQAPK	338
Z10624	VDKYYAKEMDEAQWFEI WLLPNLTHHQANAFIRKLI DDPSQSSELLSEAKKLND SQAPK	339
Z10625	VDKYYAKEADYAWFEI WALPNLT WDQAHAFIRKLNDDPSQSSELLSEAKKLND SQAPK	340
Z10628	VDKYYAKEADQAWFEI WLLPNLTHDQQVAFIQKLIDDPSQSSELLSEAKKLND SQAPK	341
Z10632	VDKYYAKEADEAWFEI WSLPNLTHDQAKAFIQKLIDDPSQSSELLSEAKKLND SQAPK	342
Z10633	VDKYYAKEHGYAWFEI WALPNLTHDQAKAFIRKLNDDPSQSSELLSEAKKLND SQAPK	343
Z10634	VDKYYAKEADYAWFEI WSLPNLTHVQQVAFIRKLI DDPSQSSELLSEAKKLND SQAPK	344
Z10636	VDKYYAKEYDEAWFEI WMLPNLT YDQGRAFIGKLNDDPSQSSELLSEAKKLND SQAPK	345
Z10637	VDKYYAKEADFAWFEI WALPNLTHVQAVAFIRKLLDDPSQSSELLSEAKKLND SQAPK	346
Z10639	VDKYYAKEADDAWFEI WALPNLTHAQAVAFIQKLND DPSSQSSELLSEAKKLND SQAPK	347

Z10640	VDKYYAKEADQAWWEI WALPNLTHDQGVAFIRKLLDDPSQSSELLSEAKKLND SQAPK	348
Z10641	VDKYYAKEYDEAWFEI WLLPNLTADQARAFIVKLNDDPSQSSELLSEAKKLND SQAPK	349
Z10644	VDKYYAKEADYAWWEI WALPNLTYDQQYAFIRKLNDDPSQSSELLSEAKKLND SQAPK	350
Z10645	VDKYYAKEADDAWWEI WMLPNLTHDQARAFIQKLLDDPSQSSELLSEAKKLND SQAPK	351
Z10646	VDKYYAKEADEAWWEI WALPNLTHRQQVAFIQKLLDDPSQSSELLSEAKKLND SQAPK	352
Z10647	VDKYYAKEADFAWFEI WALPNLTHDQATAFIVKLNDDPSQSSELLSEAKKLND SQAPK	353
Z10651	VDKYYAKEMDDAWWEI WALPNLTHAQAVAFIRKLLDDPSQSSELLSEAKKLND SQAPK	354
Z10653	VDKYYAKEADEAWWEI WALPNLTHHQAVAFIHKLLDDPSQSSELLSEAKKLND SQAPK	355
Z10654	VDKYYAKEADYAWWEI WTLPNLTHDQQYAFIQKLLDDPSQSSELLSEAKKLND SQAPK	356
Z10655	VDKYYAKEMDFAQWEI WLLPNLTHWQSNAFIRKLLDDPSQSSELLSEAKKLND SQAPK	357
Z10657	VDKYYAKENDEAWFEI WSLPNLTYDQGRAFI IKLNDDPSQSSELLSEAKKLND SQAPK	358
Z10658	VDKYYAKEADEAQWEI WLLPNLTHDQSNAFIRKLLDDPSQSSELLSEAKKLND SQAPK	359
Z10659	VDKYYAKEADYAWWEI WALPNLTHAQQKAFIRKLLDDPSQSSELLSEAKKLND SQAPK	360
Z10660	VDKYYAKEMDEAQWEI WMLPNLTHDQSHAFIAKLLDDPSQSSELLSEAKKLND SQAPK	361
Z10661	VDKYYAKEADYAWWEI WSLPNLTHDQQVAFIRKLLDDPSQSSELLSEAKKLND SQAPK	362
Z10662	VDKYYAKEMDDAWWEI WLLPNLTYDQQYAFIQKLLDDPSQSSELLSEAKKLND SQAPK	363
Z10665	VDKYYAKEMDDAQWEI WLLPNLTHWVQQNAFIRKLLDDPSQSSELLSEAKKLND SQAPK	364
Z10666	VDKYYAKEMDEAQWEI WLLPNLTHWQQNAFIRKLLDDPSQSSELLSEAKKLND SQAPK	365
Z10667	VDKYYAKEH DYAWFEI WALPNLTHAQAVAFI IKLNDDPSQSSELLSEAKKLND SQAPK	366
Z10669	VDKYYAKEADFAWWEI WLLPNLTYDQQHAFIVKLLDDPSQSSELLSEAKKLND SQAPK	367
Z10670	VDKYYAKEMLD AQWEI WMLPNLTHDQGHAFIVKLLDDPSQSSELLSEAKKLND SQAPK	368
Z10671	VDKYYAKEMDN AWFEI WTLPNLTYAQQHAFIVKLLDDPSQSSELLSEAKKLND SQAPK	369
Z10672	VDKYYAKEADYAWFEI WTLPNLTYDQQKAFIQKLLDDPSQSSELLSEAKKLND SQAPK	370
Z10677	VDKYYAKEMDEAQIEI WLLPNLTHWQGNAFIRKLLDDPSQSSELLSEAKKLND SQAPK	371
Z10678	VDKYYAKEMDNAQWEI WLLPNLTYDQSHAFIAKLLDDPSQSSELLSEAKKLND SQAPK	372
Z10679	VDKYYAKEADFAWFEI WSLPNLTHDQAVAFIRKLNDDPSQSSELLSEAKKLND SQAPK	373
Z10683	VDKYYAKEMDYAQWEI WMLPNLTHDQQHAFIQKLLDDPSQSSELLSEAKKLND SQAPK	374
Z10685	VDKYYAKEADYAWFEI WMLPNLTHDQQQTA FISKLLDDPSQSSELLSEAKKLND SQAPK	375
Z10687	VDKYYAKEMDYAQWEI WLLPNLTHAQGTAFIRKLLDDPSQSSELLSEAKKLND SQAPK	376

Z10689	VDKYYAKEMDYAWFEI WALPNLTYDQAHAFI IKLIDDPQSQSSELLSEAKKLND SQAPK	377
Z10691	VDKYYAKEMDEAWFEI WTLPNLTYDQQHAFI VKLLDDPSQSSELLSEAKKLND SQAPK	378
Z10696	VDKYYAKEADQAWFEI WLLPNLTHDQQVAFIRKLLDDPSQSSELLSEAKKLND SQAPK	379
Z10697	VDKYYAKEADEAWFEI WALPNLTHDQAKAFI IKLLDDPSQSSELLSEAKKLND SQAPK	380
Z10698	VDKYYAKEAAEAWFEI WMLPNLTYDQAVAFI HKLNDDPSQSSELLSEAKKLND SQAPK	381
Z10699	VDKYYAKEADYAWFEI WLLPNLTHVQORAFI QKLNDDPQSQSSELLSEAKKLND SQAPK	382
Z10700	VDKYYAKEMDQAWFEI WALPNLTHWQARAFI VKLIDDPQSQSSELLSEAKKLND SQAPK	383
Z10701	VDKYYAKEHDEAWFEI WSLPNLTYDQQRAFI IKLNDDPSQSSELLSEAKKLND SQAPK	384
Z10702	VDKYYAKEYDEAWFEI WMLPNLTYDQAVAFI SKLNDDPSQSSELLSEAKKLND SQAPK	385
Z10704	VDKYYAKEHDQAWFEI WLLPNLTYAQARAFI SKLNDDPSQSSELLSEAKKLND SQAPK	386
Z10705	VDKYYAKEMDFAQWEI WLLPNLTHWQSNAFI QKLIDDPQSQSSELLSEAKKLND SQAPK	387
Z10706	VDKYYAKEMDFAQWEI WMLPNLTHWDQSNAFI QKLIDDPQSQSSELLSEAKKLND SQAPK	388
Z10707	VDKYYAKEMDNAQWEI WLLPNLTHWAQQNAFI RKLIDDPQSQSSELLSEAKKLND SQAPK	389
Z10709	VDKYYAKEADYAWFEI WMLPNLTYDQAFAFI QKLIDDPQSQSSELLSEAKKLND SQAPK	390
Z10711	VDKYYAKEMDYAQWEI WLLPNLTHVQSHAFI QKLIDDPQSQSSELLSEAKKLND SQAPK	391
Z10713	VDKYYAKEADFAWFEI WALPNLTHVQAKAFI QKLIDDPQSQSSELLSEAKKLND SQAPK	392
Z10715	VDKYYAKEMDYAQWEI WLLPNLTHWDQSHAFI VKLLDDPSQSSELLSEAKKLND SQAPK	393
Z10716	VDKYYAKEADFAWFEI WLLPNLTHDQAYAFI VKLIDDPQSQSSELLSEAKKLND SQAPK	394
Z10717	VDKYYAKEMDNAQWEI WLLPNLTYAQQHAFI QKLIDDPQSQSSELLSEAKKLND SQAPK	395
Z10719	VDKYYAKEADYAWFEI WSLPNLTHVQARAFI IKLLDDPSQSSELLSEAKKLND SQAPK	396
Z10720	VDKYYAKEHDEAWFEI WTLPNLTHAQARAFI SKLNDDPSQSSELLSEAKKLND SQAPK	397
Z10724	VDKYYAKEADYAWFEI WLLPNLTYDQQYAFI QKLNDDPQSQSSELLSEAKKLND SQAPK	398
Z10725	VDKYYAKEMDRAQWEI WLLPNLTYDQSHAFI QKLDDPSQSSELLSEAKKLND SQAPK	399
Z10726	VDKYYAKEMDEAWFEI WLLPNLTYDQQYAFI AKLIDDPQSQSSELLSEAKKLND SQAPK	400
Z10727	VDKYYAKEYDYAWFEI WLLPNLTHWQQVAFI HKLNDDPSQSSELLSEAKKLND SQAPK	401
Z10735	VDKYYAKEADFAWFEI WSLPNLTHWDQARAFI IKLNDDPSQSSELLSEAKKLND SQAPK	402
Z10736	VDKYYAKEADFAWFEI WLLPNLTHWDQQKAFI HKLNDDPSQSSELLSEAKKLND SQAPK	403
Z10737	VDKYYAKEYDQAWFEI WLLPNLTHWAQQVAFI QKLNDDPQSQSSELLSEAKKLND SQAPK	404
Z10738	VDKYYAKEMDDAQWEI WLLPNLTHWDQQHAFI AKLIDDPQSQSSELLSEAKKLND SQAPK	405

Z10739	VDKYYAKEMDEAQWEIWLPLNLTWDDQGHAFIQKLLDDPSQSSELLSEAKKLNDSQAPK	406
Z10741	VDKYYAKEADYAWFEIWMPLPNLTHDQQYAFIHKLNDDPSQSSELLSEAKKLNDSQAPK	407
Z10742	VDKYYAKEADYAWFEIWAALPNLTHVQQVAFIHKLNDDPSQSSELLSEAKKLNDSQAPK	408
Z10747	VDKYYAKEADYAWFEIWAALPNLTHAQQVAFIRKLLDDPSQSSELLSEAKKLNDSQAPK	409
Z10749	VDKYYAKEMGQAQLEIWMPLPNLTWDDQGHAFIQKLLDDPSQSSELLSEAKKLNDSQAPK	410
Z10750	VDKYYAKEMDEAQWEIWLPLNLTWHQSHAFISKLLDDPSQSSELLSEAKKLNDSQAPK	411
Z10751	VDKYYAKEMDYAQWEIWLPLNLTWHQQHAFIVKLLDDPSQSSELLSEAKKLNDSQAPK	412
Z10755	VDKYYAKEADEAQWEIWLPLNLTWDDQSNAFIRKLLDDPSQSSELLSEAKKLNDSQAPK	413
Z10758	VDKYYAKEYDYAWFEIWLPLNLTTRDQQRAFIKLNDDPSQSSELLSEAKKLNDSQAPK	414
Z10761	VDKYYAKEHAEAWEIWAALPNLTVQARAFIVKLNDDPSQSSELLSEAKKLNDSQAPK	415
Z10762	VDKYYAKEADYAWFEIWLPLNLTYPHQVAFIHKLNDDPSQSSELLSEAKKLNDSQAPK	416
Z10764	VDKYYAKEYDFAWFEIWLPLNLTWDDQQVAFISKLNDDPSQSSELLSEAKKLNDSQAPK	417
Z10765	VDKYYAKEMDEAQWEIWLPLNLTWDDQSNAFIRKLLDDPSQSSELLSEAKKLNDSQAPK	418
Z10767	VDKYYAKEMDEAQIEIWLPLNLTWAQGHAFIQKLLDDPSQSSELLSEAKKLNDSQAPK	419
Z10768	VDKYYAKEADYAWFEIWLPLNLTYPHQYAFIQKLNDDPSQSSELLSEAKKLNDSQAPK	420
Z10769	VDKYYAKEMDEAQWEIWLPLNLTWDDQQNAFIRKLLDDPSQSSELLSEAKKLNDSQAPK	421
Z10770	VDKYYAKEYDQAWFEIWLPLNLTYPAQQFAFIRKLNDDPSQSSELLSEAKKLNDSQAPK	422
Z10777	VDKYYAKEMGEAQLEIWLPLNLTWHQQNAFIRKLLDDPSQSSELLSEAKKLNDSQAPK	423
Z10782	VDKYYAKEMDYAQWEIWLPLNLTYPDQQHAFIVKLLDDPSQSSELLSEAKKLNDSQAPK	424
Z10786	VDKYYAKEMDEAWWEIWLPLNLTYPAQGRAFIVKLLDDPSQSSELLSEAKKLNDSQAPK	425
Z10787	VDKYYAKEMDEAWWEIWLPLNLTYPDQQYAFISKLLDDPSQSSELLSEAKKLNDSQAPK	426
Z10794	VDKYYAKEYDYAWFEIWMPLPNLTYPDQQVAFISKLNDDPSQSSELLSEAKKLNDSQAPK	427
Z10796	VDKYYAKEMDEAQWEIWMPLPNLTWDDQQNAFIRKLLDDPSQSSELLSEAKKLNDSQAPK	428
Z10797	VDKYYAKEMDEAQWEIWMPLPNLTWDDQSHAFIQKLLDDPSQSSELLSEAKKLNDSQAPK	429
Z10798	VDKYYAKEYDYAWFEIWLPLNLTYPDQQHAFIVKLNDDPSQSSELLSEAKKLNDSQAPK	430
Z10802	VDKYYAKEADFAWWEIWAALPNLTHDQARAFIVKLLDDPSQSSELLSEAKKLNDSQAPK	431
Z10804	VDKYYAKEADYAWFEIWLPLNLTYPDQATAFISKLNDDPSQSSELLSEAKKLNDSQAPK	432
Z10806	VDKYYAKEMDYAQWEIWLPLNLTWDDQGRAFIQKLLDDPSQSSELLSEAKKLNDSQAPK	433
Z10808	VDKYYAKEMDEAQWEIWLPLNLTWDDQGNAFISKLLDDPSQSSELLSEAKKLNDSQAPK	434

Z10809	VDKYYAKEADYAWWEIWSLPNLTTHAQAYAFIVKLIDDPQSSELLSEAKKLNDSQAPK	435
Z10810	VDKYYAKEYDNEWFEI WALPNLT YAQAYAFIRKLNDDPSQSSELLSEAKKLNDSQAPK	436
Z10812	VDKYYAKEMDEAQWEIWMLPNLT YAQSHAFIVKLIDDPQSSELLSEAKKLNDSQAPK	437
Z10813	VDKYYAKEADYAWFEIWM LPNLT RDQATAFI IKLNDDPSQSSELLSEAKKLNDSQAPK	438
Z10814	VDKYYAKEADYAWFEI WALPNLT WHQATAFI IKLNDDPSQSSELLSEAKKLNDSQAPK	439
Z10815	VDKYYAKEADYAWFEI WALPNLT WDQQR AFISKLND DPQSSELLSEAKKLND SQAPK	440
Z10816	VDKYYAKEADYAWWEIWTLPNLT YDQSR AFIVKLID DPQSSELLSEAKKLND SQAPK	441
Z10817	VDKYYAKEADYAWFEI WELPNLT HDQAVAFIRKLNDDPSQSSELLSEAKKLND SQAPK	442
Z10818	VDKYYAKEMDEAQWEIWL LPNLT HDQGRAFIQKLID DPQSSELLSEAKKLND SQAPK	443
Z10819	VDKYYAKEMDNAQWEIWL LPNLT WHQSNAFIQKLID DPQSSELLSEAKKLND SQAPK	444
Z10821	VDKYYAKEMDDAQWEIWL LPNLT WDQSNAFIRKLI DDPSQSSELLSEAKKLND SQAPK	445
Z10822	VDKYYAKEMDFAQWEIWL LPNLT WHQQHAFIVKLID DPQSSELLSEAKKLND SQAPK	446
Z10823	VDKYYAKEHGYAWFEI WALPNLT WDQQVAFI IKLNDDPSQSSELLSEAKKLND SQAPK	447
Z10824	VDKYYAKEMDYAQWEIWL LPNLT WAQSNAFIAKLID DPQSSELLSEAKKLND SQAPK	448
Z10825	VDKYYAKEMDEAQWEIWM LPNLT WHQSHAFIVKLID DPQSSELLSEAKKLND SQAPK	449
Z10826	VDKYYAKEMDFAQWEIWL LPNLT WVQSNAFIRKLI DDPSQSSELLSEAKKLND SQAPK	450
Z10827	VDKYYAKEMDNAQWEIWL LPNLT HDQGNAFIRKLI DDPSQSSELLSEAKKLND SQAPK	451
Z10830	VDKYYAKEYDYAWFEI WL LPNLT WDQATAFI RKLND DPQSSELLSEAKKLND SQAPK	452
Z10831	VDKYYAKEMDYAQWEIWL LPNLT YDQQHAFI IKLI DDPSQSSELLSEAKKLND SQAPK	453
Z10832	VDKYYAKEMDQAQWEIWL LPNLT WDQQR AFIVKLID DPQSSELLSEAKKLND SQAPK	454
Z10833	VDKYYAKEMDEAQWEIWL LPNLT WHQSHAFIQKLID DPQSSELLSEAKKLND SQAPK	455
Z10834	VDKYYAKEYDQAWFEI WL LPNLT WDQAVAFI IKLNDDPSQSSELLSEAKKLND SQAPK	456
Z10835	VDKYYAKEMGDAQWEIWL LPNLT WAQQNAFIRKLI DDPSQSSELLSEAKKLND SQAPK	457
Z10836	VDKYYAKEMDEAQWEIWL LPNLT WAQGHAFISKLID DPQSSELLSEAKKLND SQAPK	458
Z10837	VDKYYAKEMDDAQWEIWL LPNLT WHQQNAFIRKLI DDPSQSSELLSEAKKLND SQAPK	459
Z10838	VDKYYAKEADDAWWEI WALPNLT WDQARAFIVKLID DPQSSELLSEAKKLND SQAPK	460
Z10840	VDKYYAKEMDFAQWEIWL LPNLT WDQGHAFISKLID DPQSSELLSEAKKLND SQAPK	461
Z10842	VDKYYAKEMDFAWFEI WALPNLT YDQQVAFIRKLI DDPSQSSELLSEAKKLND SQAPK	462
Z10843	VDKYYAKEWDEAWFEI WALPNLT YDQAVAFI HKLNDDPSQSSELLSEAKKLND SQAPK	463

Z10846	VDKYYAKEMDNAQWEIWLLPNLNTWQSHAFIVKLLDDPSQSSELLSEAKKLND	464
Z10847	VDKYYAKEYDDAWFEIWTLPNLTYVQQYAFIRKLNDDPSQSSELLSEAKKLND	465
Z10848	VDKYYAKEHAEAWFEIWSLPNLTWQQVAFIGKLNDDPSQSSELLSEAKKLND	466
Z10849	VDKYYAKEMGEAQWEIWLLPNLTYDQSHAFIVKLLDDPSQSSELLSEAKKLND	467
Z10850	VDKYYAKEHHDYAWFEIHALPNLTHDQARAFIHKLNDDPSQSSELLSEAKKLND	468
Z10851	VDKYYAKEADYAWFEIHALPNLTDQQRAFIVKLNDDPSQSSELLSEAKKLND	469
Z10854	VDKYYAKEADYAWFEIWSLPNLTYHQARAFIQKLIDDPQSQSSELLSEAKKLND	470
Z10855	VDKYYAKEADYAWFEIWSLPNLTYDQAVAFIGKLNDDPSQSSELLSEAKKLND	471
Z10856	VDKYYAKEMDRAQLEIWLLPNLNTWAQGNAFIRKLIIDDPQSQSSELLSEAKKLND	472
Z10860	VDKYYAKEMNQAWFEIWLLPNLNTWHQSHAFIQKLIDDPQSQSSELLSEAKKLND	473
Z10862	VDKYYAKEHAEAWFEIWSLPNLNTWRQQRAFI IKLNDDPSQSSELLSEAKKLND	474
Z10864	VDKYYAKEMDQAQWEIWLLPNLNTWQSHAFISKLLDDPSQSSELLSEAKKLND	475
Z10871	VDKYYAKEMDEAQWEIWLLPNLNTHAQSHAFIQKLIDDPQSQSSELLSEAKKLND	476
Z10873	VDKYYAKEMDEAQWEIWLLPNLNTWHQGNAFIQKLIDDPQSQSSELLSEAKKLND	477
Z10874	VDKYYAKEMDEAWFEIWLLPNLTYDQQRAFIVKLLDDPSQSSELLSEAKKLND	478
Z10876	VDKYYAKEYDYAWFEIWLLPNLNTHAQARAFIHKLNDDPSQSSELLSEAKKLND	479
Z10884	VDKYYAKEHAEAWFEIWMLPNLNTWAQQRAFIGKLNDDPSQSSELLSEAKKLND	480
Z10885	VDKYYAKEMDDAQWEIWLLPNLNTWQSHAFIAKLIDDPQSQSSELLSEAKKLND	481
Z10888	VDKYYAKEYDEAWFEIHALPNLTHAQAVAFIRKLNDDPSQSSELLSEAKKLND	482
Z10890	VDKYYAKEYDFAWFEIWLLPNLNTWQQRAFISKLNDDPSQSSELLSEAKKLND	483
Z10894	VDKYYAKEMDEAQWEIWLLPNLNTWHQAHAFIRKLIIDDPQSQSSELLSEAKKLND	484
Z10898	VDKYYAKEHDFAWFEIWLLPNLNTWQQVAFIHKLNDDPSQSSELLSEAKKLND	485
Z10902	VDKYYAKEWDEAQWEIWLLPNLNTWQSHAFIQKLIDDPQSQSSELLSEAKKLND	486
Z10907	VDKYYAKEMGRAQIEIWLLPNLNTWQGNAFIRKLIIDDPQSQSSELLSEAKKLND	487
Z10917	VDKYYAKEMDDAQWEIWMLPNLNTWHQGHAFIQKLIDDPQSQSSELLSEAKKLND	488
Z10919	VDKYYAKEADYAWFEIWLLPNLTYDQYAFIRKLNDDPSQSSELLSEAKKLND	489
Z10920	VDKYYAKEADYAWFEIWTLPNLTHDQAKAFIVKLNDDPSQSSELLSEAKKLND	490
Z10925	VDKYYAKEMDEAQWEIWLLPNLNTWHQSNAFIRKLIIDDPQSQSSELLSEAKKLND	491
Z10927	VDKYYAKEMDYAQWEIWLLPNLNTWVQQNAFIRKLIIDDPQSQSSELLSEAKKLND	492

Z10935	VDKYYAKEADYAWWEI WALPNLTHDQAVAFIRKLIDDPQSSELLSEAKKLND SQAPK	493
Z10938	VDKYYAKEADYAWFEI WALPNLTHRQQVAFIRKLND DPQSSELLSEAKKLND SQAPK	494
Z10942	VDKYYAKEMDQAQWEI WLLPNLTHWQQHAFIRKLIDDPQSSELLSEAKKLND SQAPK	495
Z10945	VDKYYAKEMNEAQLEI WLLPNLTHWAQGHAFIQKLIDDPQSSELLSEAKKLND SQAPK	496
Z10952	VDKYYAKEADEAWWEI WALPNLTHHQAVAFIRKLIDDPQSSELLSEAKKLND SQAPK	497
Z10954	VDKYYAKEYDYAWFEI WLLPNLTYRQARAFI IKLND DPQSSELLSEAKKLND SQAPK	498
Z10961	VDKYYAKEMGEAQWEI WLLPNLTHDQQHAFIQKLIDDPQSSELLSEAKKLND SQAPK	499
Z10962	VDKYYAKEYDYAWFEI WLLPNLTHADQQRAFI HKLND DPQSSELLSEAKKLND SQAPK	500
Z10963	VDKYYAKEHDEAWFEI WLLPNLTHDQQVAFIRKLND DPQSSELLSEAKKLND SQAPK	501
Z10971	VDKYYAKEYDDAWFEI WLLPNLTHWAQQRAFISKLND DPQSSELLSEAKKLND SQAPK	502
Z10973	VDKYYAKEYDEAWFEI WLLPNLTHRDQGFIRKLND DPQSSELLSEAKKLND SQAPK	503
Z10979	VDKYYAKEYDDAWFEI WLLPNLTHAQARAFIVKLND DPQSSELLSEAKKLND SQAPK	504
Z10986	VDKYYAKEHAEAWFEI WLLPNLTYRQQVAFISKLND DPQSSELLSEAKKLND SQAPK	505
Z10988	VDKYYAKEADYAWFEI WMLPNLTHRDQAVAFIGKLND DPQSSELLSEAKKLND SQAPK	506
Z10990	VDKYYAKEMDEAQWEI WLLPNLTHWQQKAFIQKLIDDPQSSELLSEAKKLND SQAPK	507
Z10992	VDKYYAKEADYAWFEI WMLPNLTYAQQRAFIVKLND DPQSSELLSEAKKLND SQAPK	508
Z11015	VDKYYAKEMDEAQWEI WLLPNLTHAQGRAFIQKLIDDPQSSELLSEAKKLND SQAPK	509
Z11017	VDKYYAKEMDYAQWEI WLLPNLTHWQSNAFIQKLIDDPQSSELLSEAKKLND SQAPK	510
Z11021	VDKYYAKEMDEAQWEI WLLPNLTYAQSRAFIVKLIDDPQSSELLSEAKKLND SQAPK	511
Z11027	VDKYYAKEMDYAQWEI WLLPNLTHDQSRAFIVKLIDDPQSSELLSEAKKLND SQAPK	512
Z11030	VDKYYAKEMDQAQWEI WLLPNLTYDQGRAFIQKLIDDPQSSELLSEAKKLND SQAPK	513
Z11045	VDKYYAKEMDYAQWEI WLLPNLTHDQSRAFISKLIDDPQSSELLSEAKKLND SQAPK	514
Z11052	VDKYYAKEMDEAQWEI WMLPNLTHAQSRAFIQKLIDDPQSSELLSEAKKLND SQAPK	515
Z11063	VDKYYAKEMDEAWWEI WTLPNLTYDQARAFIVKLIDDPQSSELLSEAKKLND SQAPK	516
Z11069	VDKYYAKEMDNAQWEI WLLPNLTHDQSRAFIQKLIDDPQSSELLSEAKKLND SQAPK	517
Z11085	VDKYYAKEADYAWFEI WTLPNLTHRDQARAFI HKLND DPQSSELLSEAKKLND SQAPK	518
Z11086	VDKYYAKEMDNAQWEI WLLPNLTHDQSRAFIVKLIDDPQSSELLSEAKKLND SQAPK	519
Z12058	VDKYYAKEADDAAYEIAFLPNLTHDQWYAFIQKL RD DPQSSELLSEAKKLND SQAPK	520
Z12061	VDKYYAKEADLAAYEIAELPNLTHDQWWAFIQKL RD DPQSSELLSEAKKLND SQAPK	521

Z12062	VDKYYAKEADDAALEIADLPNLTWEQWYAFISKLRDDPSQSSELLSEAKKLNDSQAPK	522
Z12064	VDKYYAKEADQAAAYEIAYLPNLTWDQWFAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	523
Z12065	VDKYYAKEADQAAVEIADLPNLTWDQWWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	524
Z12066	VDKYYAKEADEAAAMEIADLPNLTWDQWWAFISKLRDDPSQSSELLSEAKKLNDSQAPK	525
Z12067	VDKYYAKEADMAAFEIAALLPNLTWDQWEAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	526
Z12068	VDKYYAKEADDAAVEIADLPNLTWDQWWAFIRKLRDDPSQSSELLSEAKKLNDSQAPK	527
Z12069	VDKYYAKEADDAAVEIAELPNLTWEQWYAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	528
Z12070	VDKYYAKEADEAAVEIAALPNLTWDQWFAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	529
Z12071	VDKYYAKEADEAAVEIAFLPNLTWDQWYAFITKLRDDPSQSSELLSEAKKLNDSQAPK	530
Z12072	VDKYYAKEADNAALEIADLPNLTWDQWYAFIAKLRDDPSQSSELLSEAKKLNDSQAPK	531
Z12074	VDKYYAKEADDAAVEIANLPNLTWDQWWAFITKLRDDPSQSSELLSEAKKLNDSQAPK	532
Z12075	VDKYYAKEADEAAVEIAFLPNLTWDQWFAFINKLRDDPSQSSELLSEAKKLNDSQAPK	533
Z12076	VDKYYAKEADDAALEIADLPNLTWDQWIAFINKLRDDPSQSSELLSEAKKLNDSQAPK	534
Z12079	VDKYYAKEADNAAMEIADLPNLTWDQWFAFINKLRDDPSQSSELLSEAKKLNDSQAPK	535
Z12080	VDKYYAKEADDAAFEIAFLPNLTWDQWWAFINKLRDDPSQSSELLSEAKKLNDSQAPK	536
Z12082	VDKYYAKEADDAAMEIAELPNLTWDQWYAFINKLRDDPSQSSELLSEAKKLNDSQAPK	537
Z12083	VDKYYAKEADDAAVEIAYLPNLTWDQWFAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	538
Z12084	VDKYYAKEADSAAVEIADLPNLTWDQWYAFINKLRDDPSQSSELLSEAKKLNDSQAPK	539
Z12085	VDKYYAKEADEAAVEIAFLPNLTWDQWAAAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	540
Z12086	VDKYYAKEADMAAMEIADLPNLTWDQWWAFIWKLRDDPSQSSELLSEAKKLNDSQAPK	541
Z12087	VDKYYAKEADDAAVEIADLPNLTWDQWWAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	542
Z12088	VDKYYAKEADEAAAMEIADLPNLTWDQWEAFILKLRDDPSQSSELLSEAKKLNDSQAPK	543
Z12089	VDKYYAKEADEAAVEIADLPNLTWDQWYAFITKLRDDPSQSSELLSEAKKLNDSQAPK	544
Z12090	VDKYYAKEADEAAVEIASLPNLTWDQWFAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	545
Z12091	VDKYYAKEADDAAVEIANLPNLTWDQWFAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	546
Z12092	VDKYYAKEADDAAYEIAYLPNLTWDQWFAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	547
Z12093	VDKYYAKEADDAAVEIAALPNLTWDQWYAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	548
Z12094	VDKYYAKEADNAAMEIAELPNLTWDQWYAFINKLRDDPSQSSELLSEAKKLNDSQAPK	549
Z12095	VDKYYAKEADEAAVEIAYLPNLTWDQWWAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	550

Z12096	VDKYYAKEADDAAFEIALLPNLTWDQWHAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	551
Z12097	VDKYYAKEADMAAVEIAGLPNLTWDQWYAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	552
Z12098	VDKYYAKEADMAAVEIAELPNLTWDQWWAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	553
Z12099	VDKYYAKEADDAAVEIAGLPNLTWDQWFAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	554
Z12100	VDKYYAKEADAAAVEIADLPNLTWDQWWAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	555
Z12101	VDKYYAKEADDAAVEIADLPNLTWDQWYAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	556
Z12102	VDKYYAKEADDAAVEIAELPNLTWEQWFAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	557
Z12103	VDKYYAKEADDAAVEIAELPNLTWEQWAAAFISKLRDDPSQSSELLSEAKKLNDSQAPK	558
Z12104	VDKYYAKEADDAAEIEIADLPNLTWDQWWAFINKLRDDPSQSSELLSEAKKLNDSQAPK	559
Z12105	VDKYYAKEADDAAFEIAMLPNLTWDQWEAFILKLRDDPSQSSELLSEAKKLNDSQAPK	560
Z12106	VDKYYAKEADDAAMEIADLPNLTWDQWEAFILKLRDDPSQSSELLSEAKKLNDSQAPK	561
Z12107	VDKYYAKEADEAAVEIAELPNLTWDQWAAAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	562
Z12108	VDKYYAKEADDAAFEIAELPNLTWDQWFAFINKLRDDPSQSSELLSEAKKLNDSQAPK	563
Z12109	VDKYYAKEADDAAVEIASLPNLTWDQWEAFILKLRDDPSQSSELLSEAKKLNDSQAPK	564
Z12110	VDKYYAKEADAAAIEIADLPNLTWDQWYAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	565
Z12111	VDKYYAKEADEAAVEIAALPNLTWDQWWAFIMKLRDDPSQSSELLSEAKKLNDSQAPK	566
Z12112	VDKYYAKEADEAAVEIAFLPNLTWDQWFAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	567
Z12113	VDKYYAKEADAAAIEIAFLPNLTWDQWFAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	568
Z12114	VDKYYAKEADRAAFEIAELPNLTWDQWWAFIRKLRDDPSQSSELLSEAKKLNDSQAPK	569
Z12116	VDKYYAKEADDAAVEIAELPNLTWDQWWAFIHKLRDDPSQSSELLSEAKKLNDSQAPK	570
Z12117	VDKYYAKEADDAAVEIAYLPNLTWDQWFAFITKLRDDPSQSSELLSEAKKLNDSQAPK	571
Z12118	VDKYYAKEADDAAMEIADLPNLTWDQWYAFISKLRDDPSQSSELLSEAKKLNDSQAPK	572
Z12119	VDKYYAKEADDAAYEIAFLPNLTWEQWWAFISKLRDDPSQSSELLSEAKKLNDSQAPK	573
Z12120	VDKYYAKEADMAAYEIASLPNLTWDQWFAFISKLRDDPSQSSELLSEAKKLNDSQAPK	574
Z12121	VDKYYAKEADDAAFEIANLPNLTWDQWFAFINKLRDDPSQSSELLSEAKKLNDSQAPK	575
Z12122	VDKYYAKEADSAAAMEIADLPNLTWDQWMAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	576
Z12123	VDKYYAKEADMAAVEIASLPNLTWDQWHAFIMKLRDDPSQSSELLSEAKKLNDSQAPK	577
Z12124	VDKYYAKEADAAAIEIADLPNLTWDQWHAFITKLRDDPSQSSELLSEAKKLNDSQAPK	578
Z12125	VDKYYAKEADDAAVEIANLPNLTWAQWEAFIMKLRDDPSQSSELLSEAKKLNDSQAPK	579

Z12126	VDKYYAKEADIAAMEIADLPNLTWDQWWAFINKLRDDPSQSSELLSEAKKLNDSQAPK	580
Z12127	VDKYYAKEADHAAVEIAGLPNLTWDQWFAFINKLRDDPSQSSELLSEAKKLNDSQAPK	581
Z12128	VDKYYAKEADEAAVEIAELPNLTWDQWWAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	582
Z12129	VDKYYAKEADEAAFEIAELPNLTWDQWFAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	583
Z12130	VDKYYAKEADAAAVEIANLPNLTWDQWWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	584
Z12131	VDKYYAKEADDAAMEIAALPNLTWFQWWAFINKLRDDPSQSSELLSEAKKLNDSQAPK	585
Z12132	VDKYYAKEADDAAVEIAELPNLTWDQWFAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	586
Z12133	VDKYYAKEADEAAFEIASLPNLTWEQWLAFAIAKLRDDPSQSSELLSEAKKLNDSQAPK	587
Z12134	VDKYYAKEADDAAEIAIYLPNLTWDQWWAFITKLRDDPSQSSELLSEAKKLNDSQAPK	588
Z12135	VDKYYAKEADDAAVEIAFLPNLTWDQWYAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	589
Z12136	VDKYYAKEADDAAYEIAQLPNLTWDQWAAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	590
Z12137	VDKYYAKEADDAAVEIALLPNLTWDQWFAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	591
Z12138	VDKYYAKEADEAAVEIAIYLPNLTWEQWWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	592
Z12139	VDKYYAKEADEAAVEIALLPNLTWDQWFAFITKLRDDPSQSSELLSEAKKLNDSQAPK	593
Z12140	VDKYYAKEADAAAVEIADLPNLTWDQWMAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	594
Z12141	VDKYYAKEADDAAYEIAFLPNLTWDQWEAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	595
Z12142	VDKYYAKEADDAAMEIAELPNLTWDQWAAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	596
Z12144	VDKYYAKEADNAAMEIAGLPNLTWDQWFAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	597
Z12145	VDKYYAKEADDAAYEIAELPNLTWLQWEAFIAKLRDDPSQSSELLSEAKKLNDSQAPK	598
Z12146	VDKYYAKEADEAAVEIAMLPNLTWDQWWAFITKLRDDPSQSSELLSEAKKLNDSQAPK	599
Z12147	VDKYYAKEADEAAVEIAELPNLTWDQWWAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	600
Z12148	VDKYYAKEADDAAYEIASLPNLTWDQWQAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	601
Z12149	VDKYYAKEADDAAYEJAFLPNLTWDQWFAFITKLRDDPSQSSELLSEAKKLNDSQAPK	602
Z12150	VDKYYAKEADMAAFEIASLPNLTWAQWAAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	603
Z12152	VDKYYAKEADNAAYEIAELPNLTWDQWYAFIMKLRDDPSQSSELLSEAKKLNDSQAPK	604
Z12153	VDKYYAKEADDAAVEIASLPNLTWVQWDAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	605
Z12154	VDKYYAKEADDAAVEIAIYLPNLTWDQWYAFISKLRDDPSQSSELLSEAKKLNDSQAPK	606
Z12155	VDKYYAKEADDAAFEIALLPNLTWDQWDAFISKLRDDPSQSSELLSEAKKLNDSQAPK	607
Z12156	VDKYYAKEADDAAVEIADLPNLTWDQWWAFIHKLRDDPSQSSELLSEAKKLNDSQAPK	608

Z12157	VDKYYAKEADDAAVEIAADLPNLTWDQWEAFIAKLRDDPSQSSELLSEAKKLNDSQAPK	609
Z12158	VDKYYAKEADMAAIEIAADLPNLTWDQWWAFITKLRDDPSQSSELLSEAKKLNDSQAPK	610
Z12159	VDKYYAKEADDAAVEIAADLPNLTWDQWWAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	611
Z12160	VDKYYAKEADDAAFEIAALPNLTWDQWYAFINKLRDDPSQSSELLSEAKKLNDSQAPK	612
Z12161	VDKYYAKEADDAAFEIASLPNLTWDQWYAFINKLRDDPSQSSELLSEAKKLNDSQAPK	613
Z12162	VDKYYAKEADAAAAEIAADLPNLTWDQWWAFIHKLRDDPSQSSELLSEAKKLNDSQAPK	614
Z12164	VDKYYAKEADDAAYEIAFLPNLTWDQWWAFITKLRDDPSQSSELLSEAKKLNDSQAPK	615
Z12165	VDKYYAKEADDAAVEIANLPNLTWDQWFQFIQKLRDDPSQSSELLSEAKKLNDSQAPK	616
Z12166	VDKYYAKEADDAAVEIAALPNLTWDQWDAFIRKLRDDPSQSSELLSEAKKLNDSQAPK	617
Z12167	VDKYYAKEADIAAMEIAELPNLTWDQWWAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	618
Z12168	VDKYYAKEADDAAMEIAILPNLTWDQWEAFIWKLRDDPSQSSELLSEAKKLNDSQAPK	619
Z12169	VDKYYAKEADSAAVEIAADLPNLTWDQWYAFITKLRDDPSQSSELLSEAKKLNDSQAPK	620
Z12170	VDKYYAKEADEAAVEIAADLPNLTWDQWFQFINKLRDDPSQSSELLSEAKKLNDSQAPK	621
Z12171	VDKYYAKEADAAAAYEIAYPNLTWDQWYAFISKLRDDPSQSSELLSEAKKLNDSQAPK	622
Z12172	VDKYYAKEADDAAYEIAALPNLTWDQWYAFITKLRDDPSQSSELLSEAKKLNDSQAPK	623
Z12173	VDKYYAKEADIAAAVEIAELPNLTWDQWWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	624
Z12174	VDKYYAKEADRAAMEIAELPNLTWIQWEAFILKLRDDPSQSSELLSEAKKLNDSQAPK	625
Z12175	VDKYYAKEADDAAVEIANLPNLTWDQWEAFILKLRDDPSQSSELLSEAKKLNDSQAPK	626
Z12176	VDKYYAKEADEAAAMEIAELPNLTWDQWWAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	627
Z12178	VDKYYAKEADEAAVEIANLPNLTWDQWEAFILKLRDDPSQSSELLSEAKKLNDSQAPK	628
Z12179	VDKYYAKEADDAAMEIAADLPNLTWDQWIAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	629
Z12181	VDKYYAKEADDAAYEIAFLPNLTWDQWYAFINKLRDDPSQSSELLSEAKKLNDSQAPK	630
Z12182	VDKYYAKEADDAAVEIAADLPNLTWEQWWAFINKLRDDPSQSSELLSEAKKLNDSQAPK	631
Z12183	VDKYYAKEADAAAAYEIAELPNLTWDQWWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	632
Z12184	VDKYYAKEADEAAVEIAFLPNLTWDQWWAFINKLRDDPSQSSELLSEAKKLNDSQAPK	633
Z12185	VDKYYAKEADDAAYEIAELPNLTWDQWWAFINKLRDDPSQSSELLSEAKKLNDSQAPK	634
Z12186	VDKYYAKEADAAAAYEIAGLPNLTWDQWFQFINKLRDDPSQSSELLSEAKKLNDSQAPK	635
Z12187	VDKYYAKEADDAAYEIAFLPNLTWDQWDQDAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	636
Z12188	VDKYYAKEADDAAVEIAQLPNLTWDQWFQFINKLRDDPSQSSELLSEAKKLNDSQAPK	637

Z12189	VD	AK	Y	A	K	E	A	D	Q	A	A	E	I	A	F	L	P	N	L	T	W	D	Q	W	E	A	F	I	F	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12190	VD	AK	Y	A	K	E	A	D	S	A	A	V	E	I	A	D	L	P	N	L	T	W	A	Q	W	D	A	F	I	S	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z12191	VD	AK	Y	A	K	E	A	D	A	A	A	E	I	A	N	L	P	N	L	T	W	D	Q	W	E	A	F	I	Q	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12193	VD	AK	Y	A	K	E	A	D	G	A	A	L	E	I	A	E	L	P	N	L	T	W	D	Q	W	E	A	F	I	Q	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z12194	VD	AK	Y	A	K	E	A	D	E	A	A	V	E	I	A	D	L	P	N	L	T	W	D	Q	W	E	A	F	I	S	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z12195	VD	AK	Y	A	K	E	A	D	D	A	A	Y	E	I	A	E	L	P	N	L	T	W	D	Q	W	E	A	F	I	H	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z12196	VD	AK	Y	A	K	E	A	D	D	A	A	F	E	I	A	A	L	P	N	L	T	W	E	Q	W	M	A	F	I	E	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z12197	VD	AK	Y	A	K	E	A	D	D	A	A	Y	E	I	A	Y	L	P	N	L	T	W	D	Q	W	E	A	F	I	G	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z12198	VD	AK	Y	A	K	E	A	D	Q	A	A	E	I	A	D	L	P	N	L	T	W	D	Q	W	A	A	F	I	M	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12199	VD	AK	Y	A	K	E	A	D	D	A	A	Y	E	I	A	Y	L	P	N	L	T	W	D	Q	W	A	F	I	N	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12200	VD	AK	Y	A	K	E	A	D	D	A	A	E	I	A	S	L	P	N	L	T	W	D	Q	W	A	F	I	A	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12201	VD	AK	Y	A	K	E	A	D	E	A	A	V	E	I	A	D	L	P	N	L	T	W	E	Q	W	A	A	F	I	N	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z12202	VD	AK	Y	A	K	E	A	D	D	A	A	V	E	I	A	D	L	P	N	L	T	W	D	Q	W	A	F	I	N	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12203	VD	AK	Y	A	K	E	A	D	A	A	A	V	E	I	A	E	L	P	N	L	T	W	D	Q	W	A	F	I	T	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12204	VD	AK	Y	A	K	E	A	D	N	A	A	E	I	A	D	L	P	N	L	T	W	D	Q	W	M	A	F	I	E	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12205	VD	AK	Y	A	K	E	A	D	H	A	A	E	I	A	E	L	P	N	L	T	W	D	Q	W	A	F	I	D	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12206	VD	AK	Y	A	K	E	A	D	A	A	A	Y	E	I	A	A	L	P	N	L	T	W	D	Q	W	A	F	I	T	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12207	VD	AK	Y	A	K	E	A	D	E	A	A	F	E	I	A	L	P	N	L	T	W	D	Q	W	L	A	F	I	D	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12208	VD	AK	Y	A	K	E	A	D	D	A	A	L	E	I	A	D	L	P	N	L	T	W	D	Q	W	E	A	F	I	D	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z12209	VD	AK	Y	A	K	E	A	D	K	A	A	E	I	A	D	L	P	N	L	T	W	D	Q	W	E	A	F	I	L	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12210	VD	AK	Y	A	K	E	A	D	D	A	A	E	I	A	D	L	P	N	L	T	W	D	Q	W	A	F	I	T	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12213	VD	AK	Y	A	K	E	A	D	N	A	A	V	E	I	A	E	L	P	N	L	T	W	D	Q	W	E	A	F	I	G	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z12214	VD	AK	Y	A	K	E	A	D	D	A	A	I	E	I	A	E	L	P	N	L	T	W	D	Q	W	A	A	F	I	W	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z12215	VD	AK	Y	A	K	E	A	D	Q	A	A	Y	E	I	A	E	L	P	N	L	T	W	D	Q	W	A	F	I	G	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12216	VD	AK	Y	A	K	E	A	D	Q	A	A	V	E	I	A	G	L	P	N	L	T	W	D	Q	W	A	F	I	D	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12217	VD	AK	Y	A	K	E	A	D	T	A	A	Y	E	I	A	M	L	P	N	L	T	W	E	Q	W	A	F	I	T	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12218	VD	AK	Y	A	K	E	A	D	N	A	A	Y	E	I	A	G	L	P	N	L	T	W	D	Q	W	M	A	F	I	N	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z12219	VD	AK	Y	A	K	E	A	D	D	A	A	V	E	I	A	D	L	P	N	L	T	W	D	Q	W	A	F	I	G	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12220	VD	AK	Y	A	K	E	A	D	E	A	A	V	E	I	A	D	L	P	N	L	T	W	A	Q	W	A	F	I	E	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	

Z12221	VDKDYAKEADDAAVEIAYLPNLTTWQWYAFITKLRDDPSQSSELLSEAKKLNDSQAPK	667
Z12222	VDKDYAKEADKAAVEIAYLPNLTTWQWWAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	668
Z12223	VDKDYAKEADDAAYEIAADLPNLTWQWMAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	669
Z12224	VDKDYAKEADDAAVEIAADLPNLTWQWFAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	670
Z12225	VDKDYAKEADDAAVEIAADLPNLTWQWAAAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	671
Z12226	VDKDYAKEADTAAMEIAADLPNLTWQWLAFITKLRDDPSQSSELLSEAKKLNDSQAPK	672
Z12227	VDKDYAKEADAAAVEIAADLPNLTWQWYAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	673
Z12228	VDKDYAKEADDAAVEIAELPNLTTWQWFAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	674
Z12229	VDKDYAKEADDAAVEIAAALPNLTTWQWEAFIHKLRDDPSQSSELLSEAKKLNDSQAPK	675
Z12230	VDKDYAKEADDAAYEIAYLPNLTTWQWFAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	676
Z12231	VDKDYAKEADQAAVEIAADLPNLTWQWFAFISKLRDDPSQSSELLSEAKKLNDSQAPK	677
Z12232	VDKDYAKEADEAAVEIAELPNLTTWQWWAFIHKLRDDPSQSSELLSEAKKLNDSQAPK	678
Z12233	VDKDYAKEADDAAYEIAFLPNLTTWQWHAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	679
Z12234	VDKDYAKEADKAAVEIAADLPNLTWQWFAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	680
Z12235	VDKDYAKEADDAAYEIAELPNLTTWQWWAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	681
Z12236	VDKDYAKEADEAAVEIAELPNLTTWQWWAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	682
Z12237	VDKDYAKEADDAAYEIAELPNLTTWQWFAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	683
Z12238	VDKDYAKEADDAAVEIAGLPNLTWQWAAAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	684
Z12239	VDKDYAKEADSAAVEIAADLPNLTWQWYAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	685
Z12240	VDKDYAKEADEAAVEIAADLPNLTWQWFAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	686
Z12241	VDKDYAKEADDAAMEIAADLPNLTWQWMAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	687
Z12242	VDKDYAKEADDAAVEIALLPNLTWQWWAFISKLRDDPSQSSELLSEAKKLNDSQAPK	688
Z12243	VDKDYAKEADDAAVEIAADLPNLTWEQWFAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	689
Z12244	VDKDYAKEADEAAVEIAADLPNLTWQWFAFISKLRDDPSQSSELLSEAKKLNDSQAPK	690
Z12245	VDKDYAKEADQAAVEIAELPNLTTWQWYAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	691
Z12246	VDKDYAKEADEAAVEIAYLPNLTTWQWWAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	692
Z12247	VDKDYAKEADDAAMEIAADLPNLTWQWAAFIKKLRDDPSQSSELLSEAKKLNDSQAPK	693
Z12248	VDKDYAKEADDAAFEIALLPNLTWVQWEAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	694
Z12249	VDKDYAKEADDAAYEIAQLPNLTTWQWYAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	695

Z12250	VDKYYAKEADMAAVEIADLPNLTWDQWHAFISKLRDDPSQSSELLSEAKKLND	696
Z12251	VDKYYAKEADDAAFEIAQLPNLTWDQWFAFINKLRDDPSQSSELLSEAKKLND	697
Z12252	VDKYYAKEADDAAVEIAELPNLTWDQWYAFISKLRDDPSQSSELLSEAKKLND	698
Z12253	VDKYYAKEADDAAYEIAYPNLTWAQWYAFISKLRDDPSQSSELLSEAKKLND	699
Z12254	VDKYYAKEADDAAMEIANLPNLTWDQWYAFINKLRDDPSQSSELLSEAKKLND	700
Z12257	VDKYYAKEADEAAEYIAMLPNLTWDQWDAFIGKLRDDPSQSSELLSEAKKLND	701
Z12258	VDKYYAKEADEAAFEIAQLPNLTWDQWFAFIDKLRDDPSQSSELLSEAKKLND	702
Z12259	VDKYYAKEADDAAVEIAELPNLTWDQWYAFINKLRDDPSQSSELLSEAKKLND	703
Z12260	VDKYYAKEADNAAFEIAGLPNLTWDQWDAFIQKLRDDPSQSSELLSEAKKLND	704
Z12261	VDKYYAKEADMAAVEIAALPNLTWDQWWAFINKLRDDPSQSSELLSEAKKLND	705
Z12262	VDKYYAKEADDAAFEIAFLPNLTWDQWWAFIQKLRDDPSQSSELLSEAKKLND	706
Z12263	VDKYYAKEADKAAVEIADLPNLTWDQWWAFINKLRDDPSQSSELLSEAKKLND	707
Z12265	VDKYYAKEADSAAVEIADLPNLTWDQWWAFIEKLRDDPSQSSELLSEAKKLND	708
Z12266	VDKYYAKEADDAAMEIAALPNLTWDQWFAFIQKLRDDPSQSSELLSEAKKLND	709
Z12267	VDKYYAKEADDAAFEIAQLPNLTWDQWWAFINKLRDDPSQSSELLSEAKKLND	710
Z12268	VDKYYAKEADQAAVEIASLPNLTWEQWYAFIAKLRDDPSQSSELLSEAKKLND	711
Z12269	VDKYYAKEADEAAEYIAELPNLTWDQWFAFINKLRDDPSQSSELLSEAKKLND	712
Z12270	VDKYYAKEADMAAVEIADLPNLTWDQWYAFIEKLRDDPSQSSELLSEAKKLND	713
Z12271	VDKYYAKEADDAAVEIADLPNLTWWQWFAFIEKLRDDPSQSSELLSEAKKLND	714
Z12272	VDKYYAKEADDAAYEIAGLPNLTWDQWYAFIDKLRDDPSQSSELLSEAKKLND	715
Z12273	VDKYYAKEADEAAVEIADLPNLTWEQWWAFIEKLRDDPSQSSELLSEAKKLND	716
Z12274	VDKYYAKEADDAAVEIADLPNLTWDQWWAFITKLRDDPSQSSELLSEAKKLND	717
Z12276	VDKYYAKEADDAAVEIAELPNLTWDQWYAFIQKLRDDPSQSSELLSEAKKLND	718
Z12277	VDKYYAKEADQAAVEIADLPNLTWDQWYAFINKLRDDPSQSSELLSEAKKLND	719
Z12278	VDKYYAKEADKAAVEIAFLPNLTWDQWYAFIHKLRDDPSQSSELLSEAKKLND	720
Z12279	VDKYYAKEADNAAVEIAELPNLTWDQWEAFIAKLRDDPSQSSELLSEAKKLND	721
Z12280	VDKYYAKEADQAAFEIAELPNLTWDQWYAFIEKLRDDPSQSSELLSEAKKLND	722
Z12281	VDKYYAKEADDAAMEIANLPNLTWDQWEAFIQKLRDDPSQSSELLSEAKKLND	723
Z12282	VDKYYAKEADDAAVEIASLPNLTWDQWYAFINKLRDDPSQSSELLSEAKKLND	724

Z12284	VDKAKEADDAAYEIAFLPNLTWDQWAFISKLRDDPSQSSELLSEAKKLNDSQAPK	725
Z12286	VDKAKEADDAAEIAELPNLTWDQWAFINKLRDDPSQSSELLSEAKKLNDSQAPK	726
Z12287	VDKAKEADDAAMEIADLPNLTWDQWAFINKLRDDPSQSSELLSEAKKLNDSQAPK	727
Z12288	VDKAKEADDAAVEIAMLPNLTWDQWDAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	728
Z12290	VDKAKEADDAAYEIAYPNLTWDQWFAFINKLRDDPSQSSELLSEAKKLNDSQAPK	729
Z12291	VDKAKEADDAAVEIADLPNLTWDQWAFISKLRDDPSQSSELLSEAKKLNDSQAPK	730
Z12292	VDKAKEADDAAVEIAQLPNLTWDQWFAFIYKLRDDPSQSSELLSEAKKLNDSQAPK	731
Z12293	VDKAKEADNAAVEIADLPNLTWDQWYAFIWKLRDDPSQSSELLSEAKKLNDSQAPK	732
Z12294	VDKAKEADEAAVEIAALPNLTWDQWEAFIKLRDDPSQSSELLSEAKKLNDSQAPK	733
Z12295	VDKAKEADGAAVEIANLPNLTWDQWFAFINKLRDDPSQSSELLSEAKKLNDSQAPK	734
Z12296	VDKAKEADDAAFEIAELPNLTWDQWAFISKLRDDPSQSSELLSEAKKLNDSQAPK	735
Z12297	VDKAKEADDAAVEIAQLPNLTWDQWFAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	736
Z12298	VDKAKEADDAAMEIALLPNLTWDQWLAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	737
Z12299	VDKAKEADDAAVEIADLPNLTWDQWEAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	738
Z12300	VDKAKEADAAAIVEIADLPNLTWEQWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	739
Z12301	VDKAKEADEAAVEIAMLPNLTWDQWDADFIDKLRDDPSQSSELLSEAKKLNDSQAPK	740
Z12302	VDKAKEADLAAVEIAELPNLTWAQWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	741
Z12303	VDKAKEADDAAYEIALLPNLTWDQWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	742
Z12304	VDKAKEADQAAMEIAELPNLTWDQWEAFITKLRDDPSQSSELLSEAKKLNDSQAPK	743
Z12305	VDKAKEADDAAVEIAELPNLTWDQWEAFIMKLRDDPSQSSELLSEAKKLNDSQAPK	744
Z12306	VDKAKEADMAAVEIASLPNLTWDQWYAFIHKLRDDPSQSSELLSEAKKLNDSQAPK	745
Z12307	VDKAKEADNAAVEIADLPNLTWDQWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	746
Z12308	VDKAKEADDAAYEIASLPNLTWDQWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	747
Z12309	VDKAKEADAAAIVEIADLPNLTWDQWYAFISKLRDDPSQSSELLSEAKKLNDSQAPK	748
Z12310	VDKAKEADDAAYEIALLPNLTWDQWDAFIMKLRDDPSQSSELLSEAKKLNDSQAPK	749
Z12311	VDKAKEADMAAVEIADLPNLTWDQWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	750
Z12312	VDKAKEADDAAEIAGLPNLTWDQWFAFISKLRDDPSQSSELLSEAKKLNDSQAPK	751
Z12313	VDKAKEADEAAVEIAFLPNLTWDQWFAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	752
Z12314	VDKAKEADIAAVEIADLPNLTWDQWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	753

Z12315	VDKDYAKEADDAAEIAELPNLTDQWYAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	754
Z12316	VDKDYAKEADIAAMEIADLPNLTWDQWWAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	755
Z12317	VDKDYAKEADNAAMEIADLPNLTWDQWYAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	756
Z12318	VDKDYAKEADDAAYEIAADLPNLTWLQWYAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	757
Z12319	VDKDYAKEADEAAVEIASLPNLTWDQWWAFISKLRDDPSQSSELLSEAKKLNDSQAPK	758
Z12320	VDKDYAKEADAAAVEIADLPNLTWWQWEAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	759
Z12321	VDKDYAKEADMAAVEIAELPNLTDQWYAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	760
Z12322	VDKDYAKEADEAAMEIADLPNLTWDQWWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	761
Z12323	VDKDYAKEADDAAFEIAQLPNLTDQWFAFITKLRDDPSQSSELLSEAKKLNDSQAPK	762
Z12324	VDKDYAKEADDAAFEIASLPNLTWDQWWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	763
Z12325	VDKDYAKEADDAAVEIAILPNLTDQWFAFIAKLRDDPSQSSELLSEAKKLNDSQAPK	764
Z12326	VDKDYAKEADLAAVEIAELPNLTDQWEAFILKLRDDPSQSSELLSEAKKLNDSQAPK	765
Z12327	VDKDYAKEADLAAVEIADLPNLTWEQWFAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	766
Z12328	VDKDYAKEADSAAVEIAFLPNLTDQWYAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	767
Z12329	VDKDYAKEADDAAMEIADLPNLTWDQWFAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	768
Z12330	VDKDYAKEADNAAVEIADLPNLTWDQWFAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	769
Z12331	VDKDYAKEADDAAFEIAMLPNLTWDQWWAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	770
Z12332	VDKDYAKEADEAAVEIADLPNLTWEQWWAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	771
Z12333	VDKDYAKEADSAAVEIAFLPNLTDQWFAFISKLRDDPSQSSELLSEAKKLNDSQAPK	772
Z12334	VDKDYAKEADDAAYEIAFLPNLTDQWFAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	773
Z12335	VDKDYAKEADDAAYEIAFLPNLTWEQWHAFFIEKLRDDPSQSSELLSEAKKLNDSQAPK	774
Z12336	VDKDYAKEADLAALEIAELPNLTDQWDADFIMKLRDDPSQSSELLSEAKKLNDSQAPK	775
Z12337	VDKDYAKEADDAAYEIAFLPNLTDQWFAFINKLRDDPSQSSELLSEAKKLNDSQAPK	776
Z12338	VDKDYAKEADDAAEIAELPNLTDQWFAFISKLRDDPSQSSELLSEAKKLNDSQAPK	777
Z12339	VDKDYAKEADDAAEIAELPNLTWEQWWAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	778
Z12340	VDKDYAKEADMAAMEIAELPNLTDQWEAFIMKLRDDPSQSSELLSEAKKLNDSQAPK	779
Z12341	VDKDYAKEADDAAYEIAFLPNLTDQWFAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	780
Z12342	VDKDYAKEADDAAVEIADLPNLTWDQWEAFILKLRDDPSQSSELLSEAKKLNDSQAPK	781
Z12343	VDKDYAKEADDAAMEIADLPNLTWDQWWAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	782

Z12345	VD	AK	Y	A	K	E	A	D	R	A	A	E	I	A	D	L	P	N	L	T	W	D	Q	W	A	F	I	T	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12346	VD	AK	Y	A	K	E	A	D	D	A	A	E	I	A	F	L	P	N	L	T	W	D	Q	W	A	F	I	E	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12347	VD	AK	Y	A	K	E	A	D	M	A	A	E	I	A	D	L	P	N	L	T	W	D	Q	W	A	F	I	Q	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12348	VD	AK	Y	A	K	E	A	D	D	A	A	E	I	A	N	L	P	N	L	T	W	D	Q	W	A	F	I	G	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12350	VD	AK	Y	A	K	E	A	D	D	A	A	E	I	A	L	L	P	N	L	T	W	D	Q	W	A	F	I	L	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12351	VD	AK	Y	A	K	E	A	D	D	A	A	E	I	A	E	L	P	N	L	T	W	V	Q	W	A	F	I	E	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12352	VD	AK	Y	A	K	E	A	D	E	A	A	E	I	A	D	L	P	N	L	T	W	D	Q	W	A	F	I	E	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12353	VD	AK	Y	A	K	E	A	D	D	A	A	E	I	A	D	L	P	N	L	T	W	D	Q	W	A	F	I	D	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12354	VD	AK	Y	A	K	E	A	D	D	A	A	E	I	A	D	L	P	N	L	T	W	D	Q	W	A	F	I	D	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12355	VD	AK	Y	A	K	E	A	D	D	A	A	E	I	A	D	L	P	N	L	T	W	D	Q	W	A	F	I	E	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12356	VD	AK	Y	A	K	E	A	D	E	A	A	E	I	A	D	L	P	N	L	T	W	D	Q	W	A	F	I	T	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12357	VD	AK	Y	A	K	E	A	D	N	A	A	E	I	A	F	L	P	N	L	T	W	D	Q	W	A	F	I	T	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12358	VD	AK	Y	A	K	E	A	D	A	A	A	E	I	A	D	L	P	N	L	T	W	A	Q	W	A	F	I	E	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12360	VD	AK	Y	A	K	E	A	D	A	A	A	E	I	A	F	L	P	N	L	T	W	D	Q	W	A	F	I	G	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12361	VD	AK	Y	A	K	E	A	D	A	A	A	E	I	A	D	L	P	N	L	T	W	E	Q	W	A	F	I	T	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12362	VD	AK	Y	A	K	E	A	D	A	A	A	E	I	A	A	L	P	N	L	T	W	D	Q	W	A	F	I	R	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12363	VD	AK	Y	A	K	E	A	D	N	A	A	E	I	A	E	L	P	N	L	T	W	D	Q	W	A	F	I	D	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12364	VD	AK	Y	A	K	E	A	D	Q	A	A	E	I	A	D	L	P	N	L	T	W	D	Q	W	A	F	I	G	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12365	VD	AK	Y	A	K	E	A	D	Q	A	A	E	I	A	E	L	P	N	L	T	W	D	Q	W	A	F	I	Q	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12366	VD	AK	Y	A	K	E	A	D	E	A	A	E	I	A	E	L	P	N	L	T	W	D	Q	W	A	F	I	N	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12367	VD	AK	Y	A	K	E	A	D	D	A	A	E	I	A	F	L	P	N	L	T	W	E	Q	W	A	F	I	A	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12368	VD	AK	Y	A	K	E	A	D	D	A	A	E	I	A	N	L	P	N	L	T	W	D	Q	W	E	A	F	I	A	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12369	VD	AK	Y	A	K	E	A	D	M	A	A	E	I	E	I	A	D	L	P	N	L	T	W	D	Q	W	A	F	I	E	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z12370	VD	AK	Y	A	K	E	A	D	Q	A	A	E	I	A	N	L	P	N	L	T	W	D	Q	W	A	F	I	T	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12371	VD	AK	Y	A	K	E	A	D	Q	A	A	E	I	A	Y	L	P	N	L	T	W	D	Q	W	A	F	I	E	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12372	VD	AK	Y	A	K	E	A	D	K	A	A	E	I	A	E	L	P	N	L	T	W	D	Q	W	A	F	I	D	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12373	VD	AK	Y	A	K	E	A	D	E	A	A	E	I	A	S	L	P	N	L	T	W	D	Q	W	A	F	I	W	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12374	VD	AK	Y	A	K	E	A	D	M	A	A	E	I	A	D	L	P	N	L	T	W	D	Q	W	A	F	I	N	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12375	VD	AK	Y	A	K	E	A	D	A	A	A	E	I	A	M	L	P	N	L	T	W	D	Q	W	A	F	I	S	K	L	R	D	D	P	S	Q	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		

Z12376	VDKAKEADDAAYEIAFLPNLTWDQWDAFIQKLRDDPSQSELLSEAKKLNDSQAPK	812
Z12377	VDKAKEADNAAYEIAADLPNLTWDQWFAFIHKLRDDPSQSELLSEAKKLNDSQAPK	813
Z12378	VDKAKEADDAAYEIAAGLPNLTWDQWWAFIGKLRDDPSQSELLSEAKKLNDSQAPK	814
Z12379	VDKAKEADDAAYEIAAGLPNLTWDQWDAFILKLRDDPSQSELLSEAKKLNDSQAPK	815
Z12380	VDKAKEADNAAEIAELPNLTWDQWDAFIDKLRDDPSQSELLSEAKKLNDSQAPK	816
Z12381	VDKAKEADMAAMEIASLPNLTWDQWFAFIDKLRDDPSQSELLSEAKKLNDSQAPK	817
Z12382	VDKAKEADHAAVEIAALPNLTWDQWDAFIRKLRDDPSQSELLSEAKKLNDSQAPK	818
Z12383	VDKAKEADEAAEIAADLPNLTWDQWYAFINKLRDDPSQSELLSEAKKLNDSQAPK	819
Z12384	VDKAKEADNAAVEIAADLPNLTWDQWFAFIEKLRDDPSQSELLSEAKKLNDSQAPK	820
Z12385	VDKAKEADDAAYEIAELPNLTWDQWDAFIAKLRDDPSQSELLSEAKKLNDSQAPK	821
Z12386	VDKAKEADDAAYEIALLPNLTWDQWAFIEKLRDDPSQSELLSEAKKLNDSQAPK	822
Z12387	VDKAKEADKAAVEIAYLPNLTWDQWYAFIRKLRDDPSQSELLSEAKKLNDSQAPK	823
Z12388	VDKAKEADNAAFEIAELPNLTWDQWYAFIHKLRDDPSQSELLSEAKKLNDSQAPK	824
Z12389	VDKAKEADAAAYEIAFLPNLTWDQWAAFIHKLRDDPSQSELLSEAKKLNDSQAPK	825
Z12390	VDKAKEADQAAVEIAADLPNLTWDQWDAFIDKLRDDPSQSELLSEAKKLNDSQAPK	826
Z12391	VDKAKEADDAAYEIAALPNLTWDQWWAFIQKLRDDPSQSELLSEAKKLNDSQAPK	827
Z12392	VDKAKEADEAAYEIAADLPNLTWDQWAFIHKLRDDPSQSELLSEAKKLNDSQAPK	828
Z12393	VDKAKEADFAAVEIASLPNLTWDQWAAFIQKLRDDPSQSELLSEAKKLNDSQAPK	829
Z12394	VDKAKEADEAAVEIAELPNLTWDQWFAFIDKLRDDPSQSELLSEAKKLNDSQAPK	830
Z12395	VDKAKEADMAAYEIAELPNLTWDQWQAFITKLRDDPSQSELLSEAKKLNDSQAPK	831
Z12396	VDKAKEADDAAMEIADLPNLTWWQWYAFIGKLRDDPSQSELLSEAKKLNDSQAPK	832
Z12397	VDKAKEADDAAYEIAALPNLTWDQWFAFIGKLRDDPSQSELLSEAKKLNDSQAPK	833
Z12398	VDKAKEADSAAYEIAFLPNLTWDQWYAFILKLRDDPSQSELLSEAKKLNDSQAPK	834
Z12399	VDKAKEADAAAYEIAFLPNLTWDQWYAFIWKLRDDPSQSELLSEAKKLNDSQAPK	835
Z12400	VDKAKEADQAAFEIAELPNLTWDQWYAFITKLRDDPSQSELLSEAKKLNDSQAPK	836
Z12401	VDKAKEADEAAVEIANLPNLTWDQWEAFIRKLRDDPSQSELLSEAKKLNDSQAPK	837
Z12402	VDKAKEADMAAYEIAAGLPNLTWDQWYAFIDKLRDDPSQSELLSEAKKLNDSQAPK	838
Z12403	VDKAKEADAAAFEIAADLPNLTWDQWAFINKLRDDPSQSELLSEAKKLNDSQAPK	839
Z12404	VDKAKEADIAAMEIADLPNLTWDQWFAFINKLRDDPSQSELLSEAKKLNDSQAPK	840

Z12405	VDKDYAKEADEAAVEIAELPNLTDQWFAFISKLRDDPSQSSELLSEAKKLNDSQAPK	841
Z12406	VDKDYAKEADLAAVEIAIDLPNLTDQWWAFISKLRDDPSQSSELLSEAKKLNDSQAPK	842
Z12407	VDKDYAKEADDAAFEIASLPNLTDQWLAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	843
Z12408	VDKDYAKEADMAAVEIAIDLPNLTDQWFAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	844
Z12409	VDKDYAKEADDAAVEIAYLPNLTDQWYAFIRKLRDDPSQSSELLSEAKKLNDSQAPK	845
Z12410	VDKDYAKEADRAAYEIAELPNLTDQWDAFINKLRDDPSQSSELLSEAKKLNDSQAPK	846
Z12411	VDKDYAKEADEAAVEIAGLPNLTDQWFAFINKLRDDPSQSSELLSEAKKLNDSQAPK	847
Z12412	VDKDYAKEADHAAMEIADLPNLTWEQWAAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	848
Z12413	VDKDYAKEADIAALEIAGLPNLTDQWFAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	849
Z12414	VDKDYAKEADEAAVEIAFLPNLTDQWFAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	850
Z12415	VDKDYAKEADRAAVEIAALPNLTDQWDAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	851
Z12416	VDKDYAKEADEAAVEIAELPNLTDQWLAFINKLRDDPSQSSELLSEAKKLNDSQAPK	852
Z12417	VDKDYAKEADDAAMEIADLPNLTDQWAAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	853
Z12418	VDKDYAKEADEAAVEIALLPNLTDQWDAFIMKLRDDPSQSSELLSEAKKLNDSQAPK	854
Z12419	VDKDYAKEADSAAVEIASLPNLTDQWLAFINKLRDDPSQSSELLSEAKKLNDSQAPK	855
Z12420	VDKDYAKEADEAAVEIAYLPNLTDQWFAFINKLRDDPSQSSELLSEAKKLNDSQAPK	856
Z12421	VDKDYAKEADMAAYEIAFLPNLTDQWFAFITKLRDDPSQSSELLSEAKKLNDSQAPK	857
Z12422	VDKDYAKEADAAAMEIADLPNLTDQWWAFIMKLRDDPSQSSELLSEAKKLNDSQAPK	858
Z12423	VDKDYAKEADDAAYEIAFLPNLTDQWLAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	859
Z12424	VDKDYAKEADDAAVEIADLPNLTDQWYAFINKLRDDPSQSSELLSEAKKLNDSQAPK	860
Z12425	VDKDYAKEADEAAAMEIADLPNLTDQWFAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	861
Z12426	VDKDYAKEADNAAVEIAELPNLTDQWDAFITKLRDDPSQSSELLSEAKKLNDSQAPK	862
Z12427	VDKDYAKEADDAAYEIAFLPNLTDQWWAFILKLRDDPSQSSELLSEAKKLNDSQAPK	863
Z12428	VDKDYAKEADNAAEIADLPNLTDQWWAFISKLRDDPSQSSELLSEAKKLNDSQAPK	864
Z12429	VDKDYAKEADDAAYEIAELPNLTDQWFAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	865
Z12430	VDKDYAKEADGAAFEIAALPNLTDQWWAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	866
Z12431	VDKDYAKEADDAAFEIAQLPNLTDQWAAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	867
Z12432	VDKDYAKEADMAALEIADLPNLTDQWYAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	868
Z12433	VDKDYAKEADVAAVEIAGLPNLTDQWWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	869

Z12434	VDKYYAKEADIAAVEIAALPNLTTWDQWDAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	870
Z12435	VDKYYAKEADDAALEIADLPNLTWDQWWAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	871
Z12437	VDKYYAKEADDAAYEIAADLPNLTWDQWWAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	872
Z12438	VDKYYAKEADNAAFEIAGLPNLTWDQWWAFISKLRDDPSQSSELLSEAKKLNDSQAPK	873
Z12440	VDKYYAKEADQAAMEIALLPNLTWDQWEAFILKLRDDPSQSSELLSEAKKLNDSQAPK	874
Z12441	VDKYYAKEADDAAYEIALLPNLTWDQWWAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	875
Z12442	VDKYYAKEADDAAFEIAELPNLTTWDQWFAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	876
Z12444	VDKYYAKEADEAAVEIADLPNLTWDQWFAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	877
Z12445	VDKYYAKEADDAAVEIANLPNLTWDQWWAFINKLRDDPSQSSELLSEAKKLNDSQAPK	878
Z12446	VDKYYAKEADQAAVEIADLPNLTWDQWEAFISKLRDDPSQSSELLSEAKKLNDSQAPK	879
Z12447	VDKYYAKEADNAAFEIANLPNLTWMQWEAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	880
Z12448	VDKYYAKEADAAAVEIADLPNLTWYQWWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	881
Z12449	VDKYYAKEADDAAVEIANLPNLTWDQWLAFITKLRDDPSQSSELLSEAKKLNDSQAPK	882
Z12450	VDKYYAKEADDAAYEIAALPNLTTWDQWWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	883
Z12452	VDKYYAKEADKAAYEIAELPNLTTWDQWFAFIAKLRDDPSQSSELLSEAKKLNDSQAPK	884
Z12453	VDKYYAKEADIAAVEIADLPNLTWDQWFAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	885
Z12454	VDKYYAKEADDAAYEIAELPNLTTWDQWMAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	886
Z12455	VDKYYAKEADNAAVEIAALPNLTTWDQWWAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	887
Z12456	VDKYYAKEADDAAVEIAELPNLTTWDQWWAFIAKLRDDPSQSSELLSEAKKLNDSQAPK	888
Z12457	VDKYYAKEADKAAYEIAFLPNLTTWDQWWAFINKLRDDPSQSSELLSEAKKLNDSQAPK	889
Z12458	VDKYYAKEADDAAVEIAELPNLTTWDQWFAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	890
Z12459	VDKYYAKEADDAAMEIAYLPNLTWEQWFAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	891
Z12460	VDKYYAKEADDAAFEIALLPNLTWDQWFAFIAKLRDDPSQSSELLSEAKKLNDSQAPK	892
Z12461	VDKYYAKEADDAAYEIAMLPNLTWDQWHA FIEKLRDDPSQSSELLSEAKKLNDSQAPK	893
Z12462	VDKYYAKEADDAAFEIAMLPNLTWDQWFAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	894
Z12464	VDKYYAKEADEAAVEIAELPNLTTWDQWYAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	895
Z12465	VDKYYAKEADDAAFEIAMLPNLTWDQWFAFINKLRDDPSQSSELLSEAKKLNDSQAPK	896
Z12466	VDKYYAKEADTAAVEIAFLPNLTTWDQWMAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	897
Z12467	VDKYYAKEADLAAVEIAFLPNLTTWDQWWAFINKLRDDPSQSSELLSEAKKLNDSQAPK	898

Z12468	VDKDYAKEADAAAYEIAYLPNLTDQWWAFISKLRDDPSQSSELLSEAKKLNDSQAPK	899
Z12469	VDKDYAKEADDAAYEIAGLPNLTDQWWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	900
Z12470	VDKDYAKEADNAAYEIAFLPNLTDQWYAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	901
Z12471	VDKDYAKEADDAAYEIAYLPNLTDQWYAFINKLRDDPSQSSELLSEAKKLNDSQAPK	902
Z12472	VDKDYAKEADAAALEIADLPNLTDQWWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	903
Z12473	VDKDYAKEADDAAYEIAADLPNLTDQWWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	904
Z12474	VDKDYAKEADDAAMEIAGLPNLTDQWAAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	905
Z12475	VDKDYAKEADSAAYEIAQLPNLTDQWAAAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	906
Z12476	VDKDYAKEADDAAFEIAWLPNLTDQWFAFISKLRDDPSQSSELLSEAKKLNDSQAPK	907
Z12477	VDKDYAKEADEAAVEIAMLPNLTDQWYAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	908
Z12478	VDKDYAKEADDAALEIASLPNLTDQWLAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	909
Z12479	VDKDYAKEADDAAYEIAYLPNLTDQWFAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	910
Z12480	VDKDYAKEADDAAYEIAADLPNLTDQWWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	911
Z12482	VDKDYAKEADAAAYEIAELPNLTDQWWAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	912
Z12483	VDKDYAKEADDAAYEIAFLPNLTDQWYAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	913
Z12484	VDKDYAKEADDAAAEIAADLPNLTDQWAAAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	914
Z12485	VDKDYAKEADDAAFEIAVLPNLTDQWFAFISKLRDDPSQSSELLSEAKKLNDSQAPK	915
Z12486	VDKDYAKEADDAAMEIADLPNLTDQWYAFIWKLRDDPSQSSELLSEAKKLNDSQAPK	916
Z12487	VDKDYAKEADNAAYEIAADLPNLTDQWLAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	917
Z12488	VDKDYAKEADDAAYEIAFLPNLTDQWYAFILKLRDDPSQSSELLSEAKKLNDSQAPK	918
Z12489	VDKDYAKEADLAAYEIAYLPNLTDQWFAFIYKLRDDPSQSSELLSEAKKLNDSQAPK	919
Z12490	VDKDYAKEADKAAYEIAMLPNLTDQWDAFIRKLRDDPSQSSELLSEAKKLNDSQAPK	920
Z12491	VDKDYAKEADDAAYEIAFLPNLTDQWFAFINKLRDDPSQSSELLSEAKKLNDSQAPK	921
Z12492	VDKDYAKEADNAAYEIASLPNLTDQWWAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	922
Z12493	VDKDYAKEADDAAYEIAWLPNLTDQWWAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	923
Z12494	VDKDYAKEADDAAYEIAELPNLTDQWFAFINKLRDDPSQSSELLSEAKKLNDSQAPK	924
Z12495	VDKDYAKEADDAAYEIAWLPNLTDQWFAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	925
Z12496	VDKDYAKEADDAAYEIALLPNLTDQWFAFIWKLRDDPSQSSELLSEAKKLNDSQAPK	926
Z12497	VDKDYAKEADDAAYEIAALPNLTDQWYAFILKLRDDPSQSSELLSEAKKLNDSQAPK	927

Z12499	VD	A	K	Y	A	K	E	A	D	M	A	A	V	E	I	A	L	P	N	L	T	W	D	Q	W	A	F	I	Q	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K			
Z12500	VD	A	K	Y	A	K	E	A	D	H	A	A	M	E	I	A	S	L	P	N	L	T	W	D	Q	W	E	A	F	I	D	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z12501	VD	A	K	Y	A	K	E	A	D	H	A	A	Y	E	I	A	A	L	P	N	L	T	W	D	Q	W	A	F	I	N	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12502	VD	A	K	Y	A	K	E	A	D	E	A	A	Y	E	I	A	D	L	P	N	L	T	W	D	Q	W	A	F	I	N	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12503	VD	A	K	Y	A	K	E	A	D	D	A	A	Y	E	I	A	E	L	P	N	L	T	W	D	Q	W	A	F	I	T	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12504	VD	A	K	Y	A	K	E	A	D	N	A	A	Y	E	I	A	M	L	P	N	L	T	W	D	Q	W	A	F	I	D	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12505	VD	A	K	Y	A	K	E	A	D	Q	A	A	V	E	I	A	A	L	P	N	L	T	W	E	Q	W	A	F	I	T	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12506	VD	A	K	Y	A	K	E	A	D	I	A	A	V	E	I	A	G	L	P	N	L	T	W	D	Q	W	A	F	I	D	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12507	VD	A	K	Y	A	K	E	A	D	D	A	A	Y	E	I	A	M	L	P	N	L	T	W	D	Q	W	A	F	I	Q	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12508	VD	A	K	Y	A	K	E	A	D	E	A	A	V	E	I	A	N	L	P	N	L	T	W	D	Q	W	A	F	I	W	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12509	VD	A	K	Y	A	K	E	A	D	D	A	A	M	E	I	A	D	L	P	N	L	T	W	D	Q	W	A	F	I	T	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12510	VD	A	K	Y	A	K	E	A	D	Q	A	A	F	E	I	A	A	L	P	N	L	T	W	D	Q	W	A	F	I	G	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12511	VD	A	K	Y	A	K	E	A	D	R	A	A	I	E	I	A	D	L	P	N	L	T	W	D	Q	W	A	F	I	E	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12512	VD	A	K	Y	A	K	E	A	D	E	A	A	V	E	I	A	Y	L	P	N	L	T	W	D	Q	W	A	F	I	N	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12513	VD	A	K	Y	A	K	E	A	D	S	A	A	V	E	I	A	E	L	P	N	L	T	W	D	Q	W	A	F	I	N	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12514	VD	A	K	Y	A	K	E	A	D	D	A	A	V	E	I	A	E	L	P	N	L	T	W	D	Q	W	A	F	I	G	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12515	VD	A	K	Y	A	K	E	A	D	A	A	A	Y	E	I	A	Y	L	P	N	L	T	W	D	Q	W	A	F	I	N	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12516	VD	A	K	Y	A	K	E	A	D	E	A	A	F	E	I	A	H	L	P	N	L	T	W	D	Q	W	A	F	I	Q	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K		
Z12517	VD	A	K	Y	A	K	E	A	D	D	A	A	Y	E	I	A	F	L	P	N	L	T	W	D	Q	W	E	A	F	I	H	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z12518	VD	A	K	Y	A	K	E	A	D	D	A	A	F	E	I	A	Y	L	P	N	L	T	W	D	Q	W	A	F	I	T	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12519	VD	A	K	Y	A	K	E	A	D	D	A	A	Y	E	I	A	D	L	P	N	L	T	W	D	Q	W	A	F	I	N	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12520	VD	A	K	Y	A	K	E	A	D	S	A	A	Y	E	I	A	G	L	P	N	L	T	W	D	Q	W	E	A	F	I	R	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z12521	VD	A	K	Y	A	K	E	A	D	E	A	A	Y	E	I	A	S	L	P	N	L	T	W	D	Q	W	H	A	F	I	Q	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12523	VD	A	K	Y	A	K	E	A	D	D	A	A	F	E	I	A	K	L	P	N	L	T	W	Y	Q	W	E	A	F	I	Y	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K
Z12524	VD	A	K	Y	A	K	E	A	D	D	A	A	V	E	I	A	A	L	P	N	L	T	W	D	Q	W	A	F	I	E	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12525	VD	A	K	Y	A	K	E	A	D	L	A	A	M	E	I	A	D	L	P	N	L	T	W	D	Q	W	A	F	I	E	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12526	VD	A	K	Y	A	K	E	A	D	Q	A	A	Y	E	I	A	Y	L	P	N	L	T	W	D	Q	W	A	F	I	N	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12527	VD	A	K	Y	A	K	E	A	D	A	A	A	I	E	I	A	D	L	P	N	L	T	W	D	Q	W	A	F	I	A	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	
Z12528	VD	A	K	Y	A	K	E	A	D	D	A	A	M	E	I	A	D	L	P	N	L	T	W	D	Q	W	A	F	I	M	K	L	R	D	D	P	S	S	S	E	L	L	S	E	A	K	K	L	N	D	S	Q	A	P	K	

Z12529	VDKDYAKEADEAAVEIAYLPNLTTWDQWFAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	957
Z12530	VDKDYAKEADNAAVEIAELPNLTTWDQWFAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	958
Z12531	VDKDYAKEADDAAYEIAMLPNLTTWDQWFAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	959
Z12532	VDKDYAKEADNAAMEIADLPNLTTWDQWAAAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	960
Z12533	VDKDYAKEADNAAVEIAYLPNLTTWEQWFAFITKLRDDPSQSSELLSEAKKLNDSQAPK	961
Z12534	VDKDYAKEADEAAFEIAWLPNLTTWDQWYAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	962
Z12535	VDKDYAKEADEAAMEIAELPNLTTWDQWAFIFIGKLRDDPSQSSELLSEAKKLNDSQAPK	963
Z12536	VDKDYAKEADDAAFEIAMLPNLTTWDQWAAAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	964
Z12537	VDKDYAKEADQAAMEIADLPNLTTWDQWAFINKLRDDPSQSSELLSEAKKLNDSQAPK	965
Z12538	VDKDYAKEADDAAVEIAYLPNLTTWDQWAFINKLRDDPSQSSELLSEAKKLNDSQAPK	966
Z12539	VDKDYAKEADDAAVEIAWLPNLTTWDQWFAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	967
Z12540	VDKDYAKEADEAAVEIADLPNLTTWDQWYAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	968
Z12541	VDKDYAKEADQAAVEIADLPNLTTWDQWFAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	969
Z12542	VDKDYAKEADQAAFEIAGLPNLTTWDQWAAAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	970
Z12543	VDKDYAKEADDAAYEIAYLPNLTTWEQWAAAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	971
Z12544	VDKDYAKEADDAAFEIASLPNLTLWLQWEAFIMKLRDDPSQSSELLSEAKKLNDSQAPK	972
Z12545	VDKDYAKEADAAAVEIAALPNLTTWDQWMAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	973
Z12546	VDKDYAKEADDAAYEIAELPNLTTWDQWYAFIAKLRDDPSQSSELLSEAKKLNDSQAPK	974
Z12547	VDKDYAKEADEAAVEIAELPNLTTWDQWMAFIFIGKLRDDPSQSSELLSEAKKLNDSQAPK	975
Z12548	VDKDYAKEADDAAFEIAALPNLTTWDQWAAAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	976
Z12549	VDKDYAKEADDAAVEIADLPNLTTWDQWMAFINKLRDDPSQSSELLSEAKKLNDSQAPK	977
Z12550	VDKDYAKEADFAAMEIADLPNLTTWDQWMAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	978
Z12551	VDKDYAKEADDAAYEIAMLPNLTTWDQWYAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	979
Z12552	VDKDYAKEADEAAVEIAQLPNLTTWDQWAAFIWKLRDDPSQSSELLSEAKKLNDSQAPK	980
Z12553	VDKDYAKEADDAAVEIAALPNLTTWDQWFAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	981
Z12554	VDKDYAKEADDAAYEIAIDLPNLTTWDQWMAFINKLRDDPSQSSELLSEAKKLNDSQAPK	982
Z12555	VDKDYAKEADDAAVEIAFLPNLTTWDQWAAAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	983
Z12556	VDKDYAKEADDAAMEIADLPNLTTWEQWYAFIAKLRDDPSQSSELLSEAKKLNDSQAPK	984
Z12557	VDKDYAKEADQAAVEIADLPNLTLWLQWFAFINKLRDDPSQSSELLSEAKKLNDSQAPK	985

Z12558	VDK YAKEADDA AVEIAELPNLTWQWFAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	986
Z12559	VDK YAKEADMAAIEIAALPNLTWDQWDAFIRKLRDDPSQSSELLSEAKKLNDSQAPK	987
Z12560	VDK YAKEADEAAVEIAYLPNLTWDQWWAFISKLRDDPSQSSELLSEAKKLNDSQAPK	988
Z12561	VDK YAKEADQAAVEIAELPNLTWDQWWAFINKLRDDPSQSSELLSEAKKLNDSQAPK	989
Z12562	VDK YAKEADDA AAEIAELPNLTWQWFAFINKLRDDPSQSSELLSEAKKLNDSQAPK	990
Z12563	VDK YAKEADQAAFEIAELPNLTWDQWYAFIAKLRDDPSQSSELLSEAKKLNDSQAPK	991
Z12564	VDK YAKEADDA AYEIAELPNLTWDQWWAFITKLRDDPSQSSELLSEAKKLNDSQAPK	992
Z12565	VDK YAKEADDA AYEIAELPNLTWDQWFAFICKLRDDPSQSSELLSEAKKLNDSQAPK	993
Z12566	VDK YAKEADDA AYEIAMLPNLTWDQWYAFINKLRDDPSQSSELLSEAKKLNDSQAPK	994
Z12567	VDK YAKEADDA AAMEIALLPNLTWDQWWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	995
Z12568	VDK YAKEADEAAVEIAADLPNLTWDQWFAFICKLRDDPSQSSELLSEAKKLNDSQAPK	996
Z12569	VDK YAKEADDA AVEIAELPNLTWDQWAAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	997
Z12570	VDK YAKEADEAA MEIAELPNLTWDQWWAFITKLRDDPSQSSELLSEAKKLNDSQAPK	998
Z12571	VDK YAKEADNA AVEIAADLPNLTWDQWFAFINKLRDDPSQSSELLSEAKKLNDSQAPK	999
Z12572	VDK YAKEADDA AYEIAFLPNLTWDQWYAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	1000
Z12573	VDK YAKEADDA AVEIAADLPNLTWDQWFAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	1001
Z12574	VDK YAKEADNA AAEIAADLPNLTWDQWYAFICKLRDDPSQSSELLSEAKKLNDSQAPK	1002
Z12575	VDK YAKEADEAAVEIAFLPNLTWDQWWAFITKLRDDPSQSSELLSEAKKLNDSQAPK	1003
Z12576	VDK YAKEADNA AVEIAADLPNLTWDQWFAFICKLRDDPSQSSELLSEAKKLNDSQAPK	1004
Z12577	VDK YAKEADEAAVEIAADLPNLTWDQWHA FITKLRDDPSQSSELLSEAKKLNDSQAPK	1005
Z12578	VDK YAKEADDA AYEIAMLPNLTWDQWAA FIDKLRDDPSQSSELLSEAKKLNDSQAPK	1006
Z12579	VDK YAKEADDA AYEIAQLPNLTWQWFAFINKLRDDPSQSSELLSEAKKLNDSQAPK	1007
Z12580	VDK YAKEADGA AYEIAGLPNLTWDQWFAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	1008
Z12581	VDK YAKEADNA AYEIALLPNLTWDQWEAFILKLRDDPSQSSELLSEAKKLNDSQAPK	1009
Z12582	VDK YAKEADAA A MEIAGLPNLTWDQWFAFISKLRDDPSQSSELLSEAKKLNDSQAPK	1010
Z12583	VDK YAKEADDA AVEIAELPNLTWDQWAA FIMKLRDDPSQSSELLSEAKKLNDSQAPK	1011
Z12584	VDK YAKEADDA AVEIAELPNLTWDQWWAFINKLRDDPSQSSELLSEAKKLNDSQAPK	1012
Z12586	VDK YAKEADDA AFEIAMLPNLTWDQWYAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	1013
Z12588	VDK YAKEADMA AVEIAELPNLTWQWYAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	1014

Z12589	VDKYYAKEADMAAVEIAIDLPLNLTWQWYAFIWKLRDDPSQSSELLSEAKKLNDSQAPK	1015
Z12590	VDKYYAKEADAAAAMEIAIDLPLNLTWQWYAFITKLRDDPSQSSELLSEAKKLNDSQAPK	1016
Z12591	VDKYYAKEADDAAYEIAFLPLNLTWQWYAFILKLRDDPSQSSELLSEAKKLNDSQAPK	1017
Z12592	VDKYYAKEADQAAMEIAELPLNLTWQWEAFILKLRDDPSQSSELLSEAKKLNDSQAPK	1018
Z12593	VDKYYAKEADGAAYEIASLPLNLTWQWYAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	1019
Z12594	VDKYYAKEADDAAYEIAFLPLNLTWQWDAFIMKLRDDPSQSSELLSEAKKLNDSQAPK	1020
Z12595	VDKYYAKEADDAAVEIAWLPLNLTWQWYAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	1021
Z12596	VDKYYAKEADEAAVEIAYLPLNLTWQWYAFINKLRDDPSQSSELLSEAKKLNDSQAPK	1022
Z12597	VDKYYAKEADAAAFFEIAALPLNLTWQWYAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	1023
Z12598	VDKYYAKEADDAAYEIAELPLNLTWQWYAFIMKLRDDPSQSSELLSEAKKLNDSQAPK	1024
Z12599	VDKYYAKEADEAAVEIAALPLNLTWQWYAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	1025
Z12600	VDKYYAKEADDAAVEIAALPLNLTWQWYAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	1026
Z12601	VDKYYAKEADEAAAMEIADLPLNLTWEQWAAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	1027
Z12603	VDKYYAKEADAAAVEIARLPLNLTWLQWEAFILKLRDDPSQSSELLSEAKKLNDSQAPK	1028
Z12604	VDKYYAKEADAAAVEIAELPLNLTWEQWYAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	1029
Z12605	VDKYYAKEADDAAMEIAALPLNLTWQWYAFINKLRDDPSQSSELLSEAKKLNDSQAPK	1030
Z12606	VDKYYAKEADDAAFEIAFLPLNLTWQWHAFINKLRDDPSQSSELLSEAKKLNDSQAPK	1031
Z12607	VDKYYAKEADNAAVEIAALPLNLTWQWYAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	1032
Z12608	VDKYYAKEADSAAVEIAVLPLNLTWQWYAFILKLRDDPSQSSELLSEAKKLNDSQAPK	1033
Z12609	VDKYYAKEADDAAYEIAHPLNLTWQWEAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	1034
Z12610	VDKYYAKEADEAAVEIAVLPLNLTWQWAAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	1035
Z12611	VDKYYAKEADNAAMEIAELPLNLTWQWFAFIHKLRDDPSQSSELLSEAKKLNDSQAPK	1036
Z12612	VDKYYAKEADDAAMEIAELPLNLTWEQWYAFINKLRDDPSQSSELLSEAKKLNDSQAPK	1037
Z12613	VDKYYAKEADDAAFEIAQLPLNLTWQWYAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	1038
Z12614	VDKYYAKEADDAAVEIAMLPLNLTWQWYAFINKLRDDPSQSSELLSEAKKLNDSQAPK	1039
Z12615	VDKYYAKEADDAAYEIAELPLNLTWQWYAFITKLRDDPSQSSELLSEAKKLNDSQAPK	1040
Z12616	VDKYYAKEADNAALEIAELPLNLTWQWYAFIRKLRDDPSQSSELLSEAKKLNDSQAPK	1041
Z12617	VDKYYAKEADNAAYEIAELPLNLTWQWYAFINKLRDDPSQSSELLSEAKKLNDSQAPK	1042
Z12618	VDKYYAKEADLAAMEIAELPLNLTWQWYAFINKLRDDPSQSSELLSEAKKLNDSQAPK	1043

Z12619	VDKYYAKEADDAAVEIAADLPNLTWQWYAFINKLRDDPSQSSELLSEAKKLNDSQAPK	1044
Z12620	VDKYYAKEADDAAMEIAFLPNLTWDQWWAFIMKLRDDPSQSSELLSEAKKLNDSQAPK	1045
Z12621	VDKYYAKEADEAAVEIAHLPNLTWDQWFAFITKLRDDPSQSSELLSEAKKLNDSQAPK	1046
Z12622	VDKYYAKEADDAAYEIAFLPNLTWDQWWAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	1047
Z12624	VDKYYAKEADHAAVEIAFLPNLTWDQWFAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	1048
Z12625	VDKYYAKEADQAAVEIANLPNLTWDQWAAAFIMKLRDDPSQSSELLSEAKKLNDSQAPK	1049
Z12626	VDKYYAKEADQAAVEIAAGLPNLTWDQWAAAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	1050
Z12627	VDKYYAKEADEAAVEIALLPNLTWDQWFAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	1051
Z12628	VDKYYAKEADEAAVEIAYLPNLTWDQWYAFISKLRDDPSQSSELLSEAKKLNDSQAPK	1052
Z12629	VDKYYAKEADEAAVEIAGLPNLTWDQWEAFILKLRDDPSQSSELLSEAKKLNDSQAPK	1053
Z12630	VDKYYAKEADDAAMEIAELPNLTWDQWWAFIAKLRDDPSQSSELLSEAKKLNDSQAPK	1054
Z12631	VDKYYAKEADDAALEIAYLPNLTWDQWWAFITKLRDDPSQSSELLSEAKKLNDSQAPK	1055
Z12632	VDKYYAKEADAAAVEIADLPNLTWDQWWAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	1056
Z12633	VDKYYAKEADSAAVEIADLPNLTWDQWYAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	1057
Z12635	VDKYYAKEADMAAVEIAELPNLTWDQWYAFIGKLRDDPSQSSELLSEAKKLNDSQAPK	1058
Z12636	VDKYYAKEADKAAVEIAELPNLTWDQWWAFIMKLRDDPSQSSELLSEAKKLNDSQAPK	1059
Z12637	VDKYYAKEADDAAMEIADLPNLTWDQWMAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	1060
Z12638	VDKYYAKEADDAAVEIAGLPNLTWDQWWAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	1061
Z12639	VDKYYAKEADDAAYEIAELPNLTWDQWFAFIAKLRDDPSQSSELLSEAKKLNDSQAPK	1062
Z12640	VDKYYAKEADDAAMEIALLPNLTWDQWHAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	1063
Z12641	VDKYYAKEADIAAFEIAGLPNLTWDQWFAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	1064
Z12642	VDKYYAKEADQAAVEIADLPNLTWDQWWAFITKLRDDPSQSSELLSEAKKLNDSQAPK	1065
Z12643	VDKYYAKEADMAAVEIAGLPNLTWDQWYAFINKLRDDPSQSSELLSEAKKLNDSQAPK	1066
Z12644	VDKYYAKEADDAAMEIAALPNLTWDQWWAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	1067
Z12645	VDKYYAKEADDAAVEIAWLPNLTWDQWYAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	1068
Z12646	VDKYYAKEADNAAVEIAFLPNLTWDQWYAFINKLRDDPSQSSELLSEAKKLNDSQAPK	1069
Z12648	VDKYYAKEADDAAFEIAALPNLTWDQWWAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	1070
Z12649	VDKYYAKEADAAAVEIAELPNLTWDQWYAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	1071
Z12650	VDKYYAKEADDAAYEIAFLPNLTWDQWDAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	1072

Z12651	VDKYYAKEADDAAVEIAFLPNLTWEQWYAFIEKLRDDDPSSSELLSEAKKLNDSQAPK	1073
Z12652	VDKYYAKEADNAAMEIAALPNLTTWDQWYAFINKLRDDDPSSSELLSEAKKLNDSQAPK	1074
Z12653	VDKYYAKEADDAAVEIAFLPNLTTWDQWDADFINKLRDDDPSSSELLSEAKKLNDSQAPK	1075
Z12654	VDKYYAKEADAAAAYEIALLPNLTTWDQWFAFIDKLRDDDPSSSELLSEAKKLNDSQAPK	1076
Z12655	VDKYYAKEADDAAYEIAGLPNLTTWDQWWAFISKLRDDDPSSSELLSEAKKLNDSQAPK	1077
Z12656	VDKYYAKEADDAAFEIAELPNLTTWDQWWAFITKLRDDDPSSSELLSEAKKLNDSQAPK	1078
Z12657	VDKYYAKEADEAAMEIADLPNLTTWAQWYAFIDKLRDDDPSSSELLSEAKKLNDSQAPK	1079
Z12658	VDKYYAKEADMAAVEIAALPNLTTWDQWYAFIEKLRDDDPSSSELLSEAKKLNDSQAPK	1080
Z12659	VDKYYAKEADNAAVEIAELPNLTTWEQWWAFINKLRDDDPSSSELLSEAKKLNDSQAPK	1081
Z12660	VDKYYAKEADIAAVEIAALLPNLTTWDQWAAAFISKLRDDDPSSSELLSEAKKLNDSQAPK	1082
Z12661	VDKYYAKEADRAAVEIASLPNLTTWDQWYAFITKLRDDDPSSSELLSEAKKLNDSQAPK	1083
Z12662	VDKYYAKEADAAAVEIANLPNLTTWDQWEAFIHKLRDDDPSSSELLSEAKKLNDSQAPK	1084
Z12663	VDKYYAKEADDAAVEIAALLPNLTTWDQWFAFIMKLRDDDPSSSELLSEAKKLNDSQAPK	1085
Z12664	VDKYYAKEADDAAVEIANLPNLTTWAQWHAFIQKLRDDDPSSSELLSEAKKLNDSQAPK	1086
Z12665	VDKYYAKEADNAAVEIAWLPNLTTWDQWFAFITKLRDDDPSSSELLSEAKKLNDSQAPK	1087
Z12669	VDKYYAKEADFAAIEIAELPNLTTWDQWHAFIAKLRDDDPSSSELLSEAKKLNDSQAPK	1088
Z12670	VDKYYAKEADIAAFEIAMLPNLTTWLQWEAFIAKLRDDDPSSSELLSEAKKLNDSQAPK	1089
Z12671	VDKYYAKEADGAAMEIALLPNLTTWDQWYAFINKLRDDDPSSSELLSEAKKLNDSQAPK	1090
Z12672	VDKYYAKEADAAAAMEIAFLPNLTTWDQWDAFILKLRDDDPSSSELLSEAKKLNDSQAPK	1091
Z12673	VDKYYAKEADAAAAMEIANLPNLTTWDQWAAAFIRKLRDDDPSSSELLSEAKKLNDSQAPK	1092
Z12674	VDKYYAKEADDAAYEIAGLPNLTTWLQWDAFIQKLRDDDPSSSELLSEAKKLNDSQAPK	1093
Z12675	VDKYYAKEADLAAIEIANLPNLTTWDQWHAFIFKLRDDDPSSSELLSEAKKLNDSQAPK	1094
Z12677	VDKYYAKEADRAAYEIAELPNLTTWDQWYAFISKLRDDDPSSSELLSEAKKLNDSQAPK	1095
Z12679	VDKYYAKEADHAAAYEIAGLPNLTTWDQWHAFISKLRDDDPSSSELLSEAKKLNDSQAPK	1096
Z12680	VDKYYAKEADNAAEIEIALLPNLTTWDQWWAFILKLRDDDPSSSELLSEAKKLNDSQAPK	1097
Z12681	VDKYYAKEADAAAAVEIAALPNLTTWDQWDAFIFKLRDDDPSSSELLSEAKKLNDSQAPK	1098
Z12683	VDKYYAKEADTAAVEIAQLPNLTTWDQWAAAFIQKLRDDDPSSSELLSEAKKLNDSQAPK	1099
Z12684	VDKYYAKEADRAAVEIAHLPNLTTWIQWEAFINKLRDDDPSSSELLSEAKKLNDSQAPK	1100
Z12685	VDKYYAKEADSAAVEIAELPNLTTWDQWWAFIRKLRDDDPSSSELLSEAKKLNDSQAPK	1101

Z12686	VDAKYAKEADQAAFEIAGLPNLTWQWFAFIRKLRDDPSQSSELLSEAKKLNDSQAPK	1102
Z12688	VDAKYAKEADEAAVEIAALPNLTWDQWLAFILKLRDDPSQSSELLSEAKKLNDSQAPK	1103
Z12689	VDAKYAKEADNAAVEIANLPNLTWLQWAFINKLRDDPSQSSELLSEAKKLNDSQAPK	1104
Z12690	VDAKYAKEADIAALEIANLPNLTWDQWWAFITKLRDDPSQSSELLSEAKKLNDSQAPK	1105
Z12691	VDAKYAKEADIAAVEIAWLPNLTWAQWHAFFITKLRDDPSQSSELLSEAKKLNDSQAPK	1106
Z12692	VDAKYAKEADVAAAEIAELPNLTWDQWAAFIAKLRDDPSQSSELLSEAKKLNDSQAPK	1107
Z12694	VDAKYAKEADDAAVEIAELPNLTWMQWEAFISKLRDDPSQSSELLSEAKKLNDSQAPK	1108
Z12696	VDAKYAKEADQAAMEIAKLPNLTWDQWYAFITKLRDDPSQSSELLSEAKKLNDSQAPK	1109
Z12697	VDAKYAKEADQAAYEIAADLPNLTWDQWFAFINKLRDDPSQSSELLSEAKKLNDSQAPK	1110
Z12700	VDAKYAKEADKAAYEIAQLPNLTWEQWAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	1111
Z12701	VDAKYAKEADDAAVEIAWLPNLTWDQWYAFITKLRDDPSQSSELLSEAKKLNDSQAPK	1112
Z12703	VDAKYAKEADRAAVEIANLPNLTWWQWEAFIAKLRDDPSQSSELLSEAKKLNDSQAPK	1113
Z12707	VDAKYAKEADEAAAMEIANLPNLTWEQWAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	1114
Z12708	VDAKYAKEADTAAYEIANLPNLTWDQWFAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	1115
Z12709	VDAKYAKEADDAAEIAIDLPNLTWIQWLAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	1116
Z12711	VDAKYAKEADDDAAIEIALLPNLTWFQWDAFINKLRDDPSQSSELLSEAKKLNDSQAPK	1117
Z12712	VDAKYAKEADRAAMEIASLPNLTWDQWAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	1118
Z12715	VDAKYAKEADKAAVEIAQLPNLTWDQWAFIMKLRDDPSQSSELLSEAKKLNDSQAPK	1119
Z12717	VDAKYAKEADMAALEIAELPNLTWDQWYAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	1120
Z12718	VDAKYAKEADGAAVEIAMLPNLTWDQWAFITKLRDDPSQSSELLSEAKKLNDSQAPK	1121
Z12719	VDAKYAKEADDAAYEIAELPNLTWDQWYAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	1122
Z12720	VDAKYAKEADNAAYEIAQLPNLTWDQWFAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	1123
Z12721	VDAKYAKEADAAAAYEIAELPNLTWDQWLAFISKLRDDPSQSSELLSEAKKLNDSQAPK	1124
Z12722	VDAKYAKEADSAAYEIAGLPNLTWDQWDAFISKLRDDPSQSSELLSEAKKLNDSQAPK	1125
Z12723	VDAKYAKEADGAAYEIALLPNLTWDQWAAAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	1126
Z12724	VDAKYAKEADSAAEIAIYLPNLTWDQWYAFIEKLRDDPSQSSELLSEAKKLNDSQAPK	1127
Z12725	VDAKYAKEADLAAIEIAIYLPNLTWDQWAAAFIRKLRDDPSQSSELLSEAKKLNDSQAPK	1128
Z12726	VDAKYAKEADDAAFEIAIYLPNLTWEQWAFIKKLRDDPSQSSELLSEAKKLNDSQAPK	1129
Z12727	VDAKYAKEADEAAVEIAVLPNLTWEQWAFIMKLRDDPSQSSELLSEAKKLNDSQAPK	1130

Z12728	VDKDYAKEADDAAMEIAMLPNLTWTDQWYAFIEKLRDDPSQSELLSEAKKLNDSQAPK	1131
Z12730	VDKDYAKEADEAAMEIAALPNLTWTDQWYAFIGKLRDDPSQSELLSEAKKLNDSQAPK	1132
Z12732	VDKDYAKEADEFAAFEIAELPNLTWEQWFAFINKLRDDPSQSELLSEAKKLNDSQAPK	1133
Z12733	VDKDYAKEADNAAMEIANLPNLTWAQWAAFIGKLRDDPSQSELLSEAKKLNDSQAPK	1134
Z12734	VDKDYAKEADDAAVEIANLPNLTWIQWEAFIQKLRDDPSQSELLSEAKKLNDSQAPK	1135
Z12735	VDKDYAKEADDAALEIAQLPNLTWDQWEAFILKLRDDPSQSELLSEAKKLNDSQAPK	1136
Z12737	VDKDYAKEADDAAFEIAHLPNLTWLQWAAFIKKLRDDPSQSELLSEAKKLNDSQAPK	1137
Z12738	VDKDYAKEADEAAMEIALLPNLTWDQWWAFITKLRDDPSQSELLSEAKKLNDSQAPK	1138
Z12740	VDKDYAKEADLAAMEIAELPNLTWDQWFAFIYKLRDDPSQSELLSEAKKLNDSQAPK	1139
Z12741	VDKDYAKEADHAAVEIAILPNLTWAQWMAFIEKLRDDPSQSELLSEAKKLNDSQAPK	1140
Z12742	VDKDYAKEADKAAVEIANLPNLTWIQWWAFIRKLRDDPSQSELLSEAKKLNDSQAPK	1141
Z12743	VDKDYAKEADKAAFEIAILPNLTWTDQWYAFIWKLRDDPSQSELLSEAKKLNDSQAPK	1142
Z12744	VDKDYAKEADEAAVEIAELPNLTWDQWWAFIMKLRDDPSQSELLSEAKKLNDSQAPK	1143
Z12746	VDKDYAKEADRAAVEIAHLPNLTWDQWFAFIEKLRDDPSQSELLSEAKKLNDSQAPK	1144
Z12747	VDKDYAKEADGAAMEIAELPNLTWDQWDADFIRKLRDDPSQSELLSEAKKLNDSQAPK	1145
Z12749	VDKDYAKEADMAAIEIADLPNLTWYQWYAFISKLRDDPSQSELLSEAKKLNDSQAPK	1146
Z12750	VDKDYAKEADKAAVEIAMLPNLTWDQWYAFIMKLRDDPSQSELLSEAKKLNDSQAPK	1147
Z12751	VDKDYAKEADRAAVEIAYLPNLTWTDQWWAFIQKLRDDPSQSELLSEAKKLNDSQAPK	1148
Z12752	VDKDYAKEADDAAMEIAWLPNLTWYQWWAFIQKLRDDPSQSELLSEAKKLNDSQAPK	1149
Z12754	VDKDYAKEADMAAYEIAGLPNLTWTDQWWAFIDKLRDDPSQSELLSEAKKLNDSQAPK	1150
Z12755	VDKDYAKEADHAALEIAELPNLTWDQWAAAFINKLRDDPSQSELLSEAKKLNDSQAPK	1151
Z12756	VDKDYAKEADTAAVEIAMLPNLTWWQWEAFIMKLRDDPSQSELLSEAKKLNDSQAPK	1152
Z12758	VDKDYAKEADEAAVEIAFLPNLTWTDQWAAFIYKLRDDPSQSELLSEAKKLNDSQAPK	1153
Z12759	VDKDYAKEADSAAVEIAALPNLTWTDQWWAFIQKLRDDPSQSELLSEAKKLNDSQAPK	1154
Z12760	VDKDYAKEADNAAMEIAHLPNLTWTDQWYAFIAKLRDDPSQSELLSEAKKLNDSQAPK	1155
Z12761	VDKDYAKEADKAAFEIAALPNLTWVQWMAFIAKLRDDPSQSELLSEAKKLNDSQAPK	1156
Z12762	VDKDYAKEADDAAVEIAHLPNLTWTDQWEAFIFKLRDDPSQSELLSEAKKLNDSQAPK	1157
Z12763	VDKDYAKEADEFAALEIASLPNLTWAQWYAFINKLRDDPSQSELLSEAKKLNDSQAPK	1158
Z12765	VDKDYAKEADHAAAMEIAELPNLTWLQWHAFIAKLRDDPSQSELLSEAKKLNDSQAPK	1159


Z12766	VDK YAKEADHAAVEIANLPNLTW DQW HAFISKLRDDPSQSSELLSEAKKLND SQAPK	1160
Z12767	VDK YAKEADKAAFEIAFLPNLTW DQW DAFIAKLRDDPSQSSELLSEAKKLND SQAPK	1161
Z12768	VDK YAKEADLAAFEIALLPNLTWEQWFAFI TKLRDDPSQSSELLSEAKKLND SQAPK	1162
Z12770	VDK YAKEADSAA MEIAVLPNLTW DQW FAFIMKLRDDPSQSSELLSEAKKLND SQAPK	1163
Z12771	VDK YAKEADAAAAEIA DLPNLTW IQW DAFIHKLRDDPSQSSELLSEAKKLND SQAPK	1164
Z12772	VDK YAKEADFAA YEIA DLPNLTW YQW HAFIQKLRDDPSQSSELLSEAKKLND SQAPK	1165
Z12773	VDK YAKEADQAA YEIA DLPNLTW DQW DAFILKLRDDPSQSSELLSEAKKLND SQAPK	1166
Z12775	VDK YAKEADFAA MEIA DLPNLTW DQW WAFITKLRDDPSQSSELLSEAKKLND SQAPK	1167
Z12776	VDK YAKEADMAA FEIA FLPNLTW DQW YAFIQKLRDDPSQSSELLSEAKKLND SQAPK	1168
Z12777	VDK YAKEADKAA VEIA DLPNLTW DQW QAFIQKLRDDPSQSSELLSEAKKLND SQAPK	1169
Z12778	VDK YAKEADDA AIEIA DLPNLTW DQW EAFILKLRDDPSQSSELLSEAKKLND SQAPK	1170
Z12780	VDK YAKEADVAA VEIA ELPNLTW DQW WAFIDKLRDDPSQSSELLSEAKKLND SQAPK	1171
Z12781	VDK YAKEADQAA MEIA ALPNLTW DQW DAFIGKLRDDPSQSSELLSEAKKLND SQAPK	1172
Z12782	VDK YAKEADAAA VEIA YLPNLTW DQW FAFIMKLRDDPSQSSELLSEAKKLND SQAPK	1173
Z12783	VDK YAKEADNA A MEIA ELPNLTW IQW YAFINKLRDDPSQSSELLSEAKKLND SQAPK	1174
Z12784	VDK YAKEADQAA YEIA SLPNLTW DQW LAFIDKLRDDPSQSSELLSEAKKLND SQAPK	1175
Z12785	VDK YAKEADGA A MEIA ELPNLTW DQW EAFISKLRDDPSQSSELLSEAKKLND SQAPK	1176
Z12788	VDK YAKEADIA A VEIA GLPNLTW DQW FAFIGKLRDDPSQSSELLSEAKKLND SQAPK	1177
Z12790	VDK YAKEADTAA LEIA SLPNLTW DQW EAFIDKLRDDPSQSSELLSEAKKLND SQAPK	1178
Z12791	VDK YAKEADAAA FEIA ALPNLTW FQW FAFIHKLRDDPSQSSELLSEAKKLND SQAPK	1179
Z12792	VDK YAKEADHAA MEIA MLPNLTW DQW FAFIAKLRDDPSQSSELLSEAKKLND SQAPK	1180
Z12793	VDK YAKEADRA A FEIA ELPNLTW DQW EAFIGKLRDDPSQSSELLSEAKKLND SQAPK	1181
Z12794	VDK YAKEADSA A MEIA DLPNLTW DQW LAFIDKLRDDPSQSSELLSEAKKLND SQAPK	1182
Z12795	VDK YAKEADTAA VEIA ALPNLTW DQW QAFILKLRDDPSQSSELLSEAKKLND SQAPK	1183
Z12797	VDK YAKEADNA A YEIA LLPNLTW DQW FAFIQKLRDDPSQSSELLSEAKKLND SQAPK	1184
Z12798	VDK YAKEADAAA FEIA ELPNLTW LQW HAFINKLRDDPSQSSELLSEAKKLND SQAPK	1185
Z12799	VDK YAKEADSA A LEIA GLPNLTW VQW WAFIGKLRDDPSQSSELLSEAKKLND SQAPK	1186
Z12800	VDK YAKEADWA A VEIA NLPNLTW DQW DAFIDKLRDDPSQSSELLSEAKKLND SQAPK	1187
Z12801	VDK YAKEADKAA LEIA QLPNLTW DQW WAFINKLRDDPSQSSELLSEAKKLND SQAPK	1188

Z12802	VDKDYAKEADMAAVEIALLPNLTWDDQWWAFISKLRDDPSQSSELLSEAKKLNDSQAPK	1189
Z12803	VDKDYAKEADVAAVEIALLPNLTWDDQWEAFINKLRDDPSQSSELLSEAKKLNDSQAPK	1190
Z12804	VDKDYAKEADNAAFEIAFLPNLTWDDQWWAFISKLRDDPSQSSELLSEAKKLNDSQAPK	1191
Z12805	VDKDYAKEADAAAAMEIAVLPNLTWDDQWWAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	1192
Z12807	VDKDYAKEADIAAFEIAALPNLTWEQWWAFIWKLRRDPSQSSELLSEAKKLNDSQAPK	1193
Z12808	VDKDYAKEADRAAVEIALLPNLTWDDQWHAFIQKLRRDPSQSSELLSEAKKLNDSQAPK	1194
Z12809	VDKDYAKEADAAAAYEIAYLPNLTWQDAFIHKLRDDPSQSSELLSEAKKLNDSQAPK	1195
Z12810	VDKDYAKEADNAAIEIAELPNLTWDDQWAAAFIMKLRRDPSQSSELLSEAKKLNDSQAPK	1196
Z12813	VDKDYAKEADGAAMEIAGLPNLTWDDQWFAFIMKLRRDPSQSSELLSEAKKLNDSQAPK	1197
Z12814	VDKDYAKEADWAAMEIALLPNLTWDDQWEAFILKLRRDPSQSSELLSEAKKLNDSQAPK	1198
Z12815	VDKDYAKEADNAAMEIAALPNLTWEQWDAFIRKLRRDPSQSSELLSEAKKLNDSQAPK	1199
Z06260	VDKDYAKEHDYAWFEI WALPNLTWDDQATAFIRKLNDDPSQSSELLSEAKKLNDSQAPK	1200
Z06267	VDKDYAKEMNRAQIEIWLLPNLTWHQQAFAFIQKLIDDPSQSSELLSEAKKLNDSQAPK	1201
Z06270	VDKDYAKEADDAWWEI WALPNLTHAQKAFIVKLDDPSQSSELLSEAKKLNDSQAPK	1202
Z06271	VDKDYAKEAGDAQLEIWFLPNLTWAAQSNAFIRKLIDDPSQSSELLSEAKKLNDSQAPK	1203
Z06274	VDKDYAKEGDAQAMEIAELPNLTWDDQWFAFILKLRRDPSQSSELLSEAKKLNDSQAPK	1204
Z06278	VDKDYAKEADDAAVEIAALPNLTYDQWRAFI AKLRDDPSQSSELLSEAKKLNDSQAPK	1205
Z06282	VDKDYAKEADQAAMEIATLPNLTWDDQWFAFI AKLRDDPSQSSELLSEAKKLNDSQAPK	1206
Z06290	VDKDYAKEADNAALEIADLPNLTWVQWNAFIQKLRRDPSQSSELLSEAKKLNDSQAPK	1207
Z06291	VDKDYAKEADDAAFEIAALPNLTARQWYAFISKLRDDPSQSSELLSEAKKLNDSQAPK	1208
Z06447	VDKDYAKETTYAWFEIWSLPNLTWDDQQAFAFIQKLNDPSQSSELLSEAKKLNDSQAPK	1209
Z06448	VDKDYAKEADYAWFEIWSLPNLTYTQQSAFIRKLNDDPSQSSELLSEAKKLNDSQAPK	1210
Z06449	VDKDYAKEYDEFAWFEIWLLPNLTRDQQAFAFIHKLNDDPSQSSELLSEAKKLNDSQAPK	1211
Z06451	VDKDYAKEADEAWFEIWLLPNLTRSQASAFITKLNDDPSQSSELLSEAKKLNDSQAPK	1212
Z06453	VDKDYAKEADFAWFEI WALPNLTHDQSVAFIRKLNDDPSQSSELLSEAKKLNDSQAPK	1213
Z06455	VDKDYAKEMDNAQWEIWLLPNLTWAAQQAHAFIGKLI DDPSQSSELLSEAKKLNDSQAPK	1214
Z06461	VDKDYAKEMDDAWWEIWDLPNLTYYQQRAFI VKLVDDPSQSSELLSEAKKLNDSQAPK	1215
Z06462	VDKDYAKEWGEAQLEIWLLPNLTWWQGHAFIQKLDDPSQSSELLSEAKKLNDSQAPK	1216
Z10199	AEAKDYAKEADQAAMEIATLPNLTWDDQWFAFI AKLRDDPSQSSELLSEAKKLNDSQAPKVD	1217

Z12876	AEAKYAKEADDAAVEIAADLPNLTWQWYAFISKLRDDPSQSSELLSEAKKLNDSQAPK	1218
Z14253	AEAKYAKEADDAAVEIASLPNLTWQWYAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	1219
Z14254	AEAKYAKEADDAAVEIAALPNLTWQWYAFISKLRDDPSQSSELLSEAKKLNDSQAPK	1220
Z14255	AEAKYAKEADQAAVEIAADLPNLTWQWYAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	1221
Z15166	AEAKYAKEADDAAVEIASLPNLTWQWYAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	1222
Z04726	VDKAYAKELGWATWEIFNLPNLTGVQVKAFIDKLRDDPSQSSELLSEAKKLNDSQAPK	1223
PP013	LAEAKEAANAELDSYGVSDFYKRLIDKAKTVEGVEALKDAILAALP	1224
PEP07843	GSSLAEAKEAANAELDSYGVSDFYKRLIDKAKTVEGVEALKDAILAALP	1225
hIL-17A	MIVKAGITIPRNPGPCNSEDKNFPRTVMVNLNIHNRNTNTPKRSSDYNNRSTSPWNLHRNEDPERYP	1226
	SVIWEAKCRHLGCINADGNVDYHMNSVPIQQEILVLRREPPHCPNSFRLEKILVSVGCTCVTPIVHHV	
mIL-17A	AAIIPQSSACPNTAEKDFLQNVKVNKLVFNSLGAKVSSRRPSDYLNLRSTSPWTLHRNEDPDRYPSVIW	1227
	EAQCRHQRCVNAEGKLDHHMNSVLIQQEILVLKREPESCPFTFRVEKMLVGVGCTCVASIVRQAA	
hIL-17F	MRKI PKVGHTFFQKPESCPVPVGGSMKLDIGI INENQRVSMRNIESTSPWNRYTVDPNRYPSEV	1228
	VQAQCRNLGCINAAQKEDI SMNSVPIQQETLVVRRKHQGCVSFQLEKVLTVGCTCVTPVIHHVQ	
cIL-17A	MTPGKTSLVLLLLLSLEAIVKAGIAIPRNSGCPNSEDKNFPRTVMVNLNIHNRNTSTNPKRSSDYNN	1229
	RSTSPWNLHRNEDPERYPSPVIWEAKCRHLGCVKADGNVDYHMNSVPIQQEILVLRREPRHCPNSFRLE	
rmIL-17A	KILVSVGCTCVTPIVHHVA	1230
	GIAIPRNPGPCNSEDKTFPRTVMVNLNIHNRNTNTPKRSSDYNNRSTSPWNLHRNEDPERYPSPVIWE	
rmIL-17A	AKCRHLGCVNADGNVDYHMNSVPIQQEILVLRREPRHCPNSFRLEKILVSVGCTCVTPIVHHVA	


44/61

Figure 2




45/61

Figure 3




46/61

Figure 4A




47/61

Figure 4B




48/61

Figure 4C



50/61


Figure 6A-C




51/61

Figure 7A-B

A




B




52/61

Figure 8A





53/61

Figure 8B




54/61

Figure 9A-B

A**B**



55/61

Figure 10




56/61

Figure 11A-B


A**B**

57/61


Figure 12



A




B




59/61

Figure 13C-D

C




D



60/61

Figure 14A-B



61/61

Figure 15




Figure 13

B

